

INDEX



Page numbers followed by *f* indicate figures and those followed by *t* indicate tables, boxes, or special features. The titles of special features (e.g., Medication Administration; Multisystem Effects; Nursing Care Plan; Nursing Research) are also capitalized.

A

A line. *See* Arterial line

Abacavir, 357*t*, 358

ABCD rule, for melanoma, 467

Abciximab, 976, 976*t*, 988

Abdomen:

physical assessment

abnormal findings, 623–27*t*, 748–49*t*

aorta, 1098*f*, 1098*t*

technique/normal findings, 623–27*t*, 623*f*, 624*f*, 748–49*t*

trauma, 259

Abdominal aorta:

aneurysm. *See* Aortic aneurysm

physical assessment, 1098*f*, 1098*t*

Abdominal hysterectomy, 1804

Abdominal reflex, 1524*f*, 1524*t*

Abducens nerve (cranial nerve VI):

anatomy, 1510*f*

assessment, 1519*t*

functions, 1511*t*, 1671*t*

Abduction, 1386*t*

A-beta fibers, 172

ABGs. *See* Arterial blood gases

ABI (ankle-brachial blood pressure index), 965

Ablation, cardiac, 1012–13

Ablative procedure, 54*t*

ABLS Consensus formula, 499

Abrasions, 259, 259*f*

Abscess:

anorectal, 820

brain, 1565–66. *See also* Central nervous system infections

liver, 725

Absence seizures, 1549

Absorbants, intestinal, 756*t*

Abstinence, 103*t*

AC (alternating current), 488

Acanthamoeba, 1565*t*

Acapodene. *See* Toremfifene

Acarbose, 578*t*

Acceleration, in trauma, 256, 1596

Accessory nerve (cranial nerve XI):

anatomy, 1510*f*

assessment, 1520*t*

functions, 1511*t*

Accident, 255. *See also* Trauma

Accolate. *See* Zafirlukast

Accommodation, 1673, 1679*t*

Accupril. *See* Quinapril

Accutane. *See* Isotretinoin

Accuzyme, 504

ACE inhibitors. *See* Angiotensin-converting enzyme (ACE) inhibitors

Acebutolol, 1161*t*

Aceon. *See* Perindopril

Acesulfame potassium, 579

Acetaminophen:

characteristics, 179

mechanisms of action, 306

for osteoarthritis, 1451

Acetazolamide:

Medication Administration, 1033*t*, 1710*t*

in specific conditions

eye trauma, 1703

glaucoma, 1709, 1710*t*

heart failure, 1033*t*

Acetic acids, 178*t*, 306, 441*t*

Acetylcysteine, 1272

Acetylsalicylic acid. *See* Aspirin

Achalasia, 668

Achilles reflex, 1523*f*

Acid perfusion (Bernstein) test, 615*t*

Acid phosphatase (ACP), 386*t*

Acid therapy, for warts, 453

Acid–base balance:

assessment, 239, 240*t*

calcium levels and, 227

Chapter Highlights, 252

disorders

acidosis. *See* Metabolic acidosis; Respiratory acidosis

alkalosis. *See* Metabolic alkalosis; Respiratory alkalosis

classification, 239–41

compensation, 240*t*, 241–42, 243*t*

regulation of

buffer systems, 238–39, 238*f*

renal system, 239

respiratory system, 239

Acid-fast bacilli, 1287

Acidosis:

definition, 238

metabolic. *See* Metabolic acidosis

respiratory. *See* Respiratory acidosis

Acids, 238

Aciphex. *See* Rabeprazole

ACMV (assist-control mode ventilation), 1358, 1359*t*

Acne:

definition, 457

forms, 458

interdisciplinary care

diagnosis, 458

medications, 458, 459*t*

treatments, 459

manifestations, 458, 458*f*

nursing care, 459, 459*t*

pathophysiology, 457–58

Acne conglobata, 458

Acne rosacea, 458

Acne vulgaris, 458

Acoustic nerve (cranial nerve VIII):

anatomy, 1510*f*

assessment, 1520*t*

functions, 1511*t*

Acoustic neuroma, 1570*t*, 1727. *See also* Brain tumors

Acoustic reflex testing, 1730

ACP (acid phosphatase), 386*t*

Acquired hemolytic anemia, 1109

Acquired immunity, 298–99

Acquired immunodeficiency syndrome (AIDS):

classification system, 352*t*

history of epidemic, 349

incidence and prevalence, 349

interdisciplinary care. *See* Human

immunodeficiency virus (HIV) infection, interdisciplinary care

manifestations

AIDS dementia complex, 353

neurologic, 353

ophthalmic, 1718

opportunistic infections

candidiasis, 353

cytomegalovirus retinitis, 1718

other infections, 353–54

pharmacologic treatment, 359*t*

Pneumocystis carinii pneumonia, 353

tuberculosis, 353

overview, 351*t*, 352–53

secondary cancers

cervical cancer, 354

Kaposi's sarcoma, 354, 354*f*

lymphomas, 354

nursing care. *See* Human immunodeficiency

virus (HIV) infection, nursing care

Nursing Research: nurses' willingness to care for

people with HIV/AIDS, 360*t*

Acquired mutation, 152

Acral lentiginous melanoma, 467

Acromegaly, 523*t*, 529*t*, 558, 558*f*

ACS. *See* Acute coronary syndrome; American Cancer Society

ACTH. *See* Adrenocorticotropic hormone

Acthar. *See* Adrenocorticotropic hormone

Actidil. *See* Triprolidine

Actifed. *See* Pseudoephedrine

Actigall. *See* Ursodiol

Actimmune. *See* Interferon(s)

Actinic keratosis, 461, 461*f*

Action potential:

definition, 941–42, 942*f*

depolarization, 942

repolarization, 942–43

Actiq. *See* Fentanyl

Activated partial thromboplastin time, 1349

Active immunity, 298–99, 300*t*

Active transport, 200, 201*f*

Activity-exercise patterns:

altered cardiac function. *See also* Cardiovascular system

Build Clinical Competence, 1071*t*

Clinical Scenarios, 1072*t*

altered musculoskeletal function. *See also*

Musculoskeletal system

Build Clinical Competence, 1497*t*

Clinical Scenarios, 1498*t*

altered respiratory patterns. *See also* Respiratory system

Build Clinical Competence, 1375*t*

Clinical Scenarios, 1376*t*

altered tissue perfusion. *See also*

Hematologic system; Peripheral

vascular system

Build Clinical Competence, 1205*t*

Clinical Scenarios, 1206*t*

NANDA nursing diagnoses, 933*t*

Actonel. *See* Risedronate

Actos. *See* Pioglitazone

Acupressure, 1231

Acupuncture:

for pain management, 185

for smoking cessation, 1335

for upper respiratory infections, 1231

Acute abdomen, 677, 769

Acute arterial occlusion:

interdisciplinary care

diagnosis, 1184

medications, 1184

surgery, 1184

manifestations, 1184, 1184*t*

- Acute arterial occlusion—*continued*
 nursing care
 assessment, 1185
 community-based care, 1185
 nursing diagnoses and interventions
 altered protection, 1185–86
 anxiety, 1185
 ineffective tissue perfusion: peripheral, 1185
 pathophysiology
 arterial embolism, 1184
 arterial thrombosis, 1184
- Acute brain injury. *See* Traumatic brain injury
- Acute bronchitis:
 interdisciplinary care, 1266
 manifestations, 1266
 nursing care, 1267
 pathophysiology, 1266
- Acute chest syndrome, 1109
- Acute cholecystitis, 698. *See also* Gallstones
- Acute coronary syndrome (ACS):
 definition, 974
 interdisciplinary care
 diagnosis, 975–76
 medications, 976, 976t
 revascularization procedures
 coronary artery bypass grafting. *See*
 Coronary artery bypass grafting
 minimally invasive coronary artery
 surgery, 979
 percutaneous coronary revascularization,
 977, 977f, 978t
 transmyocardial laser revascularization, 979
 manifestations, 975
 Medication Administration, 976t
 Nursing Care Plan
 assessment, 983t
 critical thinking in the nursing process, 983t
 diagnoses, 983t
 evaluation, 983t
 expected outcomes, 983t
 planning and implementation, 983t
 pathophysiology, 974–75
 vs. stable angina and myocardial infarction, 975t
- Acute disease, 22t
- Acute gastritis, 677. *See also* Gastritis
- Acute heart failure, 1027. *See also* Heart failure
- Acute illness, 23. *See also* Illness
- Acute infective endocarditis, 1045, 1046t. *See also*
 Endocarditis
- Acute lymphocytic leukemia (ALL). *See also*
 Leukemia
 characteristics, 1119t
 interdisciplinary care
 diagnosis, 1123t
 treatment, 1119t, 1123t
 manifestations, 1119t, 1122
 pathophysiology, 1122
- Acute myeloid leukemia (AML). *See also*
 Leukemia
 characteristics, 1119t
 FAB classification, 1121t
 interdisciplinary care
 diagnosis, 1123t
 treatment, 1119t, 1123t
 management, 1121
 manifestations, 1119t
 Nursing Care Plan
 assessment, 1125t
 critical thinking in the nursing process, 1125t
 diagnoses, 1125t
 evaluation, 1125t
 expected outcomes, 1125t
 planning and implementation, 1125t
- pathophysiology, 1121, 1121f
 prognosis, 1121, 1121t
- Acute myocardial infarction (AMI):
 vs. acute coronary syndrome and stable
 angina, 975t
 cocaine-induced, 984
 complications
 cardiogenic shock, 985. *See also* Cardiogenic
 shock
 dysrhythmias, 985. *See also* Cardiac
 dysrhythmias
 infarct extension, 985
 pericarditis, 985–86
 pump failure, 985. *See also* Heart failure
 structural defects, 985
 definition, 979
 incidence, 982
 interdisciplinary care
 diagnosis, 986–87, 987t, 988f
 immediate goals, 986
 medications
 ACE inhibitors, 988
 analgesia, 987
 anticoagulants, 988. *See also* Anticoagulants
 antidysrhythmics, 988, 1006t
 antiplatelets, 976t, 988
 beta-blockers, 988. *See also* Beta-blockers
 dopamine, 989
 fibrinolytic therapy, 987–88, 989t
 treatments
 cardiac rehabilitation, 990
 general considerations, 989
 intra-aortic balloon pump, 990, 990f
 revascularization procedures, 990. *See also*
 Coronary artery bypass grafting;
 Percutaneous coronary revascularization
 ventricular assist devices, 990
 manifestations, 984, 984t, 985t
 mortality rate, 982
 nursing care
 assessment, 992
 of client receiving fibrinolytic therapy, 989t
 community-based care, 994
 health promotion, 991
 nursing diagnoses and interventions
 acute pain, 992
 fear, 993–94
 ineffective coping, 993
 ineffective tissue perfusion, 992–93
 using NANDA, NIC, and NOC, 994, 994t
 Nursing Care Plan
 assessment, 991t
 diagnoses, 991t
 evaluation, 992t
 expected outcomes, 991t
 planning and implementation, 991t
 Nursing Research: lifestyle changes in
 women, 995t
 pathophysiology, 961t, 982–84
 risk factors, 982
- Acute otitis media. *See* Otitis media
- Acute pain, 173–74. *See also* Pain
- Acute pancreatitis, 726–27, 727t. *See also*
 Pancreatitis
- Acute proliferative glomerulonephritis. *See also*
 Glomerular disorders
 complications, 886–87
 manifestations, 886–87, 888t
 pathophysiology, 886, 886f, 887t
 prognosis, 887
- Acute pyelonephritis, 848, 848t. *See also* Urinary
 tract infection
- Acute rejection, 921
- Acute renal artery thrombosis, 894
- Acute renal failure:
 acute tubular necrosis, 901–2, 903f
 course and manifestations
 initiation phase, 902
 maintenance phase, 902
 recovery phase, 902
 definition, 899
 incidence, 899
 interdisciplinary care
 diagnosis, 904
 fluid management, 905
 goals, 902
 medications, 904–5, 905t
 nutrition, 906
 renal replacement therapy. *See* Dialysis
 intrarenal, 900t, 901–2
 nursing care
 assessment, 911
 community-based care, 913
 health promotion, 910–11
 Medication Administration, 905–6t
 nursing diagnoses and interventions
 deficient knowledge, 913
 excess fluid volume, 911
 imbalanced nutrition: less than body
 requirements, 911–12
 using NANDA, NIC, and NOC, 913, 913t
 Nursing Care Plan
 assessment, 912t
 critical thinking in the nursing process, 912t
 diagnoses, 912t
 evaluation, 912t
 expected outcomes, 912t
 planning and implementation, 912t
 pathophysiology, 899, 900, 900t
 physical assessment, 901t
 postrenal, 900, 900t
 prerenal, 900, 900t
 risk factors, 900
- Acute respiratory distress syndrome (ARDS):
 causes, 1366, 1366t
 definition, 1365
 incidence, 1365
 interdisciplinary care
 diagnosis, 1366–67
 mechanical ventilation, 1367. *See also*
 Mechanical ventilation
 medications, 1367
 treatments, 1367
 manifestations, 1366
 mortality rate, 1365
 nursing care
 community-based care, 1372
 nursing diagnoses and interventions, 1367
 decreased cardiac output, 1367,
 1370–71
 dysfunctional ventilatory weaning
 response, 1371
 using NANDA, NIC, and NOC, 1371, 1371t
 Nursing Care Plan
 assessment, 1370t
 critical thinking in the nursing process, 1370t
 diagnoses, 1370t
 evaluation, 1370t
 expected outcomes, 1370t
 planning and implementation, 1370t
 pathophysiology, 1366, 1366f, 1368–69t
 in shock, 272
- Acute respiratory failure:
 causes, 1353–54, 1354f, 1354t
 definition, 1353
 interdisciplinary care

- airway management, 1355–56, 1357t
 diagnosis, 1355
 mechanical ventilation. *See* Mechanical ventilation
 medications, 1355
 nutrition and fluids, 1361
 oxygen therapy, 1355
 management, 1354–55
 manifestations, 1354f
 nursing care
 assessment, 1361
 community-based care, 1365
 endotracheal suctioning, 1363t
 health promotion, 1361
 nursing diagnoses and interventions
 anxiety, 1364–65
 impaired spontaneous ventilation, 1362
 ineffective airway clearance, 1362
 risk for injury, 1363–64
 using NANDA, NIC, and NOC, 1365, 1365t
 pathophysiology, 1354
 prognosis, 1355
- Acute response, in asthma, 1322
 Acute tissue rejection, 342, 343t
 Acute tubular necrosis, 901–2, 903f. *See also*
 Acute renal failure
- Acute viral rhinitis. *See* Upper respiratory disorders, viral infections
- Acutrim. *See* Phenylpropranolamine
- Acyclovir:
 Medication Administration, 322t, 658t
 in specific conditions
 Bell's palsy, 1658
 bone marrow transplant recipients, 344
 herpes infection, 359t, 452, 453, 658t, 1839
 viral encephalitis, 1566
- Adalat. *See* Nifedipine
- Adalimumab, 341, 1465
- Addiction. *See also* Substance abuse
 definition, 103t, 179t
 fear of, 175
- Addisonian crisis, 553–54
- Addison's disease:
 addisonian crisis, 553–54
 definition, 553
 interdisciplinary care
 diagnostic tests, 524–25t, 554, 554t
 medications, 554, 555t
 manifestations, 553, 554t
 nursing care
 assessment, 529–30t, 554–55
 community-based care, 557
 health promotion, 554
 Medication Administration, 555t
 nursing diagnoses and interventions
 deficient fluid volume, 555–56
 risk for ineffective therapeutic regimen management, 556–57
- Nursing Care Plan
 assessment, 556t
 critical thinking in the nursing process, 556t
 diagnoses, 556t
 evaluation, 556t
 expected outcomes, 556t
 planning and implementation, 556t
 pathophysiology, 553
- Adduction, 1386t
- A-delta fibers, 171, 171f, 172
- Adenocarcinoma:
 breast. *See* Breast cancer
 endometrial. *See* Endometrial cancer
 esophageal, 669. *See also* Esophageal cancer
 lung, 1309t. *See also* Lung cancer
 stomach, 688. *See also* Gastric cancer
- Adenocard. *See* Adenosine
- Adenoma, 800, 800f
- Adenosine, 1006, 1006t
- Adenosine triphosphate, 962
- ADH. *See* Antidiuretic hormone
- Adipex-P. *See* Phentermine
- Adjustable gastric banding (AGB), 637, 637f
- Adolescence, surgical risk and nursing implications, 58t
- Adoxa. *See* Doxycycline
- Adrenal glands:
 Adrenalectomy:
 nursing care, 550t
 procedure, 550
- Adrenaline. *See* Epinephrine
- Adrenergic agonists (mydriatics), 1710t
- Adrenergic neurotransmitters, 1505
- Adrenergic stimulants (β_2 -agonists), 1325, 1327t, 1355
- Adrenergics (sympathomimetics), 278t, 1034t
- Adrenocortical insufficiency. *See* Addison's disease
- Adrenocorticotrophic hormone (ACTH):
 abnormal, possible causes, 386t
 diagnostic tests, 380t, 525t, 549, 550, 550t
 excess. *See* Cushing's syndrome
 functions, 518
 laboratory tests, 380t
 Medication Administration, 1631t
 normal values, 386t, 525t
 in specific conditions
 cancer, 380
 multiple sclerosis, 1627, 1631t
- Adrenomedullin, 1155
- Adriamycin. *See* Doxorubicin
- Adult polycystic kidney disease, 839t
- Adult rickets. *See* Osteomalacia
- Adults, 24, 25t. *See also* Middle adults; Older adults; Young adults
- Advair. *See* Salmeterol/fluticasone
- Advance directives:
 definition, 12
 ethical dilemmas, 12
 legal issues, 90
 Medicare/Medicaid requirements, 90–91
 types, 90
- Advanced life support (ALS), 1016–17
- Advil. *See* Ibuprofen
- Advocate, nurse as, 14
- Adynamic ileus. *See* Paralytic ileus
- AED. *See* Automatic external defibrillator
- Aerobes, 311t
- AeroBid. *See* Flunisolide
- Aesthetic surgery. *See* Cosmetic surgery
- Aethoxysclerol, 478
- Afferent, 894
- AFP. *See* Alpha-fetoprotein
- African Americans. *See* Blacks/African Americans
- Afterload, 940, 1023, 1024t
- AGB (adjustable gastric banding), 637, 637f
- Agenerase. *See* Amprenavir
- Agensis, kidney, 883
- Age-related macular degeneration (AMD):
 incidence, 1713–14
 interdisciplinary care, 1714
 manifestations, 1714, 1714f
 nursing care, 1714
 Nursing Research: effect on older adults, 1715t
 pathophysiology, 1714
- Agglutination, 262
- Aggrastat. *See* Tirofiban
- Aging:
 as cancer risk factor, 370
 as coronary heart disease risk factor, 962–63
 functional changes with
 fluid and electrolyte balances, 202
 pain response, 175, 175t
 health and, 20
 physical status and
 middle adults, 27t. *See also* Middle adults
 older adults, 29t. *See also* Older adults
 young adults, 26t. *See also* Young adults
 surgical risk and nursing implications, 57t
- Agnosia, 1582
- Agranulocytosis, 1138
- Agraphia, 1620
- AHAs (alpha-hydroxy acids), 479
- AIDS. *See* Acquired immunodeficiency syndrome
- Airborne precautions, 323t
- Airway management, in acute respiratory failure, 1355–56, 1356f, 1357t
- Airway obstruction:
 in burns, 257, 499
 in trauma, 257–58, 257f
- Airway resistance, 1216
- Alanine aminotransferase (ALT), 386t
- Alaska Natives, diabetes mellitus risk and incidence, 564t
- Albendazole, 780t
- Albenza. *See* Albendazole
- Albinism, 426t, 427t
- Albumin:
 serum. *See* Serum albumin
 for shock, 277, 279t
 as volume resuscitation therapy, 263t
- Albumin 5%, 279t
- Albumin 25%, 279t
- Albuminar-5. *See* Albumin 5%
- Albuminar-25. *See* Albumin 25%
- Albuterol, 1327t
- Albuterol/ipratropium, 1327t
- Alcohol:
 abuse
 biologic factors, 104, 105
 complications, 108
 depression and, 103
 folic acid deficiency in, 1105
 genetic factors, 104, 104t
 hypertension and, 1157
 hypomagnesemia in, 233
 other drugs used with, 107t
 prevalence, 107
 screening tools, 116, 116f
 surgical risk and nursing implications, 57t
 treatment, 112
 underage, 107, 108t
 in young adults, 107, 108t
- characteristics, 107
 consumption
 cancer risk and, 372
 coronary heart disease risk and, 966
 in diabetes mellitus, 579
 effects, 108
 in hypertension, 1160
 osteoporosis risk and, 1434

I-4 INDEX

- Alcohol—*continued*
 overdose signs and treatment, 113*t*
 street names, 111*t*
 withdrawal, 108, 112, 113*t*
- Alcoholic cirrhosis. *See also* Cirrhosis
 incidence, 710
 Nursing Care Plan, 721*t*
 pathophysiology, 710
- Aldactone. *See* Spironolactone
- Aldehyde dehydrogenase, in alcohol abuse, 105
- Aldomet. *See* Methylidopa
- Aldosterone:
 diagnostic test, 525*t*
 functions, 521
 normal values, 525*t*
 in potassium balance, 217
- Alendronate:
 Medication Administration, 1442*t*
 in specific conditions
 hypercalcemia, 547
 osteoporosis, 1436
 Paget's disease, 1442, 1442*t*
- Aleve. *See* Naproxen
- Alfuzosin, 1779
- ALG (antilymphocyte globulin), 344, 346*t*
- Alkaline phosphatase (ALP):
 abnormal, possible causes, 386*t*
 in musculoskeletal system assessment, 1388*t*
 normal values, 386*t*, 728*t*
 in specific conditions
 osteomalacia, 1436*t*
 osteoporosis, 1436*t*
 Paget's disease, 1436*t*, 1442
 pancreatitis, 728*t*
- Alkalis, 238
- Alkalosis:
 definition, 238
 metabolic. *See* Metabolic alkalosis
 respiratory. *See* Respiratory alkalosis
- Alkeran. *See* Melphalan
- Alkylating agents, 390, 392*t*. *See also*
 Chemotherapy
- ALL. *See* Acute lymphocytic leukemia
- Allegra. *See* Fexofenadine
- Alleles, 151
- Allen test, 1096*t*
- Allerest. *See* Phenylpropranolamine
- Allergen, 276, 331
- Allergic rhinitis, 1229
- Allergy, 331. *See also* Hypersensitivity
- Alloderm, 503
- Allogeneic bone marrow transplant, 1124. *See also*
 Bone marrow transplant
- Allograft, 342, 503
- Allopurinol, 1445, 1446*t*
- All-*trans* retinoic acid (ATRA), 1123*t*
- Alopecia:
 causes, 435*t*
 from chemotherapy, 406
 definition, 435*t*
 interdisciplinary care, 482
 manifestations, 481, 482*f*
 medications causing, 482*t*
 nursing care, 482–83
 pathophysiology, 481
- Alopecia areata, 482
- Alopecia totalis, 482
- Alopecia universalis, 482
- ALP. *See* Alkaline phosphatase
- Alpha cells, pancreas, 521, 564
- Alpha interferon. *See also* Interferon(s)
 functions, 299*t*
 for hepatitis C, 708
 for immune system enhancement, 396
 for leukemia, 1125
 production, 299*t*
- Alpha Keri, 441*t*
- Alpha-adrenergic antagonists. *See* Alpha-blockers
- Alpha₁(α₁)-antitrypsin:
 deficiency, 1220*t*, 1331*t*, 1333–34
 normal values, 1334
 replacement therapy, 1334
- Alpha-blockers:
 Medication Administration, 1161*t*
 in specific conditions
 benign prostatic hyperplasia, 1779
 hypertension, 1161*t*, 1163
 scleroderma, 1485
- Alpha-fetoprotein (AFP):
 abnormal, possible causes, 384*t*, 386*t*
 normal values, 386*t*
 in testicular cancer, 1775
- Alphagan. *See* Brimonidine
- Alpha-glucoside inhibitors, 578*t*
- Alpha-hydroxy acids (AHAs), 479
- Alpha-thalassemia major, 1109. *See also*
 Thalassemias
- Alprostadil, 1769
- ALS. *See* Amyotrophic lateral sclerosis
- ALS (advanced life support), 1016–17
- ALT (alanine aminotransferase), 386*t*
- Altace. *See* Ramipril
- Altered level of consciousness:
 arousal, 1529–30
 coma states
 brain death, 265*t*, 1532
 definition, 1529*t*
 locked-in syndrome, 1532
 persistent vegetative state, 1532
 resources for families, 1531*t*
- interdisciplinary care
 diagnosis, 1532–33
 medications, 1533
 nutrition, 1533
 other treatments, 1533
 surgery, 1533
- motor responses, 1531
- nursing care
 nursing diagnoses and interventions
 impaired physical mobility, 1535
 ineffective airway clearance, 1534
 risk for aspiration, 1534
 risk for imbalanced nutrition: less than body requirements, 1535
 risk for impaired skin integrity, 1534–35
 support of the family, 1533–34
 pathophysiology, 1529
 prognosis, 1532
 pupillary and oculomotor responses, 1531, 1531*f*
 respiration patterns, 1530, 1530*t*
 terminology, 1529*t*
- AlternaGEL. *See* Aluminum hydroxide
- Alternating current (AC), 488
- Alternative therapies. *See* Complementary and alternative therapies
- Aludrox, 666*t*
- Aluminum hydroxide, 905, 919
- Alupent. *See* Metaproterenol
- Alveolar macrophages, 289
- Alveoli, 1212*f*, 1213, 1216
- Alzheimer's disease:
 characteristics, 1617–18
 familial, 1618
 genetic considerations, 1513*t*
 incidence, 1618
- interdisciplinary care
 complementary and alternative therapies, 1621
 diagnosis, 1620–21
 medications, 1621, 1621*t*
 manifestations
 stage 1, 1619, 1620*t*
 stage 2, 1619–20, 1620*t*
 stage 3, 1620, 1620*t*
 nursing care
 assessment, 1623
 communication techniques, 1624*t*
 community-based care, 1625–26
 health promotion, 1621, 1623
 Medication Administration, 1621*t*
 nursing diagnoses and interventions
 anxiety, 1624
 caregiver role strain, 1625
 chronic confusion, 1624
 hopelessness, 1624–25
 impaired memory, 1623–24
 safety interventions, 1623*t*
 using NANDA, NIC, and NOC, 1625, 1625*t*
- Nursing Care Plan
 assessment, 1622*t*
 critical thinking in the nursing process, 1623*t*
 diagnoses, 1622*t*
 evaluation, 1622–23*t*
 expected outcomes, 1622*t*
 planning and implementation, 1622*t*
 pathophysiology, 1618–19, 1618*t*, 1619*f*
 progression, 1618
 risk factors, 1618
 sporadic, 1618
 warning signs, 1618
- Amantadine:
 Medication Administration, 322*t*, 1637*t*
 in specific conditions
 influenza, 322*t*, 1234
 Parkinson's disease, 1637*t*, 1639
- Amaryl. *See* Glimepiride
- Amaurosis fugax, 1581
- Ambenonium, 1649*t*
- AMD. *See* Age-related macular degeneration
- Amebaquine. *See* Iodoquinol
- Amebiasis, 778, 778*t*
- Amebic meningoencephalitis, 1565*t*
- Amenorrhea, 1802. *See also* Dysfunctional uterine bleeding
- American Burn Association:
 burn injury classification, 491*t*
 guidelines for transfer to burn center, 497–98
- American Cancer Society (ACS):
 cancer prevention guidelines, 412*t*
 cancer screening guidelines, 401*t*
 cancer warning signs, 400*t*
- American Indians. *See* Native Americans
- American Nurses Association (ANA):
 Code of Ethics for Nurses, 11, 11*t*
 definition of nursing, 8
 do-not-resuscitate decisions, nursing care and, 91
 genetics nursing practice, scope and standards, 148–49, 149*t*
 Standards of Practice and Professional Performance, 11*t*
- AMI. *See* Acute myocardial infarction
- Amidopyrine, 832*t*
- Amikacin, 320*t*, 770
- Amikin. *See* Amikacin
- Amiloride HCl, 210*t*, 1033*t*
- Amino acids, in gout treatment, 1445
- Aminoglutethimide, 550
- Aminoglycosides, 320*t*, 1730
- Aminophylline, 1326, 1327*t*

- Amiodarone, 541, 1006t
- Amitriptyline:
- Medication Administration, 1545t
 - in specific conditions
 - fibromyalgia, 1487
 - headache, 1545t
 - urine color changes caused by, 832t
- AML. *See* Acute myeloid leukemia
- Amlexanox oral paste, 657t
- Amlodipine, 1162t
- Amoxicillin:
- Medication Administration, 319t
 - in specific conditions
 - endocarditis prophylaxis, 1047t
 - Lyme disease, 1477
 - otitis media, 1722
 - pneumonia, 1271t
- Amoxicillin-clavulanate, 319t, 1280
- Amoxil. *See* Amoxicillin
- Amphetamines:
- abuse, 109. *See also* Methamphetamine
 - for counteracting sedation, 189
 - effects, 109
 - for obesity, 633
 - overdose signs and treatment, 113t
 - street names, 111t
 - withdrawal signs and treatment, 110, 113t
- Amphiarthrosis, 1383t
- Amphojel. *See* Aluminum hydroxide
- Amphotec. *See* Amphotericin B
- Amphotericin B:
- indications, 318
 - Medication Administration, 450t
 - in specific conditions
 - conjunctivitis, 1694
 - corneal infections, 1697
 - fungal lung infections, 1295
 - fungal meningitis, 1566
 - fungal skin infections, 450t
- Ampicillin:
- Medication Administration, 319t
 - in specific conditions
 - endocarditis prophylaxis, 1047t
 - endocarditis treatment, 1046
 - gastroenteritis, 776
 - peritonitis, 770
 - urinary tract infection, 849
- Ampicillin/sulbactam, 1241
- Amprenavir, 358
- Ampulla of Vater, 726
- Amputation:
- causes, 1421
 - complications
 - chronic stump pain, 1423
 - contractures, 1423
 - delayed healing, 1423
 - infection, 1422–23
 - phantom pain, 1423
 - definition, 1421
 - in diabetes mellitus, 590, 1421
 - incidence, 1421
 - interdisciplinary care
 - diagnosis, 1423
 - medications, 1423–24
 - prosthesis, 1424
 - levels of, 1421, 1422f
 - nursing care
 - assessment, 1424
 - community-based care, 1426–27, 1427t
 - health promotion, 1424
 - nursing diagnoses and interventions
 - acute pain, 1424
 - disturbed body image, 1426
 - impaired physical mobility, 1426
 - risk for dysfunctional grieving, 1426
 - risk for impaired skin integrity, 1425–26
 - risk for infection, 1424–25
 - using NANDA, NIC, and NOC, 1426, 1426t
- Nursing Care Plan
- assessment, 1425t
 - critical thinking in the nursing process, 1425t
 - diagnoses, 1425t
 - evaluation, 1425t
 - expected outcomes, 1425t
 - planning and implementation, 1425t
 - in peripheral vascular disease, 1421
 - site healing, 1422, 1423f
 - terminology, 1422t
 - types, 1421–22
- Amrinone, 1034t
- Amsler grid, 1676, 1676f
- Amyl nitrite, 111, 973t
- Amylase, 612, 742. *See also* Serum amylase
- Amyloid plaques, 1618
- Amyotrophic lateral sclerosis (ALS):
- characteristics, 1645
 - complications, 1646t
 - genetic considerations, 1389t, 1513t
 - incidence, 1645
 - interdisciplinary care
 - diagnosis, 1645–46
 - medications, 1646
 - manifestations, 1645, 1646t
 - nursing care
 - community-based care, 1647
 - nursing diagnoses and interventions
 - ineffective breathing pattern, 1646
 - risk for disuse syndrome, 1646
 - pathophysiology, 1645
- Amyotrophy, 1645
- ANA. *See* American Nurses Association
- ANA (antinuclear antibody), 341, 1141
- Anabolism, 307, 613
- Anacolin. *See* Vitamin B₁₂, replacement therapy
- Anaerobes, 311t
- Anakinra, 341
- Anal fissures, 820
- Analgesics. *See also specific drugs*
- definition, 174
 - narcotic. *See* Narcotic analgesics
 - nonnarcotic, 178
 - nonsteroidal anti-inflammatory drugs. *See* Nonsteroidal anti-inflammatory drugs
 - urinary, 850t
 - WHO ladder, 177, 177f
- Anaphylactic shock:
- assessment, 279–80
 - definition, 276, 332
 - manifestations, 276, 276t
 - pathophysiology, 276
- Anaphylaxis:
- common triggers, 333t
 - definition, 276
 - epinephrine for, 337–38
 - manifestations, 332
 - pathophysiology, 332
- Anaplasia, 374
- Anaprox. *See* Naproxen sodium
- Anasarca, 209
- Anaspaz. *See* Hyoscyamine
- Anastomosed, 978
- Anbesol, 658t
- Ancef. *See* Cefazolin
- Ancobon. *See* Flucytosine
- Androgen deprivation therapy, 1786, 1787t
- Androgens, 1745
- Anemia:
- aplastic. *See* Aplastic anemia
 - assessment in light and dark skin, 426t
 - from blood loss, 1103
 - definition, 1076, 1102
 - hemolytic
 - acquired, 1109
 - causes, 1106, 1106t
 - definition, 1106
 - glucose-6-phosphate dehydrogenase anemia, 1106, 1109t
 - racial/ethnic considerations, 1106t
 - sickle cell anemia. *See* Sickle cell anemia
 - thalassemias. *See* Thalassemias
 - interdisciplinary care
 - blood transfusion, 1111
 - complementary therapies, 1111–12
 - diagnosis, 1110–11
 - focus for major anemias, 1110t
 - medications, 1111, 1112t
 - nutrition, 1111, 1111t
 - manifestations, 1102–3, 1103f
 - Multisystem Effects, 1104t
 - nursing care
 - assessment, 1112–13
 - community-based care, 1114–15
 - health promotion, 1112
 - Medication Administration, 1112t
 - nursing diagnoses and interventions
 - activity intolerance, 1113–14
 - impaired oral mucous membrane, 1114
 - risk for decreased cardiac output, 1114
 - self-care deficit, 1114
 - using NANDA, NIC, and NOC, 1114, 1115t
 - nutritional
 - folic acid deficiency. *See* Folic acid, deficiency
 - iron deficiency. *See* Iron deficiency anemia
 - vitamin B₁₂ deficiency. *See* Vitamin B₁₂, deficiency
 - pathophysiology, 1102, 1103t, 1106
 - in specific conditions
 - after gastric resection, 691
 - chronic renal failure, 916
- Anger, 300
- Anesthesia:
- conscious sedation, 63–64
 - definition, 61
 - general, 61–63
 - intraoperative awareness, 67
 - regional, 63
- Anesthesiologist, 65
- Anesthetics, local. *See* Local anesthetics
- Aneuploidy, 150t
- Aneurysm:
- aortic. *See* Aortic aneurysm
 - definition, 1170
 - femoral, 1172
 - intracranial. *See* Intracranial aneurysm
 - manifestations, 1170
 - pathophysiology, 1170, 1170f
 - popliteal, 1172, 1172f
 - types, 1170, 1592
- Angina pectoris:
- vs. acute coronary syndrome and myocardial infarction, 975t
 - course and manifestations, 970, 970t
 - definition, 969
 - interdisciplinary care
 - diagnosis, 970–71, 971f
 - medications, 973–74t
 - nitrites, 971

- Angina pectoris—*continued*
nursing care
assessment, 92
community-based care, 974
health promotion, 972
Medication Administration, 973–74*t*
nursing diagnoses and interventions
ineffective tissue perfusion: cardiac, 972
risk for ineffective therapeutic regimen
management, 972, 974
pathophysiology, 961*t*, 969–70
severity classification, 970
types, 969–70
- Angioedema, 221
- Angiography:
in aortic aneurysm, 1173
in cancer, 385
cardiac. *See* Cardiac catheterization
cerebral. *See* Cerebral angiogram
in peripheral vascular disease, 1177
principles, 385
pulmonary. *See* Pulmonary angiography
renal, 837*t*
- Angiomas, 430*t*, 443
- Angiotensin II receptor blockers (ARBs):
Medication Administration, 1033*t*, 1161*t*
in specific conditions
heart failure, 1032, 1033*t*
hypertension, 1161*t*, 1163
- Angiotensin-converting enzyme (ACE) inhibitors:
Medication Administration, 1033*t*, 1161*t*
in specific conditions
acute myocardial infarction, 988
glomerular disorders, 891
heart failure, 1032, 1033*t*
hypertension, 1161*t*, 1163
scleroderma, 1485
- Angiotensinogen, 521
- Angle-closure glaucoma. *See* Glaucoma
- Anhydrosis, 589
- Anion gap, 243, 243*f*
- Anions, 196
- Anisoylated plasminogen streptokinase activator complex (APSAC), 988
- Ankle:
fracture, 1416
physical assessment, 1394*t*
- Ankle-brachial blood pressure index (ABI), 965
- Ankylosing spondylitis:
definition, 1469
genetic considerations, 1469
incidence, 1469
interdisciplinary care, 1470
manifestations, 1470
nursing care, 1470
pathophysiology, 1470
- Annuloplasty, 1060
- Annulus, 1054
- Anorectal abscess, 820
- Anorectal disorders:
anal fissure, 820
anorectal abscess, 820
anorectal fistula, 820–21
hemorrhoids. *See* Hemorrhoids
nursing care, 821
pilonidal disease, 821
- Anorectal fistula, 820–21
- Anorexia, 380, 677
- Anorexia nervosa:
complications, 651*t*
interdisciplinary care
diagnosis, 651–52
treatment, 652
manifestations, 650, 651*t*
nursing care, 652
- Anorexia-cachexia syndrome, 380, 380*f*
- Anorgasmia:
definition, 1758
in health assessment interview, 1758
nursing care, 1795
pathophysiology, 1795
- Anosmia, 1519*t*
- Anovulation, 1802
- ANP. *See* Atrial natriuretic peptide
- Ansa. *See* Flurbiprofen
- Antabuse. *See* Disulfiram
- Antacids:
adverse/side effects, 685
magnesium-containing, 236*t*
Medication Administration, 666*t*
preoperative use and nursing implications, 51*t*
in specific conditions
cirrhosis, 716
gastritis, 666*t*
gastroesophageal reflux disease, 665, 666*t*
peptic ulcer disease, 666*t*, 685
- Anteflexion, uterus, 1805, 1806*f*
- Antegrade amnesia, 1559
- Antegrade pyelography, 904
- Anterior descending artery, 939*f*, 958
- Anterior myocardial infarction, 984. *See also*
Acute myocardial infarction
- Anterior syndrome, 1597*t*. *See also* Spinal cord injury
- Anteversion, uterus, 1805, 1806*f*
- Anthrax, 128*t*, 1293, 1294
- Anthranilates, 465*t*
- Anthranilic acids, 178*t*
- Anthracene, 128*t*, 1293, 1294
- Anthropometric assessment:
body weight, 620–21*t*
midarm circumference, 621*t*, 622*f*, 622*t*
midarm muscle circumference, 622*t*
triceps skinfold thickness, 621*t*
waist-to-hip ratio, 622*t*
- Antiandrogens, 1787*t*
- Antibiotics. *See also specific drugs*
antitumor, 391
characteristics, 318
for endocarditis prophylaxis, 1047*t*
Medication Administration, 319–21*t*
monitoring blood levels, 316
Nursing Research: antibiotics regimens, 310*t*
preoperative use and nursing implications, 62*t*
resistant microorganisms, 313–14
in specific conditions
acne, 458
acute bronchitis, 1266
appendicitis, 767
bacterial meningitis, 1566
chlamydia, 1845
diverticulitis, 816
endocarditis, 1046
epiglottitis, 1241
gastroenteritis, 776
glomerular disorders, 890
gonorrhea, 1846
H. pylori infection, 684
lung abscess, 1280
osteomyelitis, 1479
otitis media, 1722
pelvic inflammatory disease, 1851
peritonitis, 770
pharyngitis, 1239
pneumonia, 1271–72, 1271*t*
prostatitis, 1777
rheumatic fever, 1043
skin disorders, 441*t*, 447
urinary tract infection, 849
as surgical risk factor, 58*t*
topical. *See* Topical medications, antimicrobial
- Antibodies:
classes, 291
definition, 291
in immune response, 295–97, 296*f*, 297*f*
monoclonal. *See* Monoclonal antibodies
structure, 296, 297*f*
- Antibody-mediated (humoral) immune response, 291, 295–97, 296*f*, 297*f*
- Anticholinergics:
Medication Administration, 871*t*, 1327–28*t*
preoperative use and nursing implications, 62*t*
side effects, 871, 875
in specific conditions
acute respiratory failure, 1355
asthma, 1326, 1327–28*t*
diarrhea, 756*t*
irritable bowel syndrome, 762
neurogenic bladder, 871, 871*t*
urinary incontinence, 875
urinary retention, 869
- Anticholinesterases. *See* Cholinesterase inhibitors
- Anticipation, in genetics, 155
- Anticipatory grieving, 86, 96
- Anticoagulants:
bleeding risk with, 1349
Medication Administration, 1189–90*t*
non-heparin, 1141
in specific conditions
acute arterial occlusion, 1184
acute myocardial infarction, 988
aortic aneurysm, 1173
cardiomyopathy, 1067
ischemic stroke, 1585
pulmonary embolism, 1349
pulmonary hypertension, 1353
valvular heart disease, 1060
venous thrombosis, 1188, 1189–90*t*
as surgical risk factor, 58*t*, 59
- Anticonvulsants. *See* Antiepileptic drugs
- Antidepressants. *See also* Monoamine oxidase inhibitors; Selective serotonin reuptake inhibitors; Tricyclic antidepressants
for eating disorders, 652
for irritable bowel syndrome, 763
for substance abuse/withdrawal treatment, 114*t*
as surgical risk factor, 58*t*
- Antidiarrheal medications, 756*t*, 762
- Antidiuretic hormone (ADH):
in blood pressure regulation, 1155
in body fluid regulation, 201–2, 202*f*
in cancer, 380
for esophageal varices, 718
functions, 520
in heart failure, 1025
laboratory tests, 380*t*
in sodium balance regulation, 214
in urine dilution/concentration, 834
- Antidysrhythmics:
for acute myocardial infarction, 988
for cardiac dysrhythmias, 1005–6, 1006*t*
Medication Administration, 1006*t*
- Antiemetics, 62*t*, 672, 673*t*
- Antiepileptic drugs:
drug interactions with, 1551*t*
Medication Administration, 1550*t*
in specific conditions
intracranial aneurysm, 1593
pain management, 179

- seizure disorders, 1550t
 substance abuse/withdrawal, 114t
 trigeminal neuralgia, 1656
- Antifungal agents, 318, 450t, 658t
- Antigen:
 characteristics, 290
 definition, 276, 290
 detection methods, 316, 317t
 immune response to, 290–91
 as tumor marker, 384, 384t
- Antigen-binding fragment, 296, 297f
- Antigen-presenting cells (APCs), 289. *See also* Dendritic cells
- Antiglutamate, 1646
- Antihemophilic factor, 1082t
- Antihistamines:
 Medication Administration, 673t, 1230t
 in specific conditions
 hypersensitivity reactions, 337
 nausea and vomiting, 672, 673t
 upper respiratory infections, 1230, 1230t
- Antihypertensives:
 in chronic renal failure, 919
 classes, 1160, 1163
 Medication Administration, 1161–62t
 regimens, 1163
 sites of action, 1160t
 as surgical risk factor, 58t
- Antilymphocyte globulin (ALG), 344, 346t
- Antimetabolites, 390, 1483t. *See also* Chemotherapy
- Antimicrobials:
 antibiotics. *See* Antibiotics
 antifungal agents. *See* Antifungal agents
 antiparasitics. *See* Antiparasitic agents
 antivirals. *See* Antivirals
 classification, 318
 mechanisms of action, 318
 selecting, 318
 topical, in burns, 500, 500t
- Antiminth. *See* Pyrantel pamoate
- Antinuclear antibody (ANA), 341, 1141
- Antiparasitic agents, 321, 321t
- Antiplatelet drugs, 976t, 1177, 1585
- Antiprotozoal agents, 780t
- Antipsychotics, 1643
- Antiretroviral nucleoside analogs, 356, 357t, 358
- Antispas. *See* Dicyclomine
- Antispasmodics, 1600t
- Antistreptolysin A (ASO) titer:
 in glomerular disorders, 889
 in rheumatic fever, 1043
 in rheumatic heart disease, 1043t
- Antithymocyte globulin (ATG), 344, 346t
- Antituberculosis drugs:
 adverse effects, 1288, 1288t
 dosage, 1288t
 Medication Administration, 1288–89t
 prophylactic, 1287
 regimens, 1287–88
- Antitumor antibiotics, 391
- Antivert. *See* Meclizine
- Antivirals. *See also specific drugs*
 characteristics, 318
 Medication Administration, 322t, 658t
 in specific conditions
 Bell's palsy, 1658
 influenza, 1234
 stomatitis, 658t
- Antral irrigation, 1237
- Anturane. *See* Sulfinpyrazone
- Anus:
 anatomy and functions, 743, 743f
 physical assessment, 750f, 750t
- Anxiety:
 levels of, 135t
 pain perception and, 176
 preoperative management, 61, 62t
- Anzemet. *See* Dolasetron
- Aorta:
 aneurysm. *See* Aortic aneurysm
 coarctation of, 1167
 dissection. *See* Aortic dissection
 physical assessment, 1098f, 1098t
- Aortic aneurysm:
 abdominal, 1172
 dissection. *See* Aortic dissection
 interdisciplinary care
 diagnosis, 1173
 medications, 1173
 surgery, 1173, 1174f
 manifestations, 1170
 nursing care
 assessment, 1173–74
 community-based care, 1175–76
 nursing diagnoses and interventions
 anxiety, 1175
 risk for ineffective tissue perfusion, 1174–75
 risk for injury, 1175
 postoperative, 1174t
 preoperative, 1174t
 pathophysiology, 1170, 1170f
 thoracic, 1171–72, 1171t, 1172t
- Aortic dissection:
 complications, 1171t, 1173
 manifestations, 1171t, 1172–73
 pathophysiology, 1171f
 risk factors, 1172
- Aortic regurgitation. *See also* Valvular heart disease
 causes, 1058
 manifestations, 1059
 murmur characteristics, 1055t
 pathophysiology, 1058–59, 1058f
- Aortic stenosis. *See also* Valvular heart disease
 manifestations, 1057–58
 murmur characteristics, 1055t
 pathophysiology, 1057, 1058f
- Aortic valve, 937f, 938, 1054
- APCs (antigen-presenting cells), 289. *See also* Dendritic cells
- Aphasia:
 in Alzheimer's disease, 1620
 causes, 1518t
 definition, 1518t, 1583
 types, 1583
- Aphonia, 1241
- Aphthasol. *See* Amlexanox oral paste
- Aphthoid lesion, 785
- Aphthous ulcer, 657t. *See also* Stomatitis
- Apical impulse, 952–53t, 953f
- Aplastic anemia:
 interdisciplinary care, 1110t
 manifestations, 1110, 1138
 pathophysiology, 1109–10
 in sickle cell disease, 1109
 types, 1109
- Apligraf, 504
- Apnea:
 causes, 1223t
 definition, 1223t
 sleep, 1250. *See also* Obstructive sleep apnea
- Apneustic breathing, 1530, 1530t
- Apocrine sweat glands, 424
- Apo-Doxy. *See* Doxycycline
- Apo-K. *See* Potassium chloride
- Appendectomy, 766f, 767
- Appendicitis:
 complications, 767
 definition, 766
 interdisciplinary care
 diagnosis, 767
 medications, 767
 surgery, 767
 manifestations, 766
 nursing care
 assessment, 767
 community-based care, 768–69
 nursing diagnoses and interventions
 acute pain, 768
 risk for infection, 767–68
 using NANDA, NIC, and NOC, 768, 769t
 Nursing Care Plan
 assessment, 768t
 critical thinking in the nursing process, 768t
 diagnoses, 768t
 evaluation, 768t
 expected outcomes, 768t
 planning and implementation, 768t
 pathophysiology, 766, 766f
 Appetite suppressants, 633, 634t
 Apraclonidine, 1710t
 Apraxia, 1582, 1620
 Aprazone. *See* Sulfinpyrazone
 Apresoline. *See* Hydralazine
 APSAC (anisoylated plasminogen streptokinase activator complex), 988
- Aquacare, 441t
- Aquaphor, 441t
- Aqueous humor, 1671–72
- Aralen. *See* Chloroquine
- Aramine. *See* Metaraminol
- Arava. *See* Leflunomide
- Arbovirus encephalitis, 1565, 1565t
- ARBs. *See* Angiotensin II receptor blockers
- Ardeparin, 1189t
- ARDS. *See* Acute respiratory distress syndrome
- Aredia. *See* Pamidronate
- Areflexia, 1598
- Argatroban, 1141
- Aricept. *See* Donepezil
- Aromatherapy, 1231
- Around-the-clock (ATC) dosing, 181
- Arousal, 1529–30. *See also* Altered level of consciousness
- Arrhythmogenic, 985
- Arsenic, as cancer risk factor, 372t
- Artane. *See* Trihexyphenidyl
- Arterial blood gases (ABGs):
 interpretation, 240t
 normal values, 240t, 1217t
 physiology, 1216, 1216f
 purpose and description, 1217t
 related nursing care, 1217t
 in specific conditions
 acid–base balance assessment, 239, 240t
 acute myocardial infarction, 986
 acute renal failure, 904
 acute respiratory distress syndrome, 1367
 acute respiratory failure, 1355
 altered level of consciousness, 1533
 asthma, 1324
 burns, 500
 chronic obstructive pulmonary disease, 1334
 fluid volume excess, 213
 gastroenteritis and diarrhea, 776t
 heart failure, 1027
 hypokalemia, 221
 increased intracranial pressure, 1538
 inhalation injury, 1306

- Arterial blood gases (ABGs)—*continued*
 metabolic acidosis, 242*t*, 244
 metabolic alkalosis, 242*t*, 246
 pneumonia, 1271
 pulmonary edema, 1040
 pulmonary embolism, 1349
 respiratory acidosis, 242*t*, 247
 respiratory alkalosis, 242*t*, 250
 shock, 276–77
- Arterial insufficiency, 426*t*
- Arterial line (art line, A line), 1029–30
- Arteries:
 anatomy, 1082, 1083*f*, 1085*f*
 assessment, 1094–95*t*
 cerebral, 1507, 1508*f*
 physiology, 1082, 1085
- Arteriography, 837*t*, 1184
- Arterioles, 1082
- Arteriovenous fistula, 908, 909*f*
- Arteriovenous graft, 908
- Arteriovenous malformation:
 characteristics, 1595
 interdisciplinary care, 1595
 nursing care, 1595
 pathophysiology, 1595
- ArthriCare. *See* Counterirritants
- Arthritis. *See also* Osteoarthritis
 definition, 1433
 gouty. *See* Gout
 reactive. *See* Reactive arthritis
 rheumatoid. *See* Rheumatoid arthritis
 septic. *See* Septic arthritis
- Arthrocentesis, 1387*t*
- Arthropan. *See* Choline salicylate
- Arthroscopy, 1387*t*, 1452
- Asacol. *See* Mesalamine
- Asbestos, as cancer risk factor, 372*t*
- Asbestosis, 1345
- Ascariasis, 781*t*
- Ascending colon, 742*f*, 743
- Ascending contrast venography, 1188
- Aschoff bodies, 1042
- Ascites:
 in cirrhosis, 711, 715*t*
 definition, 209, 704
 in fluid volume excess, 209
 in hepatocellular failure, 704
 in ovarian cancer, 1818*t*
 in pancreatitis, 727
 physical assessment, 626*f*, 626*t*
 treatment
 diuretics, 716, 717*t*
 paracentesis, 717, 718*f*, 719*t*
- Ascorbic acid. *See* Vitamin C
- Asian Americans:
 end-of-life practices, 89
 lactate deficiency incidence, 798*t*
 osteoporosis incidence, 1434, 1434*t*
 substance use, 105, 105*t*
 tuberculosis incidence, 1281*t*
- ASO titer. *See* Antistreptolysin A (ASO) titer
- Asparaginase, 1123*t*
- Aspart, 571*t*
- Aspartame, 579
- Aspercreme. *See* Salicylates
- Aspergillosis, 1294
- Aspergillus*, 1294
- Asphyxiation, 1305
- Aspiration pneumonia, 1270. *See also* Pneumonia
- Aspirin:
 adverse/side effects, 1463
 effects, 306
 factors in selecting, 178*t*
 low-dose therapy
 for angina, 972
 contraindications, 968
 for coronary heart disease risk reduction, 968
 in diabetes mellitus, 576
 for peripheral vascular disease, 1177
 for stroke prevention, 1585*t*
 Medication Administration, 179*t*, 976*t*
 in specific conditions
 headache, 1546*t*
 rheumatoid arthritis, 1463–64, 1464*t*
 systemic lupus erythematosus, 1473
- Assessment. *See also specific body systems*
 critical thinking skills in, 7*t*
 data collection in, 8
 overview, 8
 skills needed for, 8
- Assist-control mode ventilation (ACMV),
 1358, 1359*t*
- Assistive listening device, 1731
- Astereognosis, 1620
- Asterixis, 715, 715*f*, 715*t*
- Asthma:
 classification, 1323*t*
 cough-variant, 1324
 definition, 1321
 genetic considerations, 1220*t*
 incidence, 1321–22
 interdisciplinary care
 complementary therapies, 1326
 diagnosis, 1324
 disease monitoring, 1324
 medications
 administration, 1324, 1325*t*, 1327–28*t*
 anti-inflammatory agents, 1326, 1328*t*
 bronchodilators, 1325–26, 1327–28*t*
 leukotriene modifiers, 1326, 1328*t*
 stepwise approach, 1324, 1325*t*
 preventive measures, 1324
 manifestations, 1323, 1323*t*
 mortality rate, 1322
 nursing care
 assessment, 1326
 client teaching, 1325*t*
 community-based care, 1330
 health promotion, 1326
 Medication Administration, 1327–28*t*
 nursing diagnoses and interventions
 anxiety, 1329–30
 ineffective airway clearance, 1329
 ineffective breathing pattern, 1329
 ineffective therapeutic regimen
 management, 1330
 pathophysiology
 attack triggers, 1322
 overview, 1322, 1323*f*
 responses, 1322–23
 physiology review, 1322
 risk factors, 1321–22
- Astigmatism, 1696
- Astroblastoma, 1570*t*. *See also* Brain tumors
- Astrocytes, 1628*t*
- Astrocytoma, 1570*t*. *See also* Brain tumors
- Asynchronous pacing, 1010*t*. *See also* Pacemakers
- Asystole, 1015
- Atacand. *See* Candesartan
- Atarax. *See* Hydroxyzine
- Ataxia, 1522*t*
- Ataxic respirations, 1530, 1530*t*
- ATC (around-the-clock) dosing, 181
- Atelectasis:
 in acute respiratory distress syndrome, 1367
 causes, 1343
 definition, 1223*t*, 1343
 manifestations, 1343–44
 nursing care, 1344
 postoperative
 assessment findings, 76
 nursing care, 76
 respiratory rate in, 1223*t*
 treatment, 1344
- Atenolol:
 Medication Administration, 973*t*, 1161*t*, 1545*t*
 in specific conditions
 acute myocardial infarction, 988
 angina, 973*t*
 headache, 1545*t*
 hypertension, 1161*t*
- ATG (antithymocyte globulin), 344, 346*t*
- Atherectomy, 977
- Atherogenic, 959
- Atheromas, 958, 959
- Atherosclerosis:
 coronary artery. *See* Coronary heart disease
 definition, 1176
 genetic considerations, 1089*t*
 pathophysiology, 959, 960*t*
 peripheral. *See* Peripheral vascular disease
- Athlete's foot, 448, 448*f*, 449
- Ativan. *See* Lorazepam
- Atopic dermatitis, 456–57, 457*f*. *See also* Dermatitis
- Atorvastatin, 967*t*
- ATRA (all-*trans* retinoic acid), 1123*t*
- Atracurium besylate, 1356*t*
- Atria, 938
- Atrial fibrillation:
 causes, 1001
 ECG characteristics, 998*t*, 1001
 management, 998*t*
 manifestations, 1001
 stroke risk and, 1579
 in valvular heart disease, 1060
- Atrial flutter:
 causes, 1001
 ECG characteristics, 998*t*, 1001
 management, 998*t*
 pathophysiology, 1001
 types, 1001
- Atrial kick, 996
- Atrial natriuretic peptide (ANP):
 in blood pressure regulation, 1155
 in body fluid regulation, 202
 in heart failure, 1025, 1027
 in sodium balance regulation, 214
- Atrioventricular (AV) conduction blocks. *See also*
 Cardiac dysrhythmias
 causes, 1003
 ECG characteristics, 999*t*
 management, 999*t*
 manifestations, 1003
 pathophysiology, 996
- Atrioventricular (AV) dissociation, 1003
- Atrioventricular (AV) node, 941, 941*f*
- Atrioventricular (AV) sequential pacing, 1009. *See also*
 Pacemakers
- Atrioventricular (AV) valves, 938
- Atromid-S. *See* Clofibrate
- Atropa belladonna, 1326
- Atrophic rhinitis, 1229
- Atrophic vaginitis, 1843*t*
- Atrophy, skin, 433*t*
- Atropine sulfate:
 adverse/side effects, 869
 Medication Administration, 1327–28*t*
 preoperative use and nursing implications, 62*t*
 in specific conditions
 asthma, 1327–28*t*
 diarrhea, 756*t*
- Atrovent. *See* Ipratropium bromide

- Atypical pneumonia, 1269, 1270*t*. *See also* Pneumonia
- Audiometry, 1684*t*, 1730
- Auditory brainstem response, 1684*t*
- Auditory evoked potential, 1684*t*
- Augmentin. *See* Amoxicillin-clavulanate
- Auranofin, 1465*t*
- Auricles:
anatomy, 1680, 1682*f*
physical assessment, 1688
- Aurothioglucose, 1465*t*
- Auscultatory gap, 1092*t*
- Autograft:
in burns, 503, 503*f*
definition, 342
types, 342
- Autoimmune disorders. *See also specific disorders*
examples, 330*t*
interdisciplinary care
diagnosis, 340–41
medications, 341
nursing care
community-based care, 341
diagnoses, 341
pathophysiology, 340
- Autoimmune gastritis, 678
- Autoinoculation, 1839
- Autologous bone marrow transplant, 1124. *See also* Bone marrow transplant
- Autologous peripheral blood stem cell transplant (PBSCT), 398, 1132, 1333*t*. *See also* Stem cell transplant
- Automatic external defibrillator (AED):
for cardiac arrest, 1016, 1016*f*
for cardiac dysrhythmias, 1008, 1008*t*
- Automaticity, 995
- Automatisms, 1549
- Autonomic dysreflexia, 1599
- Autonomic nervous system:
parasympathetic division. *See* Parasympathetic nervous system
physiology, 1511
sympathetic division. *See* Sympathetic nervous system
- Autonomic neuropathies, 589
- Autoregulation, 1580
- Autosomal dominant inheritance, 153, 153*f*, 153*t*
- Autosomal recessive inheritance, 153–54, 153*f*, 154*t*
- Autosomes, 149
- AV. *See* Atrioventricular
- Avage. *See* Tazarotene gel
- Avandia. *See* Rosiglitazone
- Avapro. *See* Irbesartan
- Avastin, 1825
- Aveeno. *See* Oatmeal
- Avian influenza, 1232*t*. *See also* Influenza
- Avodart. *See* Dutasteride
- Avonex. *See* Beta interferon
- Avulsed fracture, 1401, 1402*f*
- Axial loading, 1596*f*, 1597
- Axid. *See* Nizatidine
- Axilla:
lymph node dissection, 1825
physical assessment, 1749*t*, 1762*f*, 1762*t*
- Axon, 1504, 1504*f*
- Azacitidine, 1116
- Azathioprine:
adverse effects, 344
Medication Administration, 345, 1474*t*, 1631*t*
site of action, 344*f*
in specific conditions
inflammatory bowel disease, 786
multiple sclerosis, 1627, 1631*t*
in organ transplantation, 344, 921
systemic lupus erythematosus, 1474*t*
- Azelaic acid, 458
- Azithromycin:
Medication Administration, 320*t*
in specific conditions
chlamydia, 1845, 1846
otitis media, 1722
pneumonia, 1271*t*
- Azmacor. *See* Triamcinolone acetonide
- Azopt. *See* Brinzolamide
- Azotemia, 886
- AZT. *See* Zidovudine
- Azulfidine. *See* Sulfasalazine
- ## B
- B cells. *See* B lymphocytes
- B lymphocytes (B cells):
in antibody-mediated immune response, 295, 295*f*
development, 290, 290*f*
functions, 288*t*
location, 288*t*
- Babinski reflex, 1524*f*, 1524*t*
- Bacillary dysentery, 774*t*, 775
- Bacillus anthracis*, 128*t*, 1293
- Bacillus Calmette-Guérin* (BCG), 396, 863, 1287
- Bacitracin, 441*t*, 1694, 1697
- Back pain. *See* Low back pain
- Backward effects, heart failure, 1026
- Baclofen, 1600*t*, 1631*t*, 1656
- Bacteria. *See also specific bacteria*
characteristics, 311*t*
in gastroenteritis, 774–75, 774*t*. *See also* Gastroenteritis
in pneumonia, 1267*t*. *See also* Pneumonia
in skin infections. *See* Skin infections/infestations, bacterial
in urinary tract infections, 846. *See also* Urinary tract infection
- Bacterial meningitis. *See also* Central nervous system infections
complications, 1564
manifestations, 1564, 1564*t*
Nursing Care Plan
assessment, 1567*t*
critical thinking in the nursing process, 1567*t*
diagnoses, 1567*t*
evaluation, 1567*t*
expected outcomes, 1567*t*
planning and implementation, 1567*t*
pathophysiology, 1564
- Bacterial translocation, 496
- Bacterial vaginosis, 1842, 1843*t*
- Bactericidal agent, 318. *See also* Antibiotics
- Bacteriostatic agent, 318. *See also* Antibiotics
- Bactrim. *See* Trimethoprim-sulfamethoxazole
- Bagging, 111
- BAL (blood alcohol level), 108, 112
- Balanced suspension traction, 1408, 1409*f*
- Balanitis, 449*t*, 1749
- Balanoposthitis, 1749
- Balloon dilation, lower esophageal sphincter, 668, 668*f*
- Balloon tamponade, for esophageal varices, 718–19, 719*f*
- Ballotement, 1395*f*, 1395*t*
- Balnetar. *See* Coal tar derivatives
- Balsalazide, 786
- Banding, for esophageal varices, 718*t*
- Bands, 288
- Barbiturates:
abuse, 108
overdose signs and treatment, 113*t*
street names, 111*t*
withdrawal signs and treatment, 113*t*
- Bariatric surgery:
benefits, 637
complications, 638
diet following, 638*t*
indications, 636
procedures, 637–38, 637*f*
- Barium enema, 744*t*, 758
- Barium sulfate, 615*t*
- Barium swallow. *See* Upper gastrointestinal (GI) series
- Barotrauma, 1360
- Bartholin's glands:
cysts, 1808, 1809*t*
location and function, 1751*t*, 1752, 1752*f*
physical assessment, 1763*f*, 1763*t*
- Basal cell cancer, skin, 462–63, 462*t*, 463*f*. *See also* Skin cancer
- Basal metabolic rate (BMR), 631
- Base excess (BE), 239, 240*t*
- Base rate, 1010*t*
- Bases, 238
- Basic life support (BLS), 1016, 1016*f*, 1017*t*
- Basilar fracture, skull, 1555, 1555*t*. *See also* Skull fracture
- Basiliximab, 344, 345–46*t*
- Basopenia, 307*t*
- Basophilia, 307*t*
- Basophils:
abnormal, possible causes, 307*t*, 387*t*
characteristics, 288
development, 289*f*, 1077*f*
functions, 288, 288*t*
location, 288*t*
normal values, 307*t*, 387*t*, 1118*t*
- Baths, therapeutic, 441*t*
- Battle's sign, 1555
- B-cell lymphomas, 1130*t*. *See also* Non-Hodgkin's lymphoma
- BCG (*Bacillus Calmette-Guérin*), 396, 863, 1287
- BCGLive. *See* *Bacillus Calmette-Guérin*
- B-complex vitamins. *See* Vitamin B complex
- B-DAST (Brief Drug Abuse Screening Test), 117
- BE (base excess), 239, 240*t*
- Beau's line, 436*t*
- Becker's muscular dystrophy, 1459*t*
- Beclomethasone dipropionate, 1328*t*
- Beclovent. *See* Beclomethasone dipropionate
- Bedoz. *See* Vitamin B₁₂, replacement therapy
- Behavior modification:
for eating disorders, 652
for obesity, 636, 637*t*
- Belladonna alkaloids, 756*t*
- Bell's palsy:
characteristics, 1657
incidence, 1657
interdisciplinary care, 1658
manifestations, 1657–58, 1658*f*, 1658*t*
nursing care, 1658
pathophysiology, 1657
- Benadryl. *See* Diphenhydramine
- Benazepril, 1161*t*
- Bence Jones proteins, 1136
- Bendroflumethiazide, 210*t*
- Benemid. *See* Probenecid
- Bengay. *See* Counterirritants
- Benicar. *See* Olmesartan
- Benign prostatic hyperplasia (BPH):
complications, 1778
definition, 1777
interdisciplinary care
complementary and alternative therapies, 1781
diagnosis, 1778

- Benign prostatic hyperplasia (BPH)—*continued*
 medications, 1778–79
 minimally invasive procedures, 1781
 surgery
 laser, 1781
 minimally invasive, 1779
 open, 1779, 1779f
 transurethral, 1779, 1779f
 manifestations, 1778, 1778f, 1778t
 nursing care
 of client having prostatectomy
 perineal, 1781t
 postoperative, 1780t
 preoperative, 1780t
 retropubic, 1781t
 suprapubic, 1781t
 transurethral resection, 1780t
 community-based care, 1782
 discharge instructions after prostate surgery, 1783t
 nursing diagnoses and interventions
 deficient knowledge, 1781–82
 risk for imbalanced fluid volume, 1782, 1782t
 risk for infection, 1782
 urinary retention, 1782
 pathophysiology, 1777–78
 risk factors, 1777
 urinary retention in, 869
- Bentyl. *See* Dicyclomine
- Benzocaine spray, 657
- Benzodiazepines:
 abuse, 108
 overdose signs and treatment, 113t
 preoperative use and nursing implications, 62t
 street names, 111t
 for substance abuse/withdrawal treatment, 114t
 withdrawal signs and treatment, 113t
- Benzophenones, 465t
- Benzopyrene, as cancer risk factor, 372t
- Benzoyl peroxide, 458
- Benzotropine, 1638t
- Bepriidil, 973–74t
- Berberine, 701
- Bereavement, 92
- Bernstein (acid perfusion) test, 615t
- Berry aneurysm, 1170, 1171f, 1592
- Best disease, 1674t
- Beta cells, pancreas:
 functions, 521, 564
 genetic defects, 566
 in type 1 diabetes mellitus, 565
- Beta interferon, 299t, 1631t. *See also* Interferon(s)
- β_2 -agonists. *See* Adrenergic stimulants
- Beta-amyloid, 1618
- Beta-blockers:
 Medication Administration, 973t, 1006t, 1161–62t
 in specific conditions
 acute myocardial infarction, 988
 angina, 971–72, 973t
 aortic aneurysm, 1173
 cardiac dysrhythmias, 1006, 1006t
 cardiomyopathy, 1067
 headache, 1545t
 heart failure, 1032
 hypertension, 1161–62t, 1163
 topical
 in glaucoma, 1709, 1710t
 Medication Administration, 1710t
- Betagan. *See* Levobunolol
- Beta-lactamase inhibitors, 320t
- Betapace. *See* Sotalol
- Betaseron. *See* Beta interferon
- Beta-thalassemia major, 1109. *See also* Thalassemias
- Beta-thalassemia minor, 1109. *See also* Thalassemias
- Betaxolol, 1161t, 1710t
- Bethanechol chloride, 869, 870, 871t
- Bethesda system, 1813t
- Betoptic. *See* Betaxolol
- Bicarbonate (HCO_3^-):
 in body fluid compartments, 197f
 serum levels
 in gastroenteritis and diarrhea, 776t
 in metabolic acidosis, 242, 242t
 in metabolic alkalosis, 242t, 245
 normal values, 198t, 239, 240t
- Bicarbonate-carbonic acid buffer system, 238–39, 238f
- Biceps reflex, 1523f
- Bicitra. *See* Sodium citrate
- Bicuspid valve, 937f, 938. *See also* Mitral valve
- BiDil. *See* Hydralazine/isosorbide
- Bifurcate, 959
- Bigeminal pulse, 1094t
- Biguanides, 578t
- Bile, 612
- Bile acid sequestrants, 967t, 968
- Bilevel ventilation (BiPAP), 1358
- Biliary colic, 698. *See also* Gallstones
- Biliopancreatic diversion, 637
- Bilirubin:
 direct (conjugated), 699t
 indirect (unconjugated), 699t
 serum (total). *See* Serum bilirubin
- Billroth I (gastroduodenostomy), 689, 689f
- Billroth II (gastrojejunostomy), 689, 689f
- Bimatoprost, 1710t
- Binge-eating disorder:
 complications, 651t
 interdisciplinary care
 diagnosis, 651–52
 treatment, 652
 manifestations, 651, 651t
 nursing care, 652
- Biobrane, 503
- Bioelectrical impedance, 632, 642, 644
- Biofeedback:
 for nausea and vomiting, 672
 for pain management, 185
- Biologic dressing, 503
- Biological response modifiers (biologicals), 341
- Biopsy:
 breast, 1755, 1757t, 1824, 1824f
 cervical, 1758t
 endometrial, 1757t
 endomyocardial, 1049
 kidney. *See* Renal biopsy
 liver, 617t, 716
 lung. *See* Lung biopsy
 lymph nodes. *See* Lymph nodes, biopsy
 myocardial, 1067
 prostate, 1746t
 skin, 428t
 types, 388t
 urease test, 684
- Biosynthetic dressing, 503–4
- Bioterrorism:
 agents, 128t, 314
 definition, 127
 surveillance, 127
- Biotherapy, 396. *See also* Immunotherapy
- Biotin, 609t
- BiPAP (bilevel ventilation), 1358
- Biperidin, 1638t
- Bisacodyl, 759–60t
- Bisco-Lax. *See* Bisacodyl
- Bismuth subsalicylate, 685, 756t
- Bisoprolol, 1161t
- Bisphosphonates:
 Medication Administration, 1442t
 in specific conditions
 bony metastases, 181
 hypercalcemia, 232
 multiple myeloma, 1137
 osteoporosis, 1436
 Paget's disease, 1442, 1442t
- Bitolterol, 1327t
- Black cohosh, 1796, 1800
- Black lung disease, 1345
- Blacks/African Americans:
 asthma mortality rate, 1322
 breast cancer
 incidence and mortality, 1822t
 Nursing Research: improving diagnosis and treatment, 1829t
 cancer incidence and mortality rates, 369, 370t
 diabetes mellitus risk and incidence, 564t
 end-of-life practices, 89
 heart failure
 incidence, 1023t
 treatment, 1032
 hypertension prevalence, 963, 1157t
 inflammatory bowel disease incidence, 782t
 integumentary system, 427t
 lactate deficiency incidence, 798t
 obesity prevalence, 631t
 osteoarthritis, 1449t
 osteoporosis incidence, 1434, 1434t
 sickle cell anemia, 1106–7, 1106t, 1107t
 stroke risk factors, 1580t
 substance use, 105, 105t
 tuberculosis incidence, 1281t
- Bladder:
 anatomy, physiology, and functions, 834–35, 834f, 869
 cancer. *See* Bladder cancer
 physical assessment, 843t
- Bladder cancer:
 incidence, 862
 interdisciplinary care
 diagnosis, 863
 medications, 863
 radiation therapy, 863
 surgery, 863, 863f, 863t, 864t
 manifestations, 863
 nursing care
 assessment, 865
 community-based care, 868
 health promotion, 865
 nursing diagnoses and interventions
 disturbed body image, 868
 impaired urinary elimination, 865–66
 risk for impaired skin integrity, 866–67
 risk for infection, 868
 stoma care, 868t
- Nursing Care Plan
 assessment, 867t
 critical thinking in the nursing process, 867t
 diagnoses, 867t
 evaluation, 867t
 expected outcomes, 867t
 planning and implementation, 867t
 pathophysiology, 861–62, 861f
 risk factors, 862
 staging, 863t
- Bladder neck suspension:
 nursing care, 876t
 procedure, 875

- Bladder retraining, 871
 Blast injuries, 129t, 131
Blastomyces dermatitidis, 1294
 Blastomycosis, 1294
 Bleeding precautions, 722t
 Bleeding time, 386t
 Blenoxane. *See* Bleomycin
 Bleomycin:
 adverse/side effects, 393t
 nursing implications, 393t
 in specific conditions
 bone tumors, 1483t
 laryngeal cancer, 1254
 testicular cancer, 1775
 target malignancies, 393t
 Blepharitis, 1700
 Blepharoplasty, 479
 Blindness. *See* Vision, impairments
 Blocadren. *See* Timolol
 Blood. *See* Hematologic system
 Blood alcohol level (BAL), 108, 112
 Blood cultures, 316, 1046
 Blood flow, 1082
 Blood gases. *See* Arterial blood gases
 Blood glucose:
 in altered level of consciousness, 1533
 diagnostic tests
 fasting blood sugar, 386t, 526t, 569
 fasting plasma glucose, 569
 glycosylated hemoglobin, 526t
 oral glucose tolerance test, 526t, 569
 perioperative, 60t
 homeostasis, 564, 565f
 self-monitoring, 570–71, 570f
 Blood pool imaging, 945t
 Blood pressure:
 age-related changes, 1091t
 assessment
 abnormal findings, 1092–93t. *See also*
 Hypertension; Hypotension
 guidelines, 1092t
 technique/normal findings, 1092–93t
 classification, 1156t
 definition, 1085, 1154
 factors affecting, 1092t, 1154–55, 1155f
 regulation, 1085, 1154
 segmental measurements, 1177
 Blood transfusion:
 hypocalcemia and, 228
 Medication Administration, 264t
 nursing diagnoses and interventions, 339
 in specific conditions
 anemia from blood loss, 1111
 shock, 279
 trauma, 262
 Blood types, 262, 263t, 336
 Blood urea nitrogen (BUN):
 abnormal, possible causes, 386t
 normal values, 386t, 890t
 purpose and description, 835t
 related nursing care, 835t
 in specific conditions
 acute renal failure, 904
 chronic renal failure, 918
 glomerular disorders, 889–90, 890t
 neurogenic bladder, 870
 shock, 277
 Blood–brain barrier, 1507
 Blowout fracture, orbital, 1702
 BLS (basic life support), 1016, 1016f, 1017t
 Blueberry juice, for urinary tract infection, 851
 Blunt trauma. *See also* Trauma
 definition, 256
 in disasters, 129t
 effects, 256
 eyes, 1702
 BMD (bone mineral density), 1387t
 BMI (body mass index), 61t, 360, 632, 632t, 633t
 BMR (basal metabolic rate), 631
 BMT. *See* Bone marrow transplant
 BNP. *See* Brain natriuretic peptide
 Body fluids. *See also* Fluids and electrolytes
 composition, 195–96, 197f
 distribution, 196–97, 196f, 197f
 imbalances
 deficit. *See* Fluid volume deficit
 excess. *See* Fluid volume excess
 movement
 active transport, 200, 201f
 diffusion, 199–200, 200f
 filtration, 200, 200f
 osmosis
 definition, 198, 198f
 osmolality and osmolality, 198
 osmotic pressure and tonicity, 198–99, 199f
 regulation
 antidiuretic hormone, 201–2, 202f
 atrial natriuretic peptide, 202
 kidneys, 201
 renin–angiotensin–aldosterone system,
 201, 202f
 thirst, 200–201, 201f
 Body lice, 451
 Body mass index (BMI), 61t, 630, 632, 632t, 633t
 Body posture, 1391t
 Body temperature, variations in surgery, 58t, 59
 Body weight. *See also* Malnutrition; Obesity
 assessment, 620–21t
 gain, in fluid volume excess, 209, 211–12
 loss
 in fluid volume deficit, 205
 in malnutrition, 641
 in obesity
 calorie reduction requirements, 634
 maintaining, 638
 nutrient intake for, 635, 635t, 636t
 for monitoring fluid balance, 208t
 Boggy, 1229
 Boil. *See* Furuncle
 Bolus, 610
 Bone(s). *See also* Musculoskeletal system
 classification, 1380, 1382f
 healing
 factors affecting, 1403t
 phases, 1402, 1404–5t
 metabolic disorders
 gout. *See* Gout
 osteomalacia. *See* Osteomalacia
 osteoporosis. *See* Osteoporosis
 Paget's disease. *See* Paget's disease
 remodeling in adults, 1380–81
 of skeleton, 1381f
 structure, 1380, 1382f
 traumatic injury. *See* Fractures
 tumors. *See* Bone tumors
 Bone density scans, 232, 1387t
 Bone marrow:
 functions, 291
 procedure, 1124f
 tests
 in leukemia, 1123t
 in multiple myeloma, 1137
 in myelodysplastic syndrome, 1115
 nursing care, 1087t
 purpose and description, 1087t
 in thrombocytopenia, 1141
 transplant. *See* Bone marrow transplant
 Bone marrow rescue, 1124
 Bone marrow transplant (BMT):
 allogeneic, 1124
 autologous, 1124
 complications, 1124
 indications, 342t, 398
 for leukemia, 1124
 success rate, 342t
 Bone mineral density (BMD), 1387t
 Bone scan, 1387t
 Bone tumors:
 classification, 1481–82
 incidence, 1482t
 interdisciplinary care
 diagnosis, 1482–83
 treatments
 chemotherapy, 1483, 1483t
 radiation therapy, 1483
 surgery, 1483
 manifestations, 1482, 1483t
 nursing care
 community-based care, 1484
 nursing diagnoses and interventions
 acute pain, chronic pain, 1484
 decisional conflict, 1484
 impaired physical mobility, 1484
 risk for injury, 1483–84
 pathophysiology, 1482
 sites, 1482t
 types, 1482t
 Boniva. *See* Ibandronate sodium
 Bony metastases, 181
 Borborygmus (borborygmi), 624t, 748t, 751
Bordetella pertussis. *See* Pertussis
Borrelia burgdorferi, 1476–77
 Bosentan, 1353
 Botulinum toxin, 668, 1639
 Botulism:
 characteristics, 1661–62
 interdisciplinary care, 1662
 manifestations, 1662
 nursing care, 1662
 pathophysiology, 1662
 Bouchard's nodes, 1393, 1450
 Boutonnière deformity, 1393, 1461, 1461f
 Bowel disorders:
 acute infectious/inflammatory disorders
 appendicitis. *See* Appendicitis
 gastroenteritis. *See* Gastroenteritis
 helminthic disorders. *See* Helminthic disorders
 peritonitis. *See* Peritonitis
 protozoal infections. *See* Protozoal bowel
 infections
 anorectal
 anal fissure, 820
 anorectal abscess, 820
 anorectal fistula, 820–21
 hemorrhoids. *See* Hemorrhoids
 nursing care, 821
 pilonidal disease, 821
 assessment
 diagnostic tests, 743, 744–45t
 functional health pattern interview, 747t
 genetic considerations, 745, 746t
 health assessment interview, 745–46
 physical assessment
 abdomen, 747–48t
 anus and rectum, 750f, 750t
 inguinal area, 748
 overview, 746–47
 perianal area, 750t
 stool, 750–51t
 postoperative, 78–79
 sample documentation, 743
 Chapter Highlights, 821–22t

I-12 INDEX

- Bowel disorders—*continued*
Clinical Scenarios, 825*t*
inflammatory bowel disease. *See* Inflammatory bowel disease
intestinal motility disorders
constipation. *See* Constipation
diarrhea. *See* Diarrhea
fecal incontinence. *See* Fecal incontinence
neoplastic
colorectal cancer. *See* Colorectal cancer
polyps. *See* Polyps
postoperative assessment and nursing care, 78–79
structural and obstructive
diverticular disease. *See* Diverticular disease
hernia. *See* Hernia
intestinal obstruction. *See* Intestinal obstruction
- Bowel sounds, 624*t*, 748*t*
- Bowlby, theory of loss and grief, 85–86, 86*t*
- BPH. *See* Benign prostatic hyperplasia
- Brachial pulse, 1096*t*
- Brachioradialis reflex, 1523*f*
- Brachytherapy, 395, 396*t*, 1786. *See also* Radiation therapy
- Bradycardia, 953*t*
- Bradykinesia, 1635
- Bradykinin, 170, 304*t*
- Bradyphrenia, 1636
- Bradypnea, 1223*t*
- Brain. *See also* Neurologic system
anatomy, physiology, and functions
brainstem, 1506, 1506*t*
cerebellum, 1505*f*, 1506*t*
cerebrum, 1505–6, 1505*f*, 1506*f*, 1506*t*
diencephalon, 1506, 1506*t*
ventricles, 1506
- cerebral function disorders
altered level of consciousness. *See* Altered level of consciousness
epilepsy. *See* Epilepsy
headache. *See* Headache
increased intracranial pressure. *See* Increased intracranial pressure
manifestations, 1528*t*
traumatic brain injury. *See* Traumatic brain injury
tumors. *See* Brain tumors
- Brain abscess, 1565–66. *See also* Central nervous system infections
- Brain attack. *See* Stroke
- Brain death, 265*t*, 1532
- Brain herniation, 1537–38, 1538*f*. *See also* Increased intracranial pressure
- Brain natriuretic peptide (BNP):
in blood pressure regulation, 1155
in heart failure, 1025, 1027
- Brain tumors:
classification, 1569, 1570*t*
incidence and prevalence, 1569
interdisciplinary care
diagnosis, 1571
medications, 1571, 1571*f*
radiation therapy, 1572
specialty procedures, 1572
surgery, 1571, 1571*f*
manifestations, 1569–70, 1569*t*
metastatic, 1569
nursing care
community-based care, 1575
nursing diagnoses and interventions
acute pain, 1574
anxiety, 1572
ineffective protection, 1574
risk for infection, 1572–74
situational low self-esteem, 1574–75
using NANDA, NIC, and NOC, 1575, 1575*t*
- Nursing Care Plan
assessment, 1573*t*
critical thinking in the nursing process, 1573*t*
diagnoses, 1573*t*
evaluation, 1573*t*
expected outcomes, 1573*t*
planning and implementation, 1573*t*
pathophysiology, 1569
- Brainstem, 1506, 1506*t*
- Bran, 759*t*, 760
- Brawny edema, 1200
- BRCA1/BRCA2 genes, 1755*t*, 1817, 1823
- Brc/abl gene:
in acute lymphocytic leukemia, 1122
in chronic myeloid leukemia, 1121
- Breakthrough pain, 174. *See also* Pain
- Breast:
biopsy, 1755, 1757*t*, 1824, 1824*f*
female
age-related changes, 1760*t*
anatomy, physiology, and functions, 1751, 1752*f*
benign disorders
fibrocystic changes, 1820–21, 1821*t*
interdisciplinary care, 1821*t*, 1822
intraductal, 1821–22, 1821*t*
manifestations, 1820–22, 1821*t*
nursing care, 1822
pathophysiology, 1820–22
cancer. *See* Breast cancer
diagnostic tests, 1755, 1756–57*t*
physical assessment, 1761–62*t*, 1761*f*
self-examination, 1829*t*
male
anatomy, 1744
disorders
cancer, 1790. *See also* Breast cancer
gynecomastia. *See* Gynecomastia
physical assessment, 1749*t*
- Breast cancer:
Case Study, 1856*t*
genetic considerations, 1755*t*, 1758, 1823
incidence, 1822
interdisciplinary care
diagnosis, 1824–25, 1824*f*
medications, 1825, 1825*t*
radiation therapy, 1826–27
surgery
breast reconstruction, 1825–26, 1827*f*
lumpectomy, 1825
mastectomy, 1825, 1826*f*
manifestations, 1823–24, 1823*t*
nursing care
assessment, 1829
of client having a mastectomy, 1826*t*
of client having breast reconstruction, 1827*t*
community-based care, 1831, 1831*f*
health promotion, 1828, 1829*t*
nursing diagnoses and interventions
anticipatory grieving, 1830
anxiety, 1829–30
decisional conflict, 1830
disturbed body image, 1831
risk for infection, 1830
risk for injury, 1830–31
using NANDA, NIC, and NOC, 1831*t*
- Nursing Care Plan
assessment, 1828*t*
critical thinking in the nursing process, 1828*t*
diagnoses, 1828*t*
evaluation, 1828*t*
expected outcomes, 1828*t*
planning and implementation, 1828*t*
pathophysiology, 1823
racial/ethnic considerations, 1822*t*
risk factors, 1822–23
screening guidelines, 401*t*
staging, 1824*t*
- Breast reconstruction:
nursing care, 1827*t*
procedure, 1825–26, 1827*f*
- Breast self-examination (BSE), 1829*t*
- Breath odors, 623*t*
- Breath sounds:
abnormal, 1226*t*
assessment, 1225–26*t*, 1225*f*
normal, 1225*t*
types, 1225*t*
- Breathing. *See* Respiration
- Brethaire. *See* Terbutaline
- Brethine. *See* Terbutaline
- Bretylum, 1006*t*
- Bretylol. *See* Bretylum
- Brevibloc. *See* Esmolol
- Breviceon. *See* Norethindrone/ethinyl estradiol
- Brief Drug Abuse Screening Test (B-DAST), 117
- Brimonidine, 1709, 1710*t*
- Brinzolamide, 1710*t*
- Broca's aphasia, 1583
- Broca's area, 1506*t*
- Bromocriptine, 1638*t*, 1639
- Brompheniramine, 1230*t*
- Bronchi, 1212*f*, 1213
- Bronchial provocation testing, 1324
- Bronchiectasis, 1344
- Bronchitis:
acute. *See* Acute bronchitis
chronic, 1331–32, 1332*t*. *See also* Chronic obstructive pulmonary disease
definition, 1266
- Bronchodilators:
Medication Administration, 1327–28*t*
in specific conditions
asthma, 1325–26, 1327–28*t*
chronic obstructive pulmonary disease, 1334
cystic fibrosis, 1342
pneumonia, 1271–72
- Bronchogenic carcinoma, 1308. *See also* Lung cancer
- Bronchophony, 1226*t*
- Bronchoplastic reconstruction, 1312*t*
- Bronchopneumonia, 1268, 1268*t*, 1270*t*
- Bronchoscopy:
laser, 1312*t*
nursing care, 1218–19*t*
purpose and description, 1218*t*, 1219
in specific conditions
lung cancer, 1312
pneumonia, 1271
- Bronkometer. *See* Isoetharine
- Bronkosol. *See* Isoetharine
- Bronkotabs. *See* Theophylline
- Brown-Séquard syndrome, 1597*t*, 1613. *See also* Spinal cord injury: Spinal cord tumors
- Brudzinski's sign, 1524*t*, 1525*f*
- Bruises. *See* Ecchymosis
- Bruits:
abdominal, 624*t*, 749*t*, 1098*t*
carotid, 1094*t*
definition, 624*t*, 749*t*, 1094*t*
BSE (breast self-examination), 1829*t*
Buerger's disease. *See* Thromboangiitis obliterans
- Bufferin. *See* Aspirin
- Buffers, 238

- Build Clinical Competence:
 activity-exercise pattern
 responses to altered cardiac function, 1071*t*
 responses to altered musculoskeletal function, 1497*t*
 responses to altered respiratory patterns, 1375*t*
 responses to altered tissue perfusion, 1205*t*
 cognitive-perceptual pattern
 responses to altered neurologic function, 1665*t*
 responses to altered visual and auditory function, 1737*t*
 elimination pattern
 responses to altered bowel elimination, 824*t*
 responses to urinary elimination, 929*t*
 health perception-health management pattern
 alterations in patterns of health, 143*t*
 dimensions of medical-surgical nursing, 49*t*
 pathophysiology and patterns of health, 416*t*
 nutritional-metabolic pattern
 responses to altered endocrine function, 600*t*
 responses to altered integumentary structure and function, 513*t*
 responses to altered nutrition, 735*t*
 sexuality-reproductive pattern
 responses to altered reproductive function, 1854*t*
- Bulbourethral glands, 1745*t*
 Bulge sign, 1395*f*, 1395*t*
 Bulimia nervosa:
 complications, 651*t*
 interdisciplinary care
 diagnosis, 651–52
 treatment, 652
 manifestations, 650–51, 651*t*
 nursing care, 652
- Bulk-forming agents, 759*t*
 Bullous lesions, 431*t*
 Bumetanide, 210*t*, 905*t*, 1033*t*
 Bumex. *See* Bumetanide
 Buminate 5%. *See* Albumin 5%
 Buminate 25%. *See* Albumin 25%
 BUN. *See* Blood urea nitrogen
 Bunion, 1492, 1492*f*
 Buprenex. *See* Buprenorphine HCl
 Buprenorphine HCl, 182*t*
 Burkitt lymphoma, 354, 1130*t*. *See also* Lymphomas
- Burn shock, 495
- Burns:
 Case Study, 515*t*
 causative agents, 488*t*
 Chapter Highlights, 511*t*
 classification
 depth
 characteristics, 489*t*
 full-thickness, 490, 490*f*
 partial-thickness, 490, 490*f*
 superficial, 489–90
 extent, 490–91, 491*f*, 491*t*, 492*f*
 definition, 487
 eyes, 1702
 incidence, 487
 interdisciplinary care
 diagnosis, 500
 emergency and acute
 fluid resuscitation, 499
 respiratory management, 257, 499
 medications
 antimicrobial, 500, 501*t*
 gastric hyperacidity prevention, 502
 pain control, 500
 tetanus prophylaxis, 502
 prehospital management
 stop burning process, 498
 support vital function, 498
- stages
 acute, 498
 emergent/resuscitative, 497–98
 overview, 497*f*
 rehabilitative, 498
- treatments
 biological and biosynthetic dressings, 503–4
 nutritional support, 505
 positioning, splints, and exercise, 504–5
 support garments, 505, 505*f*
 surgery, 502–3, 502*f*, 502*t*
 wound dressing, 504, 505*f*
 wound management, 504
- minor, 493
 in nuclear detonation, 130*t*, 131
- nursing care
 assessment, 505–6
 community-based care, 510–11
 health promotion, 505
 interventions by stage, 506*t*
 Medication Administration, 501*t*
 nursing diagnoses and interventions
 acute pain, 508–9
 deficient fluid volume, 508
 imbalanced nutrition: less than body requirements, 509–10
 impaired physical mobility, 509
 impaired skin integrity, 506–8
 powerlessness, 510
 risk for infection, 509
 of older adults, 508*t*
 using NANDA, NIC, and NOC, 510, 511*t*
- Nursing Care Plan
 assessment, 507*t*
 critical thinking in the nursing process, 507*t*
 diagnosis, 507*t*
 evaluation, 507*t*
 expected outcomes, 507*t*
 planning and implementation, 507*t*
- Nursing Research: prevention of pressure ulcers
 in client with major burn, 510*t*
- pathophysiology, 494
 priority treatment, 488*t*
 risk factors, 487
 systemic effects
 cardiovascular
 cardiac rhythm alterations, 495
 hypovolemic shock, 495
 peripheral vascular compromise, 495
 gastrointestinal, 496
 immune, 496
 integumentary system, 494, 495*f*
 metabolic, 496–97
 overview, 494*f*
 respiratory, 495–96
 urinary, 496
- types of injury
 chemical, 488–99, 499*t*
 electrical, 488
 radiation, 488
 thermal, 487, 488*t*
 wound healing in, 493
- Burr hole, 1560*f*, 1571, 1571*f*
 Burrow's solution, 1194
 Bursitis, 1394*t*, 1428. *See also* Repetitive use injury
- Busulfan, 392*t*, 1704
 Butazolidin. *See* Phenylbutazone
 Butenafine, 450*t*
 Butorphanol, 180*t*
 Butyl nitrite, 111
 Butyrophenones, 672
 Byetta. *See* Exenatide
- C**
- C fibers, 171, 171*f*
 CA 15-3, 384*t*
 CA 19-9, 384*t*
 CA 125, 384*t*, 1818
 Ca²⁺. *See* Calcium
 CABG. *See* Coronary artery bypass grafting
 Cachectic, 689
 Cachexia, 380, 380*f*
 Café coronary, 1249
 Cafegot. *See* Ergotamine tartrate
 Caffeine, 106
 CAGE questionnaire, 116
 Calan. *See* Verapamil
 Calcimar. *See* Calcitonin
 Calcipotriene, 444
 Calcitonin:
 abnormal, possible causes, 384*t*, 386*t*
 functions, 520
 for hypercalcemia, 232, 547
 laboratory tests, 380*t*
 normal values, 386*t*
 for osteoporosis, 1436
 for Paget's disease, 1442
- Calcium (Ca²⁺):
 abnormal, possible causes, 386*t*
 balance, 227, 227*f*
 in body fluid compartments, 197*t*
 in coagulation, 1082*t*
 foods high in, 230*t*, 858*t*
 functions, 227
 imbalances. *See* Hypercalcemia; Hypocalcemia
 limiting intake, in urinary calculi, 858, 858*t*
 in osteoporosis, 1434
 recommended daily intake, 610*t*
 serum levels. *See* Serum calcium
 supplements, 230*t*, 1437*t*
- Calcium carbonate, 230*t*
 Calcium channel blockers:
 Medication Administration, 973–74*t*, 1006*t*, 1162*t*, 1545–46*t*
 in specific conditions
 angina, 972, 973–74*t*
 aortic aneurysm, 1173
 cardiac dysrhythmias, 1006*t*
 headache, 1545–46*t*
 hypertension, 1162*t*, 1163
 intracranial aneurysm, 1593
 pulmonary hypertension, 1353
 scleroderma, 1485
 thromboangiitis obliterans, 1182
- Calcium chloride:
 Medication Administration, 225*t*, 230*t*, 905–6*t*
 in specific conditions
 acute renal failure, 904, 905–6*t*
 hypocalcemia, 229
- Calcium citrate, 230*t*
 Calcium glubionate, 230*t*
 Calcium gluceptate, 230*t*
 Calcium gluconate:
 Medication Administration, 225*t*, 230*t*, 905–6*t*
 in specific conditions
 acute renal failure, 905–6*t*
 hyperkalemia, 224, 225*t*
 hypocalcemia, 229
- Calcium lactate, 230*t*
 Calcium polycarbophil, 759*t*
 Calcium salts, 230*t*
 Calcium stones, 856, 856*t*. *See also* Urinary calculi
- Calculi:
 definition, 697, 838
 gallbladder. *See* Gallstones
 urinary. *See* Urinary calculi

- Caldwell-Luc procedure, 1237
 Caloric test, 1684*t*, 1727
 Camey procedure, 865*t*
 Camphorated tincture of opium, 756*t*
Campylobacter jejuni, 1653
 Canal of Schlemm, 1672, 1672*f*
 Canasa. *See* Mesalamine
 Cancer:
 Chapter Highlights, 413*t*
 definition, 369
 etiology
 altered immune response, 379, 379*t*
 carcinogens
 chemicals, 372*t*, 375
 drugs and hormones, 375
 radiation, 375–76
 viruses, 374–75, 375*t*
 cellular characteristics, 376–77, 377*t*
 theories of carcinogenesis
 cellular mutations, 374
 oncogenes, 374
 tumor suppressor genes, 374
 tumor invasion and metastasis
 invasion, 377–78, 377*f*
 metastasis, 378–79, 378*f*, 378*t*
 types of neoplasms, 376, 376*t*
 incidence and mortality, 369
 interdisciplinary care
 diagnosis
 classification, 382, 383*t*
 cytologic examination, 382–83
 direct visualization, 385
 grading and staging, 382, 383*t*
 imaging, 384–85
 laboratory tests, 385, 386–87*t*
 psychologic support during, 387–88
 surgical procedures, 388*t*
 tumor markers, 383–84, 384*t*
 treatment
 biotherapy, 396, 398*t*
 bone marrow transplant. *See* Bone marrow transplant
 chemotherapy. *See* Chemotherapy
 complementary therapies, 398–99
 peripheral blood stem cell transplant. *See* Peripheral blood stem cell transplant
 photodynamic therapy, 398
 radiation therapy. *See* Radiation therapy
 surgery, 388–89, 388*t*
 manifestations, 405
 in middle adults, 27
 nursing care
 assessment
 focused interview, 400–402
 functional status scales, 401*t*
 physical assessment, 402–3, 402*t*, 403*t*
 community-based care
 hospice. *See* Hospice
 teaching, 412
 health education for the client and family
 prevention, 411–12, 412*t*
 rehabilitation and survival, 412
 health promotion, 400, 400*t*, 401*t*
 nursing diagnoses and interventions
 anticipatory grieving, 406
 anxiety, 403, 405
 disturbed body image, 405–6
 imbalanced nutrition: less than body requirements, 407–8
 impaired tissue integrity, 408–9, 409*t*
 risk for infection, 406–7
 risk for injury, 407, 407*t*
 nursing interventions for oncologic emergencies
 hypercalcemia, 410
 hyperuricemia. *See* Hypercalcemia
 obstructive uropathy, 410
 pericardial effusions and neoplastic cardiac tamponade, 409
 sepsis and septic shock, 410
 spinal cord compression, 410
 superior vena cava syndrome, 409, 410*f*
 syndrome of inappropriate diuretic hormone, 410
 tumor lysis syndrome, 410–11
 of older adults, 371*t*
 using NANDA, NIC, and NOC, 411, 411*t*
 Nursing Care Plan
 assessment, 403–4*t*
 critical thinking in the nursing process, 404*t*
 diagnoses, 404*t*
 evaluation, 404*t*
 expected outcomes, 404*t*
 planning and implementation, 404*t*
 pathophysiology, 372–74. *See also* Cell(s)
 physiologic and psychologic effects
 anorexia-cachexia syndrome, 380
 disruption of function, 379
 hematologic alterations, 379
 hemorrhage, 380
 infection, 379–80
 pain, 381, 399
 paraneoplastic syndromes, 380, 380*t*
 physical stress, 381, 382*t*
 psychologic stress, 381, 382*t*
 risk factors
 age, 370
 alcohol use, 372
 chemical exposure, 372*t*
 diet, 371
 gender, 370
 heredity, 370
 infection, 371
 interactions, 373*f*
 obesity, 372
 occupation, 371
 poverty, 370
 recreational drug use, 372
 stress, 370–71
 sun exposure, 372
 tobacco use, 371–72
 types
 bladder. *See* Bladder cancer
 bone. *See* Bone tumors
 breast. *See* Breast cancer
 cervical. *See* Cervical cancer
 endometrial. *See* Endometrial cancer
 esophageal. *See* Esophageal cancer
 gallbladder, 703
 gastric. *See* Gastric cancer
 larynx. *See* Laryngeal cancer
 liver, 723–24, 724*t*
 oral. *See* Oral cancer
 ovarian. *See* Ovarian cancer
 pancreas. *See* Pancreatic cancer
 penis, 1772
 prostate. *See* Prostate cancer
 skin. *See* Skin cancer
 testicular. *See* Testicular cancer
 thyroid, 546
 warning signs, 400*t*
 Candesartan, 1033*t*, 1161*t*
Candida albicans. *See* Candidiasis
 Candidiasis:
 in AIDS, 353, 359*t*
 definition, 449
 in diabetes mellitus, 592
 interdisciplinary care, 449–50, 450*t*
 manifestations, 449, 449*f*, 449*t*
 nursing care, 450
 oral. *See* Thrush
 risk factors, 449
 vaginal, 449*t*, 1842–43, 1843*f*, 1843*t*
 Canker sore, 657*t*. *See also* Stomatitis
 Cannabinoids, 672, 673*t*
 Cannabis sativa, 107. *See also* Marijuana
 CAPD (continuous ambulatory peritoneal dialysis), 920
 Capillaries, 1082, 1085*f*
 Capillary refill, 1095*t*
 Caplan, theory of loss and grief, 86, 86*t*
 Capnogram. *See* Exhaled carbon dioxide
 Capoten. *See* Captopril
 Capsaicin, 1326, 1451
 Captopril, 1033*t*, 1161*t*
 Captopril test, 895
 Capture, pacemaker, 1010*t*
 Caput medusae, 704, 715*t*
 Capzasin. *See* Capsaicin
 Carbamazepine:
 interaction with oral contraceptives, 1551*t*
 Medication Administration, 1550*t*
 in specific conditions
 seizures, 1550*t*
 trigeminal neuralgia, 1656
 Carbapenems, 319*t*
 Carbenicillin, 319*t*
 Carbox. *See* Selegiline
 Carbidopa-levodopa, 1637*t*, 1639
 Carbohydrates:
 intake in diabetes mellitus, 576–77
 recommended daily intake, 606
 recommended dietary guidelines, 606*t*
 sources, 606
 use by body, 606, 607*f*
 Carbon dioxide (CO₂). *See also* Exhaled carbon dioxide
 perioperative levels, significance and nursing implications, 60*t*
 transport from lungs, 1216–17
 Carbon monoxide poisoning:
 assessment in light and dark skin, 426*t*, 1305
 in burns, 496
 interdisciplinary care, 499
 manifestations, 496*t*, 1305
 pathophysiology, 1305
 Carbonic anhydrase inhibitors, 1703, 1710*t*
 Carboplatin, 1254, 1819
 Carboxyhemoglobin, 1306
 Carbuncle, 447
 Carcinoembryonic antigen (CEA), 384*t*, 386*t*
 Carcinogenesis, 374. *See also* Cancer, etiology
 Carcinogens, 372*t*, 374. *See also* Cancer, etiology
 Cardene. *See* Nicardipine
 Cardiac arrest, 1002, 1015. *See also* Sudden cardiac death; Ventricular fibrillation
 Cardiac auscultation, 954–55*t*, 954*f*
 Cardiac catheterization:
 in angina, 971
 in cardiomyopathy, 1067
 purpose and description, 943, 945*t*
 related nursing care, 945–46*t*
 in valvular heart disease, 1060
 Cardiac conduction system, 941, 941*f*, 995
 Cardiac cycle, 939–40, 939*f*
 Cardiac dysrhythmias:
 in acute myocardial infarction, 985
 assessment, 953*t*
 atrioventricular (AV) conduction blocks
 causes, 1003
 ECG characteristics, 999*t*
 management, 999*t*

- manifestations, 1003
- pathophysiology, 996
- classification, 996
- definition, 219, 953, 985
- in dilated cardiomyopathy, 1065
- in heart failure, 1034
- in hypokalemia, 219, 219f
- interdisciplinary care
 - cardiac mapping and catheter ablation, 1012-13
 - carotid sinus massage, 1013
 - countershock
 - defibrillation, 1008
 - synchronized cardioversion, 1007, 1007t
 - diagnosis, 1004-5, 1004t
 - implantable cardioverter-defibrillator, 1009-10
 - medications, 1005-6, 1006t
 - pacemaker therapy. *See* Pacemakers
 - Valsalva maneuver, 1013
- nursing care
 - assessment, 1014
 - community-based care, 1015
 - health promotion, 1014
 - Medication Administration, 1006t
 - nursing diagnoses and interventions, 1014-15
 - of older adults, 996t
- Nursing Care Plan
 - assessment, 1013t
 - critical thinking in the nursing process, 1013t
 - diagnoses, 1013t
 - evaluation, 1013t
 - expected outcomes, 1013t
 - planning and implementation, 1013t
- pathophysiology, 996
- supraventricular
 - ECG characteristics, 997-98t
 - management, 997-98t
 - manifestations, 1000-1001
 - pathophysiology, 1000-1001
- ventricular
 - causes, 1002-3
 - ECG characteristics, 998-99t, 1002-3
 - management, 998-99t
 - manifestations, 1002-3
 - pathophysiology, 996
- Cardiac enzymes. *See* Cardiac markers
- Cardiac index (CI), 941, 1031
- Cardiac mapping, 1012
- Cardiac markers:
 - in acute coronary syndrome, 975-76
 - in acute myocardial infarction, 986, 987t
 - in myocarditis, 1049
 - in pericarditis, 1051
 - in rheumatic heart disease, 1043t
 - in shock, 277
- Cardiac monitoring:
 - in cardiac dysrhythmias, 1004
 - indications, 1004t
 - procedure, 1005t
- Cardiac output (CO):
 - clinical indicators, 940
 - definition, 269, 940
 - in hypovolemic shock, 273f
 - normal values, 940
- Cardiac rehabilitation, 990
- Cardiac reserve, 940, 1023
- Cardiac tamponade:
 - definition, 1050
 - in end-stage renal disease, 916
 - manifestations, 409, 1050, 1051t
 - nursing interventions, 409
 - pathophysiology, 1050, 1051f
- Cardiac transplantation. *See* Heart transplant
- Cardiac-specific troponin I (cT_nI), 975-76, 986, 987t
- Cardiac-specific troponin T (cT_nT), 975-76, 986, 987t
- Cardinal fields of vision, 1677, 1677f
- Cardiogenic embolic stroke, 1581. *See also* Stroke
- Cardiogenic shock:
 - in acute myocardial infarction, 985
 - assessment, 279
 - causes, 274
 - definition, 274
 - manifestations, 274, 274t
 - pathophysiology, 274
- Cardiolite scan, 945t
- Cardiomyopathy:
 - causes, 1063
 - dilated
 - management, 1065t
 - manifestations, 1065, 1065t
 - pathophysiology, 1063-65, 1065t
 - prognosis, 1065
 - hypertrophic
 - genetic considerations, 950t
 - management, 1065t
 - manifestations, 1065t, 1066
 - pathophysiology, 1065-66, 1065t
 - prognosis, 1066
 - interdisciplinary care
 - diagnosis, 1067
 - medications, 1067
 - surgery, 1067
 - mortality rate, 1063
 - nursing care, 1067-68
 - restrictive
 - manifestations, 1066
 - pathophysiology, 1066
 - prognosis, 1066
- Cardiopulmonary bypass (CPB), 978, 979f
- Cardiopulmonary resuscitation (CPR):
 - family presence during, 1066t
 - procedure, 1016, 1017t
- Cardioquin. *See* Quinidine
- Cardiovascular disease:
 - acute coronary syndrome. *See* Acute coronary syndrome
 - acute myocardial infarction. *See* Acute myocardial infarction
 - angina pectoris. *See* Angina pectoris
 - cardiogenic pulmonary edema. *See* Pulmonary edema, cardiogenic
 - cardiomyopathy. *See* Cardiomyopathy
 - Chapter Highlights, 1019t, 1068t
 - Clinical Scenarios, 1072t
 - coronary heart disease. *See* Coronary heart disease
 - definition, 958
 - dysrhythmias. *See* Cardiac dysrhythmias
 - endocarditis. *See* Endocarditis
 - heart failure. *See* Heart failure
 - incidence, 958
 - pericarditis. *See* Pericarditis
 - rheumatic heart disease. *See* Rheumatic fever/heart disease
 - risk factors in middle adults, 26-27
 - sudden cardiac death. *See* Sudden cardiac death
 - surgical risk and nursing implications, 57t
- Cardiovascular system. *See also* Heart
 - age-related changes
 - in middle adults, 27t
 - in older adults, 29t
 - in young adults, 26t
 - postoperative complications
 - deep venous thrombosis, 75. *See also* Deep venous thrombosis
 - hemorrhage, 74-75
 - pulmonary embolism, 75. *See also* Pulmonary embolism
 - shock, 74. *See also* Shock
- Cardioversion. *See* Defibrillation; Synchronized cardioversion
- Carditis, 1042
- Cardizem. *See* Diltiazem
- Cardura. *See* Doxazosin
- Caregiver:
 - family, burdens of, 45
 - nurse as, 12-13, 12f, 13t
- Carisoprodol, 1491
- Carotene, 425
- Carotid arteries:
 - duplex study, 1515t
 - endarterectomy
 - nursing care, 1586t
 - procedure, 1586, 1586f
 - physical assessment, 1094t
 - Carotid sinus massage, 1013
- Carpal spasm, 531t
- Carpal tunnel syndrome, 1427-28. *See also* Repetitive use injury
- Carrier testing, 156
- Carriers, 153, 200
- Carteolol, 1710t
- Carter's Liver Pills. *See* Bisacodyl
- Cartrol. *See* Carteolol
- Carvedilol, 1161t
- Cascara sagrada, 759-60t, 832t
- Case Studies:
 - breast cancer, 1856t
 - burns, 515t
 - chronic obstructive pulmonary disease, 1377t
 - chronic renal failure, 931t
 - client with multiple trauma, 145t
 - diabetes mellitus, 602t
 - fracture, 1499t
 - glaucoma, 1739t
 - heart failure, 1073t
 - hypertension, 1207t
 - lung cancer, 418t
 - pelvic inflammatory disease, 51t
 - stroke, 1667t
 - ulcerative colitis, 826t
- Caseation necrosis, 1281
- Castor oil, 759-60t
- Casts:
 - bivalving, 1419f
 - nursing care of client, 1410t
 - types, 1409-10, 1410f
- Casts, urinary, 832t
- Casualty management. *See* Disasters
- Catabolism, 307, 613, 641
- Catapres. *See* Clonidine
- Cataracts:
 - incidence, 1704
 - interdisciplinary care
 - diagnosis, 1704
 - surgery, 1705, 1705f
 - manifestations, 1704, 1704f
 - nursing care
 - assessment, 1706
 - community-based care, 1706
 - health promotion, 1705
 - nursing diagnoses and interventions
 - decisional conflict: cataract removal, 1706
 - risk for ineffective therapeutic regimen management, 1706
- Nursing Care Plan
 - assessment, 1711t
 - critical thinking in the nursing process, 1711t
 - diagnoses, 1711t
 - evaluation, 1711t

- Cataracts—*continued*
 expected outcomes, 1711*t*
 planning and implementation, 1711*t*
 pathophysiology, 1704
 risk factors, 1704
- Catecholamines. *See* Epinephrine; Norepinephrine
- Catechol-*O*-methyltransferase (COMT) inhibitors, 1638*t*, 1639
- Cathartic colon, 758
- Catheter, urinary:
 client self-catheterization procedure, 1605*t*
 infections associated with, 848
 for neurogenic bladder, 872, 1605*t*
 nursing interventions, 852–53, 869–70
 Nursing Research: insertion methods in male client, 854*t*
- Cations, 196
- Caucasians/European Americans:
 breast cancer incidence, 1822*t*
 osteoarthritis, 1449*t*
 osteoporosis incidence, 1434, 1434*t*
 substance use, 105, 105*t*
 testicular cancer incidence, 1774*t*
- Caverject. *See* Alprostadil
- Cavitation, 1280
- CBC. *See* Complete blood count
- CCPD (continuous cyclic peritoneal dialysis), 920
- CCR5 gene, 152
- CD antigen, 329
- CD4 cells, 329, 352*t*, 355
- CEA (carcinoembryonic antigen), 384*t*, 386*t*
- Ceclor. *See* Cefaclor
- Cecum, 743
- Cefaclor, 319*t*, 1722
- Cefazolin:
 Medication Administration, 319*t*
 preoperative use and nursing implications, 62*t*
 in specific conditions
 endocarditis, 1046
 eye trauma, 1703
- Cefepime, 319*t*
- Cefobid. *See* Cefoperazone
- Cefoperazone, 319*t*
- Cefotaxime, 1566
- Cefoxitin, 816, 1851
- Ceftazidime, 319*t*
- Ceftin. *See* Cefuroxime
- Ceftriaxone:
 Medication Administration, 319*t*
 in specific conditions
 endocarditis, 1046
 epiglottitis, 1241
 urinary tract infection, 849
- Cefuroxime, 319*t*, 1241, 1477
- Celebrex. *See* Celecoxib
- Celecoxib, 1451
- Celiac sprue (celiac disease), 746*t*, 796, 1106. *See also* Sprue
- Cell(s):
 differentiation, 373–74
 division, 149–50
 DNA, 149, 372–73, 373*t*. *See also* Genetics
 mutations, 374
 normal growth, 372–73
 nucleus, 149
- Cell cycle:
 characteristics, 373
 chemotherapeutic drugs and, 389, 389*f*
- CellCept. *See* Mycophenolate mofetil
- Cell-kill hypothesis, 390
- Cell-mediated (cellular) immune response, 291
- Cellular immune response. *See* Cell-mediated (cellular) immune response
- Cellular immunity. *See* Cell-mediated (cellular) immune response
- Cellulitis, 447, 447*f*
- Central herniation, 1538, 1538*f*. *See also* Increased intracranial pressure
- Central nervous system (CNS). *See also* Neurologic system
 anatomy, physiology, and functions
 blood–brain barrier, 1507
 brain
 brainstem, 1506, 1506*t*
 cerebellum, 1505*f*, 1506*t*
 cerebrum, 1505–6, 1505*f*, 1506*f*, 1506*t*
 diencephalon, 1506, 1506*t*
 ventricles, 1506
 cerebral circulation, 1507, 1508*f*
 cerebrospinal fluid
 formation, 1506–7
 functions, 1507
 normal values, 1507*t*
 limbic system, 1507
 meninges, 1507, 1507*f*
 neurons, 1628*t*
 reticular formation, 1507
 spinal cord, 1508–9, 1508*f*, 1509*f*
- Central nervous system depressants:
 abuse, 108
 overdose signs and treatment, 113*t*
 withdrawal signs and treatment, 113*t*
- Central nervous system infections:
 complications, 1564
 Creutzfeldt-Jakob disease. *See* Creutzfeldt-Jakob disease
 encephalitis, 1565, 1565*t*
 interdisciplinary care
 diagnosis, 1566
 medications, 1566
 surgery, 1566
 manifestations, 1564–65, 1564*t*
 meningitis. *See* Meningitis
 nursing care
 assessment, 1567
 community-based care, 1569
 health promotion, 1567
 nursing diagnoses and interventions
 ineffective protection, 1568
 risk for deficient fluid volume, 1568
 using NANDA, NIC, and NOC, 1568, 1568*t*
- Nursing Care Plan
 assessment, 1567*t*
 critical thinking in the nursing process, 1567*t*
 diagnoses, 1567*t*
 evaluation, 1567*t*
 expected outcomes, 1567*t*
 planning and implementation, 1567*t*
 pathophysiology, 1563–66
 postpoliomyelitis syndrome. *See* Postpoliomyelitis syndrome
 rabies. *See* Rabies
 tetanus. *See* Tetanus
- Central neurogenic hyperventilation, 1530, 1530*t*
- Central obesity, 632
- Central pain, 174. *See also* Pain
- Central pain syndrome (CPS), 1582
- Central sleep apnea, 1250
- Central stroke pain, 1583
- Central syndrome, 1597*t*. *See also* Spinal cord injury
- Central venous catheter, 277, 648
- Central venous pressure (CVP):
 in fluid volume deficit, 205
 measuring with a manometer, 206*t*, 1030
 normal values, 206*t*, 1030
- Cephalexin, 319*t*
- Cephalosporins:
 Medication Administration, 319*t*
 in specific conditions
 bacterial meningitis, 1566
 peritonitis, 770
 pneumonia, 1271*t*
- Cephulac. *See* Lactulose
- Cerebellum, 1505*f*, 1506*t*
- Cerebral angiogram:
 in altered level of consciousness, 1532
 in intracranial aneurysm, 1593
 purpose and description, 1514*t*
 related nursing care, 1514*t*
- Cerebral edema, 1537. *See also* Increased intracranial pressure
- Cerebral oxygenation, 1560*t*
- Cerebral perfusion pressure (CPP), 1560*t*
- Cerebral vascular accident. *See* Stroke
- Cerebrospinal fluid:
 formation, 1506–7
 functions, 1507
 in multiple sclerosis, 1627
 normal values, 1507*t*
- Cerebrovascular accident. *See* Stroke
- Cerebrovascular disorders:
 arteriovenous malformation. *See* Arteriovenous malformation
 intracranial aneurysm. *See* Intracranial aneurysm
 stroke. *See* Stroke
- Cerebrum. *See also* Neurologic system
 anatomy, physiology, and functions, 1505, 1505*f*, 1506*t*
 manifestations of deteriorating function, 1528*t*
- Certified registered nurse anesthetist (CRNA), 65
- Cerubidine. *See* Daunorubicin
- Cerumen:
 characteristics, 424, 1682
 impacted
 interdisciplinary care, 1721
 nursing care, 1721
 pathophysiology, 1721
- Cervical cancer:
 classification systems, 1813*t*
 incidence, 1812
 interdisciplinary care
 diagnosis, 1813
 medications, 1813
 radiation therapy, 1813
 surgery, 1813, 1813*f*
 manifestations, 1813
 nursing care
 assessment, 1815
 community-based care, 1815–16
 health promotion, 1814–15
 nursing diagnoses and interventions
 fear, 1815
 impaired tissue integrity, 1815
 using NANDA, NIC, and NOC, 1815, 1815*t*
- Nursing Care Plan
 assessment, 1814*t*
 critical thinking in the nursing process, 1814*t*
 diagnoses, 1814*t*
 evaluation, 1814*t*
 expected outcomes, 1814*t*
 planning and implementation, 1814*t*
 pathophysiology, 1812
 prevention, HPV vaccine for, 1815
 risk factors, 1812
 screening guidelines, 401*t*, 1814
- Cervical disk herniation, 1608. *See also* Herniated intervertebral disk
- Cervical intraepithelial neoplasia (CIN), 1812, 1813*t*

- Cervical spine:
 immobilization, 260, 260f
 physical assessment, 1392t
- Cervical traction, 1601, 1601f
- Cervicitis, 1850
- Cervix:
 anatomy and function, 1751t, 1752, 1753f
 biopsy, 1758t
 cancer. *See* Cervical cancer
 physical assessment, 1764–65t
 polyps, 1808, 1809t
- Cesamet. *See* Nabilone
- Cetirizine, 1230t
- CFTR* gene, 152
- Chalazion, 1679, 1700, 1701f
- Challenge testing, 1324
- Chamomile tea, 679, 792
- Champion Revised Trauma Scoring System, 260t
- Chancre, 1847, 1848f
- Chapter Highlights:
 bowel disorders, 821–22t
 burn injuries, 511t
 cancer, 413t
 cardiac disorders, 1019t, 1068t
 community-based and home care, 47–48t
 coronary heart disease, 1019t
 diabetes mellitus, 598t
 disasters, 141t
 endocrine disorders, 560t
 eye and ear disorders, 1734t
 female reproductive system disorders, 1833t
 fluid, electrolyte, and acid–base imbalances, 252
 gallbladder, liver, and pancreatic disorders, 733t
 genetics, 166t
 health and illness, 33t
 hematologic disorders, 1150t
 immune system, 366t
 infections, 325–26
 kidney disorders, 927t
 loss, grief, and death, 99t
 lower respiratory disorders, 1317–18t, 1372–73t
 male reproductive system disorders, 1790–91t
 medical-surgical nursing, 16t
 musculoskeletal disorders, 1494t
 musculoskeletal trauma, 1429–30t
 neurologic system disorders, 1614t, 1663t
 pain, 192t
 peripheral vascular disorders, 1202t
 sexually transmitted infections, 1852t
 skin disorders, 483–84t
 substance abuse, 122–23t
 surgery, 82t
 trauma and shock, 283–84t
 upper gastrointestinal disorders, 694t
 urinary system disorders, 880t
- Charcot-Marie-Tooth syndrome, 1513t
- Chaste tree, 1796, 1800
- CHD. *See* Coronary heart disease
- Cheilosis:
 in anemia, 1105, 1106
 definition, 622t
 nursing interventions, 1114
 in nutritional deficiencies, 622t
- Chemical burns. *See also* Burns
 causative agents, 487–88, 488t
 in disasters, 130t
 eye, 1702
 prehospital management, 498
 priority treatment, 488t
- Chemical menopause, 1795
- Chemical peeling, 479
- Chemical terrorism, 127
- Chemotaxis, 289
- Chemotherapy:
 classes
 alkylating agents, 390, 392t
 antimetabolites, 390, 392t, 1483t
 antitumor antibiotics, 391, 392–93t
 hormones and hormone antagonists, 391, 393–94t
 mitotic inhibitors, 391
 plant alkaloids, 391, 393t
 definition, 389
 effects, 391
 management of clients receiving, 394–95
 mechanisms of action, 389–90, 390f
 preparation and administration, 391, 394, 395f
 principles, 389–90
 in specific conditions
 bladder cancer, 863
 bone tumors, 1483, 1483t
 breast cancer, 1825
 colorectal cancer, 805
 endometrial cancer, 1816
 laryngeal cancer, 1254
 leukemia, 1123, 1123t
 lung cancer, 1312
 lymphoma, 1132
 multiple myeloma, 1137
 ovarian cancer, 1819
 testicular cancer, 1775
- Chenix. *See* Chenodiol
- Chenodiol, 699
- Cherry angiomas, 443
- Chest, physical assessment, 1223–24t
- Chest injuries. *See* Thoracic trauma
- Chest pain:
 in acute coronary syndrome, 975, 975t
 in acute myocardial infarction, 975t, 984
 in angina pectoris, 970, 975t
 assessment, 950t
- Chest physiotherapy:
 in cystic fibrosis, 1342
 in pneumonia, 1272–73, 1273f, 1274f
- Chest tubes:
 equipment, 1299f, 1300f
 in lung abscess, 1280
 nursing care, 1300t
 in pneumothorax, 1299
 procedure, 1299
- Chest x-ray:
 in cardiac function assessment, 944t
 in preoperative assessment, 60
 in respiratory function assessment, 1218t
 in specific conditions
 acute respiratory distress syndrome, 1367
 aortic aneurysm, 1173
 cardiomyopathy, 1067
 chronic obstructive pulmonary disease, 1334
 heart failure, 1027
 inhalation injury, 1307
 lung cancer, 1311
 lymphoma, 1131
 pericarditis, 1051
 pneumonia, 1270
 pulmonary embolism, 1349
 rheumatic heart disease, 1043t
 severe acute respiratory syndrome, 1278
 tuberculosis, 1287
 valvular heart disease, 1060
- Cheyne-Stokes respirations, 93, 1530, 1530t
- Chinese culture, death rituals, 88
- Chlamydia*:
 cervical cancer risk and, 1812
 characteristics, 311t
 complications, 1845
 diagnostic test, 1756t
 in epididymitis, 1773
 incidence, 1844
 interdisciplinary care
 diagnosis, 1845
 medications, 1845
 manifestations, 1844–45
 nursing care, 1845
 pathophysiology, 1844
 in reactive arthritis, 1470
 risk factors, 1844t
Chlamydia pneumoniae, 1271t
Chlamydia trachomatis, 1693
- Chloral hydrate, 108
- Chlorambucil, 891, 1123t, 1137
- Chlordiazepoxide, 114t
- Chloride (Cl⁻):
 abnormal, possible causes, 386t
 in body fluid compartments, 197f
 normal values, 198t, 386t
 perioperative levels, significance and nursing implications, 60t
 recommended daily intake, 610t
 in sweat, for cystic fibrosis diagnosis, 1342
- Chlorocon. *See* Chloroquine
- Chloromycetin. *See* Chlorambucil
- Chloroquine, 321, 778t
- Chlorothiazide, 210t, 1033t
- Chlorpheniramine, 1230t
- Chlorphenoxamine, 1638t
- Chlorpromazine:
 cataract formation and, 1704
 for tetanus, 1661
 urine color changes caused by, 832t
- Chlorthalidone, 210t
- Chlor-Trimeton. *See* Chlorpheniramine
- Chlorzoxazone, 1600t
- Chocolate cysts, 1808, 1809t
- Cholangiography, 616t
- Cholangitis, 698, 784–85
- Cholecystectomy:
 nursing care, 700t
 Nursing Research: postoperative pain management, 700t
 procedure, 699
- Cholecystitis, 698, 698t. *See also* Gallstones
- Cholecystography, 616t
- Cholecystotomy, 700
- Choledochostomy, 700
- Cholelithiasis, 697, 698. *See also* Gallstones
- Cholera, 774t, 775
- Cholesteatoma, 1724
- Cholesterol:
 gallstone formation and, 697
 serum levels. *See* Serum cholesterol
 uses in body, 608
- Cholesterol-lowering drugs, 967t, 968
- Cholestyramine, 699, 967t
- Choline magnesium trisalicylate, 178t, 1464
- Choline salicylate, 178t
- Cholinergic crisis, 1648
- Cholinergic neurotransmitters, 1505
- Cholinergics, 871t, 1621t
- Cholinesterase inhibitors, 1621t, 1649, 1649t
- Chondroma, 1482t
- Chondrosarcoma, 1482t. *See also* Bone tumors
- Chorea, 1643, 1643t
- Choreiform movements, 1643
- Choroid, 1672, 1672f
- Chromium, 610t
- Chromosomes:
 alterations
 diagnosing, 157
 in number, 150, 150t
 in structure, 150–51

I-18 INDEX

- Chromosomes—*continued*
homologous, 149
structure, 149, 150*f*
- Chronic bronchitis, 1331–32, 1332*t*. *See also* Chronic obstructive pulmonary disease
- Chronic cholecystitis, 698. *See also* Gallstones
- Chronic disease, 22*t*
- Chronic gastritis, 677, 678. *See also* Gastritis
- Chronic glomerulonephritis, 888–89. *See also* Glomerular disorders
- Chronic heart failure, 1027. *See also* Heart failure
- Chronic hepatitis, 706. *See also* Hepatitis
- Chronic illness. *See also* Illness
definition, 23
family of client with, 33
responses to, 23–24
- Chronic intermittent colitis, 784. *See also* Inflammatory bowel disease
- Chronic ischemic heart disease, 962
- Chronic lymphocytic leukemia (CLL). *See also* Leukemia
characteristics, 1119*t*, 1122
interdisciplinary care
diagnosis, 1123*t*
treatment, 1119*t*, 1123*t*
manifestations, 1119*t*, 1122
pathophysiology, 1122
- Chronic myeloid leukemia (CML). *See also* Leukemia
characteristics, 1119*t*, 1121
genetic considerations, 151, 1089*t*, 1121, 1122*f*
interdisciplinary care
diagnosis, 1123*t*
treatment, 1119*t*, 1123*t*
manifestations, 1119*t*, 1121
pathophysiology, 1121
- Chronic obstructive pulmonary disease (COPD):
Case Study, 1377*t*
classification, 1332*t*
client teaching, 1341*t*
definition, 1330
genetic considerations, 1331*t*
incidence, 1330–31
interdisciplinary care
complementary therapies, 1335–36
diagnosis, 1333–34, 1333*f*
medications, 1334
oxygen therapy, 1335
smoking cessation, 1334
surgery, 1335
treatments, 1334–35
manifestations, 1332–33, 1332*t*, 1333*f*
mortality rate, 1331
nursing care
assessment, 1336
client teaching, 1341*t*
community-based care, 1340, 1341*t*
health promotion, 1336
nursing diagnoses and interventions
compromised family coping, 1339–40
decisional conflict: smoking, 1340
imbalance nutrition: less than body requirements, 1339
ineffective airway clearance, 1336–39
using NANDA, NIC, and NOC, 1340, 1340*t*
- Nursing Care Plan
assessment, 1338*t*
critical thinking in the nursing process, 1338*t*
diagnoses, 1338*t*
evaluation, 1338*t*
expected outcomes, 1338*t*
planning and implementation, 1338*t*
- Nursing Research: physical activity benefits, 1335*t*
pathophysiology
chronic bronchitis, 1331–32
emphysema, 1332
overview, 1331, 1331*f*
risk factors, 1331
- Chronic otitis media, 1724–25
- Chronic pain, 174. *See also* Pain
- Chronic pancreatitis, 727, 727*t*. *See also* Pancreatitis
- Chronic pyelonephritis, 848–49. *See also* Urinary tract infection
- Chronic rejection, 921–22
- Chronic renal failure:
Case Study, 931*t*
causes, 913–14, 914*f*
definition, 899
genetic considerations, 839*t*
incidence, 913
interdisciplinary care
diagnosis, 918
medications, 918–19
nutrition and fluid management, 919
renal replacement therapies
dialysis, 919–20. *See also* Dialysis
kidney transplant. *See* Kidney transplant
- manifestations and complications
cardiovascular, 916
dermatologic, 918
endocrine and metabolic, 918
fluid and electrolytes, 915–16
gastrointestinal, 916
hematologic, 916
immune system, 916
musculoskeletal, 918
neurologic, 916
- Multisystem Effects, 917*t*
nursing care
assessment, 923
community-based care, 926
health promotion, 923
nursing diagnoses and interventions
disturbed body image, 925
imbalanced nutrition: less than body requirements, 923, 925
ineffective tissue perfusion: renal, 923
risk for infection, 925
in older adults, 914*t*
- Nursing Care Plan
assessment, 924*t*
critical thinking in the nursing process, 924*t*
diagnoses, 924*t*
evaluation, 924*t*
expected outcomes, 924*t*
planning and implementation, 924*t*
pathophysiology, 914–15, 915*f*; 915*t*
stages, 916*t*
- Chronic sorrow, 97
- Chronic tissue rejection, 342–43, 343*t*
- Chronic venous insufficiency:
definition, 1194
interdisciplinary care, 1194–95
manifestations, 1194, 1194*f*, 1194*t*, 1195*t*
nursing care, 1195, 1196*t*
Nursing Research: rest periods for improved healing, 1196*t*
in older adults, 1196*t*
pathophysiology, 1194
- Chronulac. *See* Lactulose
- Chvostek's sign, 229, 229*f*; 531*t*
- Chylothorax, 1295
- CI (cardiac index), 941, 1031
- Cialis. *See* Tadalafil
- Cibacalcin. *See* Calcitonin
- Cigarette smoking. *See* Smoking
- Ciliary body, 1672, 1672*f*
- Cilostazol, 1177
- Cimetidine:
Medication Administration, 665*t*
preoperative use and nursing implications, 62*t*
in specific conditions
gastritis, 678
gastroesophageal reflux disease, 665
pancreatitis, 728
- CIN (cervical intraepithelial neoplasia), 1812, 1813*t*
- Cingulate herniation, 1537, 1538*f*. *See also* Increased intracranial pressure
- Cipro. *See* Ciprofloxacin
- Ciprofloxacin:
Medication Administration, 320*t*
in specific conditions
anthrax prophylaxis and treatment, 128*t*, 1294
diverticulitis, 816
epiglottitis, 1241
gastroenteritis, 776
gonorrhea, 1846
urinary tract infection, 849
- Circle of Willis, 1508*f*
- Circulating nurse, 65–66
- Circumduction, 1386*t*
- Circumferential aneurysm, 1170, 1170*f*
- Circumflex artery, 939*f*; 958
- Cirrhosis:
complications
ascites, 711
esophageal varices, 711
hepatorenal syndrome, 716
portal hypertension, 711
portal systemic encephalopathy, 715, 715*t*
splenomegaly, 711
spontaneous bacterial peritonitis, 716
definition, 710
incidence and mortality, 710
interdisciplinary care
diagnosis, 617*t*, 716
medications, 716, 717*t*
treatments
liver transplant. *See* Liver transplant
management of complications, 717–19
nutrition, 717
manifestations, 711, 715*t*
- Multisystem Effects, 714*t*
nursing care
assessment, 720–21
health promotion, 720
Medication Administration, 717*t*
nursing diagnoses and interventions
community-based care, 723
disturbed thought processes, 722
excess fluid volume, 722
imbalanced nutrition: less than body requirements, 723
impaired skin integrity, 723
inefficient protection, 722
using NANDA, NIC, and NOC, 723, 723*t*
- Nursing Care Plan
assessment, 721*t*
critical thinking in the nursing process, 721*t*
diagnoses, 721*t*
evaluation, 721*t*
expected outcomes, 721*t*
planning and implementation, 721*t*
pathophysiology, 710–11, 712–13*t*
racial/ethnic considerations, 711*t*
types
alcoholic, 710, 711
biliary, 711
posthepatic, 711
- Cisraccium, 1356*t*

- Cisplatin:
 adverse/side effects, 394*t*, 1730
 mechanisms of action, 390
 nursing implications, 394*t*
 in specific conditions
 bone tumors, 1483*t*
 laryngeal cancer, 1254
 ovarian cancer, 1819
 testicular cancer, 1775
 target malignancies, 394*t*
- Citrucel. *See* Methylcellulose
- CIWA-Ar (Clinical Institute Withdrawal Assessment of Alcohol-Revised), 112, 117, 118*f*
- CK. *See* Creatine kinase
- CK-MB. *See* Creatine kinase-MB
- Cl⁻. *See* Chloride (Cl⁻)
- Claforan. *See* Cefotaxime
- Clarifying, 6
- Clarithromycin, 320*t*
- Claritin. *See* Loratadine
- Clark staging, melanoma, 467, 468*f*
- Classic migraine, 1543. *See also* Headache
- Clavicle, fracture, 1412-13
- Clavulanic acid sulbactam, 320*t*
- Claw toe, 1492
- Clemastine, 1230*t*
- Cleocin. *See* Clindamycin
- Client, 5
- Climacteric, 1795. *See also* Menopause
- Clindamycin:
 for acne, 458
 for endocarditis prophylaxis, 1047*t*
 for epiglottitis, 1241
 for lung abscess, 1280
 for pelvic inflammatory disease, 1851
 for peritonitis, 770
- Clinical Institute Withdrawal Assessment of Alcohol-Revised (CIWA-Ar), 112, 117, 118*f*
- Clinical Opiate Withdrawal Scale (COWS), 117
- Clinical Scenarios:
 bowel elimination alterations, 825*t*
 cardiac function alterations, 1072*t*
 endocrine function alterations, 601*t*
 home care, 50*t*
 integumentary structure and function alterations, 514*t*
 musculoskeletal function alterations, 1498*t*
 neurologic function alterations, 1666*t*
 nutritional alterations, 736*t*
 pathophysiology and patterns of health, 417*t*
 patterns of health alterations, 144*t*
 peripheral tissue perfusion alterations, 1206*t*
 reproductive function alterations, 1855*t*
 respiratory function alterations, 1376*t*
 urinary elimination alterations, 930*t*
 visual and auditory function alterations, 1738*t*
- Clinoril. *See* Sulindac
- Clitoris:
 anatomy, 1751*t*, 1752, 1752*f*
 physical assessment, 1763*t*
- CLL. *See* Chronic lymphocytic leukemia
- Clofibrate, 967*t*
- Clomid. *See* Clomiphene
- Clomiphene, 1809
- Clonazepam, 1550*t*
- Clones, 297
- Clonidine, 1162*t*
- Clopidogrel:
 Medication Administration, 976*t*
 in specific conditions
 acute coronary syndrome, 976, 976*t*
 peripheral vascular disease, 1177
 stroke prevention, 1585
- Clorotione, 441*t*
- Closed (flap) amputation, 1421, 1422*t*. *See also* Amputation
- Closed (simple) fracture, 1401, 1402*f*. *See also* Fractures
- Closed pneumothorax, 1299. *See also* Pneumothorax
- Closed-loop obstruction, 811, 812, 812*f*. *See also* Intestinal obstruction
- Clostridium*, 1407
- Clostridium botulinum*, 1661-62
- Clostridium difficile*:
 colitis, 774*t*, 775
 nosocomial infection, 313, 314
 treatment, 314
- Clostridium perfringens*, 267
- Clostridium tetani*, 1661
- Clotrimazole:
 Medication Administration, 450*t*, 658*t*
 troches, for thrush, 359*t*, 657*t*, 658, 658*t*
- Clotting. *See* Coagulation
- Cloxacillin, 447
- Clubbing:
 fingers, 1342, 1342*f*
 nails, 436*f*, 436*t*
- Cluster breathing, 1530*t*
- Cluster headache, 1542*t*, 1543. *See also* Headache
- CMG. *See* Cystometrogram
- CML. *See* Chronic myeloid leukemia
- CMV. *See* Cytomegalovirus
- CNS. *See* Central nervous system
- CO. *See* Cardiac output
- CO₂. *See* Carbon dioxide
- Coagulation:
 definition, 1079
 disorders
 disseminated intravascular coagulation. *See* Disseminated intravascular coagulation
 hemophilia. *See* Hemophilia
 thrombocytopenia. *See* Thrombocytopenia
 factors, 1082*t*
 stages
 clot dissolution, 1081
 clot retraction, 1080
 fibrin clot formation, 1080, 1081*f*
 platelet plug formation, 1080, 1080*f*
 vessel spasm, 1080
- Coagulation studies:
 in disseminated intravascular coagulation, 1148
 in hemophilia, 1144
 in pulmonary embolism, 1349
- Coal tar derivatives, 441*t*, 444
- Coal worker's pneumoconiosis, 1345
- Coarctation of the aorta, 1167
- Cocaine:
 characteristics, 108
 effects, 108
 myocardial infarction induced by, 984
 overdose signs and treatment, 108, 113*t*
 street names, 111*t*
 topical, for epistaxis, 1243
 use in pregnancy, 109
 withdrawal signs and treatment, 113*t*
- Coccidioides immitis*, 1294
- Coccidiomycosis, 1294
- Coccidiosis. *See* Cryptosporidiosis
- Cochlea, 1683, 1683*f*
- Cochlear implant, 1731-32, 1732*f*
- Code of ethics, 10. *See also* Nursing ethics, codes
- Codeine, 62*t*, 180*t*, 182*t*
- Codependence, 103*t*
- Codylax. *See* Bisacodyl
- Coenzyme Q10, 1036, 1621
- Cogentin. *See* Benztropine
- Cognex. *See* Tacrine hydrochloride
- Cognition, 1529
- Cognitive behavioral therapy, 110, 652
- Cognitive function:
 assessment, 1519*t*
 health and, 19
 impairments, special considerations in disasters, 140
- Cognitive-perceptual patterns:
 altered neurologic function. *See also* Neurologic system
 Build Clinical Competence, 1665*t*
 Clinical Scenarios, 1666*t*
 altered visual and auditory function. *See also* Ears; Eyes
 Build Clinical Competence, 1737*t*
 Clinical Scenarios, 1738*t*
 NANDA nursing diagnoses, 1501*t*
- Cogwheel rigidity, 1635
- Colace. *See* Docusate
- Colchicine, 1445, 1446*t*
- Cold phase, septic shock, 275, 275*t*
- Cold sore. *See* Herpes simplex
- Cold zone, in disaster, 134*t*
- Colectomy, 788, 789*f*
- Colesevelam, 967*t*
- Colestid. *See* Colestipol
- Colestipol, 967*t*
- Colitis:
 functional. *See* Irritable bowel syndrome
 ulcerative. *See* Ulcerative colitis
- Collagen disorders. *See* Connective tissue disorders
- Collagenase, 504
- Collateral channels/vessels, 958, 984
- Colles's fracture, 1413
- Colloid solutions, 277-78, 279*t*
- Colon, 742*f*, 743
- Colonoscopy:
 in bowel disorders, 745*t*
 for colorectal cancer screening/diagnosis, 401*t*, 802, 803
 in diverticular disease, 816
- Colony-stimulating factors, 1123, 1139
- Color Doppler echocardiography, 945*t*
- Colorectal cancer:
 complications, 802
 incidence, 801
 interdisciplinary care
 chemotherapy, 805
 diagnosis, 802-3
 laser photocoagulation, 803
 prevention, 802
 radiation therapy, 805
 screening, 401*t*, 802
 staging, 803, 803*t*
 surgery
 colostomy. *See* Colostomy
 local excision, 803
 resection, 803
 manifestations, 802
 nursing care
 assessment, 805
 colostomy, 806*t*
 community-based care, 808-9
 health promotion, 805
 nursing diagnoses and interventions
 acute pain, 806-7
 anticipatory grieving, 808
 imbalance nutrition: less than body requirements, 808
 risk for sexual dysfunction, 808
 postoperative, 804*t*
 preoperative, 804*t*
 using NANDA, NIC, and NOC, 808, 809*t*

- Colorectal cancer—*continued*
 Nursing Care Plan
 assessment, 807*t*
 critical thinking in the nursing process, 807*t*
 diagnoses, 807*t*
 evaluation, 807*t*
 expected outcomes, 807*t*
 planning and implementation, 807*t*
 pathophysiology, 802, 802*f*
 risk factors, 801–2, 801*t*
- Color-flow Doppler ultrasound, 1177
- Colostomy:
 definition, 803
 dietary considerations, 806*t*
 double-barrel, 804, 805*f*
 Hartmann procedure, 805
 health assessment interview, 746
 levels and sites, 803–4, 804*f*
 nursing care, 806*t*
 sigmoid, 804
 transverse loop, 804
- Colporrhaphy, 1806
- Colposcopy, 1757*t*
- Coma, 1529*t*. *See also* Altered level of consciousness
- Comatose client, nursing care, 93
- Combivent. *See* Albuterol/ipratropium
- Combivir. *See* Lamivudine; Zidovudine
- Comedones, 457
- Comminuted fracture. *See also* Fractures
 characteristics, 1402*f*
 definition, 1401
 skull, 1555, 1555*t*. *See also* Skull fracture
- Common cold. *See* Upper respiratory disorders, viral infections
- Common migraine, 1543. *See also* Headache
- Common wart, 452, 452*f*
- Communicable disease, 22*t*
- Communication accommodation theory, 65*t*
- Community health care, 36
- Community-based care, 36. *See also* Community-based nursing care
- Community-based healthcare services:
 community centers and clinics, 37
 day care programs, 37
 Meals-on-Wheels, 38
 parish nursing, 37–38
- Community-based nursing care:
 Chapter Highlights, 47–48*t*
 definition, 36
 end-of-life care, 97
 factors affecting health
 community healthcare structure, 37
 economic resources, 37
 environment, 37
 social support systems, 37
 pain management, 190, 190*t*
 postoperative, 80
 settings, 36*t*
 substance abuse, 120–21
- Compartment syndrome:
 in burn injuries, 495
 manifestations, 1403, 1403*t*
 pathophysiology, 495, 1403
 treatment, 1406
- Compazine. *See* Prochlorperazine
- Compensation, in acid–base disorders, 241–42, 243*t*
- Complement assay, 336, 341
- Complement system, 294*t*
- Complementary and alternative therapies:
 for asthma, 1326
 for benign prostatic hyperplasia, 1781
 for cancer, 398–99, 399*t*
 for chronic obstructive pulmonary disease, 1335
 for conjunctivitis, 1694–95
 for constipation, 760–61
 for coronary heart disease, 968, 968*t*
 for diarrhea, 755
 for gallstones, 701
 for gastritis, 679
 for gout, 1445
 for headache, 1544
 for heart failure, 1036
 for hepatitis, 709
 herbal supplements as surgical risk factor, 58*t*, 59
 for hypertension, 1163
 for inflammatory bowel disease, 792
 for irritable bowel syndrome, 763
 for leukemia, 1125
 for lung cancer, 1313
 for menopausal symptoms, 1796
 for nausea and vomiting, 672
 for pain management
 acupuncture, 185
 biofeedback, 185
 cutaneous stimulation, 186
 distraction, 186
 hypnotism, 185
 relaxation, 185–86
 for pancreatitis, 728
 for peripheral vascular disease, 1178
 for urinary incontinence, 875–76
 for urinary tract infection, 851
- Complete blood count (CBC):
 components, 1078*t*
 normal values, 1078*t*
 purpose and description, 1087*t*
 in specific conditions
 acute myocardial infarction, 986
 acute renal failure, 904
 anemias, 1110
 burns, 500
 chronic obstructive pulmonary disease, 1334
 chronic renal failure, 918
 disseminated intravascular coagulation, 1148
 leukemia, 1122, 1123*t*
 lymphoma, 1131
 multiple myeloma, 1137
 myelodysplastic syndrome, 1115
 pericarditis, 1051
 pharyngitis, 1239
 pneumonia, 1271
 rheumatic fever, 1043
 systemic lupus erythematosus, 1473
- Complete fracture, 1402. *See also* Fractures
- Complete heart block, 999*t*, 1003
- Completed stroke, 1581
- Complex partial seizures, 1549
- Complex regional pain syndrome, 174
- Compliance, 1023, 1024*t*, 1536
- Compound (open) fracture, 1401, 1402*f*. *See also* Fractures
- Compressed fracture, 1401, 1402*f*
- Compression, 256
- Compression sclerotherapy, 1197
- Computed tomography (CT):
 abdomen
 adrenals, 526*t*
 in aortic aneurysm, 1173
 pancreas, 526*t*
 brain
 in altered level of consciousness, 1532
 in brain tumor, 1571
 client preparation, 1514*t*
 health education for the client and family, 1514*t*
 in multiple sclerosis, 1627
 purpose and description, 1514*t*
 related nursing care, 1514*t*
 in stroke, 1584
- in cancer, 384
- ear, 1727
- electron beam. *See* Electron beam computed tomography
- eye, 1674*t*
- gastrointestinal system, 616*t*
- heart, 945*t*
- kidneys, 837*t*, 857
- lungs
 in lung cancer, 1312
 in pulmonary embolism, 1349
- lymphatic system, 1088*t*
- musculoskeletal system, 1387*t*
- principles, 384
- sinuses, 1236
- thorax, 1218*t*
- COMT (catechol-*O*-methyltransferase) inhibitors, 1638*t*, 1639
- Comtan. *See* Entacapone
- Comtrex. *See* Phenylpropranolamine
- Concentric plaque formation, 959
- Concussion, 1558*t*, 1559. *See also* Traumatic brain injury
- Condoms:
 female, 1838*t*
 male, 1838*t*
 in safer sex practices, 359, 361*t*, 1838*t*
- Conduction system, heart, 941, 941*f*, 995
- Conductive hearing loss, 1729–30. *See also* Hearing loss
- Conductivity, 995*t*
- Condyloma lata, 1848
- Condylomata acuminata, 1841, 1841*f*. *See also* Genital warts
- Condylox. *See* Podophyllin
- Cones, 1672
- Confusion, 1529*t*
- Congenital disease, 22*t*
- Congenital lymphedema, 1199*t*
- Congenital nevi, 466
- Congestive heart failure, 1022. *See also* Heart failure
- Conization:
 purpose and description, 1757*t*, 1813, 1813*f*
 related nursing care, 1757*t*
- Conjugated bilirubin, 699*t*
- Conjunctiva, 1670
- Conjunctivitis:
 acute, 1692–93
 causes, 1694*t*
 definition, 1692
 eye disorders
 nursing care
 assessment, 1695
 community-based care, 1695
 health promotion, 1695, 1695*t*
 nursing diagnoses and interventions, 1695
 using NANDA, NIC, and NOC, 1695, 1696*t*
 interdisciplinary care
 complementary and alternative therapies, 1694–95
 diagnosis, 1694
 medications, 1694*t*
 manifestations, 1693, 1694*f*
 nursing care
 assessment, 1695
 community-based care, 1695
 health promotion, 1695, 1695*t*
 nursing diagnoses and interventions
 risk for disturbed sensory perception:
 visual, 1695
 risk for infection, 1695

- using NANDA, NIC, and NOC, 1695, 1696*t*
- pathophysiology, 1692–94
- Connective tissue disorders:
 - fibromyalgia. *See* Fibromyalgia
 - polymyositis. *See* Polymyositis
 - scleroderma. *See* Scleroderma
 - Sjögren's syndrome, 1486
 - systemic lupus erythematosus. *See* Systemic lupus erythematosus
- Conscious sedation, 63–64
- Consciousness, 1529. *See also* Altered level of consciousness
- Consolidation, 1268
- Constipation:
 - causes, 758*t*
 - definition, 743, 758
 - interdisciplinary care
 - complementary and alternative therapies, 760–61
 - diagnosis, 758
 - enemas, 760
 - medications, 758–59*t*
 - nutrition, 760
 - manifestations, 758
 - nursing care
 - assessment, 761
 - community-based care, 761–62
 - health promotion, 761
 - Medication Administration, 758–59*t*
 - nursing diagnoses and interventions, 761
 - in older adults, 761*t*
 - pathophysiology, 758
- Constructive procedure, 54*t*
- Contact. *See* Phenylpropanolamine
- Contact dermatitis, 335, 456, 456*f*, 456*t*, 457
- Contact inhibition, 376
- Contact lenses, 1695*t*, 1697
- Contact precautions, 323*t*
- Continent ileal diversion, 864, 864*f*, 865*t*
- Continent ileostomy, 789, 789*f*
- Continuous ambulatory peritoneal dialysis (CAPD), 920
- Continuous arteriovenous hemodialysis, 907*t*, 909*f*
- Continuous arteriovenous hemofiltration, 907*t*
- Continuous cyclic peritoneal dialysis (CCPD), 920
- Continuous positive airway pressure (CPAP):
 - in acute respiratory failure, 1355
 - characteristics, 1358, 1359*t*
 - nasal, for obstructive sleep apnea, 1250, 1251*f*
- Continuous renal replacement therapy (CRRT), 906, 907–8, 907*t*
- Continuous venovenous hemodialysis, 907*t*
- Contractility, 1383
- Contractility, 940, 995, 1024
- Contracting, 42
- Contractures:
 - after amputation, 1423
 - in burn injuries, 490, 490*f*, 504
 - definition, 1423
 - Volkman's, 1406, 1413
- Contralateral deficit, 1580
- Contrast venography, 1188
- Control zone, in disaster, 134*t*
- Contusions:
 - cerebral, 1557. *See also* Traumatic brain injury
 - musculoskeletal, 259, 259*f*, 1399
 - pulmonary, 1303. *See also* Thoracic trauma
- Conventional weapons, 127
- Convergence, 1673, 1678*t*
- Co-occurring disorders, 103, 103*t*
- Cooley's anemia, 1109. *See also* Thalassemias
- Coordination, assessment, 1523*f*, 1523*t*
- Copaxone. *See* Glatiramer acetate
- COPD. *See* Chronic obstructive pulmonary disease
- Copolymer-1. *See* Glatiramer acetate
- Copper, 610*t*
- Cor pulmonale, 1352–53
- Cordarone. *See* Amiodarone
- Cordotomy, 184, 185*f*
- Core competencies:
 - for healthcare professionals, 5, 5*t*
 - for nurses responding to mass casualty incidents, 126, 126*t*
- Core needle biopsy, breast, 1757*t*
- Coreg. *See* Carvedilol
- Corgard. *See* Nadolol
- Corlopam. *See* Fenoldopam
- Cornea:
 - age-related changes, 1676*t*
 - anatomy, physiology, and functions, 1671, 1672*f*, 1696
 - assessment, 1679
 - disorders. *See* Corneal disorders
 - transplant. *See* Corneal transplant
- Corneal arcus, 1679
- Corneal disorders:
 - dystrophies, 1697
 - interdisciplinary care
 - corrective lenses, 1697
 - disease, 1697
 - medications, 1697
 - surgery, 1697–98. *See also* Corneal transplant
 - keratitis, 1696
 - manifestations, 1697–98
 - nursing care
 - assessment, 1698
 - of client having eye surgery
 - health education for the client and family, 1699*t*
 - postoperative care, 1699*t*
 - preoperative care, 1699*t*
 - community-based care, 1700
 - health promotion, 1698
 - nursing diagnoses and interventions
 - acute pain, 1700
 - risk for disturbed sensory perception: visual, 1698–99
 - risk for injury, 1700
 - pathophysiology, 1697–98
 - refractive errors, 1696
 - trauma, 1694*t*, 1701–2. *See also* Eyes, trauma
 - ulcer, 1696–97
- Corneal dystrophy, 1697
- Corneal light (red) reflex, 1678*t*, 1680
- Corneal reflex, 1520*t*, 1671
- Corneal transplant:
 - graft harvest, 1697
 - indications, 342*t*
 - procedure, 1697–98, 1698*f*
 - success rate, 342*t*
- Corneal ulcer, 1696–97
- Cornstarch, 441*t*
- Coronary angiography. *See* Cardiac catheterization
- Coronary arteriography. *See* Cardiac catheterization
- Coronary artery bypass grafting (CABG):
 - effectiveness, 977–78
 - nursing care
 - postoperative nursing diagnosis and interventions
 - acute pain, 981*t*
 - decreased cardiac output, 980*t*
 - disturbed thought processes, 982*t*
 - hypothermia, 980–81*t*
 - ineffective airway clearance/impaired gas exchange, 981*t*
 - risk for infection, 981*t*
 - preoperative, 980*t*
- Nursing Care Plan
 - assessment, 983*t*
 - critical thinking in the nursing process, 983*t*
 - diagnoses, 983*t*
 - evaluation, 983*t*
 - expected outcomes, 983*t*
 - planning and implementation, 983*t*
 - off-pump, 978
 - procedure, 977*f*, 978–79
- Coronary artery disease. *See* Coronary heart disease
- Coronary circulation, 938, 938*f*
- Coronary heart disease (CHD):
 - categories, 962
 - Chapter Highlights, 1019*t*
 - Framingham Heart Study, 962*t*
 - incidence and prevalence, 958
 - interdisciplinary care
 - complementary therapies, 968, 968*t*
 - diagnosis, 965–66
 - medications, 966–68, 967*t*
 - risk factor management
 - diabetes, 966
 - diet, 966, 966*t*
 - exercise, 966
 - hypertension, 966
 - smoking, 966
 - nursing care
 - assessment, 968
 - community-based care, 969
 - health promotion, 968
 - Medication Administration, 967*t*
 - nursing diagnoses and interventions
 - imbalanced nutrition: more than body requirements, 968–69
 - ineffective health maintenance, 969
 - pathophysiology
 - angina pectoris, 961*t*
 - atherosclerosis, 959, 960*t*
 - myocardial ischemia, 959, 961*t*, 962, 962*t*
 - racial/ethnic considerations, 958*t*
 - risk factors
 - diabetes mellitus, 587–88
 - modifiable
 - cigarette smoking, 964
 - diabetes mellitus, 963
 - diet, 964
 - emerging, 964
 - hyperlipidemia, 963, 963*t*
 - hypertension, 963
 - metabolic syndrome, 964, 964*t*
 - obesity, 964
 - overview, 963*t*
 - physical inactivity, 964
 - in women, 964
 - nonmodifiable, 962, 963*t*
 - rheumatoid arthritis, 1462, 1463
 - sudden cardiac death in, 1015
 - Coronavirus, 1276–77
 - Corpora cavernosa, 1744
 - Corpus callosum, 1505
 - Corpus luteum, 1753
 - Corpus spongiosum, 1744
 - Corrective lenses, 1697
 - Corticosteroids:
 - adverse/side effects, 344, 391, 1434, 1704
 - Medication Administration, 555*t*, 787–88*t*, 1328*t*, 1631*t*
 - site of action, 344*f*
 - in specific conditions
 - acute respiratory distress syndrome, 1367
 - acute respiratory failure, 1355
 - Addison's disease, 555*t*
 - asthma, 1326, 1328*t*

- Corticosteroids—*continued*
 bacterial meningitis, 1566
 cancer, 391
 chronic obstructive pulmonary disease, 1334
 glomerular disorders, 890–91
 gout, 1445
 hypercalcemia, 232
 hypersensitivity responses, 338
 inflammation, 307, 441*t*
 inflammatory bowel disease, 786, 787–88*t*
 multiple sclerosis, 1627, 1631*t*
 myasthenia gravis, 1649
 organ transplantation, 344, 921
 pemphigus vulgaris, 460
 pruritus, 441*t*
 spinal cord injury, 1599
 systemic lupus erythematosus, 1473
 thrombocytopenia, 1141
 topical
 in pruritus, 440, 441*t*
 psoriasis, 444
 in stasis dermatitis, 1194
- Cortisol, 524*t*, 549, 550*t*
 Cortisol replacements, 555*t*
 Cortisone, 555*t*
 Cortisporin Otic. *See* Polymyxin B-neomycin-hydrocortisone
 Corvert. *See* Ibutilide
Corynebacterium diphtheriae, 1241. *See also* Diphtheria
 Coryza, 1229
 Cosmetic surgery:
 frequency, 478*t*
 procedures
 blepharoplasty, 479
 rhinoplasty, 479
 rhytidectomy, 479
- Cotton-wool spots, 1046
 Coughing exercise, 72*t*
 Coughing techniques, in respiratory disorders, 1341*t*
 Cough-variant asthma, 1324
 Coumadin. *See* Warfarin
 Countercurrent exchange system, 833–34, 833*f*
 Counterirritants, 1451
 Coup-contrecoup head injury, 1554, 1554*f*
 Cover-uncover test, 1678
 Cowper's glands. *See* Bulbourethral glands
 COWS (Clinical Opiate Withdrawal Scale), 117
 COX-2 (cyclooxygenase-2) inhibitors, 178, 681, 1451. *See also* Nonsteroidal anti-inflammatory drugs
 Cozaar. *See* Losartan
 CPAP. *See* Continuous positive airway pressure
 CPB (cardiopulmonary bypass), 978, 979*f*
 CPP (cerebral perfusion pressure), 1560*t*
 CPR. *See* Cardiopulmonary resuscitation
 CPS (central pain syndrome), 1582
 Crackles, 1226*t*
 "Cradle cap," 457
 Cranberry juice, for urinary tract infection, 851
 Cranial nerves:
 anatomy, 1509, 1510*f*
 assessment
 abnormal findings, 1223*t*, 1519–21*t*
 sample documentation, 1512
 technique/normal findings, 1223*t*, 1519–21*t*
 controlling eye muscles, 1671*f*
 disorders
 Bell's palsy. *See* Bell's palsy
 trigeminal neuralgia. *See* Trigeminal neuralgia
 functions, 1511*t*
 Craniectomy, 1571
 Craniocerebral trauma. *See* Traumatic brain injury
 Craniopharyngioma, 1570*t*. *See also* Brain tumors
- Cranioplasty, 1571
 Craniotomy, 1571, 1571*f*
 C-reactive protein (CRP):
 abnormal, possible causes, 386*t*
 in coronary heart disease, 965
 in inflammation, 306
 normal values, 386*t*
 in rheumatic fever, 1043
 Creams, for skin disorders, 441*t*
 Creatine kinase (CK):
 in acute coronary syndrome, 976
 in acute myocardial infarction, 986, 987*t*
 in musculoskeletal system assessment, 1388*t*
 Creatine kinase-MB (CK-MB):
 in acute coronary syndrome, 976
 in acute myocardial infarction, 986, 987*t*
 Creatine phosphokinase, 500
 Creatinine, 834. *See also* Serum creatinine
 Creatinine clearance:
 normal values, 890*t*
 in perioperative assessment, 61
 purpose and description, 836*t*
 related nursing care, 836*t*
 in specific conditions
 chronic renal failure, 918
 glomerular disorders, 890, 890*t*
 Credé's method, 871
 Cremasteric reflex, 1524*t*
 Crepitation, 1392*t*
 Crescendo-decrescendo pattern, 970
 CREST syndrome, 1485
 Creutzfeldt-Jakob disease:
 characteristics, 1658
 forms, 1658
 incidence, 1658
 interdisciplinary care, 1659
 manifestations, 1659
 nursing care, 1659
 physical assessment, 1659
- Cricoid cartilage, 1211
 Critical pathway, 15
 Critical thinking:
 attitudes and mental habits for, 6
 definition, 6
 in nursing process, 6, 7*t*
 skills for, 6
- Crixivan. *See* Indinavir
 CRNA (certified registered nurse anesthetist), 65
 Crohn's disease. *See also* Inflammatory bowel disease
 characteristics, 782*t*, 785
 complications, 786
 manifestations, 786
 pathophysiology, 785–86
 progression, 785*f*
 Cromolyn sodium, 338, 1326, 1328*t*
 Cross-tolerance, 103*t*
 CRP. *See* C-reactive protein
 CRRT (continuous renal replacement therapy), 906, 907–8, 907*t*
 Crushing, 256
 Crust, skin, 431*t*, 433*t*
 Cryoprecipitate, 263*t*
 Cryosurgery, 453, 477
Cryptococcus, 354
 Cryptorchidism, 1750*t*
 Cryptosporidiosis, 778*t*, 779
Cryptosporidium, 354, 778*t*, 779
 Crystalloid solutions, 277, 499
 CT. *See* Computed tomography
 cTnI (cardiac-specific troponin I), 975–76, 986, 987*t*
 cTnT (cardiac-specific troponin T), 975–76, 986, 987*t*
- Cultural background/practices. *See* Race/ethnicity; *specific racial/ethnic groups*
 Culturally sensitive nursing care, 13*t*. *See also* Race/ethnicity; *specific racial/ethnic groups*
 Cultures:
 blood. *See* Blood cultures
 in infection, 316
 skin, 428*t*
 urine. *See* Urine tests, culture
 vaginal, 1756*t*
 Cuprimine. *See* Penicillamine
 Curel, 441*t*
 Curettage:
 for nonmelanoma skin cancer, 464
 postoperative care, 477
 procedure, 477
- Curling's ulcers, 496, 677
 Cushing's disease, 549
 Cushing's response (triad), 1537
 Cushing's syndrome:
 complications, 549
 definition, 548
 interdisciplinary care
 diagnostic tests, 524–25*t*, 549–50, 550*t*
 medications, 550
 surgery, 550, 550*t*
 management, 549, 549*t*
 manifestations, 548*f*
 nursing care
 assessment, 529–30*t*, 551
 of client having adrenalectomy, 550*t*
 community-based care, 552–53
 health promotion, 550
 nursing diagnoses and interventions
 disturbed body image, 552
 fluid volume excess, 551–52
 risk for infection, 552
 risk for injury, 552
 using NANDA, NIC, and NOC, 552, 553*t*
 Nursing Care Plan
 assessment, 551*t*
 critical thinking in the nursing process, 551*t*
 diagnoses, 551*t*
 evaluation, 551*t*
 expected outcomes, 551*t*
 planning and implementation, 551*t*
 pathophysiology, 548–49
 Cushing's ulcers, 677
 Cutaneous stimulation, 186
 Cutaneous T-cell lymphoma, 1130*t*. *See also* Lymphomas
 CVP. *See* Central venous pressure
 Cyanide poisoning, 496
 Cyanocobalamin. *See* Vitamin B₁₂
 Cyanosis:
 assessment in light and dark skin, 426*t*
 in cardiogenic shock, 274
 causes, 426*t*, 1093*t*
 definition, 425, 1093*t*, 1266
 Cyclobenzaprine hydrochloride, 1491, 1600*t*
 Cyclooxygenase-2 (COX-2) inhibitors, 178, 681, 1451. *See also* Nonsteroidal anti-inflammatory drugs
 Cyclophosphamide:
 adverse/side effects, 392*t*
 Medication Administration, 345*t*, 1474*t*, 1631*t*
 nursing implications, 392*t*
 in specific conditions
 bone tumors, 1483*t*
 glomerular disorders, 891
 leukemia, 1123*t*
 multiple myeloma, 1137
 multiple sclerosis, 1627, 1631*t*

- ovarian cancer, 1819
 systemic lupus erythematosus, 1474t
 target malignancies, 392t
- Cyclosporine:
 adverse/side effects, 344, 921
 Medication Administration, 345t, 1474t
 site of action, 344f
 in specific conditions
 inflammatory bowel disease, 786
 organ transplantation, 344, 921
 rheumatoid arthritis, 341
 systemic lupus erythematosus, 1474t
- Cyrimine, 1638t
- Cyst:
 definition, 1808
 of female reproductive tissue
 interdisciplinary care
 diagnosis, 1809
 medications, 1809
 surgery, 1809
 manifestations, 1809t
 nursing care, 1809
 pathophysiology, 1808
 skin, 432t, 442
- Cystectomy:
 nursing care, 866t
 nursing considerations, 864t
 procedure, 864, 864t
- Cystic fibrosis:
 definition, 1340
 genetic considerations, 152, 1220t, 1340t
 incidence, 1340–41
 interdisciplinary care
 diagnosis, 1342
 medications, 1342
 surgery, 1342
 treatments, 1342
 manifestations, 1342
 nursing care
 community-based care, 1343
 nursing diagnoses and interventions
 anticipatory grieving, 1343
 ineffective airway clearance, 1343
 pathophysiology, 1341–42
- Cystic medial necrosis, 1172, 1172t
- Cystine stones, 856, 856t. *See also* Urinary calculi
- Cystitis. *See also* Urinary tract infection
 bladder mucosa in, 847f
 complications, 848
 definition, 847
 manifestations, 847–49, 848t
- Cystocele, 1805, 1807t
- Cystography, 837t
- Cystometrogram (CMG):
 purpose and description, 836t
 related nursing care, 836t
 in specific conditions
 neurogenic bladder, 870
 urinary incontinence, 874
 urinary tract infection, 849
- Cystoscopy:
 purpose and description, 837t
 related nursing care, 837t
 in specific conditions
 bladder cancer, 863
 urinary calculi, 857
 urinary tract infection, 849
- Cytarabine, 1123t
- Cytokines, 297, 299t
- Cytomegalovirus (CMV):
 cancers associated with, 375t
 in HIV/AIDS, 353, 359t, 1718
- Cytomel. *See* Liothyronine sodium
- Cytosar. *See* Cytarabine
- Cytotoxic agents, 1474t. *See also*
 Chemotherapy
- Cytotoxic cells, 297. *See also* T lymphocytes
- Cytotoxic edema, 1537. *See also* Increased intracranial pressure
- Cytovene. *See* Ganciclovir
- Cytoxan. *See* Cyclophosphamide
- D**
- d4T. *See* Stavudine
- Daclizumab, 344, 345–46t
- Dalteparin, 1189t
- Danazol, 1822
- Dantrium. *See* Dantrolene
- Dantrolene, 1631t
- Daranide. *See* Dichlorophenamide
- Darvocet-N. *See* Propoxyphene napsylate
- Darvon. *See* Propoxyphene napsylate
- DASH (Dietary Approaches to Stop Hypertension)
 diet, 1159, 1160t
- Daughter cell, 150
- Daunorubicin, 1123t
- Dawn phenomenon, 582
- Daypro. *See* Oxaprozin
- D&C (dilation and curettage), 1803, 1803t
- DDAVP. *See* Desmopressin acetate
- ddI. *See* Didanosine
- D-dimer, 1349
- De novo mutation, 155
- Death and dying. *See also* End-of-life care; Loss and grief
 Chapter Highlights, 99t
 cultural and spiritual practices, 88, 89t
 definition, 85
 development of concepts of, 87, 87t
 family response, 94
 Focus on Cultural Diversity, 89t
 manifestations, 93, 94t
 nurses' reaction to, 94, 94f
 physiologic changes in dying client
 altered levels of consciousness, 93
 anorexia, nausea, and dehydration, 93
 dyspnea, 92–93
 hypotension, 93
 Manifestations, 92
 pain, 92
 postmortem care, 94
 support for client and family, 93
- Death anxiety:
 definition, 97
 NANDA, NIC, and NOC Linkages, 97t
 nursing interventions, 97
- Debridement:
 for burn injuries
 definition, 504
 enzymatic, 504
 in healing process, 294
 mechanical, 504
 surgical, 502
 for osteomyelitis, 1479, 1479t
- Decadron. *See* Dexamethasone
- Decadron Phosphate Respighaler. *See*
 Dexamethasone sodium phosphate
- Deceleration, in trauma, 256, 1596
- Decerebrate posturing, 1525f, 1525t
- Decompensation, 1025
- Decongestants, 1230t
- Decorticate posturing, 1525f, 1525t
- Deep coma, 1529t. *See also* Altered level of consciousness
- Deep partial-thickness burn, 490, 490f. *See also*
 Burns
- Deep tendon reflexes (DTRs):
 assessment, 1523f, 1523t
 physiology, 1511
- Deep venous thrombosis (DVT). *See also*
 Pulmonary embolism; Venous thrombosis
 complications, 1187
 fracture and, 1406
 incidence, 1186, 1347
 locations, 1187f
 manifestations, 1187, 1187t
 Nursing Care Plan
 assessment, 1191t
 critical thinking in the nursing process, 1191t
 diagnoses, 1191t
 evaluation, 1191t
 expected outcomes, 1191t
 planning and implementation, 1191t
 in ovarian cancer, 1818t
 postoperative
 assessment findings, 75
 nursing care, 75
 risk factors, 75
 prevention, 1406
 risk factors, 1186, 1186t, 1347, 1406, 1406t
 treatment, 1406
- Defecation, 743
- Defeminization, 481
- Deferasirox, 1116
- Defibrillation, 1008, 1008f, 1008t
- Deformation, 1596
- Degenerative disease, 22t
- Degenerative joint disease. *See* Osteoarthritis
- Dehiscence, 78, 78f
- Dehydration. *See also* Fluid volume deficit
 definition, 203
 in dying client, 93
 surgical risk and nursing implications, 57t
- Delavirdine, 358
- Delayed ejaculation, 1771
- Delayed union, 1407
- Delegation, 14
- Delirium tremens, 103t, 108
- Delta cells, pancreas, 521, 564
- Deltasone. *See* Prednisone
- Demadex. *See* Torsemide
- Demand pacing, 1010t. *See also* Pacemakers
- Dementia:
 in AIDS, 353
 Alzheimer type. *See* Alzheimer's disease
 causes, 1617, 1618t
 definition, 1617
 vs. delirium, 1617
 family home care of older adult with
 interventions, 43t
 nursing diagnosis, 43t
 outcome criteria, 43t
 frontotemporal, 1618t
 incidence, 1617
 Lewy body, 1618t
 pain assessment in, 175–76
 in Parkinson's disease, 1636
 vascular, 1618t
- Demerol. *See* Meperidine HCl
- Dendrite, 1504, 1504f
- Dendritic cells, 289, 290
- Dental health. *See* Oral health
- Deoxyribonucleic acid. *See* DNA
- Depade. *See* Naltrexone
- Depakene. *See* Valproic acid
- Depakote. *See* Valproic acid
- Depen Titrateable. *See* Penicillamine
- Dependence, 103t, 179t. *See also* Substance abuse
- Dependent rubor, 1177
- Depolarization, 942, 942f

- Depressants. *See* Central nervous system depressants
- Depressed fracture. *See also* Fractures
characteristics, 1402*f*
definition, 1401
skull, 1555, 1555*t*. *See also* Skull fracture
- Depression:
alcohol dependence and, 103
in diabetes mellitus, 589
pain perception and, 176
in Parkinson's disease, 1636
- Dermabrasion, 479
- Dermassage, 441*t*
- Dermatitis:
atopic, 456–57, 457*f*
contact, 335, 456, 456*f*, 456*f*
definition, 456
exfoliative, 457
interdisciplinary care, 457
nursing care, 457
seborrheic, 457
stasis, 1194
- Dermatomes, 173, 1510*f*
- Dermatophytoses, 448–49, 448*f*
- Dermis, 423–24, 423*t*, 424*f*. *See also* Skin
- DES. *See* Diethylstilbestrol
- Desenex. *See* Undecylenic acid
- Desferal. *See* Desferrioxamine
- Desferrioxamine, 1116
- Desmopressin acetate, 1144
- Desonide, 441*t*
- Detoxification, 103*t*
- Detrol, Detrol LA. *See* Tolterodine
- Development:
adult, theories of, 25*t*
family, stages of, 31–33
- Developmental tasks (Havighurst), 25*t*
- DEXA (dual energy x-ray absorptiometry), 1387*t*, 1436
- Dexamethasone:
Medication Administration, 555*t*
in specific conditions
Addison's disease, 555*t*
bacterial meningitis, 1566
epiglottitis, 1241
hirsutism, 482
inflammation, 441*t*
nausea and vomiting, 672
polycystic ovarian syndrome, 1809
- Dexamethasone sodium phosphate, 1328*t*
- Dexamethasone suppression test, 386*t*, 525*t*
- Dexatrim. *See* Phenylpropanolamine
- Dexchlor. *See* Dexchlorpheniramine
- Dexchlorpheniramine, 1230*t*
- Dextran 40, 279*t*
- Dextran 70, 279*t*
- Dextran 75, 279*t*
- Dextrose solutions, 205–6, 207*t*
- DHT (dihydrotestosterone), 1777
- Diabeta. *See* Glyburide
- Diabetes insipidus:
antidiuretic hormone production in, 202
interdisciplinary care, 523*t*, 559
manifestations, 559
nursing care, 559
pathophysiology, 559
vs. SIADH, 559*t*
- Diabetes mellitus:
Case Study, 602*t*
Chapter Highlights, 598*t*
classification and characteristics, 564, 566*t*
complications
cardiovascular
1579–1580, 588
coronary artery disease, 587–88, 963, 966
hypertension, 588
peripheral vascular disease, 588
stroke, 588
foot problems, 590, 590*f*, 591*t*
hyperglycemia
dawn phenomenon, 582
diabetic ketoacidosis. *See* Diabetic ketoacidosis
hyperosmolar hyperglycemic state. *See* Hyperosmolar hyperglycemic state
Somogyi phenomenon, 582
hypoglycemia
assessments, 584*t*
laboratory findings, 584*t*
manifestations, 586–87, 587*t*
pathophysiology, 586–87
risk factors, 584*t*
treatment, 584*t*, 587
infections, 589, 1478
mood alterations, 589
Multisystem Effects, 583*t*
nephropathy. *See* Diabetic nephropathy
neuropathies, 588–89
in older adults, 567–68, 568*t*
periodontal disease, 589–90
retinopathy. *See* Diabetic retinopathy
ethnic considerations, 564*t*
Genetic Considerations, 527*t*
incidence and prevalence, 563–464
interdisciplinary care
diagnosis
management, 569
screening, 569
exercise, 580–81
medications
aspirin therapy, 576
hypoglycemic agents, 576, 578*t*
insulin. *See* Insulin
monitoring blood glucose
factors affecting glucose meter performance, 570–71
self-monitoring of blood glucose, 570, 570*f*
urine testing, 569–70, 570*t*
nutrition
alcohol, 579
carbohydrates, 576–77
diet plan for the older adult, 580
fiber, 579
goals, 576
meal planning, 579
protein, 577, 579
sick-day management, 580
sodium, 579
sweeteners, 579
preoperative and postoperative considerations, 581–82
surgical treatment, 581
Multisystem Effects, 583*t*
nursing care
assessment, 530*t*, 591
community-based care, 596–97
foot care teaching, 591*t*, 594*t*
health promotion, 590
Medication Administration
hypoglycemic agents, 578*t*
insulin, 573*t*
intravenous insulin, 586*t*
nursing diagnoses and interventions
ineffective coping, 595–96
risk for impaired skin integrity, 591–92
risk for infection, 592
risk for injury, 594–95
sexual dysfunction, 595
using NANDA, NIC, and NOC, 596, 596*t*
- Nursing Care Plan
assessment, 593*t*
critical thinking in the nursing process, 593*t*
diagnoses, 593*t*
evaluation, 593*t*
expected outcomes, 593*t*
planning and implementation, 593*t*
- Nursing Research: individualized teaching about
foot care, 591*t*
in older adults, 567–68, 568*t*
surgical considerations in
insulin needs, 59*t*, 61, 572–73, 581–82
perioperative management, 581–82
surgical risk and nursing implications, 57*t*
- type 1
characteristics, 566*t*
definition, 563
manifestations, 565–66*t*
pathophysiology, 565, 567*f*
risk factors, 565
- type 2
characteristics, 566*t*
definition, 563
incidence, 567
manifestations, 567
pathophysiology, 566, 567
risk factors, 567
- Diabetic ketoacidosis (DKA):
assessments, 584*t*
laboratory findings, 584*t*
manifestations, 582, 585*t*
pathophysiology, 582, 585*f*
risk factors, 584*t*
treatment, 582, 584–85, 584*t*, 585*t*
- Diabetic nephropathy, 588–89, 889. *See also* Glomerular disorders
- Diabetic retinopathy:
characteristics, 1714–15
incidence, 588, 1715
interdisciplinary care, 1715–16
manifestations, 1715, 1715*f*
nursing care, 1716
pathophysiology, 588, 1715
stages, 588
- Diagnosis, nursing. *See* Nursing diagnosis
- Diagnosis-related groups (DRGs), 38
- Diagnostic peritoneal lavage, 261, 725
- Diagnostic procedure, 54*t*
- Diagnostic Tests:
bowel disorders, 744–45*t*
cardiovascular system, 943–46*t*
ear disorders, 1684*t*
endocrine system, 523–25*t*
eye disorders, 1674*t*
female reproductive system, 1756–58*t*
gastrointestinal system, 615–17*t*
hematologic, peripheral vascular, and lymphatic disorders, 1087–88*t*
integumentary system, 428*t*
male reproductive system, 1746*t*
musculoskeletal system, 1387–88*t*
neurologic system, 1514–16*t*
respiratory system, 1217–19*t*
urinary system, 835*t*
- Dialysate, 906
- Dialysis:
continuous renal replacement therapies, 907–8, 907*t*, 909*f*
definition, 906
for end-stage renal disease, 919–20
hemodialysis
complications, 906–7

- definition, 609
nursing care, 908*t*
Nursing Research: promoting autonomy and acceptance, 926*t*
principles, 609
system components, 610*f*
in hemorrhagic colitis, 777
peritoneal
nursing care, 910*t*
procedure, 909–10, 909*f*
vascular access, 908–9, 909*f*
- Dialysis dose, 920
- Diamox. *See* Acetazolamide
- Diaphoresis, 1512
- Diaphragmatic breathing, 72*t*, 186
- Diaphragmatic excursion, 1225*f*, 1225*t*
- Diarrhea:
complications, 754
in Crohn's disease, 786. *See also* Crohn's disease
definition, 746, 754
in gastroenteritis, 773. *See also* Gastroenteritis
interdisciplinary care
complementary and alternative therapies, 755
diagnosis, 755
medications, 755, 756*t*
nutrition, 755, 755*t*
large-volume, 754
manifestations, 754
nursing care
assessment, 756–57
community-based care, 758
health promotion, 755–56
Medication Administration, 756*t*
nursing diagnoses and interventions
diarrhea, 757
risk for deficient fluid volume, 757
risk for impaired skin integrity, 757
using NANDA, NIC, and NOC, 757, 757*t*
pathophysiology, 754
small-volume, 754
in ulcerative colitis, 784. *See also* Ulcerative colitis
- Diarthrosis, 1383*t*
- Diastole, 939, 939*f*
- Diastolic blood pressure, 1154. *See also* Blood pressure
- Diastolic failure, 1025–26. *See also* Heart failure
- Diazepam:
adverse/side effects, 869
Medication Administration, 1631*t*
preoperative use and nursing implications, 62*t*
in specific conditions, 1600*t*
acute myocardial infarction, 987
acute respiratory failure, 1355
multiple sclerosis, 1631*t*
substance abuse/withdrawal treatment, 114*t*
tetanus, 1661
vertigo, 1627
- Diazoxide, 1169*t*
- DIC. *See* Disseminated intravascular coagulation
- Dichlorphenamide, 1703
- Diclofenac sodium, 178*t*, 1464*t*
- Dicloxacillin, 319*t*
- Dicyclomine, 762
- Didanosine, 356, 357*t*
- Didronel. *See* Etidronate
- Diencephalon, 1506, 1506*t*
- Diet:
cancer risk and, 371
coronary heart disease risk and, 964
for coronary heart disease risk reduction, 966, 966*t*, 968, 968*t*
in diabetes mellitus, 579–80
following bariatric surgery, 638*t*
for hypertension management, 1159, 1160*t*
prostate cancer risk and, 1786–87
protein-restricted, 718*t*
for weight loss, 635, 635*t*, 636*t*
- Diethylstilbestrol (DES):
for advanced prostate cancer, 1787*t*
as chemotherapy, 393*t*
mechanism of action, 391
in utero exposure
cervical cancer risk and, 1812
effect on male children, 1747
- Difenoxin, 756*t*
- Differentiation, 373
- Diffuse axonal injury, 1559. *See also* Traumatic brain injury
- Diffuse esophageal spasm, 668
- Diffuse lamellar keratitis, 1697
- Diffuse large B-cell lymphoma, 1130*t*. *See also* Lymphomas
- Diffusion, 199–200, 200*f*
- Diflucan. *See* Fluconazole
- Diflunisal, 178*t*, 179*t*
- Digital rectal examination (DRE):
in benign prostatic hyperplasia, 1778
procedure, 1750*t*
in prostate cancer, 1784
- Digitalis:
for heart failure, 1032, 1033–34*t*
Medication Administration, 1033–34*t*
toxicity, 222, 233, 1032, 1034*t*
- Digoxin:
adverse/side effects, 1006*t*
interaction with phenobarbital, 1551*t*
Medication Administration, 1006*t*, 1033–34*t*
in specific conditions
cardiac dysrhythmias, 1006, 1006*t*
heart failure, 1033–34*t*
- Dihydrotestosterone (DHT), 1777
- Dilacor XR. *See* Diltiazem
- Dilantin. *See* Phenytoin
- Dilated cardiomyopathy. *See also* Cardiomyopathy
management, 1065*t*
manifestations, 1065, 1065*t*
pathophysiology, 1063–65, 1065*t*
prognosis, 1065
- Dilation and curettage (D&C), 1803, 1803*t*
- Dilaudid. *See* Hydromorphone HCl
- Dilemma, 12. *See also* Nursing ethics
- Diloxanide furoate, 778*t*
- Diltiazem:
Medication Administration, 973*t*, 1006*t*, 1162*t*
in specific conditions
angina, 973–74*t*
aortic aneurysm, 1173
cardiac dysrhythmias, 1006*t*
hypertension, 1162*t*
pulmonary hypertension, 1353
thromboangiitis obliterans, 1182
- Dimenhydrinate, 672, 673*t*
- Dimetane. *See* Brompheniramine
- Diovan. *See* Valsartan
- Dipentum. *See* Olsalazine
- Diphenhydramine:
adverse/side effects, 869
Medication Administration, 1230*t*
solution, for stomatitis, 657
in specific conditions
hypersensitivity reactions, 337
upper respiratory infections, 1230*t*
- Diphenoxylate, 756*t*, 762
- Diphtheria:
characteristics, 1241
interdisciplinary care, 1241
manifestations, 1241
nursing care, 1241–42
pathophysiology, 1241
- Diphtheria vaccine, 21*t*, 1243
- Diplopia, 1648
- Dipyridamole, 1585
- Dipyridamole stress test. *See* Nuclear persantine (dipyridamole) stress test
- Diquinol. *See* Iodoquinol
- Direct (conjugated) bilirubin, 699*t*
- Direct Coombs' test, 336
- Direct current, 488
- Direct inguinal hernia, 810. *See also* Hernia
- Dirty bomb, 128. *See also* Radiologic dispersion bomb
- Disability, 47
- Disalcid. *See* Salsalate
- Disarticulation, 1422*t*
- Disasters. *See also* Terrorism
Chapter Highlights, 141*t*
definition, 126
educational competencies for registered nurses
responding to, 126, 126*t*
injuries and nursing implications
blast injuries, 129*t*, 131
blunt trauma, 129*t*
chemical burns, 130*t*
earthquake, 129*t*, 131
eye injuries, 129*t*, 131
hurricane, 128, 129*t*, 130
nuclear detonation, 130*t*, 131
pressure trauma, 129*t*
radiation exposure, 130*t*
radiologic dispersion bomb, 130*t*, 131
snowstorm, 129*t*, 131
thunderstorm, 129*t*, 130
tornado, 129*t*, 130
tsunami, 129*t*, 130
- interdisciplinary care
casualty management, 133–34, 134*t*
crowd control, 135
disaster planning, response, and mitigation, 132–33
isolation and personal protective equipment, 134–35
psychosocial needs, 135, 137
recording victim data, 135, 136*f*
stress responses, 135*t*
nursing care
nurse's role, 137, 137*t*
nursing implications, 137–38
special considerations
clients who are illiterate, 140
clients with mobility and sensory deficits, 140
clients with sensory impairments, 140
immunocompromised clients, 138, 140
non-English-speaking clients, 140
older adults, 138
spiritual considerations, 140
- Nursing Care Plan
assessment, 139*t*
critical thinking in the nursing process, 139*t*
diagnoses, 139*t*
evaluation, 139*t*
expected outcomes, 139*t*
planning and implementation, 139*t*
- Nursing Research: disaster preparedness training
in nursing education, 138*t*
stages, 132, 132*f*
terminology, 126–27
types, 126–27, 129–30*t*
- Disease, 22, 22*t*
- Disease-modifying antirheumatic drugs (DMARDs), 341, 1464–66, 1465*t*

- Dissectomy, 1608
 Dislocation:
 causes, 1400–1401
 definition, 1400
 interdisciplinary care, 1401
 manifestations, 1401
 nursing care
 community-based care, 1401
 nursing diagnoses and interventions, 1401
 pathophysiology, 1401
 Disopyramide, 1006*t*
 Disorientation, 1529*t*
 Dissecting aneurysm, 1170, 1592. *See also* Aortic dissection
 Dissection, 1172. *See also* Aortic dissection
 Disseminated intravascular coagulation (DIC):
 causes, 1146, 1146*t*
 definition, 1146
 interdisciplinary care
 diagnosis, 1148
 treatments, 1148
 manifestations, 1147, 1147*t*
 nursing care
 assessment, 1148
 community-based care, 1149
 nursing diagnoses and interventions
 fear, 1149
 impaired gas exchange, 1148–49
 ineffective tissue perfusion, 1148
 pain, 1149
 pathophysiology, 1146–47, 1147*f*
 in septic shock, 275
 Distal dissection, 1172. *See also* Aortic dissection
 Distraction, 186
 Distributive shock, 274
 Disulfiram:
 for alcohol abuse treatment, 112, 114*t*
 interaction with phenobarbital, 1551*t*
 Dithranol. *See* Anthralin
 Ditropan, Ditropan XL. *See* Oxybutynin
 Diuretics:
 Medication Administration, 210*t*, 905*t*, 1033*t*, 1539*t*
 in specific conditions
 acute renal failure, 904, 905*t*
 chronic renal failure, 919
 fluid volume excess, 210, 210*t*
 heart failure, 1032, 1033*t*
 hyperkalemia, 225*t*
 hypertension, 1160, 1163
 increased intracranial pressure, 1538, 1539*t*
 Diuril. *See* Chlorothiazide
 Divalent, 196
 Divergent thinking, 6
 Diversity. *See* Race/ethnicity
 Diverticular disease:
 characteristics, 814–15, 815*f*
 diverticulitis
 complications, 816
 definition, 815
 manifestations, 815–16
 diverticulosis, 815
 incidence, 815
 interdisciplinary care
 diagnosis, 816
 medications, 816
 nutrition, 816, 816*t*
 surgery, 816–17
 nursing care
 assessment, 817
 community-based care, 818
 health promotion, 817
 nursing diagnoses and interventions
 acute pain, 817
 anxiety, 817–18
 impaired tissue integrity: gastrointestinal, 817
 pathophysiology, 815
 risk factors, 815
 Diverticulosis, 815. *See also* Diverticular disease
 DKA. *See* Diabetic ketoacidosis
 DMARDs (disease-modifying antirheumatic drugs), 341, 1464–66, 1465*t*
 DNA, 149, 373*t*. *See also* Genetics
 DNA-based tests, 157
 DNR (do-not-resuscitate) order, 91
 Dobutamine, 278*t*, 1034*t*
 Dobutamine stress test, 944*t*. *See also* Stress/exercise tests
 Dobutrex. *See* Dobutamine
 Docusate:
 Medication Administration, 759*t*
 in specific conditions
 diverticulitis, 816
 hemorrhoids, 819
 intracranial aneurysm, 1593
 urine color changes caused by, 832*t*
 Dofetilide, 1006*t*
 Dolasetron, 672, 673*t*
 Doll's eye movements, 1531, 1531*f*
 Dolobid. *See* Diflunisal
 Dolophine. *See* Methadone
 Domestic violence. *See* Intimate partner violence
 Donepezil, 189, 1621, 1621*t*
 Dong quai, 1796
 Donnagel-MB, 756*t*
 Do-not-resuscitate (DNR) order, 91, 91*t*
 Dopamine:
 functions, 1505
 Medication Administration, 278*t*, 1034*t*
 in specific conditions
 acute myocardial infarction, 989
 acute renal failure, 904
 heart failure, 1034*t*
 Parkinson's disease, 1635
 pulmonary edema, 1041
 shock, 278*t*
 substance abuse, 104, 104*f*
 Dopamine agonists, 1638*t*
 Dopamine antagonists, 672, 673*t*
 Dopaminergics, 1637*t*
 Dopar. *See* Levodopa
 Doppler ultrasound, 1177, 1197
 Dornase alfa, 1342
 Dorsal recumbent position, 69*f*
 Dorsiflexion, 1386*t*
 Dorzolamide, 1709, 1710*t*
 Dovonex. *See* Calcipotriene
 Down syndrome. *See* Trisomy 21
 Doxazosin, 1161*t*, 1779
 Doxidan. *See* Docusate
 Doxorubicin:
 adverse/side effects, 392*t*
 nursing implications, 392*t*
 in specific conditions
 bone tumors, 1483*t*
 leukemia, 1123*t*
 target malignancies, 392*t*
 Doxy-Caps. *See* Doxycycline
 Doxycin. *See* Doxycycline
 Doxycycline:
 Medication Administration, 320*t*
 in specific conditions
 anthrax prophylaxis and treatment, 128*t*, 1294
 chlamydia, 1845, 1846
 Lyme disease, 1477
 pelvic inflammatory disease, 1851
 pneumonia, 1271*t*
 syphilis, 1849
 Dramamine. *See* Dimenhydrinate
 DRE. *See* Digital rectal examination
 Dressings:
 biological and biosynthetic, 503–4
 for pressure ulcers, 474*t*
 Dressler's syndrome, 986
 DRGs (diagnosis-related groups), 38
 Dronabinol, 672, 673*t*
 Droperidol:
 Medication Administration, 673*t*
 preoperative use and nursing implications, 62*t*
 in specific conditions
 nausea and vomiting, 672, 673*t*
 vertigo, 1727
 Droplet nuclei, 1280
 Droplet precautions, 323*t*
 Drowning, 1305–6, 1306*f*. *See also* Inhalation injury
 Drug(s). *See* Medication(s)
 Drug abuse, 179*t*. *See also* Substance abuse
 Drug tolerance, 102, 103*t*, 179*t*
 Drusen, 1714
 “Dry drowning,” 1306
 Dry powder inhaler, 1324, 1325*t*
 Dry skin, 441, 441*t*
 DTRs. *See* Deep tendon reflexes
 Dual diagnosis, 103, 103*t*
 Dual disorder, 103
 Dual energy x-ray absorptiometry (DEXA), 1387*t*, 1436
 Dual-chamber pacing, 1009, 1010*t*. *See also* Pacemakers
 DUB. *See* Dysfunctional uterine bleeding
 Duchenne muscular dystrophy:
 genetic considerations, 1389*t*, 1458
 manifestations, 1459*t*
 progression, 1459*t*
 Duct ectasia, 1821*t*, 1822
 Duct of Wirsung, 726
 Dulcolax. *See* Bisacodyl
 Dullness, in lung percussion, 1224*t*
 Dumping syndrome:
 after bariatric surgery, 638, 638*t*
 manifestations, 638, 690
 pathophysiology, 689–90, 690*f*
 treatment, 690–91
 Duodenal string test, 779
 Duodenal ulcers, 680. *See also* Peptic ulcer disease
 Duodenum, 612, 742
 DuoDerm. *See* Hydrocolloid dressing
 Duplex Doppler ultrasound:
 in peripheral vascular disease, 1177
 in varicose veins, 1197
 in venous thrombosis, 1188
 Durable power of attorney, 90. *See also* Advance directives
 Duragesic. *See* Fentanyl
 Dutasteride, 1779
 DVT. *See* Deep venous thrombosis
 Dwarfism, 530*t*
 DynaCirc. *See* Isradipine
 Dynapen. *See* Dicloxacillin
 Dyrenium. *See* Triamterene
 Dysarthria, 1518*t*, 1583
 Dysfunctional uterine bleeding (DUB):
 definition, 1802
 interdisciplinary care
 diagnosis, 1803
 medications, 1803
 surgery
 dilation and curettage, 1803
 endometrial ablation, 1803
 hysterectomy, 1803–4

- nursing care
 client having dilation and curettage, 1803*t*
 client having hysterectomy, 1804*t*
 community-based care, 1805
 nursing diagnoses and interventions
 anxiety, 1804-5
 sexual dysfunction, 1805
 pathophysiology, 1802
- Dysmenorrhea:
 definition, 1800
 interdisciplinary care
 complementary and alternative therapies, 1801-2
 diagnosis, 1801
 medications, 1801, 1802*t*
 manifestations, 1800, 1801*t*
 nursing care, 1802, 1802*t*
 pathophysiology, 1800
 primary, 1800
 secondary, 1800
- Dyspareunia, 1758, 1795
- Dysphagia, 668, 1520*t*
- Dysphonia, 1518*t*
- Dysplasia, 373
- Dysplastic nevi, 466
- Dyspnea:
 definition, 209, 1266
 in dying client, 92-93
 in fluid volume excess, 209
 paroxysmal nocturnal, 1027
- Dysrhythmias. *See* Cardiac dysrhythmias
- Dysuria, 839, 847
- E**
- Ears. *See also* Hearing
 age-related changes, 1686*t*
 anatomy, physiology, and functions
 equilibrium, 1683
 external ear, 1680, 1682*f*
 inner ear, 1682
 middle ear, 1682-83, 1682*f*
 sound conduction, 1683
- assessment
 diagnostic tests, 1683-84, 1684*t*
 functional health pattern interview, 1685*t*
 genetic considerations, 1684, 1684*t*
 health assessment interview, 1684-85
 physical assessment
 external ear, 1688-89*t*, 1688*f*
 hearing, 1687-88*t*, 1687*f*, 1688*f*
 otoscope guidelines, 1686-87*t*, 1686*f*
 sample documentation, 1684*t*
- disorders
 acoustic neuroma, 1570*t*, 1727
 Chapter Highlights, 1734*t*
 Clinical Scenarios, 1738*t*
 foreign body, 1721
 hearing loss. *See* Hearing loss
 impacted cerumen, 1721
 inner ear. *See* Inner ear disorders
 mastoiditis. *See* Mastoiditis
 nursing care of the client having surgery
 for, 1725*t*
 otitis externa. *See* Otitis externa
 otosclerosis, 1725-26
- Earthquake, 129*t*, 131
- Eastern Cooperative Oncology Group, functional status scale, 401*t*
- Eating disorders:
 anorexia nervosa, 650, 651*t*
 binge-eating disorder, 651, 651*t*
 bulimia nervosa, 650-51, 651*t*
 interdisciplinary care
 diagnosis, 651-52
 treatment, 652
 nursing care, 652
- EBCT (electron beam computed tomography), 965
- Eccentric plaque formation, 959
- Ecchymosis, 431*t*, 434*f*, 434*t*
- Eccrine sweat glands, 424
- ECF (extracellular fluid), 196-97, 196*f*, 197*f*
- ECG. *See* Electrocardiogram
- Echinacea:
 for benign prostatic hyperplasia, 1781
 for pneumonia, 1273
 for viral respiratory infections, 1231
- Echocardiography:
 purpose and description, 943, 945*t*
 related nursing care, 945*t*
 in specific conditions
 acute myocardial infarction, 987
 angina, 971
 cardiomyopathy, 1067
 endocarditis, 1046
 heart failure, 1027
 pericarditis, 1051
 rheumatic heart disease, 1043*t*
 valvular heart disease, 1060
 types, 945*t*
- Echolalia, 1620
- Econazole, 450*t*
- Ecotrin. *See* Aspirin
- Ectopic beats, 996
- Ectopic functioning, 380, 380*t*
- Ectropion, 1701, 1701*f*
- Eczema. *See* Atopic dermatitis
- ED. *See* Erectile dysfunction
- Edecrin. *See* Ethacrynic acid
- Edema. *See also* Fluid volume excess
 in acute glomerulonephritis, 886
 assessment, 435*f*, 435*t*, 1097*f*, 1097*t*
 causes, 1093*t*
 cerebral, 1537. *See also* Increased intracranial pressure
 in cirrhosis, 715*t*
 definition, 209, 1093*t*
 grading, 1097*f*, 1097*t*
 in heart failure, 1027
 in metabolic acidosis, 245
 pulmonary. *See* Pulmonary edema
- Edrophonium chloride, 1648, 1648*t*, 1649
- Education level, health and, 19
- Educator, nurse as, 13, 14*f*
- EEG. *See* Electroencephalogram
- E.E.S. *See* Erythromycin salts
- Efavirenz, 358
- Effector cells, 297. *See also* T lymphocytes
- Efferent, 894
- Effer-Syllium. *See* Psyllium hydrophilic mucilloid
- Eflornithine, 778*t*
- EGD. *See* Esophagogastroduodenoscopy
- Egophony, 1226*t*
- Ehlers-Danlos syndrome, 1172*t*
- Ejaculatory dysfunction, 1771
- Ejection fraction, 940, 1024
- Elastase. *See* Proteolytic enzymes
- Elasticity, 1383
- Elavil. *See* Amitriptyline
- Elbows:
 epicondylitis, 1428
 fracture, 1413
 physical assessment, 1393*t*
- Eldepryl. *See* Selegiline
- Elder abuse, 256*t*
- Elders. *See* Older adults
- Elective lymph node dissection (ELND), 468
- Elective procedure, 54*t*
- Electrical bone stimulation, 1411-12, 1412*f*
- Electrical burns, 488, 488*t*, 498. *See also* Burns
- Electrocardiogram (ECG):
 interpretation, 949*t*
 intervals, 948*f*, 948*t*
 leads, 947*f*
 pacing artifacts, 1009, 1010*f*
 potassium levels and, 219, 219*f*
 in preoperative assessment, 60-61
 principles, 947-48*t*, 947*f*
 in specific conditions
 acute myocardial infarction, 987, 988*f*
 angina, 970, 971*f*
 cardiac dysrhythmias, 997-99*t*, 1004
 cardiomyopathy, 1067
 heart failure, 1027
 hypercalcemia, 232
 hypomagnesemia, 234
 metabolic acidosis, 245
 myocarditis, 1049
 pericarditis, 1051
 pulmonary embolism, 1349
 valvular heart disease, 1060
 waveforms, 947*f*, 947*t*
- Electrodesiccation, 464
- Electroencephalogram (EEG):
 in brain tumor diagnosis, 7, 1571
 health education for the client and family, 1515*t*
 nursing care, 1515*t*
 purpose and description, 1512, 1515*t*
- Electrolarynx, 1256, 1258*f*, 1260*t*
- Electrolytes. *See also specific electrolytes*
 in burns, 500
 composition of body fluid compartments, 197, 197*t*
 definition, 196
 in fluid volume deficit, 205
 in fluid volume excess, 210
 functions, 196
 imbalances
 in acute renal failure, 904
 in altered level of consciousness, 1533
 calcium. *See* Hypercalcemia; Hypocalcemia
 in chronic renal failure, 918
 in cirrhosis, 716
 in glomerular disorders, 890, 890*t*
 in heart failure, 1027
 in inhalation injury, 1306-7
 magnesium. *See* Hypermagnesemia; Hypomagnesemia
 phosphate. *See* Hyperphosphatemia; Hypophosphatemia
 potassium. *See* Hyperkalemia; Hypokalemia
 sodium. *See* Hyponatremia; Hyponatremia
 surgical risk and nursing implications, 57*t*
 intravenous solutions, 207*t*
 normal values, 198*t*
 perioperative, significance and nursing implications, 60*t*
 in shock, 277
 units of measurement, 196
- Electromyogram (EMG), 1388*t*, 1515*t*
- Electron beam computed tomography (EBCT), 965
- Electrophoresis, hemoglobin, 1110-11
- Electrophysiology procedures, 1004-5
- Electrosurgery, 477
- Elimination disorders:
 bowel. *See* Bowel disorders
 urinary. *See* Urinary system, disorders
- Elimination patterns:
 altered bowel elimination. *See also* Bowel disorders
 Build Clinical Competence, 824*t*
 Clinical Scenarios, 825*t*

- Elimination patterns—*continued*
 altered urinary elimination. *See also* Urinary system
 Build Clinical Competence, 929t
 Clinical Scenarios, 930t
 NANDA nursing diagnoses, 739t
 ELISA (enzyme-linked immunosorbent assay), 355
 Ellis-van Creveld syndrome, 1389t
 ELND (elective lymph node dissection), 468
 Embolctomy, 1184
 Embolic stroke, 1581. *See also* Stroke
 Embolism:
 arterial. *See* Acute arterial occlusion
 definition, 1184
 fat, 1406
 pulmonary. *See* Pulmonary embolism
 Embolization, uterine fibroid, 1810
 Emergency:
 definition, 127
 vs. disaster, 127
 oncologic. *See* Oncologic emergencies
 Emergency defibrillation, 1008, 1008f, 1008t
 Emergency procedure, 54t
 Emesis, 671. *See also* Nausea and vomiting
 EMG (electromyogram), 1388t, 1515t
 Emmetropia, 1696
 Emollients, 441t
 Emphysema, 1332, 1332t, 1360. *See also* Chronic obstructive pulmonary disease
 Empyema:
 definition, 1269
 gallbladder, 698
 pleural, 1269, 1295
 treatment, 1296
 E-Mycin. *See* Erythromycin
 Enalapril, 1033t, 1161t
 Enalaprilat, 1169t
 Enbrel. *See* Etanercept
 Encephalitis. *See also* Central nervous system infections
 arbovirus, 1565
 causes, 1565t
 viral, 1565. *See also* Rabies
 Encephalopathy:
 hypertensive, 1158
 portal systemic, 704, 715, 715t
 spongiform. *See* Creutzfeldt-Jakob disease
 Endarterectomy, 1178
 Endocarditis:
 acute infective, 1046t
 complications, 1046
 definition, 1045
 incidence, 1045
 interdisciplinary care
 diagnosis, 1046
 medications, 1046–47
 prevention, 1046, 1047t
 surgery, 1047
 manifestations, 1045–46, 1046t
 nursing care
 assessment, 1047
 community-based care, 1048
 health promotion, 1047
 nursing diagnoses and interventions
 ineffective health maintenance, 1048
 risk for imbalanced body temperature, 1047
 risk for ineffective tissue perfusion, 1047–48
 pathophysiology, 1045, 1045f, 1046t
 risk factors, 1045, 1046t
 subacute infective, 1046t
 Endocardium, 937, 937f
 Endocrine system:
 age-related changes
 in middle adults, 27t
 in older adults, 29t, 529t
 anatomy, physiology, and functions
 adrenal gland, 520–21, 520f
 gonads. *See* Ovaries; Testes
 overview, 518f, 519t
 pancreas, 521
 parathyroid glands, 520
 pituitary gland
 anatomy, 519f
 anterior, 519, 519f, 520
 posterior, 520
 thyroid gland, 520, 520f
 assessment
 diagnostic tests, 522, 523–25t, 526. *See also* specific tests
 genetic considerations, 527, 527t
 health assessment interview, 527
 physical assessment
 face, 529t
 hypocalcemic tetany, 531t
 motor function, 530t
 musculoskeletal function, 530t
 nails and hair, 529t
 overview, 527
 sample documentation, 527
 sensory function, 530t
 skin, 529t
 thyroid, 530t
 disorders
 adrenal glands
 Addison's disease (adrenocortical insufficiency). *See* Addison's disease
 Cushing's syndrome (hypercortisolism). *See* Cushing's syndrome
 pheochromocytoma, 557
 anterior pituitary gland
 acromegaly, 529t, 558, 558f
 gigantism, 558
 hyperfunction, 557
 hypofunction, 557
 interdisciplinary care, 558
 nursing care, 558
 pathophysiology, 557
 Clinical Scenarios, 601t
 pancreas. *See* Diabetes mellitus
 parathyroid glands
 hyperparathyroidism. *See* Hyperparathyroidism
 hypoparathyroidism. *See* Hypoparathyroidism
 posterior pituitary gland
 diabetes insipidus. *See* Diabetes insipidus
 syndrome of inappropriate antidiuretic hormone. *See* Syndrome of inappropriate diuretic hormone
 thyroid gland
 cancer, 546
 hyperthyroidism. *See* Hyperthyroidism
 hypothyroidism. *See* Hypothyroidism
 End-of-life care. *See also* Death and dying; Loss and grief
 checklist for older adults, 95t
 comfort measures, 92t
 competencies, 89–90, 89f
 definition, 89
 health promotion, 95
 interdisciplinary care, 94–95
 legal and ethical issues
 advance directives. *See* Advance directives
 do-not-resuscitate orders, 91, 91t
 euthanasia, 91
 Nursing Research, 90t
 settings and services
 hospice. *See* Hospice
 palliative care, 92
 support for client and family, 93
 terminal weaning, mechanical ventilation, 1361
 Endogenous, 304
 Endogenous insulin, 566
 Endoleak, 1173
 Endolymphatic decompression, 1727
 Endolymphatic hydrops. *See* Ménière's disease
 Endometrial ablation, 1803
 Endometrial biopsy, 1757t
 Endometrial cancer:
 genetic considerations, 1755t, 1758
 incidence, 1816
 interdisciplinary care
 diagnosis, 1816
 medications, 1816
 radiation therapy, 1817
 surgery, 1816
 manifestations, 1816
 nursing care
 assessment, 1817
 community-based care, 1817
 health promotion, 1817
 nursing diagnoses and interventions
 acute pain, 1817
 disturbed body image, 1817
 ineffective sexuality pattern, 1817
 pathophysiology factors, 1816
 risk factors, 1816
 screening guidelines, 401t, 1817
 staging, 1816t
 Endometrial cysts and polyps, 1808, 1809t
 Endometriosis:
 definition, 1810
 interdisciplinary care
 diagnosis, 1810
 medications, 1811
 surgery, 1811
 manifestations, 1811t
 nursing care
 community-based care, 1812
 nursing diagnoses and interventions, 1812
 using NANDA, NIC, and NOC, 1812, 1812t
 Nursing Care Plan
 assessment, 1811t
 critical thinking in the nursing process, 1811t
 diagnoses, 1811t
 evaluation, 1811t
 expected outcomes, 1811t
 planning and implementation, 1811t
 pathophysiology, 1810
 risk factors, 1810
 Endometritis, 1850
 Endomyocardial biopsy, 1049
 Endophytic, 1819
 Endorphins, 172, 172f
 Endoscopic retrograde cholangiopancreatography (ERCP), 616t, 727
 Endoscopic sinus surgery, 1236–37
 Endoscopic transduodenal sphincterotomy, 728
 Endoscopy, 388t, 615t
 Endothelins, 1158
 Endotoxins, 312
 Endotracheal tube:
 in acute respiratory failure, 1355–56, 1356f
 for airway management, 257, 257f
 suctioning procedure, 1363t
 vs. tracheostomy, 1356, 1357t
 Endovascular stent grafts, 1173
 End-stage renal disease (ESRD), 899. *See also* Chronic renal failure

- Enemas, 760
- Energy healing, for cancer, 399*t*
- Enfuvirtide, 358
- Engle, theory of loss and grief, 86, 86*t*
- Enophthalmos, 1702
- Enoxacin, 849
- Enoxaparin, 1189*t*, 1585
- Entacapone, 1638*t*, 1639
- Entamoeba histolytica*, 725, 778, 778*t*
- Enteral nutrition:
- complications, 646
 - in Crohn's disease, 788
 - definition, 644
 - feeding tube placement, 646*f*, 646*t*
 - formulas, 646
 - in malnutrition, 644–46
 - Nursing Research
 - aspiration prevention, 772*t*
 - assessing gastric residual volume, 662*t*
 - feeding tube placement methods, 647*t*
 - tubes for, 645, 645*f*
- Enteritis. *See* Gastroenteritis
- Enterobiasis, 781*t*
- Enterococci*, vancomycin-resistant, 314
- Entero-Test. *See* Duodenal string test
- Entropion, 1694*f*, 1701
- Entry inhibitors, 358
- Enucleation, 1718
- Environment, health and, 20, 37. *See also* Physical stressors
- Enzymatic debridement, 504
- Enzyme-linked immunosorbent assay (ELISA), 355
- Enzymes, as tumor markers, 384, 384*t*
- Eosinopenia, 307*t*
- Eosinophilia, 307*t*, 779
- Eosinophils:
- abnormal, possible causes, 307*t*, 387*t*
 - characteristics, 288
 - development, 289*f*, 1077*f*
 - functions, 288, 288*t*, 1079
 - location, 288*t*
 - normal values, 307*t*, 387*t*, 1118*t*
- Ependymoma, 1570*t*. *See also* Brain tumors
- Ephedra, 1274, 1326
- Epicardial pacemaker, 1009, 1009*f*. *See also* Pacemakers
- Epicardium, 937, 937*f*
- Epicondylitis, 1428. *See also* Repetitive use injury
- Epidermis, 423, 423*t*, 424*f*. *See also* Skin
- Epididymis:
- anatomy, physiology, and functions, 1745, 1745*t*
 - physical assessment, 1750*t*
- Epididymitis:
- definition, 1773
 - interdisciplinary care, 1773
 - nursing care, 1773
 - pathophysiology, 1773
- Epidural analgesia:
- benefits, 183
 - nursing care, 184*t*
 - procedure, 184*f*, 184*t*
- Epidural anesthesia, 63
- Epidural hematoma, 1557–58, 1557*f*, 1557*t*. *See also* Traumatic brain injury
- Epiglottis, 1211
- Epiglottitis, 1240–41
- Epilepsy. *See also* Seizures
- genetic considerations, 1513*t*
 - incidence and prevalence, 1547–48
 - interdisciplinary care
 - diagnosis, 1550
 - medications, 1550–51, 1550*t*
 - surgery, 1551
 - vagal nerve stimulation surgery, 1551
- nursing care
- assessment, 1552, 1553*t*
 - of client having surgery for seizures, 1551*t*
 - community-based care, 1553–54
 - health promotion, 1551–52
 - Medication Administration, 1550*t*
 - nursing diagnoses and interventions
 - anxiety, 1553
 - risk for ineffective airway clearance, 1552–53
 - using NANDA, NIC, and NOC, 1553, 1553*t*
- Nursing Care Plan
- assessment, 1552*t*
 - critical thinking in the nursing process, 1552*t*
 - diagnoses, 1552*t*
 - evaluation, 1552*t*
 - expected outcomes, 1552*t*
 - planning and implementation, 1552*t*
 - in older adults, 1548*t*
 - pathophysiology, 1548
- Epinephrine:
- in blood pressure regulation, 1155
 - functions, 519*t*, 520
 - Medication Administration, 1327*t*
 - in specific conditions
 - anaphylaxis, 337–38
 - asthma, 1327*t*
 - topical, for epistaxis, 1243
- Epispadias, 872
- Epistaxis:
- causes, 1243
 - definition, 1243
 - interdisciplinary care
 - first-aid measures, 1243
 - medications, 1243
 - nasal packing, 1244, 1244*f*
 - surgery, 1244
 - manifestations, 1243
 - nursing care
 - assessment, 1244
 - of client with nasal packing, 1245*t*
 - community-based care, 1245
 - nursing diagnoses and interventions
 - anxiety, 1245
 - risk for aspiration, 1245
 - pathophysiology, 1243
- Epithalamus, 1506
- Epitope, 290
- Epivir. *See* Lamivudine
- Epivir HBV. *See* Lamivudine
- Epoprostenol, 1353
- Eprosartan, 1161*t*
- Epstein-Barr virus:
- cancers associated with, 375*t*
 - in Hodgkin's disease, 1130
 - in infectious mononucleosis, 1139
- Eptifibatide, 976, 976*t*
- Equal. *See* Aspartame
- Equianalgesia:
- definition, 80, 179*t*
 - drug chart with nursing considerations, 180*t*
- Equilibrium, 1683
- ERCP (endoscopic retrograde cholangiopancreatography), 616*t*, 727
- Erectile dysfunction (ED):
- causes, 1768*t*, 1769
 - in cirrhosis, 715*t*
 - definition, 1768
 - in diabetes mellitus, 595
 - incidence, 1768–69
- interdisciplinary care
- diagnosis, 1769
 - mechanical devices, 1769
 - medications, 1769
 - surgery, 1769–70, 1770*f*
- nursing care
- community-based care, 1771
 - nursing diagnoses and interventions
 - sexual dysfunction, 1770
 - situational low self-esteem, 1771
 - pathophysiology, 1769
- Erection, 1744
- Ergonovine maleate, 971
- Ergot alkaloid derivatives, 1545*t*
- Ergotamine tartrate, 1544, 1545*t*
- Erikson, psychosocial development theory, 25*t*
- Erosion, skin, 433*t*
- Erosive gastritis, 677. *See also* Stress ulcers
- Ertapenem, 319*t*
- ERV (expiratory reserve volume), 1214, 1214*t*
- Erysipelas, 447
- Erythema:
- assessment in light and dark skin, 426*t*
 - causes, 426*t*
 - definition, 425
 - figurate, 431*t*
- Erythema marginatum, 1043
- Erythema migrans, 1477
- Erythematous, 1229
- Erythrocin. *See* Erythromycin salts
- Erythrocyte sedimentation rate (ESR; sed rate):
- normal values, 1087*t*
 - purpose and description, 1087*t*
 - in specific conditions
 - glomerular disorders, 889
 - inflammation, 306
 - lymphoma, 1131
 - rheumatic fever, 1043
 - rheumatic heart disease, 1043*t*
 - systemic lupus erythematosus, 1473
- Erythrocytes. *See* Red blood cells
- Erythrocytosis. *See* Polycythemia
- Erythromycin:
- Medication Administration, 320*t*
 - in specific conditions
 - endocarditis prophylaxis, 1047*t*
 - Lyme disease, 1477
 - pertussis, 1242
 - pneumonia, 1271*t*
 - topical
 - for conjunctivitis, 1694
 - for corneal infections, 1697
- Erythromycin salts, 320*t*
- Erythroplakia, 1253
- Erythropoiesis, 1076, 1078, 1079*f*
- Erythropoietin, 834, 1111
- Escape rhythm, 1000
- Eschar, 494
- Escharotomy, 502, 502*f*, 502*t*
- Escherichia coli*:
- in hemorrhagic colitis, 774*t*, 775
 - in liver abscess, 725
 - in traveler's diarrhea, 774*t*, 775
 - in urinary tract infections, 846
- Esmolol:
- Medication Administration, 1006*t*
 - in specific conditions
 - acute myocardial infarction, 988
 - aortic aneurysm, 1173
 - cardiac dysrhythmias, 1006*t*
 - hypertensive emergencies, 1169*t*
- esomeprazole, 665, 665*t*, 678
- Esophageal acidity, 615*t*

- Esophageal cancer:
interdisciplinary care
diagnosis, 669
treatments, 669–70
manifestations, 669, 669t
nursing care
assessment, 670
community-based care, 670–71
health promotion, 670
nursing diagnoses and interventions
anticipatory grieving, 670
imbalanced nutrition: less than body requirements, 670
risk for ineffective airway clearance, 670
pathophysiology, 669
risk factors, 669, 669t
- Esophageal manometry, 615t, 665
- Esophageal speech, 1256
- Esophageal varices:
in cirrhosis, 711
pathophysiology, 704, 712–13t, 715t
treatment, 718
- Esophagectomy, 669–70
- Esophagogastroduodenoscopy (EGD):
purpose and description, 615t
related nursing care, 615t
in specific conditions
esophageal cancer, 669
gastritis, 678
gastroesophageal reflux disease, 664
peptic ulcer disease, 684
upper gastrointestinal bleeding, 674, 675
- Esophagojejunostomy, 689, 689f
- Esophagus:
anatomy, physiology, and functions, 610–11, 611f
disorders
cancer. *See* Esophageal cancer
diagnostic tests, 615t
gastroesophageal reflux disease. *See* Gastroesophageal reflux disease
hiatal hernia. *See* Hiatal hernia
impaired motility, 668, 668f
- ESR. *See* Erythrocyte sedimentation rate
- ESRD (end-stage renal disease), 899. *See also* Chronic renal failure
- Essential tremor, 1513t
- Estar. *See* Coal tar derivatives
- Estradiol, 386t, 1753
- Estrogen:
functions, 1753
osteoporosis and, 1434
replacement therapy. *See* Hormone replacement therapy
vaginal effects, 1752
- ESWL. *See* Extracorporeal shock wave lithotripsy
- Etanercept:
in autoimmune disorders, 341
in psoriasis, 444
in rheumatoid arthritis, 1465
- ETCO₂. *See* Exhaled carbon dioxide
- Ethacrynic acid:
Medication Administration, 210t, 905t, 1033t, 1539t
in specific conditions
acute renal failure, 905t
fluid volume excess, 210t
heart failure, 1033t
increased intracranial pressure, 1538, 1539t
- Ethambutol:
dosage, 1288t
Medication Administration, 1289t
nursing implications, 1288t
optic neuritis and, 1287, 1288t
for tuberculosis, 1289t
- Ether, abuse, 111
- Ethics, 10. *See also* Nursing ethics
- Ethinyl estradiol, 1802t
- Ethmozine. *See* Moricizine
- Ethnicity. *See* Race/ethnicity
- Ethnopharmacology, 176
- Ethosuximide, 1550t
- Etidronate, 232
- Etodolac, 178t, 1464t
- Etoposide, 391, 393t, 1775
- Euploidy, 150t
- European Americans. *See* Caucasians/European Americans
- Euthanasia, 91
- Euthyroid. *See* Liotrix
- Euthyroid, definition, 537
- Evac-U-Gen. *See* Phenolphthalein
- Evac-U-Lax. *See* Phenolphthalein
- Evaluation, 7t, 10
- Evening primrose, 1796
- Eversion, 1386t
- Evidence-based practice. *See* Nursing Research: Evidence-Based Practice
- Evisceration, 78, 78f
- Evista. *See* Raloxifene
- Evoked potentials, 1515t
- Evoked response, 1627
- Exacerbation, 23
- Excisional biopsy:
breast, 1824, 1824f
definition, 388t
skin, 428t
- Excitability, 995, 1383
- Exelon. *See* Rivastigmine tartrate
- Exenatide, 576
- Exercise:
in chronic obstructive pulmonary disease management, 1334–35, 1335t
coronary heart disease risk reduction and, 964, 966
in diabetes management, 580–81
in heart failure management, 1034
in hypertension management, 1159–60
in obesity treatment, 634, 634t, 635t
osteoporosis risk and, 1434
in rheumatoid arthritis treatment, 1466
- Exercise ECG tests. *See* Stress/exercise tests
- Exfoliative dermatitis, 457
- Exhaled carbon dioxide (ETCO₂):
in acute respiratory failure, 1355
in chronic obstructive pulmonary disease, 1334
in pulmonary embolism, 1349
- Exogenous, 304
- Exogenous insulin, 566
- Exophthalmos, 529t, 536, 536f
- Exophytic, 1819
- Exostoses, 1719
- Exotoxins, 311
- Expansion, infarct, 985
- Expiration, 1215, 1215f
- Expiratory reserve volume (ERV), 1214, 1214t
- Expressive aphasia, 1583
- Extended-spectrum beta-lactamase, 314
- Extensibility, 1383
- Extension, 1386t
- Extension, infarct, 985
- External auditory canal, 1680, 1682f, 1688
- External AV shunt, 908
- External fixation, 1410–11, 1411f, 1419t
- External hemorrhoids, 818, 818f. *See also* Hemorrhoids
- External rotation, 1386t
- External sphenoethmoidectomy, 1237, 1237f
- Extracapsular fracture, 1414, 1415f. *See also* Hip, fracture
- Extracellular fluid (ECF), 196–97, 196f, 197f
- Extracorporeal shock wave lithotripsy (ESWL):
for gallstones, 700–701
nursing care, 701, 859t
for urinary calculi, 858, 858f
- Extradural hematoma. *See* Epidural hematoma
- Extranodal marginal zone lymphoma, 1130t. *See also* Lymphomas
- Extubation, 1356
- Exudate, 1295
- Exudative macular degeneration, 1714
- Eyelids:
anatomy and functions, 1670, 1670f
disorders
interdisciplinary care, 1701
nursing care, 1701
pathophysiology and manifestations, 1700–1701, 1701f
- Eyes. *See also* Vision
age-related changes, 1676t
anatomy, physiology, and functions
extraocular muscles, 1671f
extraocular structures, 1670, 1670f
intraocular structures
aqueous fluid, 1671–72
internal chamber, 1672
iris, 1671
overview, 1672f
sclera and cornea, 1671
refraction, 1673
visual pathway, 1672–73, 1673f
- assessment
diagnostic tests, 1674, 1675t
genetic considerations, 1674, 1674t
health assessment interview, 1674
physical assessment
external eyes, 1679–80t, 1679f
eye movement, 1677–78t, 1677f
internal eyes, 1680t, 1681t
ophthalmoscope guidelines, 1681t
pupils, 1678–79t
vision, 1676–77t, 1677f
visual fields, 1675–76t, 1676f, 1708f
- disorders
age-related macular degeneration. *See* Age-related macular degeneration
cataracts. *See* Cataracts
Chapter Highlights, 1734t
Clinical Scenarios, 1738t
conjunctivitis. *See* Conjunctivitis
corneal. *See* Corneal disorders
diabetic retinopathy. *See* Diabetic retinopathy
enucleation for, 1718
eyelids
interdisciplinary care, 1701
nursing care, 1701
pathophysiology and manifestations, 1700–1701, 1701f
glaucoma. *See* Glaucoma
in HIV/AIDS, 1718
incidence, 1692
retinal detachment. *See* Retinal detachment
retinitis pigmentosa, 1717–18
uveitis. *See* Uveitis
functional health pattern interview, 1675t
prosthetic, removing and inserting, 1719t
trauma
blunt, 1702
burns, 1702
corneal abrasion, 1701–2
in disasters, 129t, 131
interdisciplinary care, 1702–3

- nursing care
 community-based care, 1703
 health promotion, 1703
 nursing diagnoses and interventions, 1703
 pathophysiology and manifestations, 1701-2
 penetrating, 1702
- F**
- F cells, pancreas, 521
- Fab (antigen-binding fragment), 296, 297f
- Face:
 assessment, 529t
 fracture, 1412
- Facial nerve (cranial nerve VII):
 anatomy, 1510f
 assessment, 1520t
 functions, 1511t
- Facial paralysis. *See* Bell's palsy
- Facilitated diffusion, 200
- Factor IX, 1144
- Factor VIII, 1144
- Factor XI deficiency. *See also* Hemophilia
 characteristics, 1143t
 pathophysiology, 1143
 treatment, 1143t
- Fallopian tubes, 1751t, 1753, 1753f
- Falls:
 hip fracture and, 1415. *See also* Hip, fracture
 prevention, 1418t, 1623t
- False aneurysm, 1170
- Famciclovir, 453, 1839
- Familial adenomatous polyposis (FAP), 746t, 801
- Familial Alzheimer's disease, 1618
- Familial hypercholesterolemia, 950t
- Family:
 of client with chronic illness, 33
 definition, 31
 developmental stages and tasks
 couple, 32
 family with adolescents and young adults, 33
 family with infants and preschoolers, 32
 family with middle adults, 33
 family with older adults, 33
 family with school-age children, 33
 overview, 31-32
 functions, 31
 in grieving process, 88
 risk factors for alterations in health, 32t
- Famotidine:
 Medication Administration, 665t
 preoperative use and nursing implications, 62t
 in specific conditions
 burns, 502
 gastritis, 678
 gastroesophageal reflux disease, 502
- Famvir. *See* Famciclovir
- Fanconi anemia, 1109
- FAP (familial adenomatous polyposis), 746t, 801
- Far point of accommodation, 1673
- Fascial excision, 502
- Fasciculations, 1522t, 1645
- Fasciectomy, 502
- Fasciolopsiasis, 781t
- Fascioscapulohumeral muscular dystrophy, 1459t
- FAST (focused assessment by sonography in trauma), 261
- Fastin. *See* Phentermine
- Fasting blood sugar, 386t, 526t. *See also* Blood glucose
- Fast-tracking, 62
- Fat embolism syndrome (FES), 1406
- Fat necrosis, breast, 1821t
- Fats, dietary:
 in diabetes mellitus, 579
 foods high in, 702t
 recommended dietary guidelines, 606t
 sources, 579, 608
 types, 607-8
 uses in body, 607f, 608
- Fat-soluble vitamins, 608, 608t
- F_c (crystallized fragment), 296, 296f
- FCC (fibrocystic changes), 1820-21, 1821t, 1822f
- Fecal impaction, 758
- Fecal incontinence:
 causes, 763, 763t
 definition, 763
 interdisciplinary care, 764-65
 nursing care
 assessment, 765
 community-based care, 765-66
 health promotion, 765
 nursing diagnoses and interventions
 bowel incontinence, 765
 risk for impaired skin integrity, 765
 Nursing Research: self-care practices, 764t
 pathophysiology, 764
- Fecalith, 766
- Feces. *See* Stool
- Feedback mechanisms, 521-22, 522f
- Feeding tube. *See* Enteral nutrition
- Feen-A-Mint. *See* Phenolphthalein
- Feet:
 care
 in diabetes mellitus, 594t
 in peripheral vascular disease, 1178t
 deformities
 hallux valgus, 1492, 1492f
 hammertoe, 1492
 interdisciplinary care, 1493
 Morton's neuroma, 1492-93, 1493f
 nursing care
 community-based care, 1493
 nursing diagnoses and interventions, 1493
 in diabetes mellitus, complications, 590, 590f
 fracture, 1416
 physical assessment, 1394t
- Feldene. *See* Piroxicam
- Felodipine, 973-74t, 1162t
- Female reproductive system:
 age-related changes, 27t, 29t, 1760t
 anatomy, physiology, and functions
 breasts, 1751, 1752f
 external genitalia, 1751-52, 1751t, 1752f
 internal organs, 1751t
 menstrual cycle, 1754-55, 1754f
 oogenesis and the ovarian cycle, 1754, 1754f
 sex hormones, 1753
 assessment
 diagnostic tests, 1755, 1756-58t
 functional health pattern interview, 1759-60t
 genetic considerations, 1755, 1755t
 health assessment interview, 1758
 physical assessment
 axillary lymph nodes, 1762f, 1762t
 breasts, 1761-62t, 1761f
 external genitalia, 1762-63t
 overview, 1760
 sample documentation, 1755
- disorders
 benign breast disorders
 fibrocystic changes, 1820-21, 1821t
 interdisciplinary care, 1821t, 1822
 intraductal, 1821-22, 1821t
 manifestations, 1820-22, 1821t
 nursing care, 1822
 pathophysiology, 1820-22
 breast cancer. *See* Breast cancer
- cervical cancer. *See* Cervical cancer
 Chapter Highlights, 1833t
 Clinical Scenarios, 1855t
 cysts or polyps
 interdisciplinary care, 1808-9
 manifestations, 1808
 nursing care, 1809
 pathophysiology, 1808
 dysfunctional uterine bleeding. *See*
 Dysfunctional uterine bleeding
 dysmenorrhea. *See* Dysmenorrhea
 endometrial cancer. *See* Endometrial cancer
 endometriosis. *See* Endometriosis
 leiomyoma. *See* Leiomyoma
 menopause-related. *See* Menopause
 ovarian cancer. *See* Ovarian cancer
 premenstrual syndrome. *See* Premenstrual
 syndrome
 sexual dysfunction
 anorgasmia, 1795
 dyspareunia, 1795
 inhibited sexual desire, 1795
 nursing care, 1795
 sexually transmitted infections. *See* Sexually
 transmitted infections
 uterine displacement. *See* Uterine displacement
 vaginal fistula, 1807-8
 vulvar cancer. *See* Vulvar cancer
- Femara, 1825
- Femoral artery, 1097t, 1172
- Femur:
 fracture of head or neck. *See* Hip, fracture
 fracture of shaft, 1414
- Fenamates, 178t, 306
- Fenofibrate, 967t
- Fenoldopam, 1169t
- Fenopropfen calcium, 178t, 179t, 1464t
- Fentanyl, 62t, 190t
- Ferric chloride, 465t
- Ferlecit. *See* Sodium ferric gluconate
- Ferrous gluconate, 1112t
- Ferrous sulfate, 716, 1112t
- FES (fat embolism syndrome), 1406
- FEV₁ (forced expiratory volume), 1214t
- Fever blister. *See* Herpes simplex
- Fexofenadine, 1230t
- FFP (fresh frozen plasma), 263t
- Fiber, dietary:
 in constipation, 760, 761
 for coronary heart disease risk reduction, 966
 in diabetes mellitus, 579
 in diverticular disease, 816, 817
 in irritable bowel syndrome, 763
 sources, 579, 816t
- Fibercon. *See* Calcium polycarbophil
- Fiberoptic bronchoscopy. *See* Bronchoscopy
- Fibrates. *See* Fibric acid derivatives
- Fibric acid derivatives, 967t, 968
- Fibrin degradation products, 1148
- Fibrin split products, 1148
- Fibrin stabilizing factor, 1082t
- Fibrinogen, 386t, 1082t
- Fibrinolysis, 1081
- Fibrinolytic therapy:
 nursing care
 during the infusion, 989t
 postinfusion, 989t
 preinfusion, 989t
 in specific conditions
 acute arterial occlusion, 1184
 acute myocardial infarction, 987-88
 pulmonary embolism, 1349
 thrombotic stroke, 1585
 venous thrombosis, 1188

- Fibrinous exudate, 293
 Fibroadenoma, 1821*t*
 Fibrocystic changes (FCC), 1820–21, 1821*t*, 1822*f*
 Fibroid tumor. *See* Leiomyoma
 Fibromyalgia:
 incidence, 1486–87
 interdisciplinary care, 1487
 manifestations, 1487, 1487*f*
 nursing care, 1487
 pathophysiology, 1487
 Fibrosarcoma, 1482*t*. *See also* Bone tumors
 Fibula, fracture, 1416
 Fifth vital sign, 170. *See also* Pain
 Figurate erythema, 431*t*. *See also* Erythema
 Filariasis, 1199
 Filtration, 200, 200*f*
 Finasteride, 1778
 Fine-needle biopsy:
 breast, 1757*t*, 1824, 1824*f*
 definition, 388*t*
 Fingers, 1393*t*
 FIO₂ (oxygen concentration), 1360, 1360*t*
 Fires, 487. *See also* Burns
 First episode infection, 1839
 First-degree AV block:
 causes, 1003
 ECG characteristics, 999*t*, 1003
 management, 999*t*
 pathophysiology, 1003
 Fissures:
 anal, 820
 skin, 433*t*
 Fistula:
 anorectal, 820–21
 in diverticular disease, 816
 vaginal, 1807–8
 Fixed cells, 295
 Flaccid neurogenic bladder, 870. *See also*
 Neurogenic bladder
 Flaccidity:
 causes, 1522*t*
 definition, 1522*t*, 1584
 in stroke, 1584
 Flagyl. *See* Metronidazole
 Flail chest, 1303, 1303*f*, 1414. *See also* Thoracic
 trauma
 Flap (closed) amputation, 1421, 1422*t*
 Flash blindness, 131
 Flashover effect, 488
 Flat bones, 1380
 Flat wart, 452, 1841. *See also* Genital warts
 Flatus, 746
 Flavoxate hydrochloride, 871, 871*t*
 Flaxseed oil, 760
 Flaxseeds, 761, 1796
 Flecainide, 1006*t*
 Fleet enema. *See* Phosphate enema
 Fletcher's Castoria. *See* Senna
 Flexall 454. *See* Counterirritants
 Flexeril. *See* Cyclobenzaprine
 Flexion, 1386*t*
 Flolan. *See* Epoprostenol
 Flomax. *See* Tamsulosin
 Flovent. *See* Fluticasone propionate
 Flow-cycled ventilators, 1358
 Floxin. *See* Ofloxacin
 Flu. *See* Influenza
 Fluconazole:
 indications, 318, 321
 Medication Administration, 450*t*
 in specific conditions
 fungal meningitis, 1566
 thrush, 657*t*, 658
 Flucytosine, 1566
 Fludara. *See* Fludarabine
 Fludarabine, 1123*t*
 Fludrocortisone, 555*t*
 Fluid challenge, 206
 Fluid exudate, 292–93
 Fluid replacement:
 in diarrhea, 755
 in increased intracranial pressure, 1539, 1539*t*
 Medication Administration, 1539*t*
 Fluid restriction:
 in acute renal failure, 905
 in chronic renal failure, 919
 guidelines, 210*t*
 Fluid resuscitation:
 for burns, 499
 definition, 499
 for diabetic ketoacidosis, 585–86
 for shock
 colloid solutions, 277–78
 crystalloid solutions, 277
 Fluid volume deficit (FVD):
 causes, 203
 definition, 203
 interdisciplinary care
 assessment findings, 205*t*
 diagnosis, 205
 fluid challenge, 206
 fluid management
 intravenous therapy, 205–6
 oral rehydration, 205
 manifestations, 203, 204*t*, 205, 205*t*
 Multisystem Effects, 204*t*
 nursing care
 assessment, 207, 207*t*, 208*t*
 community-based care, 208–9
 health promotion, 206
 nursing diagnoses and interventions
 deficient fluid volume, 207–8
 ineffective tissue perfusion, 208
 risk for injury, 208
 of older adults, 203*t*
 using NANDA, NIC, and NOC, 208, 209*t*
 Nursing Research: weight vs. input-output
 records for assessment, 208*t*
 pathophysiology, 203
 third spacing, 203
 Fluid volume excess:
 definition, 209
 interdisciplinary care
 assessment findings, 205*t*
 diagnosis, 210
 medications, 210, 210*t*
 treatment
 dietary management, 210–11
 fluid management, 210, 210*t*
 manifestations and complications, 205*t*, 209–10
 nursing care
 assessment, 211
 community-based care, 213
 health promotion, 211
 Medication Administration, 210*t*
 nursing diagnoses and interventions, 211
 excess fluid volume, 211–12
 risk for impaired gas exchange, 213
 risk for impaired skin integrity, 213
 Nursing Care Plan
 assessment, 212*t*
 critical thinking in the nursing process, 212*t*
 diagnoses, 212*t*
 evaluation, 212*t*
 expected outcomes, 212*t*
 planning and implementation, 212*t*
 pathophysiology, 209
 Fluids. *See* Body fluids
 Fluids and electrolytes:
 body fluid composition
 electrolytes, 196, 197, 197*f*. *See also*
 Electrolytes
 water, 195–96
 body fluid distribution, 196–97, 196*f*, 197*f*
 body fluid movement
 active transport, 200, 201*f*
 diffusion, 199–200, 200*f*
 filtration, 200, 200*f*
 osmosis
 definition, 198, 198*f*
 osmolarity and osmolality, 198
 osmotic pressure and tonicity, 198–99, 199*f*
 body fluid regulation
 antidiuretic hormone, 201–2, 202*f*
 atrial natriuretic peptide, 202
 kidneys, 201
 renin-angiotensin-aldosterone system, 201, 202*f*
 thirst, 200–201, 201*f*
 changes in older adults, 202
 Chapter Highlights, 252
 imbalances
 calcium. *See* Hypercalcemia; Hypocalcemia
 in chronic renal failure, 915–16
 fluid volume deficit. *See* Fluid volume
 deficit
 fluid volume excess. *See* Fluid volume
 excess
 magnesium. *See* Hypermagnesemia;
 Hypomagnesemia
 phosphate. *See* Hyperphosphatemia;
 Hypophosphatemia
 potassium. *See* Hyperkalemia; Hypokalemia
 sodium. *See* Hyponatremia; Hyponatremia
 normal gain and loss in an adult, 196*t*
 Flumadine. *See* Rimantadine
 Flunisolide, 1328*t*
 Fluorescein angiogram, 1714
 Fluorescein stain, 1694, 1697
 Fluorescent treponemal antibody absorption (FTA-
 ABS), 1746*t*, 1756*t*, 1849
 Fluoride therapy, 1436, 1437*t*
 Fluoroquinolones:
 Medication Administration, 320*t*
 in specific conditions
 gonorrhea, 1846
 pneumonia, 1271, 1271*t*
 5-Fluorouracil (5-FU):
 adverse/side effects, 392*t*
 nursing implications, 392*t*
 in specific conditions
 colorectal cancer, 805
 laryngeal cancer, 1254
 target malignancies, 392*t*
 Fluoxetine:
 for eating disorders, 652
 for irritable bowel syndrome, 763
 for premenstrual syndrome, 1798
 for substance abuse/withdrawal treatment, 114*t*
 Flurbiprofen, 178*t*, 1464*t*
 Flutamide, 1787*t*
 Fluticasone propionate, 1328*t*
 Fluvastatin, 967*t*
 Focal sclerosis, 888. *See also* Glomerular disorders
 Focus on Cultural Diversity. *See also*
 Race/ethnicity
 breast cancer, 1822*t*
 cancer, 370*t*
 cirrhosis, 711*t*
 diabetes mellitus, 564*t*
 dying and death, 89*t*
 G6PD anemia, 1106*t*
 gallstones, 697

- heart disease, 958t
heart failure, 1023t, 1035t
hemolytic anemias, 1106t
HIV/AIDS, 349t
hypertension, 1157t
inflammatory bowel disease, 782t
lactase deficiency, 798t
obesity, 631t
osteoarthritis, 1449t
osteoporosis, 1434t
prostate cancer, 1783t
sickle cell anemia, 1106t, 1107t
stroke, 1580t
substance use, 105t
testicular cancer, 1774t
thalassemia, 1106t
tuberculosis, 1281t
- Focused assessment by sonography in trauma (FAST), 261
- Folate. *See* Folic acid
- Folic acid:
for anemia in cirrhosis, 716
deficiency
causes, 1106, 1106t
interdisciplinary care, 1110t, 1111t, 1112t
manifestations, 1106
neural tube defects and, 1106
Nursing Care Plan
assessment, 1113t
critical thinking in the nursing process, 1113t
diagnoses, 1113t
expected outcomes, 1113t
planning and implementation, 1113t
pathophysiology, 1105-6
functions, 609t
recommended daily intake, 609t
replacement therapy, 1112t
sources, 609t, 1111t
for substance abuse/withdrawal treatment, 114t
- Folinic acid, 805
- Follicle-stimulating hormone (FSH):
functions, 520, 1753
in ovarian cycle, 1754, 1754f
- Follicular lymphoma, 1130t. *See also* Lymphomas
- Follicular thyroid cancer, 546
- Folliculitis, 446, 446f
- Folvite. *See* Folic acid, replacement therapy
- Food allergy:
anaphylaxis caused by, 332, 332t
testing, 337
- Food Guide Pyramid, 21f
- Food poisoning. *See* Gastroenteritis
- Foot care. *See* Feet, care
- Foradil. *See* Formoterol
- Foraminotomy, 1610
- Forced expiratory volume (FEV₁), 1214t
- Forced vital capacity (FVC), 1214t
- Foreign bodies:
in ear, 1721
retained after surgery, 59
- Forequarter amputation, 1422t
- Foreskin, 1749t, 1771
- Formoterol, 1327t
- Formulas, enteral feeding, 646t
- Fornix, 1752
- Fortaz. *See* Cefotaxime
- Forteo. *See* Teriparatide
- Forward effects, heart failure, 1026
- Fosamax. *See* Alendronate
- Foscarnet, 359t, 1718, 1839
- Foscavir. *See* Foscarnet
- Fosinopril, 1033t, 1161t
- Fototar. *See* Coal tar derivatives
- Fowler, spiritual development theory, 25t
- Fractures:
Case Study, 1499t
classification, 1401-2, 1402f
complications. *See also* Deep venous thrombosis
compartment syndrome. *See* Compartment syndrome
deep venous thrombosis, 1406, 1406t
delayed union and nonunion, 1407
fat embolism syndrome, 1406
infection, 1406-7
reflex sympathetic dystrophy, 1407
Volkmann's contracture, 1406
definition, 1401
healing
factors affecting, 1403t
phases, 1402, 1404-5t
interdisciplinary care
diagnosis, 1407, 1407f
emergency care, 1407
medications, 1408
pain management, 1408t
treatments
casts, 1409-10, 1410f, 1419t
electrical bone stimulation, 1411-12, 1412f
surgery, 1410-11, 1411f
traction, 1408, 1409t, 1419t
manifestations, 1402-3, 1403t
nursing care
assessment, 1417-18
client in traction, 1409t
client with a cast, 1410t
client with internal fixation, 1412t
clients with fracture of the humerus, 1413t
community-based care, 1420-21
health promotion, 1416-17
nursing diagnoses and interventions
acute pain, 1418
impaired physical mobility, 1420
risk for disturbed sensory perception:
tactile, 1420
risk for infection, 1419-20
risk for peripheral neurovascular dysfunction, 1418-19, 1419f
using NANDA, NIC, and NOC, 1420, 1420t
Nursing Research: care of pin insertion sites, 1419t
in osteoporosis, 1435
pathophysiology, 1401
of specific bones or areas
clavicle, 1412-13
elbow, 1413
face, 1412
femoral shaft, 1414
hip. *See* Hip, fracture
humerus
characteristics, 1413
nursing interventions, 1413t
nose. *See* Nasal trauma
pelvis, 1414
radius and/or ulna, 1413
rib, 1302-3, 1414. *See also* Thoracic trauma
skull. *See* Skull fracture
spine, 1412
wrist or hand, 1413-14
- Fragmin. *See* Dalteparin
- Framingham Heart Study, 962t
- Frank-Starling mechanism, 1024t, 1025
- FRC (functional residual capacity), 1214t
- Freestanding outpatient surgical facilities, 55
- Fresh frozen plasma (FFP), 263t
- Freud, theory of loss and grief, 85, 86t
- Friction rub, 1226t
- Friedreich's ataxia, 1513t
- Frontal lobe, 1506f, 1506t
- Frontotemporal dementia, 1618t
- Frostbite, 476-77
- Fructose, 579
- FSH. *See* Follicle-stimulating hormone
- FTA-ABS (fluorescent treponemal antibody absorption), 1746t, 1756t, 1849
- 5-FU. *See* 5-Fluorouracil
- Fulguration:
of bladder tumor, 864
of colorectal tumors, 803
- Full-thickness avulsion injuries, 259
- Full-thickness burn, 490, 490f. *See also* Burns
- Full-thickness graft, 478, 478f
- Fulminant colitis, 784. *See also* Inflammatory bowel disease
- Fulminant hepatitis, 706. *See also* Hepatitis
- Fulvicin. *See* Griseofulvin
- Functional colitis. *See* Irritable bowel syndrome
- Functional disease, 22t
- Functional health pattern interviews:
ears, 1685t
endocrine system, 528t
eyes, 1675t
female reproductive system, 1759-60t
heart, 951-52t
hematologic, peripheral vascular, and lymphatic systems, 1090t
integumentary system, 429t
intestinal tract, 747t
male reproductive system, 1748t
musculoskeletal system, 1390t
neurologic system, 1517t
nutritional status and gastrointestinal system, 618t
respiratory system, 1221-22t
urinary system, 840t
- Functional health patterns:
activity-exercise. *See* Activity-exercise patterns
cognitive-perceptual. *See* Cognitive-perceptual patterns
definitions, 9t
elimination. *See* Elimination patterns
nutritional-metabolic. *See* Nutritional-metabolic patterns
sexuality-reproductive. *See* Sexuality-reproductive patterns
- Functional residual capacity (FRC), 1214t
- Functional urinary incontinence, 874t. *See also* Urinary incontinence
- Fundoplication, 666
- Fundoscopy, 1708
- Fungi:
characteristics, 311t
lung infections
aspergillosis, 1294
blastomycosis, 1294
coccidiomycosis, 1294
geographic distribution, 1294
histoplasmosis, 1294
interdisciplinary care, 1294-95
nursing care, 1295
pathophysiology, 1294
skin infections
interdisciplinary care, 449-50, 450t
nursing care, 450
types
candidiasis. *See* Candidiasis
dermatophytoses, 448-49
- Fungizone. *See* Amphotericin B
- Furadantin. *See* Nitrofurantoin
- Furazolidone, 778t, 780t
- Furosemide:
adverse/side effects, 1730
Medication Administration, 210t, 717t, 905t, 1033t, 1539t

- Furosemide—*continued*
 in specific conditions
 acute renal failure, 904, 905*t*
 ascites, 716, 717*t*
 fluid volume excess, 210*t*
 heart failure, 1033*t*
 hyperkalemia, 225*t*
 increased intracranial pressure, 1538, 1539*t*
 pulmonary edema, 1041
- Furoxone. *See* Furazolidone
- Furstenberg diet, 1727
- Furuncle, 446–47, 447*f*
- Fusiform aneurysm, 1170, 1592
- Fusiform excision, 477
- Fuzeon. *See* Enfuvirtide
- FVC (forced vital capacity), 1214*t*
- FVD. *See* Fluid volume deficit
- G**
- G6PD (glucose-6-phosphate dehydrogenase)
 anemia, 1106*t*, 1109
- GABA (gamma aminobutyric acid), 1505
- Gabapentin, 1550*t*, 1656
- Gabitril. *See* Tiagabine
- Gait, 1391*t*, 1522–23*t*
- Galactorrhea, 1762*t*
- Galantamine hydrobromide, 1621
- Gallbladder:
 anatomy, physiology, and functions, 611*f*,
 613, 697
- disorders
 cancer, 703
- diagnostic tests, 616*t*, 699
- gallstones. *See* Gallstones
- Gallstone ileus, 698
- Gallstones:
 complications, 698, 698*t*
 ethnic considerations, 697
- interdisciplinary care
 diagnosis, 616*t*, 699, 699*t*
 medications, 699
- treatments
 complementary therapies, 701
- extracorporeal shock wave lithotripsy,
 700–701
- nutrition, 700
- percutaneous cholecystostomy, 701
- surgery, 699–700, 699*f*
- manifestations, 698, 698*t*
- nursing care
 assessment, 701
- community-based care, 703
- health promotion, 701
- nursing diagnoses and interventions
 imbalanced nutrition: less than body
 requirements, 702–3
- pain, 701–2, 702*t*
- risk for infection, 703
- Nursing Care Plan
 assessment, 702*t*
- critical thinking in the nursing process, 702*t*
- diagnosis, 702*t*
- evaluation, 702*t*
- expected outcomes, 702*t*
- planning and implementation, 702*t*
- pathophysiology, 697–98
- risk factors, 697*t*
- GALT (gut-associated lymphoid tissue), 292
- Gamma aminobutyric acid (GABA), 1505
- Gamma benzene hexachloride, 451
- Gamma glutamyltransferase (GGT), 386*t*
- Gamma interferon, 299*t*. *See also* Interferon(s)
- Gamma knife, 1572
- Ganciclovir:
 Medication Administration, 322*t*
 in specific conditions
 bone marrow transplant recipients, 344
- cytomegalovirus infection, 359*t*, 1718
- Gangrene, 588, 1093*t*
- Gangrenous appendicitis, 766
- Gantanol. *See* Sulfamethoxazole
- Gantrisin. *See* Sulfisoxazole
- Garamycin. *See* Gentamicin
- Gardasil, 1815, 1841
- Gardnerella vaginalis*, 1842
- Gardner-Wells tongs, 1601, 1601*f*
- Garlic, 679, 1231
- Gas gangrene, 267
- Gastrectomy, 689, 689*f*
- Gastric acid pump inhibitors. *See* Proton-pump
 inhibitors
- Gastric analysis:
 purpose and description, 615*t*
 related nursing care, 615*t*
 in specific conditions
 gastritis, 678
- Zollinger-Ellison syndrome, 684
- Gastric bypass procedures, 636–37, 637*f*
- Gastric cancer:
 incidence, 688
- interdisciplinary care
 complications, 689–91
- diagnosis, 689
- gastrostomy, 691
- gastrostomy/jejunostomy, 691*f*
- surgery, 689, 690*f*
- manifestations, 689
- nursing care
 assessment, 691
- health promotion, 691
- nursing diagnoses and interventions
 anticipatory grieving, 693
- community-based care, 694
- imbalanced nutrition: less than body
 requirements, 691, 693
- using NANDA, NIC, and NOC, 693, 693*t*
- postoperative, 690*t*
- preoperative, 690*t*
- Nursing Care Plan
 assessment, 692*t*
- critical thinking in the nursing process, 693*t*
- diagnoses, 692*t*
- expected outcomes, 692*t*
- planning and implementation, 692–93*t*
- pathophysiology, 688, 689*f*
- risk factors, 688
- Gastric emptying studies, 616*t*
- Gastric lavage:
 for botulism, 777
- closed-system irrigation, 676*f*, 676*t*
- for esophageal varices, 718
- for gastritis, 678–79
- intermittent open system, 676
- nursing responsibilities, 676*t*
- for upper gastrointestinal bleeding, 675
- Gastric mucosal barrier, 671
- Gastric outlet obstruction, 681*t*, 684
- Gastric residual volume, 662*t*. *See also* Enteral
 nutrition
- Gastric ulcers, 680. *See also* Peptic ulcer disease
- Gastritis:
 definition, 677
- interdisciplinary care
 diagnosis, 678
- medications, 665–66*t*, 678
- treatments
 complementary therapies, 679
- gastric lavage, 678–79
- nutrition, 678
- manifestations, 677, 677*t*, 678
- nursing care
 assessment, 679
- community-based care, 680
- health promotion, 679
- Medication Administration, 665–66*t*
- nursing diagnoses and interventions
 deficient fluid volume, 679
- imbalanced nutrition: less than body
 requirements, 679–80
- pathophysiology, 677–78
- types, 677
- Gastroduodenostomy (Billroth I), 689, 689*f*
- Gastroenteritis:
 complications, 774
- definition, 773
- interdisciplinary care
 diagnosis, 776, 776*t*
- dialysis, 777
- gastric lavage, 777
- medications, 776
- nutrition and fluids, 776–77
- plasmapheresis, 777
- manifestations, 773, 773*t*
- nursing care
 assessment, 777
- community-based care, 777
- health promotion, 777
- nursing diagnoses and interventions, 777
- pathophysiology, 773
- types
C. difficile colitis, 774*t*, 775
- cholera, 774*t*, 775
- hemorrhagic colitis, 774*t*, 775
- salmonellosis, 774*t*, 775
- shigellosis, 774*t*, 775
- staphylococcal food poisoning,
 774*t*, 775
- traveler's diarrhea, 774–75, 774*t*
- Gastroesophageal reflux, 663
- Gastroesophageal reflux disease (GERD):
 definition, 663
- incidence, 663
- interdisciplinary care
 diagnosis, 664–65
- medications, 665–66*t*
- nutrition and lifestyle management, 666
- surgery, 666
- manifestations, 663–64, 664*t*
- nursing care
 assessment, 666
- community-based care, 667
- Medication Administration, 665–66*t*
- nursing diagnoses and interventions, 667
- using NANDA, NIC, and NOC,
 667, 667*t*
- pathophysiology, 663, 664*f*
- Gastrografin. *See* Meglumine diatrizoate
- Gastrointestinal bleeding:
 causes, 674, 681. *See also* Esophageal varices;
 Gastritis; Peptic ulcer disease
- complications, 674
- interdisciplinary care
 diagnosis, 674
- treatments
 endoscopy, 675
- fluid and blood replacement, 674
- gastric lavage. *See* Gastric lavage
- nursing care
 assessment, 675
- community-based care, 677
- health promotion, 675

- nursing diagnoses and interventions
 - decreased cardiac output, 675
 - impaired tissue integrity: gastrointestinal, 675
- pathophysiology, 674
- Gastrointestinal system:
 - age-related changes
 - in middle adults, 27*t*
 - in older adults, 29*t*, 619*t*, 746*t*
 - anatomy, physiology, and functions
 - esophagus, 610–11, 611*f*
 - exocrine pancreas, 613
 - gallbladder, 611*f*, 613
 - large intestine, 742–43, 742*f*
 - liver, 612–13, 613*t*
 - mouth, 610, 611*f*
 - overview, 605*f*
 - pharynx, 611*f*
 - rectum and anus, 743, 743*f*
 - small intestine, 605*f*, 612, 742
 - stomach, 611–12, 611*f*
- assessment
 - diagnostic tests, 614, 615–17*t*. *See also specific tests*
 - functional health pattern interview, 618*t*
 - genetic considerations, 614, 614*t*
 - health assessment interview, 614, 617–19
 - physical assessment
 - abdomen, 623–27*t*, 623*f*, 624*f*, 748–49*t*
 - oral cavity, 622–23*t*
 - overview, 619
- disorders
 - anus and rectum
 - anal fissure, 820
 - anorectal abscess, 820
 - anorectal fistula, 820–21
 - hemorrhoids. *See Hemorrhoids*
 - nursing care, 821
 - pilonidal disease, 821
 - Clinical Scenarios, 736*t*
 - esophagus
 - cancer. *See Esophageal cancer*
 - diagnostic tests, 615*t*
 - gastroesophageal reflux disease. *See Gastroesophageal reflux disease*
 - hiatal hernia. *See Hiatal hernia*
 - impaired motility, 668, 668*f*
 - gallbladder
 - cancer, 703
 - diagnostic tests, 616*t*, 699
 - gallstones. *See Gallstones*
 - liver. *See Liver, disorders*
 - mouth
 - cancer. *See Oral cancer*
 - stomatitis. *See Stomatitis*
 - pancreas
 - cancer. *See Pancreatic cancer*
 - diagnostic tests, 526*t*, 616–17*t*, 728*t*
 - endocrine function. *See Diabetes mellitus*
 - pancreatitis. *See Pancreatitis*
 - small and large intestine. *See Bowel disorders*
 - stomach
 - cancer. *See Gastric cancer*
 - nausea and vomiting. *See Nausea and vomiting*
 - peptic ulcer disease. *See Peptic ulcer disease*
 - upper gastrointestinal bleeding. *See Gastrointestinal bleeding*
- Gastrojejunostomy (Billroth II), 689, 689*f*
- Gastroparesis, 589
- Gastroscopy. *See Esophagogastroduodenoscopy*
- Gastrostomy tube:
 - characteristics, 691, 691*f*
 - nursing care, 692*t*
- Gate-control theory, of pain, 172, 172*f*
- Gatifloxacin, 320*t*
- Gaucher disease, 614*t*, 1089*t*
- Gaviscon, 665, 666*t*
- Gelusil, 666*t*
- Gemfibrozil, 967*t*
- Gender:
 - cancer risk and, 370
 - coronary heart disease risk and, 962–63
 - health and, 20
- General adaptation syndrome, 135*t*
- General anesthesia, 61–63
- Generalized seizures, 1549
- Genes. *See also Genetics*
 - alterations, 152
 - characteristics, 151
 - expression, 155
 - function and distribution, 151
 - mitochondrial, 151
 - single nucleotide polymorphisms, 152
- Genetic locus, 151
- Genetics:
 - cancer risk and, 370
 - Chapter Highlights, 166*t*
 - considerations in specific conditions
 - Alzheimer's disease, 1513*t*
 - amyotrophic lateral sclerosis, 1389*t*, 1513*t*
 - ankylosing spondylitis, 1469
 - asthma, 1220*t*
 - atherosclerosis, 1089*t*
 - cardiac disorders, 943, 950*t*
 - chronic myeloid leukemia, 151, 1089*t*, 1121, 1122*f*
 - chronic obstructive pulmonary disease, 1331*t*
 - chronic renal failure, 839*t*
 - cystic fibrosis, 152, 1220*t*, 1340*t*
 - diabetes mellitus, 527*t*, 565
 - Duchenne muscular dystrophy, 1389*t*, 1458
 - ear disorders, 1684*t*
 - Ellis-van Creveld syndrome, 1389*t*
 - endocrine system disorders, 527, 527*t*
 - epilepsy, 1513*t*
 - essential tremor, 1513*t*
 - eye disorders, 1674*t*
 - female reproductive system disorders, 1755*t*
 - Friedreich's ataxia, 1513*t*
 - Gaucher disease, 614*t*, 1089*t*
 - hematologic, peripheral vascular, and lymphatic disorders, 1088, 1089*t*
 - hemophilia, 1089*t*, 1143*f*, 1143*t*
 - hirsutism, 427*t*
 - hypertrophic cardiomyopathy, 950*t*
 - integumentary system disorders, 427, 427*t*
 - intestinal tract disorders, 745, 746*t*
 - keloid, 427*t*
 - lung cancer, 1220*t*
 - lymphedema, 1199*t*
 - lymphoma, 1129*t*
 - male reproductive system disorders, 1747*t*
 - Marfan syndrome, 950*t*, 1057*t*
 - multiple sclerosis, 1389*t*, 1458
 - musculoskeletal disorders, 1389*t*
 - myotonic dystrophy, 155, 1389*t*
 - narcolepsy, 1513*t*
 - neurologic disorders, 1513*t*
 - nutritional and gastrointestinal system disorders, 614, 614*t*
 - obesity, 631
 - Parkinson's disease, 1513*t*
 - peripheral vascular disorders, 1088, 1089*t*
 - polycystic kidney disease, 839*t*, 844, 884*t*
 - porphyria, 1089*t*
 - respiratory disorders, 1219, 1220*t*
 - sickle cell anemia, 1089*t*, 1106, 1107*f*
 - substance abuse, 104, 104*t*
 - Tay-Sachs disease, 1513*t*
 - thalassemias, 1089*t*
 - thoracic aortic aneurysm, 1172*t*
 - urinary system disorders, 839*t*
 - health and, 19
 - interdisciplinary care
 - genetic testing
 - diagnosing chromosomal alterations, 157
 - diagnosing gene alterations, 157
 - implications, 156
 - indications, 156
 - positive and negative outcomes, 156*t*
 - quality and accuracy, 157–58
 - types, 156–57
 - nursing care
 - assessment
 - client intake and history, 159
 - ethical implications, 164*t*
 - genetic physical assessment, 160
 - health promotion and health maintenance, 159
 - pedigrees, 159–60, 160*f*, 161*f*, 162*t*, 163*t*
 - evaluation, 165
 - in genetic testing
 - client education and rights, 158
 - confidentiality and privacy issues, 158
 - economic issues, 159
 - psychosocial issues, 158–59
 - nursing diagnoses and interventions
 - client teaching, 163
 - diagnoses to consider, 160–61
 - genetic referrals and counseling, 161–62, 163, 165*t*
 - psychosocial care, 163–64
 - in nursing practice
 - “people-first” approach, 149*t*
 - scope and standards, 148–49, 149*t*
 - principles
 - cell division, 149–50
 - chromosomes
 - alterations in number, 150, 150*t*
 - alterations in structure, 150–51
 - structure, 149, 150*f*
 - DNA, 149
 - genes. *See Genes*
 - inheritance. *See Inheritance*
 - Genital herpes:
 - incidence, 1838
 - interdisciplinary care
 - diagnosis, 1839
 - medications, 1839
 - management, 1839*t*
 - manifestations, 1839, 1839*f*
 - nursing care
 - community-based care, 1840
 - nursing diagnoses and interventions
 - acute pain, 1840
 - sexual dysfunction, 1840
 - pathophysiology, 1839
 - Genital warts:
 - characteristics, 452
 - incidence, 1840
 - interdisciplinary care
 - diagnosis, 1841
 - medications, 1841, 1842*t*
 - treatments, 1841
 - manifestations, 1841, 1841*f*
 - nursing care
 - community-based care, 1842
 - Medication Administration, 1842*t*
 - nursing diagnoses and interventions
 - anxiety, 1842
 - deficient knowledge, 1841
 - fear, 1842
 - pathophysiology, 1840

- Genitourinary system. *See* Female reproductive system; Male reproductive system; Urinary system
- Genitourinary tuberculosis, 1283
- Genotype, 151
- Gentamicin:
 - Medication Administration, 320*t*
 - in specific conditions
 - endocarditis, 1046
 - eye trauma, 1703
 - pelvic inflammatory disease, 1851
 - peritonitis, 770
 - skin infections, 441*t*
 - urinary tract infection, 849
 - topical
 - for conjunctivitis, 1694
 - for corneal infections, 1697
- Gentran 40. *See* Dextran 40
- Gentran 70. *See* Dextran 70
- Gentran 75. *See* Dextran 75
- Geocillin. *See* Carbenicillin
- Geographic area, health and, 20
- Geopen. *See* Carbenicillin
- GERD. *See* Gastroesophageal reflux disease
- Germ cell tumors, 1774
- Germline mutations, 152
- Gestational diabetes, 566*t*
- GFR. *See* Glomerular filtration rate
- GGT (gamma glutamyltransferase), 386*t*
- GH. *See* Growth hormone
- Giant cell tumor, 1482*t*
- Giardia lamblia*, 778, 779*t*
- Giardiasis, 778, 778*t*
- Gigantism, 523*t*, 558
- Ginger:
 - for diarrhea, 755
 - for gastritis, 679
 - for irritable bowel syndrome, 763
 - for nausea and vomiting, 672, 709
 - for premenstrual syndrome, 1800
- Gingivitis, 623*t*
- Ginkgo biloba, 1621
- Ginseng, 1796
- Glasgow Coma Scale, 1513*t*
- Glatiramer acetate, 1627, 1631*t*
- Glaucoma:
 - angle-closure, 1684*t*, 1707–8, 1708*t*
 - Case Study, 1739*t*
 - definition, 1706
 - genetic considerations, 1674*t*
 - incidence, 1706
 - interdisciplinary care
 - diagnosis, 1708, 1708*f*, 1709*f*
 - medications, 1709
 - surgery, 1709
 - manifestations, 1707, 1707*f*, 1708
 - nursing care
 - assessment, 1712
 - community-based care, 1713
 - health promotion, 1712
 - nursing diagnoses and interventions
 - anxiety, 1713
 - disturbed sensory perception: visual, 1712
 - risk for injury, 1712–13
 - using NANDA, NIC, and NOC, 1713, 1713*t*
- Nursing Care Plan
 - assessment, 1711*t*
 - critical thinking in the nursing process, 1711*t*
 - diagnoses, 1711*t*
 - evaluation, 1711*t*
 - expected outcomes, 1711*t*
 - planning and implementation, 1711*t*
 - open-angle, 1707, 1707*f*, 1708*t*
 - pathophysiology, 1706–7, 1707*f*
 - risk factors, 1706
- Gleevec. *See* Imatinib mesylate
- Glimepiride, 578*t*
- Glioblastoma, 1569, 1570*t*. *See also* Brain tumors
- Glioma, 1570*t*
- Gliososis, 1626, 1629*t*
- Glipizide, 578*t*
- Global aphasia, 1583
- Glomerular capsule, 830, 885–86
- Glomerular disorders:
 - acute proliferative glomerulonephritis
 - complications, 886–87
 - manifestations, 886–87
 - pathophysiology, 886, 886*f*, 887*t*
 - prognosis, 887
 - interdisciplinary care
 - diagnosis, 889–90, 890*t*
 - medications, 890–91
 - treatments, 891, 891*t*
 - nursing care
 - assessment, 891
 - health promotion, 891
 - nursing diagnoses and interventions
 - community-based care, 894
 - excess fluid volume, 891–93
 - fatigue, 893
 - ineffective protection, 893
 - ineffective role performance, 894
- Nursing Care Plan
 - assessment, 892*t*
 - critical thinking in the nursing process, 892*t*
 - diagnoses, 892*t*
 - evaluation, 892*t*
 - expected outcomes, 892*t*
 - planning and implementation, 892*t*
 - pathophysiology, 885–86
 - rapidly progressive glomerulonephritis, 887–88
- Glomerular filtration rate (GFR):
 - age-related changes, 883, 884*t*
 - in chronic renal failure, 916*t*
 - definition, 214, 831
 - factors affecting, 831–33
 - normal, 831, 831*f*
 - in sodium balance regulation, 214
- Glomerulonephritis, 886. *See also* Glomerular disorders
- Glossitis:
 - in anemia, 1106
 - definition, 622*t*
 - nursing interventions, 1114
 - in nutritional deficiencies, 622*t*
- Glossopharyngeal nerve (cranial nerve IX):
 - anatomy, 1510*f*
 - assessment, 1520*t*
 - functions, 1511*t*
- Glucagon:
 - functions, 521, 564, 565*f*
 - for severe hypoglycemia, 587
- Glucocorticoids. *See also* Corticosteroids
 - feedback mechanism, 519*t*
 - functions, 519*t*, 521
 - target organ and feedback mechanism, 519*t*
- Gluconeogenesis, 272, 564
- Glucophage. *See* Metformin
- Glucose:
 - blood. *See* Blood glucose
 - in increased intracranial pressure, 1539*t*
 - urine. *See* Urine tests, glucose
- Glucose-6-phosphate dehydrogenase (G6PD)
 - anemia, 1106*t*, 1109
- Glucosuria, 566
- Glucotrol. *See* Glipizide
- Glucotrol XL. *See* Glipizide
- Glulisine, 571*t*
- Gluten:
 - dietary sources, 796, 797*t*
 - sensitivity to. *See* Sprue
- Glyburide, 578*t*
- Glycerol test, 1727
- Glycogenolysis, 272, 564
- Glycopyrrolate, 62*t*, 869
- Glycosylated hemoglobin (Hb A_{1c}), 526*t*, 569
- Glyset. *See* Miglitol
- Goiter:
 - definition, 536
 - in hypothyroidism, 541
 - physical assessment, 530*t*
 - toxic multinodular, 536*f*
- Gold salts, 1465, 1465*t*
- Gold sodium thiomalate, 1465*t*
- Goldenseal, 701, 1273, 1796
- Golfer's elbow, 1428
- Gonadotropin-releasing hormone agonists, 1798
- Gonioplasty, 1709
- Gonioscopy, 1708
- Gonococcus*, 1692
- Gonorrhea:
 - complications, 1846
 - incidence, 1845
 - interdisciplinary care
 - diagnosis, 1746*t*, 1756*t*, 1846
 - medications, 1846
 - manifestations, 1845
 - nursing care
 - community-based care, 1846
 - nursing diagnoses and interventions
 - impaired social interaction, 1846
 - noncompliance, 1846
- Nursing Care Plan
 - assessment, 1847*t*
 - critical thinking in the nursing process, 1847*t*
 - diagnoses, 1847*t*
 - evaluation, 1847*t*
 - expected outcomes, 1847*t*
 - planning and implementation, 1847*t*
 - pathophysiology, 1845
 - risk factors, 1845
- Goodpasture's syndrome, 888. *See also* Glomerular disorders
- Gout:
 - complications, 1444
 - definition, 1443
 - incidence, 1444
 - interdisciplinary care
 - complementary therapies, 1445
 - diagnosis, 1445
 - medications
 - acute attack, 1445
 - Medication Administration, 1446*t*
 - prophylactic therapy, 1445
 - treatments
 - nutrition, 1445, 1446
 - rest, 1446
 - manifestations
 - acute gouty arthritis, 1444, 1444*t*
 - hyperuricemia, 1444
 - tophaceous (chronic) gout, 1444, 1444*t*
 - nursing care
 - community-based care, 1447
 - Medication Administration, 1446*t*
 - nursing diagnoses and interventions, 1447
 - pathophysiology, 1444
 - primary, 1443
 - secondary, 1443
- Gouty arthritis, 1433

- Grafts, skin, 478, 478f
- Graft-versus-host disease (GVHD):
in bone marrow/stem cell transplantation, 343, 1124
manifestations, 343, 1124
pathophysiology, 343, 1124
- Gram stain, urine, 849
- Gram-negative bacteria, 311t
- Gram-positive bacteria, 311t
- Granisetron, 672, 673t
- Granulocyte colony-stimulating factors, 1123
- Granulocyte-macrophage colony-stimulating factors, 1123, 1139
- Granulocytes, 288, 288t, 289f. *See also* White blood cells (WBCs)
- Granuloma, 305
- Granulopoiesis, 1138
- Grape seed extract, 1326
- Graphesthesia, 1522f, 1522t
- Graves' disease. *See also* Hyperthyroidism
manifestations, 534, 536, 536f
Nursing Care Plan
assessment, 540t
critical thinking in the nursing process, 540t
diagnoses, 540t
evaluation, 540t
expected outcomes, 540t
planning and implementation, 540t
pathophysiology, 534
- Greater vestibular glands. *See* Bartholin's glands
- Grief, 85. *See also* Loss and grief
- Grieving:
anticipatory, 86, 96
definition, 85
- Griseofulvin, 449, 450t
- Group A beta-hemolytic streptococcus:
in pharyngitis, 1238
in rheumatic fever, 1042
in skin infections, 447
- Growth hormone (GH):
diagnostic test, 523t
feedback mechanism, 519t
functions, 518, 519f, 519t
- Guaiifenesin, 1272
- Guanfacine, 1162t
- Guglielmi detachable coils, 1594
- Guided imagery, 186
- Guillain-Barré syndrome:
characteristics, 1653
incidence, 1653
influenza vaccine and, 1234
interdisciplinary care
diagnosis, 1653
medications, 1653–54
nutrition and fluids, 1654
physical and occupational therapy, 1654
plasmapheresis, 1654
surgery, 1654
manifestations, 1653
nursing care
community-based care, 1655
nursing diagnoses and interventions
acute pain, 1654
risk for impaired skin integrity, 1654–55
pathophysiology, 1653
stages, 1653t
- Guillotine (open) amputation, 1421, 1422t
- Gummas, 1848
- Gums, 623t
- Gut-associated lymphoid tissue (GALT), 292
- GVHD. *See* Graft-versus-host disease
- Gynecomastia:
definition, 1749t
nursing care, 1790
- pathophysiology, 1789–90
physical assessment, 1749t
in testicular cancer, 1774
treatment, 1790
- Gyrate atrophy, 1674t
- H**
- H₂ receptor blockers. *See* Histamine₂ (H₂)-receptor blockers
- Haemophilus influenzae*, 1271t
- Hageman factor, 1082t
- Hair. *See also* Integumentary system
age-related changes
in middle adults, 27t
in older adults, 29t
in young adults, 26t
anatomy, physiology, and functions, 425, 425f
assessment, 435–36t
disorders
alopecia. *See* Alopecia
hirsutism. *See* Hirsutism
interdisciplinary care, 482
nursing care, 482–83
pathophysiology, 481–82, 482t
- Haldol. *See* Haloperidol
- Hallucinogens:
abuse, 110–11
overdose signs and treatment, 113t
street names, 111t
withdrawal signs and treatment, 113t
- Hallux valgus, 1492, 1492f
- Halo external fixation:
characteristics, 1601, 1601f
nursing care, 1602t
- Haloperidol, 672, 673t, 1621
- HALT acronym, relapse behaviors, 121t
- Hammertoe, 1492
- Hand:
fracture, 1413–14
physical assessment, 1393t
- Handicap, 47
- Haptoglobin, 386t
- Hartmann procedure, 805
- Hashimoto's thyroiditis, 543
- Haversian system, 1380
- Havighurst, developmental tasks, 25t
- Hawthorn, 1036
- Hazardous materials, 127
- Hb A₁C (glycosylated hemoglobin), 526t, 569
- hCG. *See* Human chorionic gonadotropin
- Hct. *See* Hematocrit
- HDL. *See* High-density lipoprotein
- Head injury. *See* Traumatic brain injury
- Headache:
cluster, 1542t, 1543
interdisciplinary care
complementary and alternative therapies, 1544
diagnosis, 1543–44
medications, 1544, 1545–46t
migraine, 1542–43, 1542t
nursing care
assessment, 1544
community-based care, 1547
health promotion, 1544, 1544t
Medication Administration, 1545–46t
nursing diagnoses and interventions, 1544, 1546
- Nursing Care Plan
assessment, 1547t
critical thinking in the nursing process, 1547t
diagnoses, 1547t
evaluation, 1547t
expected outcomes, 1547t
planning and implementation, 1547t
- pathophysiology, 1542
tension, 1542t, 1543
- Healing:
burn wounds, 493. *See also* Burns
impaired, 305, 306t
nutrition and, 307–8
phases, 294–95
wound, 76–77, 76f, 77t
- Health:
Chapter Highlights, 33t
community factors affecting
community healthcare structure, 37
economic resources, 37
environment, 37
social support systems, 37
definition, 19
factors affecting
age, gender, and developmental level, 20
cognitive abilities and educational level, 19
genetic makeup, 19
geographic area, 20
lifestyle and environment, 20
race, ethnicity, and cultural background, 20
socioeconomic background, 20
family-related risk factors for alterations in, 32t
needs
in middle adults. *See* Middle adults, health needs
in older adults. *See* Older adults, health needs
in young adults. *See* Young adults, health needs
promotion and maintenance. *See* Health promotion and maintenance
vs. wellness, 19
- Health perception-health management pattern:
Build Clinical Competence
alterations in patterns of health, 143t
dimensions of medical-surgical nursing, 49t
pathophysiology and patterns of health, 416t
NANDA nursing diagnoses, 2t
- Health promotion and maintenance:
healthy living
dietary guidelines, 20t, 21f
immunizations, 21t
recommended practices, 20–21
in middle adults, 28, 28t
national goals and health indicators, 21, 22t
in older adults, 30, 31t
in young adults, 26, 27t
- Healthcare professionals, core competencies, 5, 5t
- Healthcare surrogate, 90. *See also* Advance directives
- Healthcare-associated infections (HIAs). *See* Nosocomial infections
- Health–illness continuum, 19, 19f. *See also* Disease; Health; Illness
- Healthy People 2010*, 22t
- Hearing. *See also* Ears
age-related changes
in middle adults, 27t
in older adults, 29t, 1686t
physical assessment, 1687–88t, 1687f, 1688f
- Hearing aids, 1730–31, 1731f
- Hearing loss:
conductive, 1729–30
genetic considerations, 1684
incidence, 1729
interdisciplinary care
amplification, 1730–31, 1731f
diagnosis, 1730
surgery, 1731–32, 1732f
manifestations, 1729–30
nursing care
assessment, 1732
community-based care, 1733–34

Hearing loss—*continued*

- health promotion, 1732
- nursing diagnoses and interventions
 - disturbed sensory perception: auditory, 1732
 - impaired verbal communication, 1732–33
 - social isolation, 1733
 - using NANDA, NIC, and NOC, 1733, 1733*t*
- pathophysiology, 1729–30
- presbycusis, 1730
- sensorineural, 1730
- special considerations in disasters, 140

Heart:

anatomy, physiology, and functions

- action potential
 - definition, 941–42, 942*f*
 - depolarization, 942
 - repolarization, 942–43
 - cardiac cycle, 939–40, 939*f*
 - cardiac output
 - afterload, 940, 1023–24, 1024*t*
 - clinical indicators, 940–41
 - contractility, 940
 - heart rate, 940
 - normal ranges, 940
 - overview, 1023
 - preload, 940, 1023
 - cardiac reserve, 1023
 - chambers and valves, 937–38, 937*f*
 - conduction system, 941, 941*f*, 995
 - coronary circulation, 938–39, 939*f*, 959
 - explanations for clients, 1024*t*
 - layers of heart wall, 937, 937*f*
 - location in thorax, 936*f*
 - pericardium, 936–37, 937*f*
 - pulmonary circulation, 938, 938*f*
 - systemic circulation, 938, 938*f*
 - valves, 1054
- assessing cardiac function
- age-related changes, 952*t*
 - diagnostic tests, 943–46*t*
 - electrocardiogram. *See* Electrocardiogram
 - functional health pattern interview, 951–52*t*
 - genetic considerations, 943, 950*t*
 - health assessment interview, 943, 949–50, 950*t*
 - physical assessment
 - apical impulse, 952–53*t*, 953*f*
 - cardiac rate and rhythm, 953*t*
 - heart sounds, 954–55*t*, 954*f*
 - murmurs, 955*t*
 - overview, 950, 952
 - sample documentation, 943*t*
- disorders
- acute myocardial infarction. *See* Acute myocardial infarction
 - angina pectoris. *See* Angina pectoris
 - cardiomyopathy. *See* Cardiomyopathy
 - Chapter Highlights, 1019*t*, 1068*t*
 - coronary heart disease. *See* Coronary heart disease
 - dysrhythmias. *See* Cardiac dysrhythmias
 - endocarditis. *See* Endocarditis
 - heart failure. *See* Heart failure
 - myocarditis, 1049
 - pericarditis. *See* Pericarditis
 - rheumatic heart disease. *See* Rheumatic fever/heart disease
 - sudden cardiac death. *See* Sudden cardiac death
- Heart block, 996
- Heart failure:
- Case Study, 1073*t*
 - causes, 985, 1022, 1022*t*

classification

- acute vs. chronic, 1027
 - left-side vs. right-sided, 1026–27, 1026*f*
 - low-output vs. high-output, 1027
 - systemic vs. diastolic, 1025–26
 - complications, 1027
 - definition, 1022
 - incidence and prevalence, 1022–23
 - interdisciplinary care
 - cardiac transplantation. *See* Heart transplant
 - cardiomyoplasty, 1036
 - circulatory assistance, 1034–35
 - complementary therapies, 1036
 - diagnosis, 1027
 - end-of-life care, 1036
 - hemodynamic monitoring
 - complications, 1029*t*
 - intra-arterial pressure monitoring, 1029–30
 - nursing care, 1031*t*
 - principles, 1027, 1029, 1030*f*
 - pulmonary artery pressure monitoring, 1030–31
 - venous pressure monitoring, 1030
 - medications, 1031–32, 1033–34*t*, 1034
 - nutrition and activity, 1034
 - by stage, 1029*t*
 - ventricular reduction surgery, 1036
 - manifestations, 1025–27, 1026*f*
- Multisystem Effects, 1028*t*
- nursing care
- assessment, 1036
 - community-based care, 1039
 - health promotion, 1036
 - hemodynamic monitoring, 1031*t*
 - home activity guidelines, 1040*t*
 - Medication Administration, 1033–34*t*
 - nursing diagnoses and interventions
 - activity intolerance, 1038
 - decreased cardiac output, 1037–38
 - deficient knowledge: low-sodium diet, 1038–39
 - excess fluid volume, 1038
 - of older adults, 1023*t*
 - using NANDA, NIC, and NOC, 1039, 1039*t*
- Nursing Care Plan
- assessment, 1037*t*
 - critical thinking in the nursing process, 1037*t*
 - diagnoses, 1037*t*
 - evaluation, 1037*t*
 - expected outcomes, 1037*t*
 - planning and implementation, 1037*t*
 - pathophysiology, 1024–25, 1024*t*
 - prognosis, 1023
 - risk factors, 1023
 - stages, 1029*t*
- Heart rate, 940, 953*t*
- Heart sounds:
- in aortic regurgitation, 1059
 - in aortic stenosis, 1058
 - assessment, 954–55*t*, 954*f*
 - in dilated cardiomyopathy, 1065
 - in heart failure, 1026
 - in mitral regurgitation, 1056
 - in mitral stenosis, 1055
 - in valvular heart disease, 1055*t*
- Heart transplant. *See also* Transplant procedures
- for cardiomyopathy, 1067
 - complications, 1036
 - for heart failure, 1035
 - indications, 342*t*
 - nursing care, 1035–36
 - procedure, 1035, 1035*f*
 - success rate, 342*t*, 1035

Heaves, 952

- Heberden's nodes, 1393, 1450
- Heel-to-shin test, 1523*f*, 1523*t*
- Heimlich maneuver, 1249, 1249*f*
- Helicobacter pylori*:
 - in chronic gastritis, 678
 - diagnostic tests, 684*t*
 - in gastric cancer, 688
 - medications, 684
 - in peptic ulcer disease, 680, 680*t*, 682–83*t*
- Helminthic disorders:
 - cestodes, 781*t*
 - interdisciplinary care
 - diagnosis, 779
 - medications, 779–80
 - nematodes, 781*t*
 - nursing care, 780–81
 - pathophysiology, 779
- Helper T cells, 297, 298*f*. *See also* T lymphocytes
- Hemangioblastoma, 1570*t*. *See also* Brain tumors
- Hemangiomas, 430*t*, 443
- Hematemesis, 674. *See also* Gastrointestinal bleeding
- Hematochezia. *See also* Gastrointestinal bleeding
 - in cirrhosis, 722
 - definition, 674, 722
 - in inflammatory bowel disease, 793
- Hematocrit (Hct):
 - abnormal, possible causes, 386*t*
 - normal values, 386*t*, 1078*t*
 - perioperative, significance and nursing implications, 60*t*
 - in specific conditions
 - fluid volume deficit, 205
 - fluid volume excess, 210
 - gastroenteritis and diarrhea, 776*t*
 - leukemia, 1123*t*
 - shock, 276
- Hematologic system:
 - age-related changes, 1091*t*
 - anatomy, physiology, and functions
 - blood cell formation from stem cells, 1077*f*
 - blood composition, 1076
 - hemostasis
 - clot dissolution, 1081
 - clot retraction, 1080
 - coagulation factors, 1082*t*
 - definition, 1079
 - fibrin clot formation, 1080, 1081*f*
 - platelet plug formation, 1080, 1080*f*
 - vessel spasm, 1080
 - platelets. *See* Platelets
 - red blood cells. *See* Red blood cells
 - white blood cells. *See* White blood cells
- assessment
 - diagnostic tests, 1087, 1087*t*
 - functional health pattern interview, 1090*t*
 - genetic considerations, 1088
- disorders
 - anemia. *See* Anemia
 - Chapter Highlights, 1150*t*
 - Clinical Scenarios, 1206*t*
 - disseminated intravascular coagulation. *See* Disseminated intravascular coagulation
 - hemophilia. *See* Hemophilia
 - infectious mononucleosis, 1139
 - multiple myeloma. *See* Multiple myeloma
 - myelodysplastic syndrome. *See* Myelodysplastic syndrome
 - neutropenia, 1139
 - polycythemia. *See* Polycythemia
 - thrombocytopenia. *See* Thrombocytopenia
- Hematopoiesis, 1380

- Hematopoietic growth factors, 396
- Hematuria:
 definition, 839, 848
 in polycystic kidney disease, 885
 in urinary tract infection, 848
- Hemianopia, 1582, 1582*f*
- Hemilaryngectomy, 1255
- Hemiparesis, 1584
- Hemiplegia, 1584, 1584*f*
- Hemodialysis:
 complications, 906–7
 definition, 609
 nursing care, 908*t*
 Nursing Research: promoting autonomy and acceptance, 926*t*
 principles, 609
 system components, 610*f*
- Hemodynamic monitoring:
 complications, 1029*t*
 nursing care, 1031*t*
 principles, 1027, 1029, 1030*f*
 in specific conditions
 aortic aneurysm, 1173
 pericarditis, 1051
 types
 intra-arterial pressure monitoring, 1029–30
 pulmonary artery pressure monitoring, 1030–31
 venous pressure monitoring, 1030
- Hemodynamics, 1027
- Hemoglobin (Hgb):
 abnormal, possible causes, 386*t*
 electrophoresis, 1110–11
 normal values, 386*t*, 1078*t*
 perioperative, significance and nursing implications, 60*t*
 in specific conditions
 fluid volume deficit, 205
 fluid volume excess, 210
 leukemia, 1123*t*
 shock, 276
 structure, 1076, 1078*f*
- Hemoglobin-A, 60*t*
- Hemolysis, 1078
- Hemolytic anemias:
 causes, 1106, 1106*t*
 definition, 1106
 pathophysiology, 1106
 racial/ethnic considerations, 1106*t*
 sickle cell anemia. *See* Sickle cell anemia
- Hemolytic jaundice, 704
- Hemolytic reaction, 262
- Hemolyze, 199
- Hemophilia:
 definition, 1142
 genetic considerations, 1089*t*, 1143*f*, 1143*t*
 interdisciplinary care
 diagnosis, 1144
 medications, 1144
 manifestations, 1143–44
 nursing care
 assessment, 1144
 community-based care, 1146
 health promotion, 1144
 nursing diagnoses and interventions
 ineffective protection, 1145
 risk for ineffective health maintenance, 1145–46
 using NANDA, NIC, and NOC, 1146, 1146*t*
- Nursing Care Plan
 assessment, 1145*t*
 critical thinking in the nursing process, 1145*t*
 diagnoses, 1145*t*
 evaluation, 1145*t*
 expected outcomes, 1145*t*
 planning and implementation, 1145*t*
 pathophysiology, 1142–43
 types
 factor XI deficiency (hemophilia C), 1143, 1143*t*
 hemophilia A, 1089*t*, 1142–43, 1143*f*, 1143*t*
 hemophilia B, 1143, 1143*f*, 1143*t*
 von Willebrand's disease, 1143, 1143*t*
- Hemoptysis, 1266
- Hemorrhage:
 assessment in light and dark skin, 426*t*
 causes, 74
 definition, 74
 gastrointestinal. *See* Gastrointestinal bleeding
 in peptic ulcer disease, 681
 postoperative, 74–75
 in trauma, 258, 258*f*
- Hemorrhagic exudate, 293
- Hemorrhagic pleural effusion, 1295. *See also* Pleural effusion
- Hemorrhagic stroke, 1581–82. *See also* Stroke
- Hemorrhoidectomy, 819
- Hemorrhoids:
 causes, 743
 characteristics, 818
 interdisciplinary care
 diagnosis, 819
 hemorrhoidectomy, 819
 medications, 819
 nutrition, 819
 sclerotherapy, 819
 locations, 818
 manifestations, 818–19
 nursing care, 819–20, 820*t*
 pathophysiology, 818–19
- Hemostasis:
 clot dissolution, 1081
 clot retraction, 1080
 coagulation factors, 1082*t*
 definition, 1079
 disorders
 disseminated intravascular coagulation. *See* Disseminated intravascular coagulation
 hemophilia. *See* Hemophilia
 thrombocytopenia. *See* Thrombocytopenia
 fibrin clot formation, 1080, 1081*f*
 platelet plug formation, 1080, 1080*f*
 vessel spasm, 1080
- Hemothorax:
 definition, 1295, 1302
 manifestations, 1302
 nursing care, 1302
 treatment, 1302
- Hemotympanum, 1722
- Heparin:
 low-molecular-weight. *See* Low-molecular-weight (LMW) heparins
 Medication Administration, 1189*t*
 in specific conditions
 acute myocardial infarction, 988
 disseminated intravascular coagulation, 1148
 ischemic stroke, 1585
 pulmonary embolism, 1349
 venous thrombosis, 1188
- Heparin-induced thrombocytopenia (HIT), 1140–41
- Hepatic encephalopathy, 704, 715, 715*t*
- Hepatic jaundice, 704
- Hepatitis:
 definition, 705
 incidence, 705
- interdisciplinary care
 complementary therapies, 709
 diagnosis, 707
 medications, 708
 prevention
 postexposure prophylaxis, 302*t*, 707, 708*t*
 vaccines, 21*t*, 301*t*, 707, 708*t*
- manifestations, 705–6, 705*t*, 706*t*
- nursing care
 assessment, 709
 health promotion, 709
 nursing diagnoses and interventions
 community-based care, 710
 disturbed body image, 710
 fatigue, 709
 imbalanced nutrition: less than body requirements, 709–10
 risk for infection (transmission), 709
 using NANDA, NIC, and NOC, 710, 710*t*
- pathophysiology, 705–6
 types
 chronic, 706
 fulminant, 706
 hepatobiliary, 707
 toxic, 707
 viral, 705–6, 705*t*. *See also* Hepatitis A; Hepatitis B; Hepatitis C
- Hepatitis A. *See also* Hepatitis
 characteristics, 705*t*, 706
 incidence, 705
 postexposure prophylaxis, 302*t*, 707, 708*t*
 vaccine, 707, 708*t*
- Hepatitis B. *See also* Hepatitis
 cancers associated with, 375, 375*t*
 characteristics, 705*t*, 706
 incidence, 705
 interdisciplinary care
 medications, 708
 postexposure prophylaxis, 302*t*, 707, 708*t*
 vaccine
 characteristics, 707, 707*t*
 contraindications, 21*t*
 indications, 21*t*, 300, 301*t*, 707*t*
 nursing implications, 301*t*
- Hepatitis C. *See also* Hepatitis
 characteristics, 705*t*, 706
 incidence, 705
 interdisciplinary care
 medications, 708
- Hepatitis delta (D), 705*t*, 706
- Hepatitis E, 705*t*, 706
- Hepatobiliary hepatitis, 707. *See also* Hepatitis
- Hepatocellular carcinoma, 723–24, 724*t*
- Hepatorenal syndrome:
 cirrhosis and, 716
 definition, 704
 portal hypertension and, 704
- Herbal supplements/therapy:
 for Alzheimer's disease, 1621
 for asthma, 1326
 for benign prostatic hyperplasia, 1781
 for cancer, 399*t*
 for chronic obstructive pulmonary disease, 1335
 for constipation, 760–61
 for coronary heart disease, 968
 for diarrhea, 755
 for gallstones, 701
 for gastritis, 679
 for heart failure, 1036
 for hepatitis, 709
 for inflammatory bowel disease, 792
 for irritable bowel syndrome, 763
 for menopausal symptoms, 1796

- Herbal supplements/therapy—*continued*
 for nausea and vomiting, 672
 for osteoarthritis, 1455
 for pneumonia, 1273
 for premenstrual syndrome, 1800
 as surgical risk factor, 58*t*, 59
 for upper respiratory infections, 1231
 for urinary tract infection, 851
- Herceptin. *See* Trastuzumab
- Hereditary nonpolyposis colorectal cancer, 801–2.
See also Colorectal cancer
- Hernia:
 classification, 809, 809*f*
 complications, 810
 definition, 749*t*, 809
 hiatal. *See* Hiatal hernia
 inguinal, 809–10, 809*f*
 interdisciplinary care, 10
 manifestations, 810
 nursing care
 assessment, 749*t*, 810
 community-based care, 811
 nursing diagnoses and interventions, 810–11
 pathophysiology, 809
 physical assessment, 1749*f*, 1749*t*
 umbilical, 810
- Herniated intervertebral disk:
 cervical, 1608
 characteristics, 1607, 1607*f*
 incidence and prevalence, 1607
 interdisciplinary care
 diagnosis, 1608
 medications, 1608
 treatments
 conservative, 1608
 surgical, 1608, 1610
 lumbar, 1608
 manifestations, 1607*t*, 1608
 nursing care
 assessment, 1610
 of client having posterior laminectomy
 postoperative, 1609–10*t*
 preoperative, 1609*t*
 client teaching, 1611*t*
 community-based care, 1611–12
 health promotion, 1610
 nursing diagnoses and interventions
 acute pain, 1610
 chronic pain, 1610–11
 constipation, 1611
 pathophysiology, 1607–8
- Herniorrhaphy, 810
- Heroin:
 abuse, 110
 overdose signs and treatment, 113*t*
 street names, 111*t*
 withdrawal signs and treatment, 110, 113*t*
- Herpes simplex:
 in AIDS, 353, 359*t*
 cancers associated with, 375*t*
 in encephalitis, 1565*t*
 genital infection. *See* Genital herpes
 interdisciplinary care, 453
 manifestations, 452, 452*f*, 657*t*
 treatment, 657*t*
 virus types, 452, 1839
 vulvar cancer and, 1819
- Herpes zoster:
 in AIDS, 353, 359*t*
 characteristics, 452
 complications, 453
 interdisciplinary care, 453
 manifestations, 452, 453*f*
- nursing care
 community-based care, 455
 nursing diagnoses and interventions
 acute pain, 453, 455
 disturbed sleep pattern, 455
 risk for infection, 455
 using NANDA, NIC, and NOC, 455, 455*t*
- Nursing Care Plan
 assessment, 454*t*
 critical thinking in the nursing process, 454*t*
 diagnoses, 454*t*
 evaluation, 454*t*
 expected outcomes, 454*t*
 planning and implementation, 454*t*
 risk factors, 452
 vaccine, 453
- Hespan. *See* Hetastarch
- Hetastarch, 279*t*
- Heterograft:
 definition, 503
 for valve replacement, 1061, 1061*f*, 1061*t*
- Heterozygous, 151
- Hexachlorophene, 441*t*
- Hgb. *See* Hemoglobin
- HHS. *See* Hyperosmolar hyperglycemic state
- HHT (homoharringtonine), 1123*t*
- Hiatal hernia:
 definition, 667
 diagnosis, 668
 management, 668
 manifestations, 668*t*
 types, 667, 668*f*
- Hibernating, 984
- High-density lipoprotein (HDL):
 functions, 959
 high-risk levels, 963, 963*t*
 normal values, 944*t*, 963*t*
- High-output failure, 1027
- Hip:
 fracture
 classification, 1414, 1415*f*
 incidence, 1415
 mortality rate, 1415
 Nursing Care Plan
 assessment, 1417*t*
 critical thinking in the nursing process, 1417*t*
 diagnoses, 1417*t*
 evaluation, 1417*t*
 expected outcomes, 1417*t*
 planning and implementation, 1417*t*
 in older adults, 1415
 risk factors, 1415
 treatment
 hip replacement. *See* Total joint replacement
 surgical fixation, 1415, 1416*f*
 physical assessment, 1394*t*, 1396*f*, 1396*t*
- Hirsutism:
 definition, 435*t*
 genetic considerations, 427*t*
 interdisciplinary care, 482
 manifestations, 481
 nursing care, 482–83
 pathophysiology, 481
- Hispanic Americans:
 cancer incidence and mortality, 370*t*
 cirrhosis incidence and mortality, 711
 diabetes mellitus risk and incidence, 564*t*
 end-of-life practices, 88, 89
 obesity prevalence, 631*t*
 stroke risk factors, 1580*t*
 substance use, 105, 105*t*
 tuberculosis incidence, 1281*t*
- Histamine, 292*t*, 304*t*
- Histamine₂ (H₂)-receptor blockers:
 Medication Administration, 665*t*
 preoperative use and nursing implications, 62*t*
 in specific conditions
 burns, 502
 gastritis, 665*t*, 678
 gastroesophageal reflux disease, 665, 665*t*
 pancreatitis, 728
 peptic ulcer disease, 665*t*, 684
 scleroderma, 1485
 stress ulcers, 1360
- Histocompatibility, 342
- Histocytes, 289
- Histoplasma capsulatum*, 1294
- Histoplasmosis, 1294
- HIT (heparin-induced thrombocytopenia), 1140–41
- HIV infection. *See* Human immunodeficiency virus (HIV) infection
- Hives. *See* Urticaria
- HLA. *See* Human leukocyte antigen
- Hodgkin's disease. *See also* Lymphomas
 classification, 1130
 HIV infection and, 354
 manifestations, 1130, 1131*t*
 Nursing Care Plan
 assessment, 1134*t*
 critical thinking in the nursing process, 1134*t*
 diagnoses, 1134*t*
 evaluation, 1134*t*
 expected outcomes, 1134*t*
 planning and implementation, 1134*t*
 pathophysiology, 1129–30
- Holistic health care, 19
- Holter monitoring, 1004
- Home care:
 Chapter Highlights, 47–48*t*
 clients
 characteristics, 38, 39
 rights, 41*t*
 Clinical Scenarios, 50*t*
 definition, 38
 history of, 38
 hospice, 38
 Medicare reimbursement, 40, 40*t*
 nursing practice. *See* Home care nursing
 respite, 38
 services provided in, 38
 system
 agencies, 38–39
 clients, 39
 legal considerations, 41, 41*t*
 physicians, 40
 referrals, 39–40
 reimbursement, 40–41, 40*f*
- Home care nursing:
 Clinical Scenarios, 50*t*
 Meeting Individualized Needs
 client being discharged from acute care to
 home care, 39*t*
 older adult with dementing disorder, 43*t*
 nursing interventions
 assess home environment, 45
 establish trust and rapport, 45
 improvisation, 46–47
 infection control, 46–47
 limit distractions, 46
 proceed slowing, 45
 promote learning, 45
 safety assessment, 46, 46*t*
 set goals and boundaries, 45
 nursing process in
 assessment, 42
 diagnosis, 42

- evaluation, 42
- implementation, 42
- planning, 42
- roles of nurse
 - advocate, 43
 - coordinator of services, 43*f*
 - educator, 43, 43*f*
 - provider of direct care, 43
 - special considerations, 44–45
- Homeopathic therapies, for diarrhea, 755
- Homeostasis:
 - cellular, 268
 - definition, 195
 - fluids and electrolytes in, 195
- Homocysteine levels, in coronary heart disease, 964
- Homograft:
 - definition, 503
 - for valve replacement, 1061, 1061*t*
- Homoharringtonine (HHT), 1123*t*
- Homologous chromosomes, 149
- Homonymous hemianopia, 1582, 1582*f*
- Homozygous, 151
- Hookworm disease, 781*t*
- Hordeolum (sty), 1700, 1701*f*
- Hormone(s). *See also specific hormones*
 - cancer risk and, 375
 - feedback mechanisms, 521–22, 522*f*
 - release mechanisms, 521, 522*f*
 - as tumor markers, 384, 384*t*
- Hormone antagonists, 391
- Hormone replacement therapy:
 - benefits, 1796
 - coronary heart disease risk and, 964
 - for menopausal symptoms, 1796
 - Nursing Research: risks vs. benefits, 965*t*
 - for osteoporosis prevention, 1436
 - risks, 1796
- Horner's syndrome, 1597*t*. *See also* Spinal cord injury
- Horseshoe kidney, 883–84
- Hospice:
 - for cancer clients, 412–13
 - definition, 38, 91
 - history of, 91
 - length of services, 91–92
 - Medicare requirements, 92
 - philosophy, 91
- Hot flashes, 1796, 1796*t*
- Hot tub folliculitis, 446
- Hot zone, in disaster, 134*t*
- HPV. *See* Human papillomavirus
- HRIG (human rabies immune globulin), 302*t*
- HTLV (human T-lymphotropic virus), 375*t*
- Huffing, 111
- Humalog. *See* Insulin lispro
- Human chorionic gonadotropin (hCG):
 - abnormal, possible causes, 384*t*, 386*t*
 - normal values, 386*t*
 - in testicular cancer, 1775
- Human genome, 148, 148*f*
- Human Genome project, 148, 148*t*
- Human growth hormone (hGH). *See* Growth hormone
- Human immune globulin (IG), 302*t*
- Human immunodeficiency virus (HIV) infection. *See also* Acquired immunodeficiency syndrome (AIDS)
 - classification system, 352*t*
 - history of epidemic, 349
 - incidence and prevalence, 349–51
 - interdisciplinary care
 - diagnosis, 354–56
 - goals, 354
 - medications
 - adherence considerations, 356
 - entry inhibitors, 358
 - goals, 356
 - investigational immune-based, 355*t*
 - nonnucleoside reverse transcriptase inhibitors, 358
 - nucleoside reverse transcriptase inhibitors, 356, 357*t*, 358
 - protease inhibitors, 358
 - vaccines, 358
 - manifestations, 351–53, 351*t*
 - nursing care
 - assessment, 361–62
 - community-based care, 365
 - Medication Administration, 357*t*
 - nursing diagnoses and interventions
 - imbalanced nutrition: less than body requirements, 364
 - impaired skin integrity, 362, 364
 - ineffective coping, 362
 - ineffective sexuality patterns, 364–65
 - prevention, 359–61, 361*f*
 - using NANDA, NIC, and NOC, 365, 365*t*
- Nursing Care Plan
 - assessment, 363*t*
 - critical thinking in the nursing process, 363*t*
 - diagnoses, 363*t*
 - evaluation, 363*t*
 - expected outcomes, 363*t*
 - planning and implementation, 363*t*
- Nursing Research: nurses' willingness to care for
 - people with HIV/AIDS, 360*t*
- in older adults, 349–50
- pathophysiology, 350*f*, 351–53
- progression, 351*f*
- racial/ethnic considerations, 349*t*
- risk factors, 349
- sexually transmitted infections and, 1837
- Human leukocyte antigen (HLA):
 - definition, 329
 - in diabetes mellitus, 565
 - testing
 - in musculoskeletal system assessment, 1388*t*
 - in organ transplantation, 343
- Human papillomavirus (HPV):
 - cancers associated with, 375, 375*t*
 - cervical cancer and, 1812, 1840
 - diagnostic test, 1756*t*
 - vaccine, 1815, 1841
 - vulvar cancer and, 1819
 - in warts, 451–52. *See also* Genital warts
- Human rabies immune globulin (HRIG), 302*t*
- Human T-lymphotropic virus (HTLV), 375*t*
- Humatin. *See* Paromomycin
- Humerus, fracture, 1413, 1413*t*
- Humira. *See* Adalimumab
- Humoral immune response. *See* Antibody-mediated (humoral) immune response
- Humulin, 571*t*
- Huntington's disease:
 - characteristics, 1642
 - genetic considerations, 1513*t*, 1643
 - interdisciplinary care
 - diagnosis, 1643
 - medications, 1643
 - manifestations, 1642–43, 1643*t*
 - nursing care
 - community-based care, 1645
 - nursing diagnoses and interventions
 - imbalanced nutrition: less than body requirements, 1644
 - impaired skin integrity, 1644
- impaired verbal communication, 1644
- risk for aspiration, 1644
- pathophysiology, 1642
- Huperzine A, 1621
- Hurricane, 128, 129*t*, 130
- Hyalgan. *See* Hyaluronan injections
- Hyaluronan injections, 1452
- Hyaluronidase, 447
- Hydralazine, 1162*t*, 1169*t*
- Hydralazine and, 1471
- Hydralazine/isosorbide, 1032, 1035*t*
- Hydration status, 403*t*
- Hydrocele:
 - characteristics, 1773*f*
 - definition, 1750*t*, 1772
 - nursing care, 1773
 - physical assessment, 1750*t*
- Hydrocephalus, 1537, 1593. *See also* Increased intracranial pressure
- Hydrochloric acid, 611
- Hydrochlorothiazide:
 - Medication Administration, 210*t*, 1033*t*
 - in specific conditions
 - hypertension, 1160
 - Ménière's disease, 1727
- Hydrocodone, 62*t*, 110
- Hydrocolloid dressing, 403, 474*t*
- Hydrocortisone, 441*t*, 555*t*, 786
- Hydrodensitometry, 632
- HydroDIURIL. *See* Hydrochlorothiazide
- Hydromorphone HCl, 180*t*, 182*t*
- Hydronephrosis, 857, 857*t*, 883
- Hydrophobia, 1660
- Hydrostatic pressure, 200, 831
- Hydroureter, 857
- Hydroxychloroquine:
 - for autoimmune disorders, 341
 - for parasitic infections, 321
 - for rheumatoid arthritis, 1465*t*, 1466
 - for systemic lupus erythematosus, 1473
- Hydroxyproline, 1436*t*
- Hydroxyurea, 1111, 1123*t*
- Hydroxyzine, 672, 673*t*, 1727
- Hygroton. *See* Chlorthalidone
- Hyoscyamine, 762
- Hyperacute tissue rejection, 342, 343*t*
- Hyperaldosteronism, 218
- Hyperalgesias, 174
- Hyperbaric oxygen therapy, 1307
- Hypercalcemia:
 - causes, 228*t*
 - complications, 231
 - definition, 231
 - ECG changes, 232
 - effects, 231
 - interdisciplinary care
 - diagnosis, 232
 - fluid management, 232
 - medications, 232, 547
 - laboratory values, 228*t*, 232
 - manifestations, 228*t*, 231
 - nursing care
 - assessment, 232
 - community-based care, 233
 - health promotion, 232
 - nursing diagnoses and interventions
 - risk for excess fluid volume, 233
 - risk for injury, 232–33
 - as oncologic emergency, 410
 - pathophysiology, 231
- Hypercapnia, 239
- Hypercortisolism. *See* Cushing's syndrome
- Hyperemia, 426*t*

- Hyperesthesias, 174
- Hyperextension, 1596*f*, 1597
- Hyperflexion, 1596*f*, 1597
- Hyperglycemia, 565
- Hyperkalemia:
 - in acute renal failure, 904
 - causes, 218*t*
 - definition, 223
 - ECG changes in, 219, 219*f*
 - interdisciplinary care
 - diagnosis, 224
 - dialysis, 224
 - medications, 224, 225*t*
 - laboratory values, 218*t*, 224
 - manifestations, 218*t*, 224
 - nursing care
 - assessment, 225
 - community-based care, 227
 - health promotion, 224–25
 - Medication Administration, 225*t*
 - nursing diagnoses and interventions
 - risk for activity intolerance, 226
 - risk for decreased cardiac output, 225–26
 - risk for imbalanced fluid volume, 226–27
- Nursing Care Plan
 - assessment, 226*t*
 - critical thinking in the nursing process, 226*t*
 - diagnoses, 226*t*
 - evaluation, 226*t*
 - expected outcomes, 226*t*
 - planning and implementation, 226*t*
 - pathophysiology, 223–24
- Hyperkeratosis, 443
- Hyperkinetic pulse, 1094*t*
- Hyperlipidemia, 963, 963*t*, 1580
- Hypermagnesemia:
 - causes, 234*t*
 - definition, 235
 - interdisciplinary care, 235
 - laboratory values, 234*t*
 - manifestations, 234*t*, 235
 - nursing care, 235–36
 - pathophysiology, 235
- Hypernatremia:
 - causes, 214*t*
 - definition, 213
 - interdisciplinary care
 - diagnosis, 216
 - medications, 216
 - laboratory values, 214*t*, 216
 - manifestations, 214*t*, 216
 - nursing care
 - assessment, 217
 - community-based care, 217
 - health promotion, 217
 - nursing diagnoses and interventions, 217
 - pathophysiology, 216
- Hyperopia, 1677*t*, 1696
- Hyperosmolar hyperglycemic state (HHS):
 - assessments, 584*t*
 - laboratory findings, 584*t*, 585
 - manifestations, 586
 - pathophysiology, 586
 - risk factors, 584*t*, 586, 586*t*
 - treatment, 584*t*, 586
- Hyperparathyroidism:
 - definition, 547
 - interdisciplinary care, 524*t*, 547
 - manifestations, 547, 547*t*
 - nursing care. *See* Hypercalcemia
 - pathophysiology, 547
- Hyperphosphatemia:
 - causes, 236*t*, 237
 - definition, 237
- in hypocalcemia, 229
- interdisciplinary care, 237–38
- laboratory values, 236*t*
- manifestations, 236*t*, 237
- nursing care, 238
- pathophysiology, 237
- Hyperplasia, 373
- Hyperresonance, in lung percussion, 1224*t*
- Hypersensitivity:
 - definition, 331
 - interdisciplinary care
 - diagnosis, 336–37, 337*f*
 - goals, 336
 - immediate care, 336
 - medications, 337–38
 - other therapies, 338
 - nursing care
 - assessment, 338
 - community-based care, 339
 - health promotion, 338
 - nursing diagnoses and interventions
 - decreased cardiac output, 339
 - ineffective airway clearance, 338–39
 - risk for injury, 339
 - pathophysiology
 - latex allergy, 335–36
 - type I Ig-E mediated, 331–33, 332*f*
 - type II cytotoxic, 333–34, 333*f*
 - type III immune complex-mediated, 334–35
 - type IV delayed, 335, 335*f*
 - to transfusion, 262
- Hypersensitivity pneumonitis, 1345–46
- Hyperstat. *See* Diazoxide
- Hypertension:
 - Case Study, 1207*t*
 - classification, 1156*t*
 - complications, 1158
 - coronary heart disease and, 963, 966
 - definition, 1092*t*, 1154, 1156
 - in diabetes mellitus, 588
 - in end-stage renal disease, 916
 - genetic considerations, 1156
 - incidence, 1156
 - interdisciplinary care
 - algorithm, 1159*f*
 - complementary therapies, 1163
 - diagnosis, 1158
 - goals, 1158
 - lifestyle modifications
 - alcohol and tobacco use, 1160
 - diet, 1158, 1160*t*
 - overview, 1159*t*
 - physical activity, 1158–59
 - stress reduction, 1160
 - medications
 - ACE inhibitors, 1161*t*, 1163
 - alpha-blockers, 1161*t*, 1163
 - ARBs, 1161*t*, 1163
 - beta-blockers, 1161–62*t*, 1163
 - calcium channel blockers, 1162*t*, 1163
 - diuretics, 1160, 1163
 - drug regimens, 1163
 - sympatholytics, 1162*t*
 - vasodilators, 1162*t*, 1163
 - intracranial. *See* Increased intracranial pressure
 - kidney disease and, 897
 - manifestations, 1158
 - nursing care
 - assessment, 1164
 - community-based care, 1166–67
 - health promotion, 1163–64, 1164*t*
 - Medication Administration, 1161–62*t*
 - nursing diagnoses and interventions
 - excess fluid volume, 1166
 - imbalanced nutrition: more than body requirements, 1165–66
 - ineffective health maintenance, 1164–65
 - risk for noncompliance, 1165
 - of older adults, 1157*t*
 - using NANDA, NIC, and NOC, 1166, 1166*t*
- Nursing Care Plan
 - assessment, 1168*t*
 - critical thinking in the nursing process, 1168*t*
 - diagnoses, 1168*t*
 - evaluation, 1168*t*
 - expected outcomes, 1168*t*
 - planning and implementation, 1168*t*
- Nursing Research: relaxation training, 1164*t*
- in obesity, 632
- in older adults, 1157*t*
- pathophysiology, 1157–58
- racial/ethnic considerations, 1156, 1157*t*
- risk factors, 1156–57, 1156*t*
- secondary, 897, 1167
- stroke risk and, 1579
- Hypertensive emergencies:
 - complications, 894
 - definition, 894, 1168
 - manifestations, 1169, 1169*t*
 - nursing care, 1170
 - treatment, 1169–70, 1169*t*
- Hypertensive encephalopathy, 1158
- Hyperthermia, malignant, 61–62, 63*t*
- Hyperthyroidism:
 - definition, 534
 - etiologies
 - excess TSH stimulation, 536
 - Graves' disease. *See* Graves' disease
 - thyroid storm, 537
 - thyroiditis, 536–37
 - toxic multinodular goiter, 536, 536*f*
 - interdisciplinary care
 - diagnosis, 523–24*t*, 536*t*, 537
 - medications, 537, 538*t*
 - radioactive iodine therapy, 537
 - surgery, 537–38
- Multisystem Effects, 535*t*
- nursing care
 - assessment, 529–30*t*, 538
 - of client having subtotal thyroidectomy, 539*t*
 - community-based care, 541
 - health promotion, 538
 - Medication Administration, 538*t*
 - nursing diagnoses and interventions
 - disturbed body image, 541
 - disturbed sensory perception: visual, 539–40
 - imbalanced nutrition: less than body requirements, 540–41
 - risk for decreased cardiac output, 538–39
 - pathophysiology, 534
- Hypertonic dehydration, 216
- Hypertonic dextrose, 225*t*
- Hypertonic solutions, 198, 199*f*
- Hypertrichosis. *See* Hirsutism
- Hypertrophic cardiomyopathy. *See also* Cardiomyopathy
 - genetic considerations, 950*t*
 - management, 1065*t*
 - manifestations, 1065*t*, 1066
 - pathophysiology, 1065–66, 1065*t*
 - prognosis, 1066
- Hypertrophic obstructive cardiomyopathy, 1066
- Hypertrophic scar, 493
- Hypervolemia, 209. *See also* Fluid volume excess
- Hyphema, 1702
- Hypnotism, 185
- Hypoalbuminemia, 704, 886

- Hypocalcemia:**
 causes, 228, 228*t*
 complications, 229
 definition, 227
 hypomagnesemia and, 229
 interdisciplinary care
 diagnosis, 229
 medications, 229, 230*t*, 548
 nutrition, 230, 230*t*
 laboratory values, 228*t*, 229
 manifestations, 228*t*, 229, 229*f*, 531*t*
 nursing care
 assessment, 230, 531*t*
 community-based care, 231
 health promotion, 230
 Medication Administration, 230*t*
 nursing diagnoses and interventions, 230–31
 pathophysiology, 228–29
 risk factors, 227–28
- Hypocapnia**, 239
- Hypochromic RBCs**, 1103
- Hypoglossal nerve (cranial nerve XII):**
 anatomy, 1510*f*
 assessment, 1521*t*
 functions, 1511*t*
- Hypoglycemia:**
 assessments, 584*t*
 definition, 586
 laboratory findings, 584*t*
 manifestations, 586–87, 587*t*
 medications causing, 586
 pathophysiology, 586–87
 risk factors, 584*t*
 treatment, 584*t*, 587
- Hypoglycemia unawareness**, 587
- Hypokalemia:**
 causes, 218*t*
 in diabetic ketoacidosis, 585
 ECG change in, 219, 219*f*
 interdisciplinary care
 diagnosis, 219, 221
 medications, 221, 221*t*
 nutrition, 221
 laboratory values, 218*t*, 219, 221
 manifestations, 218*t*, 219, 219*f*, 219*t*
 Multisystem Effects, 219*t*
 nursing care
 assessment, 221
 community-based care, 223
 health promotion, 221
 Medication Administration, 221*t*
 nursing diagnoses and interventions
 activity intolerance, 223
 acute pain, 223
 decreased cardiac output, 222
 risk for imbalanced fluid volume, 223
 using NANDA, NIC, and NOC, 223, 223*t*
- Nursing Care Plan**
 assessment, 222*t*
 critical thinking in the nursing process, 222*t*
 diagnoses, 222*t*
 evaluation, 222*t*
 expected outcomes, 222*t*
 planning and implementation, 222*t*
 pathophysiology, 218–19
- Hypokinetic pulse**, 1094*t*
- Hypomagnesemia:**
 causes, 234*t*
 complications, 234
 definition, 233
 ECG changes in, 234
 hypocalcemia and, 229
 interdisciplinary care, 234, 235*t*
 laboratory values, 234*t*
 manifestations, 234, 234*t*
 nursing care
 assessment, 235
 community-based care, 235
 health promotion, 235
 Medication Administration, 235*t*
 nursing diagnoses and interventions, 235*t*
 pathophysiology, 233
 risk factors, 233
- Hyponatremia:**
 causes, 214*t*
 definition, 213, 214
 interdisciplinary care
 diagnosis, 215
 fluid and dietary management, 215
 medications, 215
 laboratory values, 214*t*, 215
 manifestations, 214–15, 214*t*
 nursing care
 assessment, 215
 community-based care, 216
 health promotion, 215
 nursing diagnoses and interventions
 risk for imbalanced fluid volume, 215
 risk for ineffective cerebral tissue perfusion, 216
 pathophysiology, 214
- Hypoparathyroidism:**
 definition, 548
 interdisciplinary care, 524*t*, 548
 manifestations, 548, 548*t*
 nursing care. *See* Hypocalcemia
 pathophysiology, 548
- Hypophosphatemia:**
 causes, 236–37, 236*t*, 1448, 1448*t*
 definition, 236
 interdisciplinary care, 237
 laboratory values, 236*t*
 manifestations, 236*t*, 237
 nursing care, 237
 osteomalacia and, 1448
 pathophysiology, 237
- Hypophysis. See** Pituitary gland
- Hypoplasia, kidney**, 883
- Hypotension:**
 in dying client, 93
 orthostatic. *See* Orthostatic hypotension
- Hypothalamus**, 270, 1506
- Hypothermia**, 58*t*, 59
- Hypothyroidism:**
 definition, 541
 etiologies
 Hashimoto's thyroiditis, 543
 iodine deficiency, 543
 interdisciplinary care
 diagnosis, 523–24*t*, 543, 543*t*
 medications, 543, 544*t*
 surgery, 543
 manifestations, 541
 medications causing, 541
 Multisystem Effects, 542*t*
 myxedema coma in, 543
 nursing care
 assessment, 529–30*t*, 543, 545*t*
 community-based care, 545
 health promotion, 543
 Medication Administration, 544*t*
 nursing diagnoses and interventions
 constipation, 544
 decreased cardiac output, 544
 risk for impaired skin integrity, 544–45
- Nursing Care Plan**
 assessment, 546*t*
 critical thinking in the nursing process, 546*t*
 diagnoses, 546*t*
 evaluation, 546*t*
 expected outcomes, 546*t*
 planning and implementation, 546*t*
 pathophysiology, 541
 Hypotonic solutions, 198, 199*f*
 Hypovolemia, 203. *See also* Fluid volume deficit
- Hypovolemic shock:**
 assessment, 279
 in burns, 495
 definition, 273
 manifestations, 273, 274*t*
 in older adults, 273–74
 pathophysiology, 273
 stages, 273
- Hypoxemia**, 239, 1275
- Hypoxis rooperi***, 1781
- Hysterectomy:**
 in cervical cancer, 1813
 in endometrial cancer, 1816
 nursing care, 1804*t*
 in ovarian cancer, 1819
 procedure, 1803–4
- Hysterosalpingogram**, 1757*t*
- Hytrin. See** Terazosin
- I**
- IABP (intra-aortic balloon pump)**, 990, 990*f*
- Iatrogenic**, 209
- Iatrogenic disease**, 22*t*
- Iatrogenic pneumothorax**, 1299. *See also* Pneumothorax
- Ibandronate sodium**, 1436
- IBD. See** Inflammatory bowel disease
- IBS. See** Irritable bowel syndrome
- Ibuprofen:**
 factors in selecting, 178*t*
 Medication Administration, 179*t*
 in specific conditions
 gout, 1445
 osteoarthritis, 1451
 rheumatoid arthritis, 1464*t*
- Ibutilide**, 1006*t*
- ICF (intracellular fluid)**, 196, 196*f*, 197*f*
- Ichthyol**, 465*t*
- Ichthyosis**, 441
- ICN (International Council of Nurses), Code of Ethics for Nurses**, 10
- ICSH (interstitial cell-stimulating hormone)**, 520
- Icteric phase, hepatitis**, 705, 706*t*
- Icterus. See** Jaundice
- Icy Hot. See** Counterirritants
- I&D (incision and drainage)**, 304
- Idamycin. See** Idarubicin
- Idarubicin**, 1123*t*
- Ideal body weight (IBW)**, 620*t*
- IDET (intradiscal electrothermal therapy)**, 1610
- Idiopathic aplastic anemia**, 1109
- Idiopathic disease**, 22*t*
- Idiopathic hypertrophic subaortic stenosis**, 1066
- Idiopathic thrombocytopenic purpura**, 1140. *See also* Thrombocytopenia
- Idoxuridine**, 1694, 1697
- Ifosfamide**, 1483*t*
- IgA (immunoglobulin A)**, 295*t*
- IgD (immunoglobulin D)**, 295*t*
- IgE (immunoglobulin E)**, 295*t*, 331–33, 332*f*
- IGF-1 (insulin-like growth factor)**, 523*t*
- IgG (immunoglobulin G)**, 295*t*
- IgM (immunoglobulin M)**, 295*t*

- IICP. *See* Increased intracranial pressure
- IL-. *See* Interleukin
- Ileal conduit, 864, 864f, 865t
- Ileal pouch-anal anastomosis, 788, 788f
- Ileocystoplasty, 865t
- Ileostomy:
 definition, 789
 health assessment interview, 746
 low-residue diet, 791t
 nursing care
 changing a one- or two-piece drainable ostomy pouch, 791t
 health education for the client and family, 789t
 lavage, 792t
 postoperative, 789–90t
 preoperative, 789t
 surgical procedure, 789, 789f
- Ileum, 612, 742
- Ileus. *See* Paralytic ileus
- Illness:
 acute, 23
 chronic, 23. *See also* Chronic illness
 definition, 22
 vs. disease, 22
 prevention
 primary, 24
 secondary, 24
 tertiary, 24
- Ilosone. *See* Erythromycin salts
- Imaging:
 angiography. *See* Angiography
 computed tomography. *See* Computed tomography
 magnetic resonance imaging. *See* Magnetic resonance imaging
 nuclear. *See* Nuclear imaging
 ultrasonography. *See* Ultrasonography
 x-ray. *See* X-ray imaging
- Imatinib mesylate, 1119t, 1123t
- Imipenem, 319t
- Imipramine, 869, 1545t
- Imiquimod, 1841
- Imitrex. *See* Sumatriptan
- Immune complex assay, 336, 355
- Immune system:
 age-related changes, 330, 1091t
 altered function
 assessment, 330–31
 in cancer, 379, 379t
 Chapter Highlights, 366t
 hypersensitivity. *See* Hypersensitivity
 impaired immune response. *See* Human immunodeficiency virus (HIV)
 immunodeficiency virus (HIV)
 infection
 Chapter Highlights, 325–26
 components
 antigen response, 290–91
 leukocytes. *See* White blood cells
 lymphoid system, 291–92, 291f
 functions, 287
 interdisciplinary care
 diagnosis, 299–300
 immunizations. *See* Immunizations
 nonspecific inflammatory response. *See also* Inflammation
 cellular response, 293, 293f
 complement system, 294t
 healing, 294–95
 phagocytosis, 293–94, 294
 vascular response, 292–93
 in older adults, 330, 1091t
 overview, 329
 specific immune response
 antibody-mediated (humoral), 291, 295–97, 296f, 297f
 cell-mediated (cellular), 291
 Immune thrombocytopenic purpura (ITP), 1140. *See also* Thrombocytopenia
- Immunity:
 acquired, 298–99
 active, 298–99, 300t
 definition, 298
 passive, 299, 300t
 pathophysiology, 298–99
- Immunizations. *See also specific vaccines*
 nursing care
 assessment, 302
 community-based care, 303
 health promotion, 301
 nursing diagnoses and interventions, 302
 Nursing Care Plan
 assessment, 303t
 critical thinking in the nursing process, 303t
 diagnoses, 303t
 evaluation, 303t
 expected outcomes, 303t
 planning and implementation, 303t
 nursing implications, 301t
 postexposure, 303t
 reactions to, 301
 recommended for adults, 21t, 300–301, 301t
 sensitivity test for, 301
- Immunocompetent, 295
- Immunofluorescent slides, 428t
- Immunogenicity, 290
- Immunoglobulin (Ig):
 characteristics and functions, 295t
 definition, 295
 in multiple myeloma, 384t
- Immunoglobulin A (IgA), 295t
- Immunoglobulin D (IgD), 295t
- Immunoglobulin E (IgE), 295t, 331–33, 332f
- Immunoglobulin G (IgG), 295t
- Immunoglobulin M (IgM), 295t
- Immunomodulators, 1631t
- Immunosuppression, 341
- Immunosuppressive agents. *See also specific drugs*
 Medication Administration, 345–46t, 1474t, 1631t
 sites of action, 344f
 in specific conditions
 aplastic anemia, 1111
 glomerular disorders, 890
 graft-versus-host disease, 1124
 kidney transplant, 921–23
 multiple sclerosis, 1627, 1631t
 myasthenia gravis, 1649
 organ transplantation, 344
 pemphigus vulgaris, 460
 rheumatoid arthritis, 1466
 systemic lupus erythematosus, 1473, 1474t
- Immunotherapy:
 in breast cancer, 1825
 in hypersensitivity reactions, 337
 in malignant melanoma, 468
 nursing care, 398t
 principles, 396–97
- Immunotoxin, 1124
- Imodium. *See* Loperamide hydrochloride
- Impacted fracture, 1401
- Impairment, 47
- Impedance audiometry, 1722
- Implantable cardioverter-defibrillator (ICD), 1009–10
- Implementation, 7t, 10
- Impotence, 1747, 1768. *See also* Erectile dysfunction
- Imuran. *See* Azathioprine
- Inapsine. *See* Droperidol
- Incarcerated hernia, 810. *See also* Hernia
- Incident pain, 174
- Incision and drainage (I&D), 304
- Incisional biopsy, 388t, 428t
- Incisional hernia, 810. *See also* Hernia
- INCMCE (International Nursing Coalition for Mass Casualty Education), 126, 126t
- Incomplete fracture, 1402
- Incontinence:
 fecal. *See* Fecal incontinence
 urinary. *See* Urinary incontinence
- Increased intracranial pressure (IICP):
 brain herniation, 1537–38, 1538f
 cerebral edema, 1537
 definition, 1535
 hydrocephalus, 1537
 interdisciplinary care
 diagnosis, 1538
 intracranial pressure monitoring, 1540, 1540f, 1540t
 mechanical ventilation, 1539
 medications, 1538–39, 1539t
 surgery, 1539
 manifestations, 1536–37, 1536t
 nursing care
 client and family education, 1542
 Medication Administration, 1539t
 nursing diagnoses and interventions
 ineffective tissue perfusion: cerebral, 1541
 risk for infection, 1541
 pathophysiology, 1535–36
- Incus, 1682, 1682f
- Indapamide, 210t
- Independent nursing care, 54
- Inderal. *See* Propranolol
- Indiana continent urinary reservoir, 865t
- Indinavir, 358
- Indirect (unconjugated) bilirubin, 699t
- Indirect Coombs' test, 336
- Indirect inguinal hernia, 809–10. *See also* Hernia
- Indocin. *See* Indomethacin
- Indocin SR. *See* Indomethacin SR
- Indomethacin:
 factors in selecting, 178t
 Medication Administration, 179t
 in specific conditions
 ankylosing spondylitis, 1470
 gout, 1445
 rheumatoid arthritis, 1464t
 urinary calculi, 857
 venous thrombosis, 1188
- Indomethacin SR, 178t
- Infections:
 abdominal/gastrointestinal
 gastroenteritis. *See* Gastroenteritis
 helminthic. *See* Helminthic disorders
 peritonitis. *See* Peritonitis
 protozoal. *See* Protozoal bowel infections
 antibiotic-resistant microorganisms, 313–14
 biological threat. *See* Bioterrorism
 bone. *See* Osteomyelitis
 in cancer, 410
 cancer risk and, 371
 central nervous system. *See* Central nervous system infections
 Chapter Highlights, 325–26
 complications, 312–13
 in diabetes mellitus, 589
 ear. *See* Otitis externa; Otitis media

- interdisciplinary care
 diagnosis, 316–17, 316f
 goals, 315–16
 isolation techniques, 321
 medications
 antibiotics. *See* Antibiotics
 antifungal agents. *See* Antifungal agents
 antiparasitic agents. *See* Antiparasitic agents
 antivirals. *See* Antivirals
 classification, 318
 selecting, 318
 standard precautions, 321–22
 transmission-based precautions, 322, 323t
 lower respiratory. *See* Lower respiratory disorders
 nosocomial, 313
 nursing care
 assessment, 322–23
 community-based care, 324–25
 health promotion, 322
 Medication Administration
 antibiotics, 319–21t. *See also* Antibiotics
 antifungal agents, 450t. *See also* Antifungal agents
 nursing diagnoses and interventions
 anxiety, 324
 hyperthermia, 324
 pain, acute, 324
 risk for infection, 323–24
 using NANDA, NIC, and NOC, 324, 325t
 Nursing Research: antibiotics regimens, 310t
 in older adults
 age-related changes, 314–15
 nursing care, 315t
 opportunistic, in AIDS, 353–54, 359t
 pathophysiology
 chain of infection, 310, 311f
 host factors, 312
 pathogens, 310–12
 reservoir and transmission, 312
 postexposure prophylaxis, 302t
 prevalence, 309–10
 skin. *See* Skin infections/infestations
 stages, 312
 upper respiratory. *See* Upper respiratory disorders
 Infectious hepatitis. *See* Hepatitis A
 Infectious mononucleosis, 1139
 Infective endocarditis. *See* Endocarditis
 Infergen. *See* Interferon(s)
 Inferior infarct, 984
 Infiltrating ductal carcinoma, 1823. *See also*
 Breast cancer
 Inflammation:
 in burn wound healing, 493
 causes, 304
 complement system and, 294t
 complications, 305, 306t
 coronary heart disease risk and, 964
 definition, 292
 interdisciplinary care
 diagnosis, 305–6, 306t
 medications, 306–7
 nutrition, 307–8
 manifestations, 304, 304t, 305f
 mediators, 292t, 304t
 middle adults, 304
 nursing care
 assessment, 308
 community-based care, 309
 health promotion, 308
 nursing diagnoses and interventions
 impaired tissue integrity, 308–9
 pain, 308
 risk for infection, 309
 pathophysiology, 304–5
 stages
 cellular response, 293, 293f
 healing, 294–95
 phagocytosis, 293–94, 294f
 vascular response, 292–93
 Inflammatory bowel disease (IBD):
 definition, 782
 ethnic considerations, 782t
 incidence, 782t
 interdisciplinary care
 complementary therapies, 792
 diagnosis, 786
 medications, 786, 787–88t, 788
 nutrition, 788
 surgery
 colectomy, 789
 ileostomy. *See* Ileostomy
 Multisystem Effects, 783t
 nursing care
 assessment, 792
 community-based care, 794–95
 health promotion, 792
 Medication Administration, 787–88t
 nursing diagnoses and interventions
 diarrhea, 792–94
 disturbed body image, 794
 imbalanced nutrition: less than body requirements, 794
 using NANDA, NIC, and NOC, 794, 795t
 Nursing Care Plan: ulcerative colitis
 assessment, 793t
 critical thinking in the nursing process, 793t
 diagnoses, 793t
 evaluation, 793t
 expected outcomes, 793t
 planning and implementation, 793t
 types
 Crohn's disease. *See* Crohn's disease
 ulcerative colitis. *See* Ulcerative colitis
 Inflammatory response. *See* Inflammation
 Influximab, 341, 788
 Influenza:
 avian, 1232t
 characteristics, 1231
 complications, 1233. *See also* Pneumonia
 epidemics, 1231
 interdisciplinary care
 diagnosis, 1233
 medications, 1234
 prevention. *See* Influenza vaccine
 manifestations, 1233, 1233t
 nursing care
 assessment, 1234
 community-based care, 1235
 health promotion, 1234
 nursing diagnoses and interventions
 disturbed sleep pattern, 1234–35
 ineffective breathing pattern, 1234
 risk for infection, 1235
 using NANDA, NIC, and NOC, 1235, 1235t
 pathophysiology, 1232
 viral strains, 1231–32
 Influenza vaccine:
 adverse reactions, 1234
 contraindications, 21t, 1271
 indications, 21t, 300, 301t, 1233, 1271
 nursing implications, 301t
 Informed consent, 55, 56f
 Infratentorial herniation, 1538, 1538f. *See also*
 Increased intracranial pressure
 Ingrown toenail, 483
 Inguinal area, 749–50t, 1749f, 1749t
 Inguinal hernia, 809–10, 809f. *See also* Hernia
 INH. *See* Isoniazid
 Inhalants, abuse, 111, 113t
 Inhalation anthrax:
 as biological weapon, 128t
 decontamination procedures, 128t
 manifestations, 128t, 1293
 treatment, 128t, 1294
 Inhalation injury:
 interdisciplinary care
 diagnosis, 1306–7
 emergency treatment, 1306
 prevention, 1306
 treatments, 1307
 manifestations, 1304–5
 near-drowning, 1304–5
 nursing care
 assessment, 1307
 community-based care, 1308
 health promotion, 1307
 nursing diagnoses and interventions
 impaired gas exchange, 1307–8
 ineffective airway clearance, 1307
 ineffective tissue perfusion: cerebral, 1308
 pathophysiology, 1304–5
 smoke inhalation, 1304
 Inheritance:
 Mendelian patterns
 autosomal dominant, 153, 153f, 153t
 autosomal recessive, 153–54, 153f, 154t
 recessive vs. dominant, 152–53
 variability
 anticipation, 155
 new mutation, 155
 penetrance, 155
 variable expressivity, 155
 X-linked dominant, 155
 X-linked recessive, 154, 154f, 155t
 multifactorial, 155–56
 principles, 152
 Injuries. *See also* Trauma
 mechanisms, 255t
 risk for
 in older adults, 29–30
 in young adults, 24
 types, 256
 Inner ear disorders:
 interdisciplinary care
 diagnosis, 1727
 medications, 1727
 surgery, 1727
 treatments, 1727
 labyrinthitis, 1726
 manifestations, 1726–27
 Ménière's disease, 1726–27
 nursing care
 assessment, 1727–28
 community-based care, 1729
 health promotion, 1727
 nursing diagnoses and interventions
 disturbed sleep pattern, 1728
 risk for trauma, 1728
 using NANDA, NIC, and NOC, 1728, 1728t
 pathophysiology, 1726–27
 vertigo, 1726
 Innohep. *See* Tinzaparin
 Inocor. *See* Amrinone
 Inotropes:
 Medication Administration, 278t, 1033–34t
 in specific conditions
 heart failure, 1033–34t
 shock, 278t
 INR (International Normalized Ratio), 1349

- Insensible water loss, 196
 Inspiration, 1215, 1215f
 Inspiratory capacity, 1214t
 Inspiratory reserve volume (IRV), 1214, 1214t
 Insulin:
 abnormal, possible causes, 386t
 administration
 continuous subcutaneous infusion, 572
 health education for client and family, 573t
 injection preparation, 574
 injection sites, 574–75, 575f, 575t
 intravenous, 586t
 lipodystrophy, 575
 mixing insulins, 575, 576t
 nursing responsibilities, 573t
 regimens, 575, 577t
 routes, 572
 sliding scale, 572–73, 574t
 syringe and needle selection, 573–74
 concentrations, 572
 functions, 521, 564, 565f
 for hyperkalemia, 224, 225t
 indications, 571
 laboratory tests, 380t
 Medication Administration, 573t, 586t
 normal values, 386t
 perioperative needs, 59t, 61, 572–73, 581–82
 preparations, 571–72, 571t
 sources, 571
 Insulin glargine, 571t, 572
 Insulin lispro, 571, 571t
 Insulin pump, 570, 572
 Insulin reaction, 586
 Insulin resistance, 964, 1157, 1158
 Insulin-like growth factor (IGF-1), 523t
 Intal. *See* Cromolyn sodium
 Integra, 503
 Integriлин. *See* Eptifibatid
 Integumentary system. *See also* Hair; Nails; Skin
 anatomy, physiology, and functions, 423t
 assessment
 abnormal findings, 431t
 diagnosis, 427, 428t
 functional health pattern interview, 429t
 genetic considerations, 427, 427t
 health assessment interview, 427, 429
 physical assessment, 429–30, 431t, 435–36t
 sample documentation, 427t
 technique/normal findings, 431t
 Intercostal spaces, 1213, 1213f, 1223t
 Interdisciplinary care, 54
 Interferon(s). *See also* Alpha interferon; Beta interferon
 functions, 299t
 mechanism of action, 299t, 322t
 Medication Administration, 322t, 1631t
 production, 299t
 in specific conditions
 cancer, 396–97
 hepatitis, 708
 HIV/AIDS, 358
 leukemia, 1125
 multiple sclerosis, 1627, 1631t
 Interferon beta-1a, 1631t
 Interferon beta-1b, 1631t
 Interleukin-1 (IL-1), 299t
 Interleukin-2 (IL-2), 299t, 396–97
 Interleukin-3 (IL-3), 299t
 Interleukin-4 (IL-4), 299t
 Interleukin-5 (IL-5), 299t
 Intermittent claudication, 1172, 1176
 Internal hemorrhoids, 818, 818f. *See also* Hemorrhoids
 Internal rotation, 1386t
 International Council of Nurses (ICN), Code of Ethics for Nurses, 10
 International Normalized Ratio (INR), 1349
 International Nursing Coalition for Mass Casualty Education (INCMCE), 126, 126t
 International Prostate Symptom Score, 1778
 International Society of Nurses in Genetics (ISONG), 148–49, 149t
 Internet, for health information in older adults, 1458t
 Interstitial cells. *See* Leydig's cells
 Interstitial cell–stimulating hormone (ICSH), 520
 Interstitial edematous pancreatitis, 726. *See also* Pancreatitis
 Interstitial fluid, 196, 196f, 197f
 Interstitial pneumonia, 1268t. *See also* Pneumonia
 Intestinal decompression, 770, 771f, 813
 Intestinal fluke, 780
 Intestinal obstruction:
 interdisciplinary care
 diagnosis, 812–13
 gastrointestinal decompression, 813
 surgery, 813
 large-bowel
 complications, 812
 manifestations, 812
 pathophysiology, 812
 nursing care
 assessment, 813
 community-based care, 815
 health promotion, 813
 nursing diagnoses and interventions
 deficient fluid volume, 813–14
 ineffective breathing pattern, 814
 ineffective tissue perfusion:
 gastrointestinal, 814
 using NANDA, NIC, and NOC, 814
 in ovarian cancer, 1818t
 pathophysiology, 811
 small-bowel
 complications, 812
 manifestations, 812
 pathophysiology, 811–12
 Intimate partner violence, 256t
 Intra-aortic balloon pump (IABP), 990, 990f
 Intra-arterial pressure monitoring, 1029–30
 Intracapsular fractures, 1414, 1415f. *See also* Hip, fracture
 Intracellular fluid (ICF), 196, 196f, 197f
 Intracerebral hematoma, 1557t, 1558, 1558f. *See also* Traumatic brain injury
 Intracoronary stents, 977
 Intracranial aneurysm:
 complications
 hydrocephalus, 1593
 rebleeding, 1593
 vasospasm, 1593
 incidence and prevalence, 1592
 interdisciplinary care
 diagnosis, 1593
 medications, 1593
 treatments, 1593–94
 manifestations, 1592–93
 nursing care
 nursing diagnoses and interventions, 1594–95
 pathophysiology, 1592
 Intracranial hypertension. *See* Increased intracranial pressure
 Intracranial pressure:
 abnormal findings, 1560t. *See also* Increased intracranial pressure
 monitoring, 1540, 1540f, 1540t
 normal values, 1535, 1560t
 Intradermal testing, 337, 337f
 Intradiscal electrothermal therapy (IDET), 1610
 Intraductal papilloma, 1821, 1821t
 Intraductal papillomatosis, 1821
 Intramural fibroid tumors, 1809, 1810f
 Intraocular lens implant, 1705, 1705f
 Intraoperative awareness, 67
 Intraoperative period. *See also* Surgery
 definition, 54
 interdisciplinary care
 intraoperative awareness, 67
 malignant hyperthermia, 63t
 medications. *See* Anesthesia
 special considerations for older adults, 67, 70
 surgical environment
 surgical attire, 66–67, 66f
 surgical scrub, 66
 team members, 64–66, 66f
 nursing care, 73
 Intraoperative radiotherapy, 1827
 Intrarenal acute renal failure, 900t, 901–2. *See also* Acute renal failure
 Intraspinial analgesia:
 nursing care, 184t
 procedure, 184f, 184t
 Intravascular fluid. *See* Plasma
 Intravenous administration:
 fluids
 in fluid volume deficit, 205–6
 in gastroenteritis, 777
 in hyponatremia, 215
 Medication Administration, 1539t
 types, 207t
 pain medication, 183, 183f
 Intravenous pyelogram (IVP):
 client preparation, 836t
 health education, 836t
 purpose and description, 836t
 related nursing care, 836t
 in specific conditions
 acute renal failure, 904
 bladder cancer, 863
 polycystic kidney disease, 885
 urinary calculi, 857
 urinary incontinence, 874
 urinary tract infection, 849
 Intraventricular conduction blocks, 1004
 Intravascular, 847
 Intrinsic (intrarenal) acute renal failure, 900t, 901–2. *See also* Acute renal failure
 Intrinsic factor, 611, 1105
 Introitus, 1752
 Intron A. *See* Interferon(s)
 Intropin. *See* Dopamine
 Inversion, 1386t
 Invirase. *See* Saquinavir
 Iodine:
 deficiency, 543
 Medication Administration, 538t
 radioactive. *See* Radioactive iodine therapy;
 Radioactive iodine uptake
 recommended daily intake, 610t
 Iodoquinol:
 Medication Administration, 780t
 in specific conditions
 amebic liver abscess, 725
 protozoal bowel infections, 778t, 779, 780t
 Ionamin. *See* Phentermine
 Ionized calcium, 229
 Ions, 196. *See also* Electrolytes
 Ipratropium bromide, 1326, 1327–28t, 1334
 Iranian culture, end-of-life practices, 89
 Iraqi culture, death rituals, 88
 Irbesartan, 1033t, 1161t
 Iridectomy, 1709

- Iridotomy, laser, 1709
 Irinotecan (CPT-11), 805
 Iris, 1671, 1672*f*, 1680
 Iritis, 1703
 Iron:
 deficiency. *See* Iron deficiency anemia
 diagnostic tests, 1110
 dietary sources, 1111*t*
 recommended daily intake, 610*t*
 replacement therapy, 1111, 1112*t*, 1114
 Iron chelation therapy, 1116
 Iron deficiency anemia. *See also* Anemia
 causes, 1105, 1105*t*
 interdisciplinary care
 diagnostic tests, 1110
 focus, 1110*t*
 medications, 1110, 1112*t*
 nutrition, 1111, 1111*t*
 manifestations, 642*t*, 1105
 pathophysiology, 1103, 1105, 1105*f*
 Iron dextran injection, 1112*t*
 Iron polysaccharide, 1112*t*
 Iron sucrose, 1111, 1112*t*
 Irregular bones, 1380
 Irritable bowel syndrome (IBS):
 definition, 762
 interdisciplinary care
 complementary therapies, 763
 diagnosis, 762
 medications, 762–63
 nutrition, 763
 manifestations, 762, 762*t*
 nursing care
 assessment, 763
 community-based care, 763
 nursing diagnoses and interventions, 763
 pathophysiology, 762
 Irritant laxatives, 759–60*t*
 IRV (inspiratory reserve volume), 1214, 1214*t*
 Ischemia, 969
 Ischemic, 940
 Ischemic stroke, 1581. *See also* Stroke
 Islet cells:
 hormones secreted by, 564
 transplantation, 342*t*, 581
 ISMO. *See* Isosorbide mononitrate
 Isobutyl nitrite, 111
 Isoetharine, 1327*t*
 Isograft, 342
 Isolation:
 in disasters, 134
 precautions, 321
 ISONG (International Society of Nurses in Genetics), 148–49, 149*t*
 Isoniazid:
 adverse/side effects, 1288*t*
 dosage, 1288*t*
 drug-induced lupus and, 1471
 Medication Administration, 1288*t*
 nursing implications, 1288*t*
 for tuberculosis, 1287, 1288*t*
 Isoproterenol, 278*t*, 1327*t*
 Isoptin. *See* Verapamil
 Isordil. *See* Isosorbide dinitrate
 Isosorbide dinitrate, 973*t*, 1032
 Isosorbide mononitrate, 973*t*
 Isotonic fluid volume deficit, 203. *See also* Fluid volume deficit
 Isotonic solutions, 198, 199*f*
 Isotretinoin, 458, 459*t*
 Isradipine, 973–74*t*, 1162*t*
 Israeli culture, death rituals, 88
 Isuprel. *See* Isoproterenol
 Itch-scratch-itch cycle, 440
 ITP (immune thrombocytopenic purpura), 1140.
 See also Thrombocytopenia
 Itraconazole, 1295
 IVP. *See* Intravenous pyelogram
J
 Jackknife position, 69*f*
 Jacksonian march/seizure, 1549
 Janeway lesions, 1046
 Jannetta procedure, 1656
 Jarisch-Herxheimer reaction, 1849
 Jaundice:
 assessment in light and dark skin, 426*t*
 causes, 426*t*
 definition, 425*t*, 704
 pathophysiology, 704
 types, 704
 Jejunostomy tube, nursing care, 692*t*
 Jejunum, 612, 742
 Jews, inflammatory bowel disease incidence, 782*t*
 Joint(s):
 cartilaginous, 1383
 degenerative disease. *See* Osteoarthritis
 dislocation
 causes, 1400–1401
 definition, 1400
 interdisciplinary care, 1401
 manifestations, 1401
 nursing care
 community-based care, 1401
 nursing diagnoses and interventions, 1401
 pathophysiology, 1401
 fibrous, 1383
 functional classification, 1383*t*
 inflammatory disease. *See* Rheumatoid arthritis
 subluxation, 1401
 synovial, 1383, 1386, 1386*f*, 1386*t*
 Joint arthroplasty, 1452. *See also* Total joint replacement
 “Joint mice,” 1450
 Jugular venous pressure, 1095*t*
 Junctional escape rhythm, 998*t*, 1001–2
 Junctional tachycardia, 1002
K
 K⁺. *See* Potassium
 K + Care ET. *See* Potassium bicarbonate
 Kaiser mouthwash, 409*t*
 Kaletra. *See* Lopinavir; Ritonavir
 Kanamycin, 320*t*
 Kantrex. *See* Kanamycin
 Kaolin, 465*t*
 Kaolin and pectin, 756*t*
 Kaon Elixir. *See* Potassium gluconate
 Kaopectate, 756*t*
 Kaposi’s sarcoma (KS), 354, 354*f*, 359*t*, 1718
 Karnofsky scale, functional status, 401*t*
 Kaybovite. *See* Vitamin B₁₂, replacement therapy
 Kayexalate. *See* Sodium polystyrene sulfonate
 Keflex. *See* Cephalexin
 Kegel exercises, 876, 877*t*, 1806
 Kehr’s sign, 617
 Keloid:
 in burn injuries, 493
 characteristics, 433*t*, 442*f*
 definition, 442
 genetic considerations, 427*t*
 risk factors, 442
 Kemadrin. *See* Procyclidine
 Keratectomy, 1697
 Keratin, 423
 Keratitis, 1696, 1697
 Keratoconjunctivitis, 1696
 Keratoconus, 1697
 Keratoplasty. *See* Corneal transplant
 Keratoses, 430*t*, 443
 Keratotic warts, 1841. *See also* Genital warts
 Kerlone. *See* Betaxolol
 Kernig’s sign, 1524*f*, 1524*t*
 Ketamine, 1772
 Ketoconazole:
 Medication Administration, 450*t*
 in specific conditions
 Cushing’s syndrome, 550
 hirsutism, 482
 thrush, 657*t*, 658
 Ketonuria, 569
 Ketoprofen, 178*t*, 1451, 1464*t*
 Ketoprofen SR, 178*t*
 Ketorolac tromethamine, 178*t*, 179*t*
 Ketosis, 565
 17-Ketosteroids, 525*t*
 Kidney(s):
 age-related changes, 883, 884*t*
 anatomy and physiology, 800, 829–31, 830*f*, 885–86
 biopsy, 838*t*
 in blood pressure regulation, 1085
 diagnostic tests, 836–38*t*
 disorders
 acute renal failure. *See* Acute renal failure
 calculi. *See* Urinary calculi
 Chapter Highlights, 927*t*
 congenital malformation, 883–84
 glomerular disorders. *See* Glomerular disorders
 incidence, 883
 polycystic kidney disease
 genetic considerations, 884, 884*t*
 interdisciplinary care, 885
 manifestations, 885
 nursing care, 885
 pathophysiology, 884, 885*f*
 tumors, 896. *See also* Renal cell carcinoma
 vascular
 hypertension, 894
 renal artery occlusion, 894–95
 renal artery stenosis, 895
 renal vein occlusion, 895
 functions
 in body fluid regulation, 201
 hormonal, 834
 maintenance of urine composition and volume, 833–34, 833*f*
 in potassium balance, 217
 in sodium balance, 214
 urine formation
 glomerular filtration, 831–33, 831*f*
 tubular reabsorption, 831*f*, 833
 tubular secretion, 831*f*, 833
 waste clearance, 834
 physical assessment, 841*t*, 842–43*t*
 transplantation. *See* Kidney transplant
 trauma
 interdisciplinary care, 895–96
 manifestations, 895
 nursing care, 896
 pathophysiology, 895
 Kidney, ureters, and bladder (KUB) x-ray, 857, 889
 Kidney biopsy. *See* Renal biopsy
 Kidney failure. *See* Acute renal failure; Chronic renal failure
 Kidney transplant. *See also* Transplant procedures
 allocation of organs, 921*t*
 incidence, 920
 indications, 342*t*
 nursing care, 922*t*
 postoperative care, 921–23

- Kidney transplant—*continued*
 procedure, 921, 921f
 results, 920
 source of organs, 920–21
 success rate, 342t
- Kiesselbach's area, 1243
- Killer T cells, 297, 298f. *See also* T lymphocytes
- Kilocalorie (kcal), 613
- Kimmelstiel-Wilson syndrome, 588
- Kindling, 103, 103t
- Kineret. *See* Anakinra
- Kinesthesia, 1521t
- Kinetic continuous rotation bed, 267, 267f
- Kinins, 304t
- Klean-Prep. *See* Polyethylene glycol
- K-Lease. *See* Potassium chloride
- Klebsiella pneumoniae*, 1271t
- Klonopin. *See* Clonazepam
- K-Lyte. *See* Potassium citrate
- Knee:
 physical assessment, 1394t, 1395f, 1395t, 1396f, 1396t
 replacement. *See* Total joint replacement
- Kock pouch, 865t
- Kock's ileostomy, 789, 789f
- KOH (potassium hydroxide), 428t
- Kohlberg, moral development theory, 25t
- Korotkoff's sounds, 1092t
- Korsakoff's psychosis, 103t, 108
- KS (Kaposi's sarcoma), 354, 354f, 359t, 1718
- Kübler-Ross, stages of loss and grief, 86–87, 86t
- Kupffer cells, 289
- Kussmaul's respirations, 244, 585t, 1051
- Kwell. *See* Lindane
- Kyphosis:
 definition, 1391t, 1487
 interdisciplinary care
 diagnosis, 1489
 treatments, 1489
 manifestations, 1488f, 1488t
 nursing care
 nursing diagnoses and interventions
 community-based care, 1490
 risk for injury, 1489
 risk for peripheral neurovascular dysfunction, 1489–90
 pathophysiology, 1488–89
- Kytril. *See* Granisetron
- L**
- Labetalol, 1161t, 1169t
- Labia majora:
 anatomy, 1751, 1751t, 1752f
 physical assessment, 1762t
- Labia minora:
 anatomy, 1751t, 1752, 1752f
 physical assessment, 1762t
- Labile cells, 295
- Labyrinth, 1683
- Labyrinthectomy, 1727
- Labyrinthitis, 1726. *See also* Inner ear disorders
- Lacerations, 259, 259f
- Lactase deficiency:
 ethnic considerations, 798t
 interdisciplinary care
 diagnosis, 799
 nursing care, 799
 nutrition, 799
 manifestations, 798
 pathophysiology, 798
- Lactic dehydrogenase (LDH), 386t, 1775
- Lactose breath test, 799
- Lactose intolerance, 798. *See also* Lactase deficiency
- Lactulose, 716, 717t, 759t
- Laënnec's cirrhosis. *See* Alcoholic cirrhosis
- Lamictal. *See* Lamotrigine
- Laminectomy:
 nursing care, 1609–10t
 procedure, 1608
- Lamivudine, 358, 708
- Lamotrigine, 1550t
- Laniazid. *See* Isoniazid
- Lanoxin. *See* Digoxin
- Lansoprazole, 62t, 665t, 678
- Lantus. *See* Insulin glargine
- Laparoscopic appendectomy, 767
- Laparoscopic cholecystectomy:
 nursing care, 700t
 Nursing Research: postoperative pain management, 700t
 procedure, 699
- Laparoscopic fundoplication, 666
- Laparoscopy:
 definition, 388t
 in female reproductive system disorders
 nursing care, 1758t, 1801t
 purpose and description, 1758t, 1801, 1801f
- Laparotomy:
 for appendectomy, 767
 for cholecystectomy, 699
 definition, 699
 for intestinal obstruction, 813
 for peritonitis, 770
- Large intestine:
 anatomy, physiology, and functions, 742–43, 742f
 disorders. *See* Bowel disorders
 obstruction, 812. *See also* Intestinal obstruction
- Large-bowel obstruction, 812. *See also* Intestinal obstruction
- Larodopa. *See* Levodopa
- Laryngeal cancer:
 interdisciplinary care
 chemotherapy, 1254
 diagnosis, 1254
 radiation therapy, 1254
 speech rehabilitation, 1255–56, 1255f, 1258f
 staging, 1254t
 surgery, 1254–55, 1255f
 treatments, 1254t
 manifestations, 1253, 1253t
 nursing care
 of client having total laryngectomy, 1256t
 community-based care, 1262–63
 health promotion, 1258
 nursing diagnoses and interventions
 anticipatory grieving, 1261
 imbalanced nutrition: less than body requirements, 1260–61
 impaired swallowing, 1260
 impaired verbal communication, 1259–60
 risk for impaired airway clearance, 1258
 using NANDA, NIC, and NOC, 1261, 1262t
 Nursing Research: use of speech-generating devices, 1260t
 pathophysiology, 1253, 1253f
 risk factors, 1253
- Laryngectomy:
 nursing care
 postoperative, 1256t
 preoperative, 1256t
- Nursing Care Plan
 assessment, 1259t
 critical thinking in the nursing process, 1259t
 diagnoses, 1259t
 evaluation, 1259t
 expected outcomes, 1259t
 planning and implementation, 1259t
- Nursing Research: use of speech-generating devices, 1260t
 partial, 1255
 procedure, 1255, 1255f
 total, 1255
- Laryngitis, 1241
- Laryngopharynx, 1211
- Laryngospasm, 1249
- Larynx:
 anatomy, physiology, and functions, 1211
 infections, 1240–41
 obstruction or trauma
 interdisciplinary care, 1249–50, 1249f
 manifestations, 1249
 nursing care, 1250
 pathophysiology, 1249
 tumors, 1252, 1253. *See also* Laryngeal cancer
- Laser epithelial keratomileusis (LASEK), 1697
- Laser eye surgery, 1697
- Laser *in situ* keratomileusis (LASIK), 1697
- Laser iridotomy, 1709
- Laser lithotripsy, 858
- Laser photocoagulation:
 of bladder tumors, 864
 of colorectal tumors, 803
 in diabetic retinopathy, 1716
 in peptic ulcer disease, 685
- Laser surgery, 477–78, 1697
- Laser thermokeratoplasty (LTK), 1697
- Laser trabeculoplasty, 1709
- Lasix. *See* Furosemide
- Latanoprost, 1709, 1710t
- Late phase response, in asthma, 1322
- Latency, 1839
- Latent syphilis, 1848
- Lateral chest position, 69f
- Lateral myocardial infarction, 984. *See also* Acute myocardial infarction
- Lateral transtentorial herniation, 1538, 1538f
- Latex allergy, 335–36, 456
- Latin Americans, substance abuse in, 105t
- Laudanum, 756t
- Laxatives:
 bulk-forming, 759t
 in irritable bowel syndrome, 762
 irritant/stimulant, 759–60t
 lubricant, 760t
 magnesium-containing, 236t
 Medication Administration, 759–60t
 osmotic/saline, 759t
 wetting agents, 759t
- LDH (lactic dehydrogenase), 386t, 1775
- LDL. *See* Low-density lipoprotein
- LE (lupus erythematosus) cell test, 341
- Lead, pacemaker, 1010t. *See also* Pacemakers
- Leader, nurse as, 14–15
- LEEP (loop electrosurgical excision procedure), 1757t, 1813
- LEETZ (loop electrosurgical excision of transformation zone), 1757t
- Leflunomide, 341, 1465
- Left main coronary artery, 939f, 959
- Left-sided heart failure, 1026, 1026f. *See also* Heart failure
- Leg, ankle, and foot exercises, preoperative teaching, 73t
- Legal issues:
 in end-of-life care, 12
 informed consent, 55, 56f
- Legionnaire's disease, 1269, 1270t. *See also* Pneumonia
- Leiomyoma:
 definition, 1809
 incidence, 1809

- interdisciplinary care
 medications, 1810
 surgery, 1810
 manifestations, 1809
 pathophysiology, 1809
 types, 1809, 1810*f*
- Lens:
 age-related changes, 1676*t*
 anatomy, physiology, and functions, 1672, 1672*f*
 assessment, 1680
- Lentiginosities, 430*t*
- Lentigo maligna, 466-67
- Lepirudin, 1141
- Lescol. *See* Fluvastatin
- Lesser vestibular glands. *See* Skene's glands
- Leucovorin. *See* Folinic acid
- Leukemia:
 classification, 1119, 1119*t*, 1121
 definition, 1118
 incidence, 1118
 interdisciplinary care
 biologic therapy, 1124-25
 bone marrow transplant, 1124, 1124*f*
 chemotherapy, 1123, 1123*t*
 complementary therapies, 1125
 diagnosis, 1122-23, 1123*t*
 stem cell transplant, 1124
 manifestations, 1119
 Multisystem Effects, 1120*t*
 nursing care
 anticipatory grief, 1128
 assessment, 1126
 community-based care
 encouraging self-care, 1129
 information about leukemia and treatment, 1129
 preventing infection and injury, 1129
 promoting nutrition, 1129
 health promotion, 1125-26
 imbalanced nutrition: less than body requirements, 1127
 impaired oral mucous membrane, 1127
 ineffective protection, 1127-28
 nursing diagnoses and interventions
 risk for infection, 1126-27
 using NANDA, NIC, and NOC, 1128, 1128*t*
- Nursing Care Plan
 assessment, 1125*t*
 critical thinking in the nursing process, 1125*t*
 diagnoses, 1125*t*
 evaluation, 1125*t*
 expected outcomes, 1125*t*
 planning and implementation, 1125*t*
- Nursing Research: care of physical problems
 during treatment, 1126*t*
- pathophysiology, 1119
 risk factors, 1118
 survival rates, 1119
 types
 acute lymphocytic. *See* Acute lymphocytic leukemia
 acute myeloid. *See* Acute myeloid leukemia
 chronic lymphocytic. *See* Chronic lymphocytic leukemia
 chronic myeloid. *See* Chronic myeloid leukemia
- Leukeran. *See* Chlorambucil
- Leukocyte esterase test, 849
- Leukocytes. *See* White blood cells
- Leukocytosis, 287, 307*t*, 1079
- Leukopenia, 287, 307*t*, 1079, 1138
- Leukoplakia, 623*t*, 1253
- Leukotriene modifiers, 1326, 1328*t*
- Leukotrienes, 292*t*, 304*t*
- Leuprolide, 1787*t*, 1810
- Levaquin. *See* Levofloxacin
- Levatol. *See* Penbutolol
- Level of consciousness, altered. *See* Altered level of consciousness
- Levitra. *See* Vardenafil hydrochloride
- Levobunolol, 1710*t*
- Levodopa, 1637*t*, 1639
- Levo-Dromoran. *See* Levorphanol
- Levofloxacin, 320*t*
- Levophed. *See* Norepinephrine
- Levorphanol, 180*t*
- Levothroid. *See* Levothyroxine sodium
- Levothyroxine sodium, 544*t*
- Levoxyl. *See* Levothyroxine sodium
- Lewy body dementia, 1618*t*
- Leydig's cells, 1744
- LH. *See* Luteinizing hormone
- Libido, 1768
- Librium. *See* Chlordiazepoxide
- Lichen planus, 460
- Lichenification, 433*t*
- Licorice root, 709, 1335
- Lidocaine:
 adverse/side effects, 1006*t*
 for dysrhythmias, 1006*t*
 for long-term analgesia at home, 190*t*
 Medication Administration, 658*t*, 1006*t*
 viscous, for stomatitis, 657, 658*t*
- Lifestyle:
 health and, 20
 modifications for hypertension, 1159-60, 1159*t*, 1160*t*
- Lifts, 952
- Ligaments, 1386
- Lightning injury, 488
- Limb-girdle muscular dystrophy, 1459*t*
- Limbic system, 1507
- Lindane, 451
- Lindemann, theory of loss and grief, 86, 86*t*
- Linear fracture, skull, 1555, 1555*t*. *See also* Skull fracture
- Linezolid, 320*t*
- Linoleic acid, 608
- Lioresal. *See* Baclofen
- Liothyronine sodium, 544*t*
- Liotrix, 544*t*
- Lipancratin. *See* Pancrelipase
- Lipid profile:
 in coronary heart disease diagnosis, 965
 high-risk levels, 963*t*
 normal values, 944*t*, 963*t*, 965
 purpose and description, 944*t*
 related nursing care, 944*t*
- Lipiduria, 888
- Lipitor. *See* Atorvastatin
- Lipoatrophy, 575
- Lipodystrophy, 575
- Lipoprotein (a), 965
- Lipoproteins, 959. *See also* High-density lipoprotein; Lipid profile; Low-density lipoprotein
- Liposuction, 479
- Lisinopril, 1033*t*, 1161*t*
- Lispro, 571, 571*t*
- Lithiasis, 855
- Lithotomy position, 69*f*
- Lithotripsy. *See also* Extracorporeal shock wave lithotripsy
 nursing care, 859*t*
 procedure, 858
- Liver:
 anatomy, physiology, and functions, 612-13, 613*t*, 703-4
- disorders
 abscess
 interdisciplinary care, 725
 manifestations, 725
 nursing care, 725
 pathophysiology, 725
 cancer
 causes, 724*t*
 incidence, 723-24
 interdisciplinary care, 724
 manifestations, 724, 724*t*
 nursing care, 724
 pathophysiology, 724
 cirrhosis. *See* Cirrhosis
 diagnostic tests
 laboratory, 716
 liver biopsy, 617*t*, 716
 hepatitis. *See* Hepatitis
 manifestations
 hepatocellular failure, 704
 jaundice, 704
 portal hypertension. *See* Portal hypertension
 surgical risk and nursing implications, 57*t*
 trauma
 interdisciplinary care, 725
 nursing care, 725
 pathophysiology, 725
 physical assessment, 625*f*, 625*t*, 627*f*, 627*t*
 transplantation. *See* Liver transplant
 "Liver spots," 430*t*
- Liver transplant. *See also* Transplant procedures
 contraindications, 719-20
 indications, 342*t*, 719
 nursing care, 720*t*
 success rate, 342*t*
- Living will, 90. *See also* Advance directives
- LMW (low-molecular-weight) heparins, 1188, 1189*t*
- Lobar pneumonia, 1268, 1268*t*, 1270*t*. *See also* Pneumonia
- Lobectomy, 1312*t*
- Local anesthetics:
 for long-term analgesia at home, 190*t*
 for pain management, 179
 for regional anesthesia, 63
 for skin disorders, 441*t*
- Local nerve infiltration, 63
- Locked-in syndrome, 1532. *See also* Altered level of consciousness
- Lodine. *See* Etodolac
- Lomotil. *See* Diphenoxylate
- Long bones, 1380, 1393*f*
- Long QT syndrome, 950*t*, 1002
- Loniten. *See* Minoxidil
- Loop diuretics:
 mechanism of action, 210
 Medication Administration, 210*t*, 905*t*, 1539*t*
 in specific conditions
 acute renal failure, 904, 905*t*
 fluid volume excess, 210*t*
 heart failure, 1032
 hyponatremia, 215
 increased intracranial pressure, 1538, 1539*t*
 pulmonary edema, 1041
- Loop electrosurgical excision of transformation zone (LEETZ), 1757*t*
- Loop electrosurgical excision procedure (LEEP), 1757*t*, 1813
- Loop ileostomy, 789
- Loop of Henle, 830, 833-34, 833*f*
- Loperamide hydrochloride, 756*t*, 762, 764
- Lopid. *See* Gemfibrozil
- Lopinavir, 358
- Lopressor. *See* Metoprolol

- Loratadine, 1230t
- Lorazepam:
 - preoperative use and nursing implications, 62t
 - in specific conditions
 - acute respiratory failure, 1355
 - burns, 500
 - nausea and vomiting, 672
 - substance abuse/withdrawal treatment, 114t
 - vertigo, 1727
- Lordosis, 1391t
- Losartan, 1033t, 1161t
- Loss and grief. *See also* Death and dying; End-of-life care
 - Chapter Highlights, 99t
 - definitions, 85
 - factors affecting response to
 - age, 87, 87t
 - cultural and spiritual practices, 88, 89t
 - family, 88
 - mourning rituals, 88
 - social support, 87
 - Meeting Individualized Needs, 98t
 - nurses' response to clients', 88
 - nursing care
 - assessment
 - physical, 95
 - psychosocial, 96
 - spiritual, 96
 - community-based care, 97
 - nursing diagnoses and interventions, 96
 - anticipatory grieving, 96
 - chronic sorrow, 96
 - death anxiety, 96
 - using NANDA, NIC, and NOC, 97, 97t
- Nursing Care Plan
 - assessment, 98t
 - critical thinking in the nursing process, 98t
 - diagnoses, 98t
 - evaluation, 98t
 - expected outcomes, 98t
 - planning and implementation, 98t
 - teaching for clients experiencing, 98t
 - theories of
 - Bowlby: protest, despair, and detachment, 85-86, 86t
 - Caplan: stress and loss, 86, 86t
 - Engel: acute grief, restitution, and long-term grief, 86, 86t
 - Freud: psychoanalytic theory, 85
 - Kübler-Ross: stages of coping with loss, 86-87, 86t
 - Lindemann: categories of symptoms, 86, 86t
 - types, 85t
- Lotensin. *See* Benazepril
- Lotions, skin, 441t
- Lotrol. *See* Diphenoxylate
- Lou Gehrig's disease. *See* Amyotrophic lateral sclerosis
- Lovastatin, 967t, 968
- Lovenox. *See* Enoxaparin
- Low back pain:
 - causes, 1490t
 - interdisciplinary care
 - conservative treatment, 1491
 - diagnosis, 1491
 - medications, 1491
 - manifestations, 1490, 1490t
 - nursing care
 - community-based care, 1492
 - health promotion, 1491
 - nursing diagnoses and interventions
 - acute pain, 1491
 - deficient knowledge, 1491-92
 - risk for impaired adjustment, 1492
 - pathophysiology, 1490
- Low-density lipoprotein (LDL):
 - functions, 959
 - high-risk levels, 963, 963t
 - normal values, 944t, 963t
- Lower body obesity, 632. *See also* Obesity
- Lower extremity:
 - amputation sites, 1422f
 - fracture, 1414, 1416
 - physical assessment, 1096-97t, 1097f
- Lower motor neurons, 1509
- Lower respiratory disorders:
 - Chapter Highlights, 1317-18t, 1372-73t
 - hemothorax. *See* Hemothorax
 - infections and inflammatory disorders
 - acute bronchitis. *See* Acute bronchitis
 - fungal infections
 - aspergillosis, 1294
 - blastomycosis, 1294
 - coccidiomycosis, 1294
 - geographic distribution, 1294
 - histoplasmosis, 1294
 - interdisciplinary care, 1294-95
 - nursing care, 1295
 - pathophysiology, 1294
 - inhalation anthrax, 128t, 1293-94
 - lung abscess. *See* Lung abscess
 - in older adults, 315t
 - pleural effusion. *See* Pleural effusion
 - pleuritis, 1269, 1295
 - pneumonia. *See* Pneumonia
 - severe acute respiratory syndrome. *See* Severe acute respiratory syndrome
 - tuberculosis. *See* Tuberculosis
- inhalation injury. *See* Inhalation injury
- interstitial pulmonary disorders
 - occupational lung diseases. *See* Occupational lung diseases
 - sarcoidosis, 1346-47
- lung cancer. *See* Lung cancer
- pneumothorax. *See* Pneumothorax
- pulmonary vascular disorders
 - pulmonary embolism. *See* Pulmonary embolism
 - pulmonary hypertension. *See* Pulmonary hypertension
- reactive airway disorders
 - asthma. *See* Asthma
 - atelectasis. *See* Atelectasis
 - bronchiectasis. *See* Bronchiectasis
 - chronic obstructive pulmonary disease. *See* Chronic obstructive pulmonary disease
 - cystic fibrosis. *See* Cystic fibrosis
 - respiratory failure
 - acute respiratory distress syndrome. *See* Acute respiratory distress syndrome
 - acute respiratory failure. *See* Acute respiratory failure
 - surgical risk and nursing implications, 57t
 - thoracic trauma. *See* Thoracic trauma
- Low-molecular-weight (LMW) heparins, 1188, 1189t
- Low-output failure, 1027
- Lozol. *See* Indapamide
- LTK (laser thermokeratoplasty), 1697
- Lubath, 441t
- Lubricant laxative, 760t
- Lubriderm, 441t
- Lugol's solution. *See* Strong iodine solution
- Lumbar puncture:
 - client and family teaching, 1515t
 - client preparation, 1515t
 - in pneumonia, 1566
 - purpose and description, 1515t
 - related nursing care, 1515-16t
 - in stroke, 1584
- Lumbar spine:
 - disk herniation, 1608. *See also* Herniated intervertebral disk
 - physical assessment, 1392t, 1393f
- Lumigan. *See* Bimatoprost
- Lumpectomy, 1825, 1826f
- Lund and Browder burn assessment method, 491, 492f
- Lung:
 - anatomy, physiology, and functions, 1211-12, 1212f
 - disorders. *See* Lower respiratory disorders
 - physical assessment, 1224-26t, 1224f, 1225f
 - transplantation. *See* Lung transplant
 - trauma. *See* Thoracic trauma
- Lung abscess:
 - definition, 1280
 - interdisciplinary care, 1280
 - manifestations, 1280
 - nursing care, 1280
 - pathophysiology, 1280
 - in pneumonia, 1269
- Lung biopsy, 1219t, 1312
- Lung cancer:
 - Case Study, 418t
 - complications, 1311
 - course, 1311
 - genetic considerations, 1220t
 - incidence, 1308
 - interdisciplinary care
 - complementary therapies, 1313
 - diagnosis, 1311-12
 - medications, 1312
 - radiation therapy, 1312-13
 - staging, 1311, 1311t
 - surgery, 1312, 1312t
 - manifestations, 1309, 1311
 - mortality rate, 1308
 - Multisystem Effects, 1310t
 - nursing care
 - assessment, 1313-14
 - of client having lung surgery, 1313t
 - of client having radiation therapy, 1314t
 - community-based care, 1316-17
 - health promotion, 1313
 - nursing diagnoses and interventions
 - activity intolerance, 1315-16
 - anticipatory grieving, 1316
 - ineffective breathing pattern, 1314-15
 - pain, 1316
 - using NANDA, NIC, and NOC, 1316, 1317t
- Nursing Care Plan
 - assessment, 1315t
 - critical thinking in the nursing process, 1315t
 - diagnoses, 1315t
 - evaluation, 1315t
 - expected outcomes, 1315t
 - planning and implementation, 1315t
 - pathophysiology, 1308-9
 - risk factors, 1308
- Lung compliance, 1216
- Lung elasticity, 1216
- Lung reduction surgery, 1335
- Lung transplant:
 - in chronic obstructive pulmonary disease, 1335
 - in cystic fibrosis, 1342
 - indications, 342t
 - nursing considerations, 1336t
 - success rate, 342t
- Lupron. *See* Leuprolide
- Lupus erythematosus (LE) cell test, 341
- Lupus nephritis, 889. *See also* Glomerular disorders

- Luteinizing hormone (LH):
 functions, 520, 1753
 in ovarian cycle, 1754, 1754f
- Luteinizing hormone-releasing hormone agonist, 1787t
- Lyme disease:
 cause, 1476
 complications, 1477
 incidence, 1476
 interdisciplinary care, 1477
 manifestations, 1477
 nursing care, 1477
 pathophysiology, 1476–77
- Lymph, 1086, 1199
- Lymph nodes:
 assessment by palpation, 305f, 1098t, 1749t, 1762f, 1762t
 biopsy, 1088t, 1131–32
 functions, 291
 locations, 291, 291f, 1086f
- Lymphadenitis, 1098t
- Lymphadenopathy:
 causes, 1098t
 definition, 1098t
 in Hodgkin's lymphoma, 1130, 1131t
 in non-Hodgkin's lymphoma, 1131, 1131f, 1131t
 pathophysiology, 1199
 treatment, 1199
- Lymphangiography, 1088t, 1200
- Lymphangitis, 1093t, 1199
- Lymphatic system:
 anatomy, physiology, and functions, 1085–86, 1086f. *See also* Lymph nodes
 assessment
 diagnostic tests, 1088, 1088t
 functional health pattern interview, 1090t
 genetic considerations, 1088
 health assessment interview, 1089, 1091
 physical assessment, 1091, 1098–99t, 1099f
 disorders
 lymphadenopathy. *See* Lymphadenopathy
 lymphedema. *See* Lymphedema
- Lymphedema:
 after axillary node dissection, 1825
 causes, 1093, 1199
 definition, 1093, 1825
 genetic considerations, 1199t
 interdisciplinary care
 diagnosis, 1200
 treatments, 1200
 manifestations, 1200
 nursing care
 community-based care, 1201
 nursing diagnoses and interventions
 disturbed body image, 1201
 excess fluid volume, 1201
 impaired tissue integrity, 1200–1201
 in ovarian cancer, 1818t
 pathophysiology, 1200
- Lymphedema praecox, 1199t
- Lymphedema tarda, 1199t
- Lymphoblasts, 1122, 1123t
- Lymphocytes:
 abnormal, possible causes, 307t, 387t
 development, 289f
 differentiation, 290f, 1077f
 functions, 289, 1079
 in leukemia, 1123t
 normal values, 307t, 387t, 1118t
 types, 290, 290f. *See also* B lymphocytes;
 Natural killer cells; T lymphocytes
- Lymphocytic leukemia, 1119. *See also* Leukemia
- Lymphocytopenia, 307t
- Lymphocytosis, 307t
- Lymphoid system, 291–92, 291f
- Lymphomas:
 in AIDS, 354, 359t, 1129
 characteristics, 1129
 definition, 1129
 genetic considerations, 1129t
 Hodgkin's disease. *See* Hodgkin's disease
 incidence, 1129
 interdisciplinary care
 chemotherapy, 1132
 complications of treatment, 1133
 diagnosis, 1131–32
 radiation therapy, 1132, 1132f
 staging, 1132
 stem cell transplant, 1132
 manifestations, 1130–31, 1131t
 non-Hodgkin's. *See* Non-Hodgkin's lymphoma
 nursing care
 assessment, 1133
 community-based care, 1135–36
 nursing diagnoses and interventions
 disturbed body image, 1135
 fatigue, 1133–34
 nausea, 1134–35
 risk for impaired skin integrity, 1135
 sexual dysfunction, 1135
 using NANDA, NIC, and NOC, 1135, 1136t
- Nursing Care Plan
 assessment, 1134t
 critical thinking in the nursing process, 1134t
 diagnoses, 1134t
 evaluation, 1134t
 expected outcomes, 1134t
 planning and implementation, 1134t
- Nursing Research: care of physical problems
 during treatment, 1126t
 pathophysiology, 1129–31
 risk factors, 1129
- Lymphoscintigraphy, 1200
- Lynch syndrome, 801–2. *See also* Colorectal cancer
- D-Lysergic acid diethylamide (LSD), 111, 113t
- ## M
- M protein, 1136
- Ma huang, 1274, 1326
- Maalox, 665, 666t
- MAC (midarm circumference), 621t, 622f, 622t
- MAC (*Mycobacterium avium* complex), 353, 353f, 359t
- Macrobid. *See* Nitrofurantoin
- Macrochantin. *See* Nitrofurantoin
- Macrodex. *See* Dextran 70
- Macrolides, 320t, 1271, 1271t
- Macrophages, 288, 288t, 289f
- Macula, 1680, 1681t
- Macular degeneration:
 incidence, 1713–14
 interdisciplinary care, 1714
 manifestations, 1714, 1714f
 nursing care, 1714
 Nursing Research: effect on older adults, 1715t
 pathophysiology, 1714
- Macule, 432t
- “Mad-cow disease,” 1658
- Mafenide acetate, 500, 501t
- Magnesium (Mg²⁺):
 balance, 233
 in body fluid compartments, 197t
 foods high in, 234t
 functions, 233
 imbalances. *See* Hypermagnesemia;
 Hypomagnesemia
- medications containing, 236t
 normal values, 198t
 recommended daily intake, 610t
- Magnesium citrate, 759t
- Magnesium hydroxide, 759t
- Magnesium salicylate, 178t
- Magnesium silicate, 465t
- Magnesium sulfate, 114t, 234, 235t
- Magnetic resonance angiography (MRA):
 brain and spinal cord, 1514t
 in peripheral vascular disease, 1177
 purpose and description, 1088t
 related nursing care, 1088t
- Magnetic resonance cholangiopancreatography (MRCP), 616t
- Magnetic resonance imaging (MRI):
 abdominal, 744t, 1173
 brain and spinal cord, 1514t
 in cancer, 384
 in deep venous thrombosis, 1188
 heart, 944t
 kidneys, 837t
 lymphatic system, 1088t
 musculoskeletal system, 1387t
 pituitary gland, 523t
 sinuses, 1236
 stomach, 615t
 thorax, 1218t
- Magnetic resonance spectroscopy (MRS), 1514t
- Magnetoencephalogram (MEG), 1512, 1515t
- Major burn injury, 491t. *See also* Burns
- Major histocompatibility complex (MHC), 329
- Major procedure, 54t
- Malabsorption:
 causes, 795, 795t
 definition, 795
 manifestations, 795–96, 796t
 syndromes
 lactase deficiency
 ethnic considerations, 798t
 interdisciplinary care, 798–99
 manifestations, 798
 nursing care, 799
 short bowel syndrome
 causes, 799
 interdisciplinary care, 799
 nursing care, 799–800
 pathophysiology, 799
 sprue. *See* Sprue
- Malathion, 451
- Maldigestion, 795, 795t
- Male reproductive system:
 age-related changes, 27t, 29t, 1749t
 anatomy, physiology, and functions
 breasts, 1744
 overview, 1744f
 penis, 1744
 scrotum, 1744
 sex hormones, 1745–46
 testes, 1744
- assessment
 diagnostic tests, 1746–47, 1746t
 functional health pattern interview, 1748t
 genetic considerations, 1747, 1747t
 health assessment interview, 1747
 physical assessment
 breasts and lymph nodes, 1749t
 external genitalia, 1749–50t, 1749f, 1750f
 overview, 1747–48
 prostate, 1750t
- disorders
 benign prostatic hyperplasia. *See* Benign prostatic hyperplasia

- Male reproductive system—*continued*
 benign scrotal mass
 nursing care, 1773
 pathophysiology, 1772–73
 breast cancer, 1790. *See also* Breast cancer
 cancer of the penis
 incidence, 1772
 interdisciplinary care, 1772
 nursing care, 1772
 pathophysiology, 1772
 Chapter Highlights, 1790–91*t*
 Clinical Scenarios, 1855*t*
 ejaculatory dysfunction, 1771
 epididymitis, 1773
 erectile dysfunction. *See* Erectile dysfunction
 gynecomastia, 1749*t*, 1789–90
 orchitis, 1774
 phimosis, 1749*t*, 1771
 priapism, 1771–72, 1772*t*
 prostatitis. *See* Prostatitis
 sexually transmitted infections. *See* Sexually transmitted infections
 testicular cancer. *See* Testicular cancer
 testicular torsion, 1774
- Malignant cells, 376–77, 377*t*. *See also* Cancer
- Malignant disease, 22*t*. *See also* Cancer
- Malignant hypertension. *See* Hypertensive emergencies
- Malignant hyperthermia, 61–62, 63*t*
- Malignant lymphoma. *See* Lymphomas
- Malignant melanoma:
 classification
 acral lentiginous, 467
 lentigo maligna, 466–67
 nodular, 467
 superficial spreading, 466, 467*f*
 incidence, 465
 interdisciplinary care
 ABCD rule, 467
 diagnosis, 467
 identification, 467
 microstaging, 467, 468*f*
 treatments
 immunotherapy, 468
 new modalities, 468
 radiation therapy, 468
 surgery, 468
 nursing care
 assessment, 470, 470*t*. *See also* Skin, assessment
 community-based care, 471
 health promotion, 468–69
 nursing diagnoses and interventions
 anxiety, 471
 hopelessness, 470–71
 impaired skin integrity, 470
 using NANDA, NIC, and NOC, 471, 471*t*
- Nursing Care Plan
 assessment, 469*t*
 critical thinking in the nursing process, 469*t*
 diagnoses, 469*t*
 evaluation, 469*t*
 expected outcomes, 469*t*
 planning and implementation, 469*t*
 pathophysiology, 466
 precursor lesions
 congenital nevi, 466
 dysplastic nevi, 466
 lentigo maligna, 466
 risk factors, 466, 466*t*
- Malignant pain, 174. *See also* Pain
- Malleus, 1682, 1682*f*
- Malnutrition:
 in cirrhosis, 715*t*
 conditions associated with, 641*t*
 definition, 641
 incidence and prevalence, 641
 interdisciplinary care
 diagnosis, 642, 644, 644*t*
 medications, 644, 645*t*
 nutrition
 enteral. *See* Enteral nutrition
 parenteral, 646, 647*f*, 648
 manifestations, 641, 642*t*
 Multisystem Effects, 643*t*
 nursing care
 assessment, 619*t*, 622–23*t*, 648
 community-based care, 650
 health promotion, 648
 Medication Administration, 645*t*
 nursing diagnoses and interventions
 imbalanced nutrition: less than body requirements, 648–49
 risk for deficient fluid volume, 649
 risk for impaired skin integrity, 650
 risk for infection, 649
 using NANDA, NIC, and NOC, 650, 650*t*
- Nursing Care Plan
 assessment, 649*t*
 critical thinking in the nursing process, 649*t*
 diagnoses, 649*t*
 evaluation, 649*t*
 expected outcomes, 649*t*
 planning and implementation, 649*t*
 in older adults, 641, 642*t*
 pathophysiology, 641
 risk factors, 641
 surgical risk and nursing implications, 57*t*
- MALT (mucosa-associated lymphoid tissue), 292
- Mammary duct ectasia, 1821*t*, 1822
- Mammary glands, 1751*t*
- Mammogram, 1755, 1756*t*, 1824*t*
- Manager, nurse as, 14–15
- Manganese, 610*t*
- Manifestations, definition, 22
- Manifestations of...:
 acute arterial occlusion, 1184*t*
 acute glomerulonephritis, 888*t*
 acute hepatitis, 706*t*
 acute myocardial infarction, 985*t*
 acute pyelonephritis, 848*t*
 Addison's disease, 554*t*
 Alzheimer's disease, 1620*t*
 amyotrophic lateral sclerosis, 1646*t*
 anaphylactic shock, 276*t*
 angina, 970*t*
 asthma, 1323*t*
 bacterial meningitis, 1564*t*
 Bell's palsy, 1658*t*
 bone tumors, 1483*t*
 brain tumors, 1569*t*
 breast cancer, 1823*t*
 cancer, 405*t*
 carbon monoxide poisoning, 496*t*
 cardiac tamponade, 1051*t*
 cardiogenic shock, 274*t*
 chronic venous insufficiency, 1194*t*
 cirrhosis, 715*t*
 compartment syndrome, 1403*t*
 concussion, 1558*t*
 Cushing's syndrome, 549*t*
 cystitis, 848*t*
 death, 94*t*
 deep venous thrombosis, 1187*t*
 diabetic ketoacidosis, 585*t*
 disseminated intravascular coagulation, 1147*t*
 dysmenorrhea, 1801*t*
 eating disorders, 651*t*
 endometriosis, 1811*t*
 esophageal cancer, 669*t*
 fracture, 1403*t*
 gastritis, 677*t*
 gastroenteritis, 773
 gastroesophageal reflux disease, 664*t*
 genital herpes, 1839*t*
 gout, 1444*t*
 herniated intervertebral disk, 1607*t*
 hiatal hernia, 668*t*
 HIV infection and AIDS, 351*t*
 Huntington's disease, 1643
 hydronephrosis, 857*t*
 hyperparathyroidism, 547*t*
 hypertensive emergencies, 1169*t*
 hypoglycemia, 587*t*
 hypovolemic shock, 274*t*
 impending death, 92*t*
 increased intracranial pressure, 1536*t*
 infective endocarditis, 1046*t*
 inflammation, 304*t*
 influenza, 1233*t*
 irritable bowel syndrome, 762*t*
 kyphosis, 1488*t*
 laryngeal cancer, 1253*t*
 liver cancer, 724*t*
 low back pain, 1490*t*
 metabolic acidosis, 244*t*
 metabolic alkalosis, 246*t*
 multiple sclerosis, 1627*t*
 musculoskeletal neoplasms, 1483*t*
 myasthenia gravis, 1648*t*
 nasal fracture, 1246*t*
 neurogenic shock, 276*t*
 nutrient deficiencies, 642*t*
 obstructive sleep apnea, 1251*t*
 oral cancer, 660*t*
 osteoarthritis, 1451*t*
 osteomalacia, 1448*t*
 osteomyelitis, 1479*t*
 Paget's disease, 1441*t*
 pancreatitis, 727*t*
 Parkinson's disease, 1636*t*
 perimenopausal period, 1796*t*
 peripheral vascular disease, 590*t*, 1177*t*
 peritonitis, 769*t*
 pertussis, 1242*t*
 pharyngitis, 1239*t*
 polycythemia, 1117*t*
 prostatitis and prostatodynia, 1777
 pulmonary edema, 1040*t*
 pulmonary embolism, 1348*t*
 pulmonary tuberculosis, 1283*t*
 renal tumors, 896
 retinal detachment, 1716*t*
 rheumatic fever, 1043*t*
 scoliosis, 1488*t*
 septic shock, 275*t*
 soft tissue sarcomas, 1483*t*
 spinal cord injury, 1598*t*
 spinal cord tumor, 1612*t*
 stroke, 1582*t*, 1583*t*
 syphilis, 1848*t*
 systemic lupus erythematosus, 1473*t*
 testicular cancer, 1775*t*
 tonsillitis, 1239*t*
 urinary calculi, 856*t*
 varicose veins, 1196*t*
 venous thrombosis, 1187*t*
- Man-made disasters, 126–27. *See also* Disasters

- Mannitol:
 Medication Administration, 905*t*, 1539*t*
 in specific conditions
 acute renal failure, 904, 905*t*
 increased intracranial pressure, 1538, 1539*t*
 Manometer, 206*t*
 Manometry, esophageal. *See* Esophageal manometry
 manometry
 Mantle cell lymphoma, 1130*t*. *See also* Lymphomas
 Mantoux test, 1286, 1286*f*, 1286*t*
 Manual traction, 1408
 MAP. *See* Mean arterial pressure
 Marfan syndrome:
 characteristics, 1389*t*
 genetic considerations, 950*t*, 1057*t*
 thoracic aortic aneurysm in, 1171, 1172*t*
 Marginal blepharitis, 1700
 Margination, 293, 293*f*
 Marijuana, 107, 111*t*
 Marinol. *See* Dronabinol
 Marshall-Marchetti-Krantz procedure, 1806
 Mass casualty incidents (MCIs). *See also* Disasters
 definition, 127
 educational competencies for registered nurses
 responding to, 126, 126*t*
 Mass Trauma Data Instrument, 135, 136*f*
 MAST (Michigan Alcohol Screening Test), 116, 116*f*
 Mast cell stabilizers, 1328*t*
 Mastectomy:
 exercises following, 1832*f*
 nursing care, 1826*t*
 procedure, 1825, 1826*f*
 reconstruction following, 1825–26, 1827*f*, 1827*t*
 Mastitis, 1821*t*
 Mастоectomy, 1724
 Mastoiditis:
 characteristics, 1723
 complications, 1723–24
 incidence, 1723
 interdisciplinary care, 1724
 manifestations, 1724
 nursing care, 1724
 pathophysiology, 1723
 Mavik. *See* Trandolapril
 Maxair. *See* Pirbuterol
 Maxalt. *See* Rizatriptan benzoate
 Maxillofacial trauma, 257
 Maxipime. *See* Cefepime
 McBurney's point, 766, 766*f*
 MCD (minimal change disease), 888. *See also* Glomerular disorders
 McGill pain questionnaire, 187*f*
 MCH (mean corpuscular hemoglobin), 1078*t*
 MCHC (mean corpuscular hemoglobin concentration), 1078*t*
 MCIs. *See* Mass casualty incidents
 McMurray's test, 1395*f*, 1395*t*
 MCV (mean corpuscular volume), 1078*t*
 MD. *See* Muscular dystrophy
 MDMA (Ecstasy), 111
 MDR-TB (multidrug-resistant tuberculosis), 313
 MDS. *See* Myelodysplastic syndrome
 Meals-on-Wheels, 38
 Mean arterial pressure (MAP):
 abnormal findings, 1560*t*
 definition, 269, 1030, 1085, 1154
 in heart failure, 1030
 in hypovolemic shock, 273*f*
 intra-arterial monitoring, 1030
 normal values, 1560*t*
 regulation, 1085
 Mean corpuscular hemoglobin (MCH), 1078*t*
 Mean corpuscular hemoglobin concentration (MCHC), 1078*t*
 Mean corpuscular volume (MCV), 1078*t*
 Measles, postexposure prophylaxis, 302*t*
 Measles-mumps-rubella (MMR) vaccine:
 contraindications, 21*t*
 indications, 21*t*, 300, 300*t*
 nursing implications, 300*t*
 Mebendazole, 779–80
 Mechanical debridement, 504
 Mechanical ventilation:
 complications
 barotrauma, 1360
 cardiovascular effects, 1360
 gastrointestinal effects, 1360
 nosocomial pneumonia, 1360
 indications, 1356
 modes of ventilators, 1358, 1359*t*
 Nursing Research: pain assessment in intubated clients, 1364*t*
 in specific conditions
 acute respiratory distress syndrome, 1367
 increased intracranial pressure, 1540
 terminal weaning, 1361
 types of ventilators, 1356–58, 1357*f*
 ventilator settings, 1358, 1360*t*
 weaning, 1360–61, 1360*f*
 Mechlorethamine, 392*t*
 Meclizine, 672, 673*t*, 1727
 Meclofenamate, 178*t*, 1464*t*
 Meclomen. *See* Meclofenamate
 Mediastinoscopy, 1312*t*
 Medicaid, 37
 Medical-surgical nursing:
 Chapter Highlights, 16*t*
 definition, 5
 nurse's roles
 advocate, 14
 caregiver, 12–13, 12*f*, 13*t*
 educator, 13, 14*f*
 leader and manager
 in case management, 14
 delegation, 14
 evaluation of outcomes of nursing care, 15
 in primary nursing, 14
 in team nursing, 14
 researcher, 15
 practice. *See* Nursing practice
 Medicare:
 coverage, 37
 home care reimbursement, 40, 40*t*
 Medication(s). *See also specific drugs*
 administration. *See* Medication Administration
 affected by decreased glomerular filtration rate, 883
 causing alopecia, 482*t*
 causing constipation, 758*t*
 causing drug-induced lupus, 1471
 causing gout, 1443
 causing hearing loss, 1730
 causing hypoglycemia, 586
 causing hypothyroidism, 541
 causing platelet dysfunction, 1142*t*
 causing urinary retention, 869
 causing urine color changes, 832*t*
 surgical risk and nursing implications, 58*t*, 59
 topical. *See* Topical medications
 toxicity in older adults, 30
 Medication Administration:
 acne medications, 459*t*
 adrenergic agonists (mydriatics), 1710*t*
 adrenergics, 278*t*, 1327*t*
 alpha-adrenergic blockers, 1161*t*
 angiotensin II receptor blockers (ARBs)
 for heart failure, 1033*t*
 for hypertension, 1161*t*
 angiotensin-converting enzyme (ACE) inhibitors
 for heart failure, 1033*t*
 for hypertension, 1161*t*
 antacids, 666*t*
 antibiotics, 319–21*t*
 anticholinergics
 for asthma, 1327–28*t*
 for neurogenic bladder, 871*t*
 for Parkinson's disease, 1638*t*
 antidiarrheal preparations, 756*t*
 antidysrhythmic drugs, 1006*t*
 antiemetics, 673*t*
 antiepileptic drugs, 1550*t*
 antifungal agents, 450*t*
 antihistamines
 for nausea and vomiting, 673*t*
 for upper respiratory infections, 1230*t*
 antihypertensives, 1161–62*t*
 antiprotozoal agents, 780*t*
 antispasmodics, 1600*t*
 antituberculosis drugs, 1288–89*t*
 antiviral agents
 antiretroviral nucleoside analogs, 357*t*
 for oral herpes simplex, 658*t*
 beta-blockers
 for angina, 973*t*
 for cardiac dysrhythmias, 1006*t*
 for hypertension, 1161–62*t*
 topical ophthalmic, 1710*t*
 bisphosphonates, 1442*t*
 blood transfusion, 264*t*
 calcitonin, 1437*t*
 calcium channel blockers
 for angina, 973–74*t*
 for cardiac dysrhythmias, 1006*t*
 for headache, 1545–46*t*
 for hypertension, 1162*t*
 calcium supplements, 230*t*, 1437*t*
 cannabinoids, 673*t*
 carbonic anhydrase inhibitors, 1710*t*
 cholesterol-lowering drugs, 967*t*
 cholinergic drugs
 for Alzheimer's disease, 1621*t*
 to stimulate micturition, 871*t*
 cholinesterase inhibitors, 1621*t*
 corticosteroids
 for Addison's disease, 555*t*
 for asthma, 1328*t*
 for multiple sclerosis, 1631*t*
 cortisol replacements, 555*t*
 decongestants, 1230*t*
 diuretics
 for acute renal failure, 905*t*
 for fluid volume excess, 210*t*
 for increased intracranial pressure, 1539*t*
 dopamine agonists, 1638*t*
 dopamine antagonists, 673*t*
 dopaminergics, 1637*t*
 ergot alkaloid derivatives, 1545*t*
 ergotamine, 1546*t*
 fluoride, 1437*t*
 folic acid, 1112*t*
 H₂-receptor blockers, 665*t*
 hypertension, 1161–62*t*
 immunomodulators, 1631*t*
 immunosuppressive agents
 for multiple sclerosis, 1631*t*
 overview, 345–46*t*
 insulin, 573*t*, 586*t*

- Medication(s)—*continued*
- intravenous fluids, 1539t
 - intravenous insulin, 586t
 - iron replacement, 1112t
 - laxatives and cathartics, 759–60t
 - leukotriene modifiers, 1328t
 - loop diuretics
 - for acute renal failure, 905t
 - for fluid volume excess, 210t
 - for increased intracranial pressure, 1539t
 - magnesium sulfate, 235t
 - mast cell stabilizers, 1328t
 - methylxanthines, 1327t
 - metoclopramide, 666t
 - monoamine oxidase inhibitors, 1638t
 - muscle relaxants, 1631t
 - narcotic analgesics (opiates/opioids), 182t
 - nonsteroidal anti-inflammatory drugs
 - for headache, 1546t
 - overview, 179t
 - oral hypoglycemic agents, 578t
 - osmotic diuretics
 - for acute renal failure, 905t
 - for increased intracranial pressure, 1539t
 - pancreatic enzyme replacement, 728t
 - prostaglandin analogs, 1710t
 - proton-pump inhibitors, 665t
 - serotonin receptor antagonists, 673t
 - serotonin selective agonists, 1545t
 - sodium channel blockers, 1006t
 - in specific conditions
 - acne, 459t
 - Addison's disease, 555t
 - Alzheimer's disease, 1621t
 - anemia, 1112t
 - angina, 973–74t
 - asthma, 1327–28t
 - burns, 501t
 - cardiac dysrhythmias, 1006t
 - cirrhosis, 717t
 - gastritis, 665–66t
 - gastroesophageal reflux disease, 665–66t
 - genital warts, 1842t
 - glaucoma, 1710t
 - gout, 1446t
 - headache, 1545–46t
 - heart failure, 1033t
 - hyperkalemia, 225t
 - hypersensitivity reactions, 673t
 - hypertension, 1161–62t
 - hyperthyroidism, 538t
 - hypokalemia, 221t
 - hypothyroidism, 544t
 - increased intracranial pressure, 1539t
 - inflammatory bowel disease, 787–88t
 - multiple sclerosis, 1631t
 - myasthenia gravis, 1649t
 - neurogenic bladder, 871t
 - obesity, 634t
 - oral herpes simplex, 658t
 - osteoporosis, 1437t
 - Paget's disease, 1442t
 - Parkinson's disease, 1637–38t
 - peptic ulcer disease, 665–66t
 - seizures, 1550t
 - shock, 278t
 - spastic bladder, 871t
 - spinal cord injury, 1600t
 - stomatitis, 658t
 - upper respiratory infections, 1230t
 - sucalfate, 666t
 - sympatholytics, 1162t
 - tamoxifen, 1825t
 - therapeutic baths, 441t
 - topical agents
 - antifungal, 658t
 - antimicrobial, 501t
 - local anesthetics, 658t
 - podophyllin, 1842t
 - trichloroacetic acid, 1842t
 - tricyclic antidepressants, 1545t
 - urinary anti-infectives and analgesics, 850t
 - vasodilators, 278t, 1162t
 - vitamin and mineral supplements, 645t
 - vitamin B₁₂, 1112t
- Meditation, 186
- Medrol. *See* Methylprednisolone
- Medulla oblongata, 1505f, 1506
- Medulloblastoma, 1570t. *See also* Brain tumors
- Meeting Individualized Needs:
- acute myocardial infarction in women and older adults, 984t
 - amputation, home care, 1427t
 - assessing intimate partner violence, 256t
 - breast cancer in older women, 1823t
 - burns in older adults, 508t
 - client being discharged from acute care to home care, 39t
 - client experiencing a loss, 98t
 - constipation in the older adult, 761t
 - dementing disorder in an older adult, family home care, 43t
 - diet following bariatric surgery, 638t
 - epilepsy in older adults, 1548t
 - fall prevention in older adults, 1418t
 - foot care teaching, 594t
 - nutrition for older adults, 642t
 - prostate surgery discharge instructions, 1783t
 - ruptured intervertebral disk, client teaching, 1611t
 - safety interventions in Alzheimer's disease, 1623t
 - sexuality function in the aging woman, 1794t
 - sexually transmitted infections, health promotion, 1838t
 - stroke risk factors in women, 1589t
 - substance abuse in older adults, 115t
 - trigeminal neuralgia, home care teaching, 1657t
- Mefenamic acid, 178t
- Mefoxin. *See* Cefoxitin
- MEG (magnetoencephalogram), 1512, 1515t
- Megestrol, 1787t
- Meglitinides, 578t
- Meglumine diatrizoate, 615t, 812–13
- Meiosis, 150
- Melanin, 423, 462
- Melanoma. *See* Malignant melanoma
- Melanosis coli, 758
- Melena, 674, 750t. *See also* Gastrointestinal bleeding
- Mellaril. *See* Thioridazine
- Melphalan, 1137
- Memantine, 1621
- Membranoproliferative glomerulonephritis, 888. *See also* Glomerular disorders
- Membranous glomerulonephropathy, 888. *See also* Glomerular disorders
- Mendelian inheritance. *See* Inheritance, Mendelian patterns
- Ménière's disease, 1726–27. *See also* Inner ear disorders
- Meninges, 1507, 1507f
- Meningioma, 1570t. *See also* Brain tumors
- Meningitis. *See also* Central nervous system infections
- bacterial
 - causes, 1564
 - complications, 1564t
 - manifestations, 1564, 1564t
 - definition, 1564
- interdisciplinary care
 - diagnosis, 1566
 - medications, 1566
- Nursing Care Plan
- assessment, 1567t
 - critical thinking in the nursing process, 1567t
 - diagnoses, 1567t
 - evaluation, 1567t
 - planning and implementation, 1567t
 - pathophysiology, 1564
 - tuberculous, 1583
 - viral, 1564–65
- Meningomyocele, 872
- Menopause:
- chemical, 1795
 - definition, 1795
 - hormone changes, 1753
 - interdisciplinary care
 - complementary and alternative therapies, 1796
 - diagnosis, 1796
 - medications, 1796
 - manifestations, 1796, 1796t
 - nursing care
 - assessment, 1797
 - health promotion, 1796–97
 - nursing diagnoses and interventions
 - deficient knowledge, 1797
 - disturbed body image, 1798
 - ineffective sexuality pattern, 1797
 - situational low self-esteem, 1797–98
 - physiology, 1795–96
 - premature, coronary heart disease risk and, 964
 - sexuality function in, 1794t
 - surgical, 1795
 - uterine bleeding in. *See* Dysfunctional uterine bleeding
- Menorrhagia, 1802. *See also* Dysfunctional uterine bleeding
- Menstrual cycle, 1754–55, 1754f
- Menstrual disorders:
- dysfunctional uterine bleeding. *See* Dysfunctional uterine bleeding
 - dysmenorrhea. *See* Dysmenorrhea
 - premenstrual syndrome. *See* Premenstrual syndrome
- Menstruation, 1753
- Mental status assessment, 1518–19t
- Mentax. *See* Butenafine
- Meperidine HCl, 113t, 177, 180t
- Meprobamate, 108
- Mercaptopurine, 786
- Meridia. *See* Sibutramine
- Meropenem, 319t
- Mesalamine, 786, 787t, 788
- Mestinon. *See* Pyridostigmine
- Metabolic acidosis:
- arterial blood gases in, 240t
 - causes, 242t
 - compensation, 243t
 - definition, 240, 241f
 - interdisciplinary care
 - diagnosis, 244
 - medications, 244
 - laboratory values, 242t
 - manifestations, 244, 244t
 - nursing care
 - assessment, 244–45
 - community-based care, 245
 - health promotion, 244
 - nursing diagnoses and interventions
 - decreased cardiac output, 245
 - risk for excess fluid volume, 245
 - risk for injury, 245

- pathophysiology, 242–44
risk factors, 242
- Metabolic alkalosis:
arterial blood gases in, 240*t*
causes, 242*t*
compensation, 243*t*
complications, 246
definition, 240, 241*f*
interdisciplinary care
 diagnosis, 246
 medications, 246
laboratory values, 242*t*, 245
manifestations, 246, 246*t*
nursing care
 assessment, 246–47
 community-based care, 247
 health promotion, 246
 nursing diagnoses and interventions
 deficient fluid volume, 247
 risk for impaired gas exchange, 247
pathophysiology, 246
risk factors, 246
- Metabolic syndrome:
atherosclerosis risk and, 632
characteristics, 632, 964
coronary heart disease risk and, 632, 964
diabetes risk and, 567
- Metabolism, 613
- Metamucil. *See* Psyllium hydrophilic mucilloid
- Metaplasia, 373
- Metaprel. *See* Metaproterenol
- Metaproterenol, 1327*t*
- Metaraminol, 278*t*
- Metastasis. *See also* Cancer
definition, 376
mechanisms, 378–79, 378*f*
sites, 378*t*
- Metered-dose inhaler, 1324, 1325*t*
- Metformin, 578*t*
- Methadone:
characteristics and uses, 110
equianalgesic drug chart, 180*t*
nursing considerations, 180*t*
overdose signs and treatment, 113*t*
for substance abuse treatment, 114*t*
withdrawal signs and treatment, 113*t*
- Methamphetamine, 109, 109*f*, 110. *See also* Amphetamines
- Methicillin, 319*t*
- Methicillin-resistant *S. aureus* (MRSA), 313–14
- Methimazole, 538*t*
- Methocarbamol, 832*t*, 1491
- Methotrexate:
adverse/side effects, 392*t*
Medication Administration, 345*t*
nursing implications, 392*t*
in specific conditions
 autoimmune disorders, 341
 bone tumors, 1483*t*
 laryngeal cancer, 1254
 rheumatoid arthritis, 1466
target malignancies, 392*t*
- Methoxsalen, 445
- Methyl methacrylate, 1452
- Methylaminobenzene, 372*t*
- Methylcellulose, 633, 759*t*
- Methyldopa, 457, 1162*t*
- Methylphenidate, 189
- Methylprednisolone:
Medication Administration, 555*t*, 787–88*t*, 1631*t*
in specific conditions
 Addison's disease, 555*t*
 inflammatory bowel disease, 787–88*t*
 multiple sclerosis, 1631*t*
 nausea and vomiting, 672
 organ transplantation, 344, 921
 spinal cord injury, 1599
- Methylxanthines, 1327*t*, 1355
- Methysergide maleate, 1544, 1545*t*
- Meticorten. *See* Prednisone
- Metipranolol, 1710*t*
- Metoclopramide:
Medication Administration, 666*t*, 673*t*
preoperative use and nursing implications, 62*t*
in specific conditions
 gastroesophageal reflux disease, 665, 666*t*
 nausea and vomiting, 672, 673*t*
- Metolazone, 210*t*
- Metoprolol:
Medication Administration, 973*t*, 1006*t*, 1161*t*
in specific conditions
 acute myocardial infarction, 988
 angina, 973*t*
 aortic aneurysm, 1173
 cardiac dysrhythmias, 1006*t*
 hypertension, 1161*t*
- Metronidazole:
Medication Administration, 321*t*, 780*t*
in specific conditions
 amebic liver abscess, 725
 diverticulitis, 816
 peritonitis, 770
 pneumonia, 1271*t*
 protozoal bowel infections, 778*t*, 779, 780*t*
 protozoal infections, 321
 trichomoniasis, 1843
- Metrorrhagia, 1802. *See also* Dysfunctional uterine bleeding
- Metzol. *See* Metronidazole
- Mevacor. *See* Lovastatin
- Mexate. *See* Methotrexate
- Mexican Americans. *See* Hispanic Americans
- Mexiletine, 1006*t*
- Mexitil. *See* Mexiletine
- Mezlin. *See* Mezlocillin
- Mezlocillin, 319*t*
- Mg²⁺. *See* Magnesium
- MHC (major histocompatibility complex), 329
- Miacalcin. *See* Calcitonin
- Micardis. *See* Telmisartan
- Michigan Alcohol Screening Test (MAST), 116, 116*f*
- Miconazole, 450*t*
- Microalbuminuria, 588
- Microcytic RBCs, 1103
- Microdiskectomy, 1610
- Microglia, 289, 1628*t*
- Micro-K 10. *See* Potassium chloride
- Micronase. *See* Glyburide
- Microstaging, malignant melanoma, 467, 468*f*
- Microvilli, 612, 742
- Micturition, 834–35, 869. *See also* Urinary system
- Midamor. *See* Amiloride HCl
- Midarm circumference (MAC), 621*t*, 622*f*, 622*t*
- Midarm muscle circumference (MMAC), 622*t*
- Midazolam, 62*t*, 500, 1355
- Midbrain, 1505*f*, 1506
- Middle adults (ages 40 to 65):
family-related risk factors for alterations in health, 32*t*, 33
health needs
 assessment guidelines, 28
 promoting healthy behaviors, 28, 28*t*
risks for alterations in health
 cancer, 27
 cardiovascular disease, 26–27
 obesity, 26
 physical and psychosocial stressors, 27
 substance abuse, 27
physical changes, 27*t*
- Miglitol, 578*t*
- Migraine headache. *See also* Headache
characteristics, 1542*t*
classic, 1543
common, 1543
incidence, 1542
manifestations, 1542*t*
Nursing Care Plan
 assessment, 1547*t*
 critical thinking in the nursing process, 1547*t*
 diagnoses, 1547*t*
 evaluation, 1547*t*
 expected outcomes, 1547*t*
 planning and implementation, 1547*t*
risk factors, 1542*t*
triggers, 1543
- Miliary pneumonia, 1268*t*. *See also* Pneumonia
- Miliary tuberculosis, 1283
- Milk of Magnesia. *See* Magnesium hydroxide
- Milk thistle, 709
- Milliequivalent, 196
- Milrinone, 1034*t*
- Milroy's disease, 1093*t*
- Mind–body therapies:
for cancer, 399*t*
for hypertension, 1163, 1164*t*
for nausea, 672
- Mineral oil, 441*t*, 760*t*
- Mineralocorticoids, 519*t*
- Minerals:
functions, 608
recommended daily intake, 610*t*
sources, 608
supplements, 645*t*
- Minimal change disease (MCD), 888. *See also* Glomerular disorders
- Minimally invasive coronary artery surgery, 979
- Minipress. *See* Prazosin
- Minocin. *See* Minocycline HCl
- Minocycline HCl, 320*t*
- Minor burn injury, 491*t*. *See also* Burns
- Minor procedure, 54*t*
- Minor trauma, 256
- Minoxidil, 482, 1162*t*
- Mint oil aromatherapy, 679
- Minute volume (MV), 1214*t*
- Mirapex. *See* Pramipexole
- Misoprostol, 685
- Mithracin. *See* Pllicamycin
- Mithramycin, 232
- Mitigation, disaster, 132–33
- Mitochondria, 151
- Mitochondrial DNA (mtDNA), 151
- Mitosis, 149
- Mitotane, 550
- Mitotic inhibitors, 391. *See also* Chemotherapy
- Mitral regurgitation. *See also* Valvular heart disease
manifestations, 1056
murmur characteristics, 1055*t*
pathophysiology, 1056, 1056*f*
- Mitral stenosis. *See also* Valvular heart disease
complications, 1055–56
manifestations, 1055
murmur characteristics, 1055*t*
pathophysiology, 1055, 1056*f*
- Mitral valve, 937*f*, 938, 1054
- Mitral valve prolapse. *See also* Valvular heart disease
complications, 1057
manifestations, 1057

- Mitral valve prolapse—*continued*
 Nursing Care Plan
 assessment, 1064t
 critical thinking in the nursing process, 1064t
 diagnoses, 1064t
 evaluation, 1064t
 expected outcomes, 1064t
 planning and implementation, 1064t
 pathophysiology, 1056–57, 1057f
 in polycystic kidney disease, 884
- Mittelschmerz, 1802
- Mixed aphasia, 1583
- Mixed incontinence, 873. *See also* Urinary incontinence
- Mixed lymphocyte culture (MLC) assay tests, 343
- MMAC (midarm muscle circumference), 622t
- M-mode echocardiogram, 945t. *See also* Echocardiography
- MMR vaccine. *See* Measles-mumps-rubella (MMR) vaccine
- Mobitz type I AV block, 999t, 1003
- Mobitz type II AV block, 999t, 1003
- Modafinil, 189
- Moderate burn injury, 491t. *See also* Burns
- Modified radical mastectomy, 1825, 1826f. *See also* Mastectomy
- MODS (multiple organ dysfunction syndrome), 259
- Moexipril, 1033t, 1161t
- Mohs surgery, 464
- Moles. *See* Nevi
- Molybdenum, 610t
- Monistat. *See* Miconazole
- Monoamine oxidase inhibitors (MAOIs), 58t, 1638t
- Monoclonal antibodies. *See also specific drugs*
 development, 317t, 344
 Medication Administration, 345–46t
 in organ transplantation, 344
 site of action, 344f
- Monocytes:
 abnormal, possible causes, 307t, 387t
 characteristics, 288–89
 development, 289f
 functions, 288–89, 288t, 1079
 in leukemia, 1123t
 location, 288t
 normal values, 307t, 387t, 1118t
- Monocytopenia, 307t
- Monocytosis, 307t
- Monogenic disorders, 152
- Mono-Gesic. *See* Salsalate
- Mononeuropathies, in diabetes mellitus, 589
- Mononucleosis, infectious, 1139
- Monopril. *See* Fosinopril
- Monosomy, 150, 150t
- Monro-Kellie hypothesis, 1535
- Mons pubis, 1751, 1751t, 1752f
- Mons veneris. *See* Mons pubis
- Montelukast, 1328t
- Mood disorders, in diabetes mellitus, 589
- Moral development theory (Kohlberg), 25t
- Morbid grief reaction, 86
- Morbid obesity, 632
- Moricizine, 1006t
- Morphine sulfate:
 in end-of-life care, 92t, 93t
 equianalgesic drug chart, 180t
 for long-term analgesia at home, 190t
 Medication Administration, 182t
 nursing considerations, 180t
 overdose signs and treatment, 113t
 preoperative use and nursing implications, 62t
 in specific conditions
 acute myocardial infarction, 987
 burns, 500
 pulmonary edema, 1040–41
 street names, 111t
 withdrawal signs and treatment, 113t
- Morton's neuroma, 1492–93, 1493f
- Mother cell, 150
- Motofen. *See* Difenoxin
- Motor function, assessment, 530t, 1522t
- Motor speech area, 1506t
- Motrin. *See* Ibuprofen
- Mourning, 85, 88, 89t
- Mouth:
 anatomy, physiology, and functions, 610, 611f
 disorders
 cancer. *See* Oral cancer
 stomatitis. *See* Stomatitis
 physical assessment, 622–23t
- Mouthwashes, for oropharyngeal pain control, 409t
- 6-MP. *See* Mercaptopurine
- MRA. *See* Magnetic resonance angiography
- MRCP (magnetic resonance cholangiopancreatography), 616t
- MRI. *See* Magnetic resonance imaging
- MRS (magnetic resonance spectroscopy), 1514t
- MRSA (methicillin-resistant *S. aureus*), 313–14
- MS. *See* Multiple sclerosis
- mtDNA (mitochondrial DNA), 151
- Mucomyst. *See* Acetylcysteine
- Mucosa-associated lymphoid tissue (MALT), 292
- Multidrug-resistant tuberculosis (MDR-TB), 313
- Multifactorial conditions, 155–56
- Multiple casualty incidents, 127
- Multiple endocrine neoplasia, 527t
- Multiple myeloma:
 definition, 1136
 incidence, 1136
 interdisciplinary care
 diagnosis and staging, 1137
 treatment, 1137
 manifestations, 1136
 nursing care
 assessment, 1137
 community-based care, 1138
 nursing diagnoses and interventions
 chronic pain, 1137–38
 impaired physical mobility, 1138
 risk for injury, 1138
 pathophysiology, 1136, 1137f
 risk factors, 1136
- Multiple organ dysfunction syndrome (MODS), 259
- Multiple sclerosis (MS):
 characteristics, 1626
 classification, 1626
 genetic considerations, 1513t
 incidence and prevalence, 1626
 interdisciplinary care
 diagnosis, 1627
 medications, 1627, 1631t
 nutrition and fluids, 1632
 rehabilitation, 1632
 surgery, 1632
 manifestations, 1626–27, 1627t
- Multisystem Effects, 1630t
- nursing care
 assessment, 1632
 community-based care, 1634–35
 health promotion, 1632
 Medication Administration, 1631t
 nursing diagnoses and interventions
 fatigue, 1632–33
 self-care deficit, 1633–34
 using NANDA, NIC, and NOC, 1634, 1634t
- Nursing Care Plan
 assessment, 1633t
 critical thinking in the nursing process, 1633t
 diagnoses, 1633t
 evaluation, 1633t
 expected outcomes, 1633t
 planning and implementation, 1633t
- Nursing Research: care of aging clients, 1634t
- pathophysiology, 1626, 1628–29t
- Multiple trauma, 256
- Multisystem Effects:
 anemia, 1104t
 cirrhosis, 714t
 diabetes mellitus, 583t
 fluid volume deficit, 204t
 heart failure, 1028t
 hyperthyroidism, 535t
 hypokalemia, 219t
 hypothyroidism, 542t
 inflammatory bowel disease, 783t
 leukemia, 1120t
 lung cancer, 1310t
 malnutrition, 643t
 multiple sclerosis, 1630t
 premenstrual syndrome, 1799t
 rheumatoid arthritis, 1462t
 shock, 273t
 systemic lupus erythematosus, 1472t
 uremia (chronic renal failure), 917t
- Mumps vaccine. *See* Measles-mumps-rubella vaccine
- Murmurs. *See also* Valvular heart disease
 in aortic regurgitation, 1055t, 1059
 in aortic stenosis, 1055t, 1058
 assessment, 955t
 definition, 1054
 in mitral regurgitation, 1055t, 1056
 in mitral stenosis, 1055, 1055t
 in mitral valve prolapse, 1057
 in pulmonic regurgitation, 1059
 in pulmonic stenosis, 1059
 in tricuspid regurgitation, 1055t, 1059
 in tricuspid stenosis, 1055t, 1059
- Muromonab-CD3:
 adverse/side effects, 921
 Medication Administration, 345–46t
 in organ transplantation, 344, 921
- Murphy's sign, 627f, 627t
- Muscle(s). *See also* Musculoskeletal system
 anterior body, 1384f
 contusion, strain, or sprain
 interdisciplinary care, 1399–1400, 1400t
 manifestations, 1399
 nursing care, 1400
 pathophysiology, 1399
 function assessment. *See* Motor function
 functional properties, 1383
 posterior body, 1384f
 range of motion assessment, 1391f, 1391t, 1392–94t, 1392f, 1393f
 strength assessment, 1391t
 structure, 1381
 types, 1381, 1383t
- Muscle relaxants, 1491, 1631t
- Muscle wasting, in cirrhosis, 715t
- Muscular dystrophy (MD):
 definition, 1458
 genetic considerations, 1389t, 1458
 interdisciplinary care, 1458
 manifestations, 1458
 nursing care, 1459
 pathophysiology, 1458
 types, 1459t

- Musculoskeletal system:
 age-related changes
 in middle adults, 27t
 in older adults, 29t, 1389t
 in young adults, 26t
 anatomy, physiology, and functions
 joints. *See* Joint(s)
 ligaments, 1386
 skeleton
 bones. *See* Bone(s)
 muscles. *See* Muscle(s)
 overview, 1380, 1381f
 tendons, 1386
 assessment
 abnormal findings, 530t
 diagnostic tests, 1386, 1387-88t, 1388
 functional health pattern interview, 1390t
 genetic considerations, 1388, 1389t
 health assessment interview, 1388-89
 physical assessment
 ballottement, 1395f, 1395t
 bulge sign, 1395f, 1395t
 gait and body posture, 1391t
 joints, 1392t
 McMurray's test, 1396f, 1396t
 muscle strength, 1391t
 overview, 1389-91
 Phalen's test, 1395f, 1395t
 range of motion, 1391f, 1391t, 1392-94t, 1392f, 1393f
 Thomas test, 1396f, 1396t
 sample documentation, 1386
 autoimmune and inflammatory disorders
 ankylosing spondylitis. *See* Ankylosing spondylitis
 Lyme disease, 1476-77
 polymyositis, 1476
 rheumatoid arthritis. *See* Rheumatoid arthritis
 Chapter Highlights, 1429-30t, 1494t
 Clinical Scenarios, 1498t
 connective tissue disorders
 fibromyalgia. *See* Fibromyalgia
 scleroderma. *See* Scleroderma
 Sjögren's syndrome, 1486
 degenerative disorders
 muscular dystrophy. *See* Muscular dystrophy
 osteoarthritis. *See* Osteoarthritis
 infectious disorders
 osteomyelitis. *See* Osteomyelitis
 septic arthritis, 1481
 metabolic bone disorders
 gout. *See* Gout
 osteomalacia. *See* Osteomalacia
 osteoporosis. *See* Osteoporosis
 Paget's disease. *See* Paget's disease
 neoplastic disorders. *See* Bone tumors
 structural disorders
 foot deformities. *See* Feet, deformities
 kyphosis. *See* Kyphosis
 low back pain. *See* Low back pain
 scoliosis. *See* Scoliosis
 trauma
 amputation. *See* Amputation
 contusion, strain, or sprain
 interdisciplinary care, 1399-1400, 1400t
 manifestations, 1399
 nursing care, 1400
 pathophysiology, 1399
 dislocation
 causes, 1400-1401
 definition, 1400
 interdisciplinary care, 1401
 manifestations, 1401
 nursing care, 1401
 pathophysiology, 1401
 fractures. *See* Fractures
 repetitive use injury. *See* Repetitive use injury
 Music therapy, 672
 Musset's sign, 1059
 Mustargen. *See* Mechlorethamine
 Mutations, 152, 155
 MV (minute volume), 1214t
 Myambutol. *See* Ethambutol
 Myasthenia gravis:
 characteristics, 1647
 complications, 1648, 1648t
 interdisciplinary care
 diagnosis, 1649
 medications, 1649, 1649t
 plasmapheresis, 1650, 1650t, 1651f
 surgery, 1649-50, 1650t
 manifestations, 1648, 1648f, 1648t
 nursing care
 client and family teaching, 1651t
 of client having a thymectomy, 1650t
 of client undergoing plasmapheresis, 1650t
 community-based care, 1651-52
 Medication Administration, 1649t
 nursing diagnoses and interventions
 impaired swallowing, 1651
 ineffective airway clearance, 1651
 Nursing Care Plan
 assessment, 1652t
 critical thinking in the nursing process, 1652t
 diagnoses, 1652t
 evaluation, 1652t
 expected outcomes, 1652t
 planning and implementation, 1652t
 pathophysiology, 1647-48, 1647f
 Myasthenic crisis, 1648
 Mycelex. *See* Clotrimazole
Mycobacterium avium complex (MAC), 353, 353f, 359t
Mycobacterium tuberculosis, 1280. *See also* Tuberculosis
 Mycophenolate mofetil, 344, 345t, 921
 Mycoplasma, 311t
Mycoplasma pneumoniae, 1269, 1271t
 Mycoses. *See* Skin infections/infestations, fungal
 Mycosis fungoides, 1130t. *See also* Lymphomas
 Mycostatin. *See* Nystatin
 Mycotic aneurysm, 1592
 Myelin sheath, 1504, 1504f
 Myelodysplastic syndrome (MDS):
 interdisciplinary care
 diagnosis, 1115
 treatment, 1115-16
 manifestations, 1115
 nursing diagnoses and interventions
 activity intolerance, 1116
 community-based care, 1117
 risk for ineffective health maintenance, 1116
 pathophysiology, 1115
 risk factors, 1115
 Myelogram, 1512, 1516t
 Myeloid leukemia, 1119. *See also* Leukemia
 Mydil. *See* Triprolidine
 Mylanta, 665, 666t
 Myleran. *See* Busulfan
 Myocardial biopsy, 1067
 Myocardial infarction. *See* Acute myocardial infarction
 Myocardial ischemia:
 factors contributing to, 962t
 pathophysiology, 959, 962
 silent, 970
 Myocardial perfusion imaging, 966
 Myocardial remodeling, 984
 Myocardial steal syndrome, 971
 Myocarditis:
 definition, 1048
 interdisciplinary care, 1048
 manifestations, 1048
 nursing care, 1048
 pathophysiology, 1048
 risk factors, 1048
 Myocardium, 937, 937f
 Myochrysin. *See* Gold sodium thiomalate
 Myofascial pain syndrome, 174
 Myoglobin, 986
 Myomectomy, 1810
 Myopia, 1677t, 1696
 Myotonia, 1794
 Myotonic dystrophy:
 disease progression, 1459t
 genetic considerations, 155, 1389t
 interdisciplinary care, 1458
 manifestations, 1459t
 nursing care, 1459
 Myringotomy, 1722, 1723
 Mysoline. *See* Primidone
 Mytelase. *See* Ambenonium
 Myxedema, 541
 Myxedema coma, 543t
- N**
- N⁺. *See* Sodium
 Nabilone, 672, 673t
 Nabumetone, 178t, 1464t
 Nadolol:
 Medication Administration, 973t, 1161t, 1545t
 in specific conditions
 angina, 973t
 cirrhosis, 716
 headache, 1545t
 hypertension, 1161t
 Naegleria, 1565t
 Nafcillin, 319t, 1046, 1271t
 NAHC. *See* National Association of Home Care
 Nails. *See also* Integumentary system
 age-related changes, 29t
 anatomy, physiology, and functions, 425-26, 425f
 assessment, 436f, 436t, 529t
 candidiasis, 449t
 clubbing, 436f, 436t
 disorders
 interdisciplinary care, 483
 nursing care, 483
 pathophysiology, 483
 spoon-shaped, 436f, 436t
 Nalbuphine HCl, 180t, 182t
 Nalfon. *See* Fenoprofen calcium
 Naltrexone, 112, 114t
 Namenda. *See* Memantine
 NANDA, NIC, and NOC Linkages:
 acute brain injury, 1562t
 acute myocardial infarction, 994t
 acute renal failure, 913t
 acute respiratory distress syndrome, 1371t
 acute respiratory failure, 1365t
 Alzheimer's disease, 1625t
 amputation, 1426t
 anemia, 1115t
 appendicitis, 769t
 brain tumor, 1575t
 breast cancer, 1831t
 cancer, 411t
 cervical cancer, 1815t
 chronic obstructive pulmonary disease, 1340t
 chronic pain, 190t

NANDA, NIC, and NOC Linkages—*continued*

- cirrhosis, 723*t*
 colorectal cancer, 809*t*
 compound fracture, 1420*t*
 Cushing's syndrome, 553*t*
 death anxiety, 97*t*
 deep venous thrombosis, 1193*t*
 diabetes mellitus, 596*t*
 diarrhea, 757*t*
 endometriosis, 1812*t*
 eye infection or inflammation, 1696*t*
 fluid volume deficit, 209*t*
 gastroesophageal reflux disease, 667*t*
 glaucoma, 1713*t*
 hearing loss, 1733*t*
 heart failure, 1039*t*
 hemophilia, 1146
 hepatitis, 710*t*
 herpes zoster, 455*t*
 HIV infection, 365*t*
 hypertension, 1166*t*
 infections, 325*t*
 inflammatory bowel disease, 795*t*
 influenza, 1235*t*
 inner ear disorders, 1728*t*
 laryngeal cancer, 1262*t*
 leukemia, 1128*t*
 lung cancer, 1317*t*
 lymphoma, 1136*t*
 malignant melanoma, 471*t*
 malnutrition, 650*t*
 multiple sclerosis, 1634*t*
 nasal trauma, 1248*t*
 obesity, 640*t*
 osteoarthritis, 1457*t*
 osteoporosis, 1440*t*
 pancreatitis, 731*t*
 Parkinson's disease, 1642*t*
 peptic ulcer disease, 688*t*
 peripheral vascular disease, 1180*t*
 peritonitis, 769*t*
 pneumonia, 1276*t*
 postoperative client, 80*t*
 potassium imbalance, 223*t*
 prostate cancer surgery, 1789*t*
 pulmonary embolism, 1352*t*
 respiratory acidosis, 250*t*
 rheumatoid arthritis, 1469*t*
 seizures, 1553*t*
 shock, 283*t*
 spinal cord injury, 1606*t*
 stomatitis, 659*t*
 stroke, 1592*t*
 substance abuse problems, 120*t*, 121*t*
 trauma, 268*t*
 tuberculosis, 1293*t*
 urinary incontinence, 879*t*
- NANDA nursing diagnoses:
 activity-exercise patterns, 933*t*
 cognitive-perceptual patterns, 1501*t*
 elimination patterns, 739*t*
 health perception-health management patterns, 2*t*
 nutritional-metabolic patterns, 420*t*
 sexuality-reproductive patterns, 1501*t*
- Naphthylalkanone, 178*t*
 Naprosyn. *See* Naproxen
 Naproxen:
 factors in selecting, 178*t*
 Medication Administration, 179*t*
 in specific conditions
 gout, 1445
 osteoarthritis, 1451
 rheumatoid arthritis, 1464*t*
 venous thrombosis, 1188
- Naproxen sodium, 178*t*
 Naqua. *See* Trichlormethiazide
 Narcolepsy, 1513*t*
 Narcotic analgesics. *See also specific drugs*
 abuse
 by nurses, 121, 122*t*
 prevalence, 110, 110*f*
 in burns, 500
 myths and misconceptions, 177
 overdose signs and treatment, 113*t*
 for pain management
 in cancer, 399–400
 effects, 182*t*
 equianalgesic drug chart, 180*t*
 health education for client and family, 182*t*
 Medication Administration, 182*t*
 myths, 179
 nursing responsibilities, 182*t*
 oral vs. parenteral dosage, 64*t*
 postoperative, 64
 preoperative use and nursing implications, 62*t*
 in substance abuser, 181*t*
 street names, 111*t*
 withdrawal signs and treatment, 113*t*
- Nasal continuous positive airway pressure, 1251, 1251*f*
 Nasal endotracheal tube, 1357*t*. *See also*
 Endotracheal tube
 Nasal packing:
 nursing care, 1245*t*
 procedure, 1244, 1244*f*
 Nasal polyps:
 definition, 1252
 interdisciplinary care, 1252
 manifestations, 1252
 nursing care, 1252
 pathophysiology, 1252
 Nasal trauma:
 complications, 1246
 interdisciplinary care
 diagnosis, 1246
 surgery, 1246–47
 treatments, 1246
 manifestations, 1246, 1246*t*
 nursing care
 assessment, 1247
 community-based care, 1248–49
 health promotion, 1247
 nursing diagnoses and interventions
 ineffective airway clearance, 1247–48
 risk for infection, 1248
 using NANDA, NIC, and NOC, 1248, 1248*t*
- Nursing Care Plan
 assessment, 1247*t*
 critical thinking in the nursing process, 1247*t*
 diagnoses, 1247*t*
 evaluation, 1247*t*
 expected outcomes, 1247*t*
 planning and implementation, 1247*t*
 pathophysiology, 1246
 NasalCrom. *See* Cromolyn sodium
 Nasogastric tube, 719, 719*f*. *See also* Enteral
 nutrition
 Nasopharynx, 1211
 Nateglidine, 578*t*
 National Academy of Sciences, core competencies
 for healthcare professionals, 5, 5*t*
 National Association of Home Care (NAHC):
 client's bill of rights, 41*t*
 definition of home care, 38
 Native Americans:
 cancer incidence and mortality rates, 370*t*
 cirrhosis incidence and mortality, 711
 diabetes mellitus risk and incidence, 564*t*
 end-of-life practices, 89
 gallstone incidence, 697*t*
 heart disease prevalence, 958*t*
 lactate deficiency incidence, 798*t*
 substance use, 105*t*
 Native Hawaiians, substance use, 105*t*
 Natriuretic hormone, 834
 Natural disasters, 126. *See also* Disasters
 Natural killer cells (NK cells, null cells):
 development, 290, 290*f*
 functions, 288*t*, 290
 location, 288*t*
 Naturetin. *See* Bendroflumethiazide
 Nausea, 671. *See also* Nausea and vomiting
 Nausea and vomiting:
 in dying client, 93
 interdisciplinary care
 complementary and alternative therapies, 672
 medications, 672, 673*t*
 nursing care
 community-based care, 674
 Medication Administration, 673*t*
 nursing diagnoses and interventions, 672
 pathophysiology, 671
 Near point of vision, 1673
 Near-drowning, 1305–6, 1306*f*. *See also* Inhalation
 injury
 Nebcin. *See* Tobramycin
 Necrotizing pancreatitis, 726. *See also* Pancreatitis
 Necrotizing ulcerative gingivitis, 657*t*. *See also*
 Stomatitis
 Nedocromil, 1326, 1328*t*
 Needle core biopsy, 388*t*
 Needle thoracostomy, 258, 258*f*
 Neglect syndrome, 1582
 Neisseria gonorrhoeae, 1238, 1773. *See also*
 Gonorrhoea
 Nelfinavir, 358
 Neo Tabs. *See* Neomycin sulfate
 Neomycin sulfate, 716, 717*t*
 Neoplasms:
 benign, 376, 376*t*
 classification, 382, 383*t*
 malignant, 376, 376*t*. *See also* Cancer
 Neoral. *See* Cyclosporine
 Neostigmine, 870, 1649*t*
 Neo-Synephrine. *See* Phenylephrine
 Neotame, 579
 Nephrectomy:
 definition, 896
 incisions for, 898*f*
 in kidney trauma, 896
 nursing care, 897
 for renal tumors, 896–97
 Nephrolithiasis, 855. *See also* Urinary calculi
 Nephrolithotomy, 859
 Nephrons, 830, 831*f*
 Nephropathy, diabetic, 588–89, 889. *See also*
 Glomerular disorders
 Nephrotic syndrome, 888. *See also* Glomerular
 disorders
 Nephrox. *See* Aluminum hydroxide
 Nerve blocks, 63, 183
 Nervous system. *See* Neurologic system
 Netilmicin, 320*t*
 Netromycin. *See* Netilmicin
 Neuralgias, 174
 Neurectomy, 184, 185*f*; 1727
 Neuro check, 1517*t*, 1518, 1518*t*
 Neurofibrillary tangles, 1618, 1619*f*
 Neurofibromatosis, 1684*t*
 Neurogenic bladder:
 flaccid, 870
 interdisciplinary care

- bladder retraining, 871
 catheterization, 872
 diagnosis, 870
 medications, 870–71
 nutrition, 871
 surgery, 872
- nursing care
 assessment, 872
 community-based care, 872
 nursing diagnoses and interventions, 872
- pathophysiology, 870
 spastic, 870
- Neurogenic shock:
 assessment, 279
 causes, 276
 definition, 275
 manifestations, 276, 276t
 pathophysiology, 275
- Neurologic system:
 age-related changes, 1518t
 anatomy, physiology, and functions
 action potentials, 1504–5
 blood–brain barrier, 1507
 brain
 brainstem, 1506, 1506t
 cerebellum, 1505f, 1506t
 cerebrum, 1505–6, 1505f, 1506f, 1506t
 diencephalon, 1506, 1506t
 ventricles, 1506
 cerebral circulation, 1507, 1508f
 cerebrospinal fluid
 formation, 1506–7
 functions, 1507
 normal values, 1507t
 limbic system, 1507
 meninges, 1507, 1507f
 neurons, 1504, 1504f
 neurotransmitters, 1505
 peripheral nervous system
 autonomic nervous system, 1511. *See also*
 Parasympathetic nervous system;
 Sympathetic nervous system
 cranial nerves, 1509, 1510f, 1511t
 reflexes, 1510–11, 1511f
 spinal nerves, 1508f, 1509, 1510f
 reticular formation, 1507
 spinal cord, 1508–9, 1508f, 1509f
- assessment
 diagnostic tests, 1512–13, 1514–16t
 functional health pattern interview, 1517t
 health assessment interview, 1513, 1516
 physical assessment
 abbreviated, 1518t
 Brudzinski's sign, 1524f, 1524t
 cerebellar function, 1522–23t
 cranial nerves, 1519–21t
 decerebrate posturing, 1525f, 1525t
 decorticate posturing, 1525f, 1525t
 Kernig's sign, 1524f, 1524t
 mental status, 1518–19t
 motor function, 1522t
 overview, 1516, 1518
 reflexes, 1523–24f, 1523–24t
 sensory function, 1521–22t, 1522f
 sample documentation, 1512
- disorders
 altered cerebral function
 altered level of consciousness. *See* Altered level of consciousness
 brain tumors. *See* Brain tumors
 epilepsy. *See* Epilepsy
 headache. *See* Headache
 increased intracranial pressure. *See* Increased intracranial pressure
 manifestations, 1528t
 traumatic brain injury. *See* Traumatic brain injury
- cerebrovascular
 arteriovenous malformation. *See* Arteriovenous malformation
 intracranial aneurysm. *See* Intracranial aneurysm
 stroke. *See* Stroke
- Chapter Highlights, 1614t, 1663t
 Clinical Scenarios, 1666t
- degenerative
 Alzheimer's disease. *See* Alzheimer's disease
 amyotrophic lateral sclerosis. *See* Amyotrophic lateral sclerosis
 dementia. *See* Dementia
 Huntington's disease. *See* Huntington's disease
 multiple sclerosis. *See* Multiple sclerosis
 Parkinson's disease. *See* Parkinson's disease
- infections. *See* Central nervous system infections
- peripheral nerves
 Guillain-Barré syndrome. *See* Guillain-Barré syndrome
 myasthenia gravis. *See* Myasthenia gravis
- spinal cord
 herniated intervertebral disk. *See* Herniated intervertebral disk
 injury. *See* Spinal cord injury
 tumor. *See* Spinal cord tumors
- genetic considerations, 1513, 1513t
- Neuromatrix theory, of pain, 172
- Neuromuscular blockers, nondepolarizing, 1355, 1356t
- Neurons, 1628t
- Neurontin. *See* Gabapentin
- Neuropathies, peripheral, 589
- Neuro-specific enolase (NSE), 384t
- Neurotransmitters:
 functions, 1505
 in pain impulse, 172f
 in substance abuse, 104, 104f
 types, 1505
- Neutropenia:
 causes, 307t, 1138
 definition, 1138
 interdisciplinary care, 1139
 manifestations, 1138–38
 nursing care, 1139
 pathophysiology, 1138
- Neutrophilia, 307t
- Neutrophils:
 abnormal, possible causes, 307t, 387t
 development, 289f, 1077f
 functions, 288, 288t, 1079
 laboratory assessment, 316, 316t
 in leukemia, 1123t
 location, 288t
 normal values, 307t, 387t, 1118t
- Nevi:
 characteristics, 442–43, 442f
 congenital, 466
 dysplastic, 466
- Nevirapine, 358
- Nevus flammeus, 443
- New variant Creutzfeldt-Jakob disease, 1658
- Newborn screening, 156
- Nexium. *See* Esomeprazole
- Niacin. *See* Nicotinic acid
- Niaspan. *See* Nicotinic acid
- Nicardipine:
 Medication Administration, 973t, 1162t
 in specific conditions
 angina, 973–74t
 hypertension, 1162t
 hypertensive emergencies, 1169t
- Nicobid. *See* Nicotinic acid
- Nicolar. *See* Nicotinic acid
- Nicotinamide. *See* Vitamin B₃
- Nicotine, 106–7. *See also* Smoking
- Nicotinic acid, 967t, 968
- Nifedipine:
 Medication Administration, 973–74t, 1545–46t
 in specific conditions
 angina, 973–74t
 headache, 1545–46t
 pulmonary hypertension, 1353
 scleroderma, 1485
- Night sweats, 1796, 1796t
- Nikolsky's sign, 460
- Nilstat. *See* Nystatin
- Nimbex. *See* Cisatracurium
- Nimodipine, 973–74t, 1593
- Nimotop. *See* Nimodipine
- Nipple, 1761–62t
- Nipride. *See* Nitroprusside
- Nisoldipine, 1162t
- Nissen fundoplication, 666, 667f
- Nitrates, 971, 973t, 1032
- Nitric oxide, inhaled, 1367
- Nitrite dipstick, 849
- Nitrites, 113t
- Nitro-Bid. *See* Nitroglycerin
- Nitrodisc. *See* Nitroglycerin
- Nitro-Dur. *See* Nitroglycerin
- Nitrofurantoin, 832t, 850, 850t
- Nitrogard. *See* Nitroglycerin
- Nitroglycerin:
 adverse/side effects, 987
 Medication Administration, 278t, 973t
 in specific conditions
 acute myocardial infarction, 987
 angina, 971, 973t
 heart failure, 1032
 hypertensive emergencies, 1169t
 shock, 278t
- Nitrol. *See* Nitroglycerin
- Nitropaste. *See* Nitroglycerin
- Nitroprusside:
 Medication Administration, 278t
 in specific conditions
 aortic aneurysm, 1173
 heart failure, 1032
 hypertensive emergencies, 1169t
 shock, 278t
- Nitrous oxide, 111, 113t
- NIX. *See* Permethrin
- Nizatidine, 665, 665t, 678
- Nizoral. *See* Ketoconazole
- NK cells. *See* Natural killer cells
- Nociception, age-related changes, 175
- Nociceptors, 170, 171f
- “No-code” order, 91, 91t
- Nocturia:
 definition, 839, 847, 1027
 in heart failure, 1027
 in urinary tract infection, 847
- Nocturnal penile tumescence and rigidity (NPTR), 1768
- Nodes of Ranvier, 1504
- Nodular melanoma, 467
- Nodule/nodular lesions, 431t, 432t
- Nolvadex. *See* Tamoxifen
- Noncapture, pacemaker, 1011t
- Nonconventional terrorist weapons, 127
- Nondepolarizing neuromuscular blockers. *See* Neuromuscular blockers

- Non-disjunction, 150t
- Nonexudative macular degeneration, 1714
- Non-Hodgkin's lymphoma. *See also* Lymphomas in AIDS, 354
- B-cell, 1130t
- incidence, 1130
- manifestations, 1131, 1131t
- pathophysiology, 1130
- prognosis, 1131
- T-cell, 1130t
- Noninvasive ventilation (spontaneous breathing), 1357-58, 1359t
- Nonnarcotic analgesics, 178
- Nonnucleoside reverse transcriptase inhibitors, 358
- Nonoxynol-9, 359, 361t
- Non-Q-wave infarction, 983. *See also* Acute myocardial infarction
- Nonseminomas, 1774
- Non-small-cell carcinoma, 1308, 1309t. *See also* Lung cancer
- Nonspecific vaginitis, 1842, 1843t
- Nonsteroidal anti-inflammatory drugs (NSAIDs). *See also specific drugs*
- categories, 178t, 306
- factors in selecting, 178t
- Medication Administration, 179t, 1546t
- peptic ulcer disease and, 680-81
- for postoperative pain, 64
- in specific conditions
- ankylosing spondylitis, 1470
- gout, 1445
- headache, 1546t
- low back pain, 1491
- osteoarthritis, 1451
- premenstrual syndrome, 1798
- venous thrombosis, 1188
- Nonulcerative keratitis, 1696
- Nonunion, 1407
- Noradrenaline. *See* Norepinephrine
- Norepinephrine:
- in blood pressure regulation, 1155
- functions, 519t, 520
- in heart failure, 1024-25
- Medication Administration, 278t
- in shock, 278t
- Norethindrone/ethinyl estradiol, 1802t
- Norflex. *See* Orphenadrine citrate
- Norgestrel/ethinyl estradiol, 1802t
- Norinyl. *See* Norethindrone/ethinyl estradiol
- Normal pressure hydrocephalus, 1537
- Normal saline, 263t
- Normal sinus rhythm (NSR), 997t, 1000
- Normiflo. *See* Ardeparin
- Normocytic RBCs, 1103
- Normodyne. *See* Labetalol
- Norpac. *See* Disopyramide
- Norpac CR. *See* Disopyramide
- North American Nursing Diagnosis Association (NANDA), 9. *See also* NANDA, NIC, and NOC Linkages; NANDA nursing diagnoses; Nursing diagnosis
- Norvasc. *See* Amlodipine
- Norvir. *See* Ritonavir
- Nose:
- anatomy, physiology, and functions, 1210-11, 1210f
- physical assessment, 1222-23t
- trauma. *See* Nasal trauma
- Nosebleed. *See* Epistaxis
- Nosocomial infections, 313, 847
- Novolin, 571t
- NPH Humulin, 571t
- NPTR (nocturnal penile tumescence and rigidity), 1768
- NSAIDs. *See* Nonsteroidal anti-inflammatory drugs
- NSE (neuro-specific enolase), 384t
- NSR (normal sinus rhythm), 997t, 1000
- Nubain. *See* Nalbuphine HCl
- Nuclear, 128
- Nuclear detonation, 130t, 131
- Nuclear dobutamine stress test, 944t
- Nuclear imaging:
- in cancer, 385
- kidney, 837t, 869
- principles, 385
- radioactive iodine uptake, 524t
- Nuclear persantine (dipyridamole) stress test, 944t
- Nucleoside reverse transcriptase inhibitors, 356, 357t, 358
- Null cells. *See* Natural killer cells
- Numorphan. *See* Oxymorphone HCl
- Nurse extenders, 14
- Nursing, 8
- Nursing care. *See also* Nursing Care Plans
- autoimmune disorders
- community-based care, 341
- diagnoses, 341
- bowel disorders
- anorectal lesions, 821
- appendicitis
- assessment, 767
- community-based care, 768-69
- nursing diagnoses and interventions, 767-68
- using NANDA, NIC, and NOC, 768, 769t
- colorectal cancer
- assessment, 805
- colostomy, 806t
- community-based care, 808-9
- health promotion, 805
- nursing diagnoses and interventions, 805-8
- using NANDA, NIC, and NOC, 808, 809t
- constipation
- assessment, 761
- community-based care, 761-62
- nursing diagnoses and interventions, 761
- diarrhea
- assessment, 756-57
- community-based care, 758
- health promotion, 755-56
- Medication Administration, 756t
- nursing diagnoses and interventions, 757
- using NANDA, NIC, and NOC, 757, 757t
- diverticular disease
- assessment, 817
- community-based care, 818
- health promotion, 817
- nursing diagnoses and interventions, 817-18
- fecal incontinence
- assessment, 765
- community-based care, 765
- health promotion, 765
- nursing diagnoses and interventions, 765
- gastroenteritis
- assessment, 777
- community-based care, 777
- health promotion, 777
- nursing diagnoses and interventions, 777
- helminthic disorders, 780-81
- hemorrhoids, 819-20, 820t
- hernia
- assessment, 749t, 810
- community-based care, 811
- nursing diagnoses and interventions, 810-11
- inflammatory bowel disease
- assessment, 792
- Case Study, 825t
- community-based care, 794-95
- health promotion, 792
- ileostomy, 789-90t
- nursing diagnoses and interventions, 792-94
- using NANDA, NIC, and NOC, 794, 795t
- intestinal obstruction
- assessment, 813
- community-based care, 814
- health promotion, 813
- nursing diagnoses and interventions, 813-14
- using NANDA, NIC, and NOC, 814
- irritable bowel syndrome
- assessment, 763
- community-based care, 763
- nursing diagnoses and interventions, 763
- lactase deficiency, 799
- peritonitis
- assessment, 771
- community-based care, 773
- nursing diagnoses and interventions, 771-73
- using NANDA, NIC, and NOC, 769t, 773
- polyps
- assessment, 801
- community-based care, 801
- health promotion, 801
- nursing diagnoses and interventions, 801
- protozoal infections, 779, 780t
- short bowel syndrome, 799-800
- sprue
- assessment, 797
- community-based care, 798
- nursing diagnoses and interventions, 797-98
- burns
- assessment, 505-6
- Case Study, 515t
- community-based care, 510-11
- health promotion, 505
- Medication Administration, 501t
- nursing diagnoses and interventions, 506-10
- using NANDA, NIC, and NOC, 510, 511t
- cancer
- assessment, 400-403
- client undergoing radiation therapy, 396t
- community-based care, 412
- health education for the client and family, 411-12
- health promotion, 400
- nursing diagnoses and interventions, 403-9
- nursing interventions for oncologic emergencies, 409-11
- in older adults, 371t
- using NANDA, NIC, and NOC, 411, 411t
- cardiac disorders
- acute myocardial infarction
- assessment, 992
- community-based care, 994
- health promotion, 991
- nursing diagnoses and interventions, 992-94
- using NANDA, NIC, and NOC, 994, 994t
- angina pectoris
- assessment, 972
- community-based care, 974
- health promotion, 972
- Medication Administration, 973-74t
- nursing diagnoses and interventions, 972, 974
- cardiac dysrhythmias
- assessment, 1014
- client having permanent pacemaker implant, 1012t
- community-based care, 1015
- health promotion, 1014
- Medication Administration, 1006t
- nursing diagnoses and interventions, 1014-15
- in older adults, 996t

- cardiomyopathy, 1067–68
- coronary heart disease
 - assessment, 968
 - client having percutaneous coronary revascularization, 978*t*
 - community-based care, 969
 - health promotion, 968
 - Medication Administration, 967*t*
 - nursing diagnoses and interventions, 968–69
- endocarditis
 - assessment, 1047
 - community-based care, 1048
 - health promotion, 1047
 - nursing diagnoses and interventions, 1047–48
- heart failure
 - assessment, 1036
 - Case Study, 1073*t*
 - community-based care, 1039, 1040*t*
 - health promotion, 1036
 - hemodynamic monitoring, 1031*t*
 - nursing diagnoses and interventions, 1036–39
 - in older adults, 1023*t*
 - using NANDA, NIC, and NOC, 1039, 1039*t*
- myocarditis, 1049
- pericarditis
 - assessment, 1052
 - community-based care, 1053
 - health promotion, 1052
 - nursing diagnoses and interventions, 1052–53
- pulmonary edema
 - community-based care, 1042
 - nursing diagnoses and interventions, 1041–42
- sudden cardiac death, 1018
- valvular heart disease
 - assessment, 1062
 - community-based care, 1063
 - health promotion, 1062
 - nursing diagnoses and interventions, 1062–63
- disasters
 - nurse's role, 137
 - nursing implications, 137–38
 - Nursing Research: disaster preparedness training in nursing education, 138*t*
 - special considerations, 138
- ear disorders
 - client having surgery for, 1725*t*
 - foreign body, 1721
 - hearing loss
 - assessment, 1732
 - community-based care, 1733–34
 - health promotion, 1732
 - nursing diagnoses and interventions, 1732–33
 - using NANDA, NIC, and NOC, 1733, 1733*t*
- impacted cerumen, 1721
- inner ear
 - assessment, 1727–28
 - community-based care, 1729
 - health promotion, 1727
 - nursing diagnoses and interventions, 1728
 - using NANDA, NIC, and NOC, 1728, 1728*t*
- mastoiditis, 1724
- otitis externa
 - community-based care, 1720–21
 - nursing diagnoses and interventions, 1720
 - teaching to prevent, 1720*t*
- otitis media
 - assessment, 1723
 - community-based care, 1723
 - health promotion, 1723
 - nursing diagnoses and interventions, 1723
- endocrine disorders
 - Addison's disease
 - assessment, 554–55
 - community-based care, 557
 - health promotion, 554
 - Medication Administration, 555*t*
 - nursing diagnoses and interventions, 555–57
 - Cushing's syndrome
 - assessment, 551
 - client having adrenalectomy, 550*t*
 - community-based care, 552–53
 - health promotion, 550
 - nursing diagnoses and interventions, 551–52
 - using NANDA, NIC, and NOC, 552, 552*t*
 - diabetes mellitus
 - assessment, 530*t*, 591
 - Case Study, 602*t*
 - community-based care, 596–97
 - foot care teaching, 591*t*, 594*t*
 - health promotion, 590
 - Medication Administration, 573*t*, 578*t*, 586*t*
 - nursing diagnoses and interventions, 591–96
 - using NANDA, NIC, and NOC, 596, 596*t*
 - hyperthyroidism
 - assessment, 538
 - client having subtotal thyroidectomy, 539*t*
 - community-based care, 541
 - health promotion, 538
 - Medication Administration, 538*t*
 - nursing diagnoses and interventions, 538–41
 - hypothyroidism
 - assessment, 543, 545*t*
 - community-based care, 545
 - health promotion, 543
 - Medication Administration, 544*t*
 - nursing diagnoses and interventions, 544–45
- eye disorders
 - cataracts
 - assessment, 1706
 - community-based care, 1706
 - health promotion, 1705
 - nursing diagnoses and interventions, 1706
 - client having surgery for, 1699*t*
 - corneal disorders
 - assessment, 1698
 - community-based care, 1700
 - health promotion, 1698
 - nursing diagnoses and interventions, 1698–1700
 - glaucoma
 - assessment, 1712
 - Case Study, 1739*t*
 - community-based care, 1713
 - health promotion, 1712
 - nursing diagnoses and interventions, 1712–13
 - using NANDA, NIC, and NOC, 1713, 1713*t*
 - retinal detachment
 - community-based care, 1717
 - nursing diagnoses and interventions, 1717
 - trauma
 - community-based care, 1703
 - health promotion, 1703
 - nursing diagnoses and interventions, 1703
 - visual impairment/blindness, 1693*t*
- female reproductive system disorders
 - benign breast disorders, 1822
 - breast cancer
 - assessment, 1829
 - Case Study, 1856*t*
 - client having a mastectomy, 1826*t*
 - client having breast reconstruction, 1827*t*
 - community-based care, 1831, 1831*f*
 - health promotion, 1828, 1829*t*
 - nursing diagnoses and interventions, 1829–31
 - using NANDA, NIC, and NOC, 1831*t*
 - cysts and polyps, 1809
 - dysfunctional uterine bleeding
 - client having dilation and curettage, 1803*t*
 - client having hysterectomy, 1804*t*
 - community-based care, 1805
 - nursing diagnoses and interventions, 1804–5
 - dysmenorrhea, 1802, 1802*t*
 - endometrial cancer
 - assessment, 1817
 - community-based care, 1817
 - health promotion, 1817
 - nursing diagnoses and interventions, 1817
 - menopausal symptoms
 - assessment, 1797
 - health promotion, 1796–97
 - nursing diagnoses and interventions, 1797–98
 - ovarian cancer, 1819
 - premenstrual syndrome
 - community-based care, 1800
 - nursing diagnoses and interventions, 1800
 - uterine displacement
 - community-based care, 1807
 - nursing diagnoses and interventions, 1807
 - vaginal fistula, 1808
 - vulvar cancer
 - community-based care, 1820
 - nursing diagnoses and interventions, 1820
- fluid, electrolyte, and acid–base imbalances
- fluid volume deficit
 - assessment, 207, 207*t*, 208*t*
 - community-based care, 208–9
 - health promotion, 206
 - nursing diagnoses and interventions, 207–8
 - in older adults, 203*t*
 - using NANDA, NIC, and NOC, 208, 209*t*
- fluid volume excess
 - assessment, 211
 - community-based care, 213
 - health promotion, 211
 - nursing diagnoses and interventions, 211–13
- hypercalcemia
 - assessment, 232
 - community-based care, 233
 - health promotion, 232
 - nursing diagnoses and interventions, 232–33
- hyperkalemia
 - assessment, 225
 - community-based care, 227
 - health promotion, 224–25
 - Medication Administration, 225*t*
 - nursing diagnoses and interventions, 225–27
- hypermagnesemia, 235–36
- hypernatremia
 - assessment, 217
 - community-based care, 217
 - health promotion, 217
 - nursing diagnoses and interventions, 217
- hyperphosphatemia, 238
- hypocalcemia
 - assessment, 230
 - community-based care, 231
 - health promotion, 230
 - Medication Administration, 230*t*
 - nursing diagnoses and interventions, 230–31
- hypokalemia
 - assessment, 221
 - community-based care, 223
 - health promotion, 221
 - Medication Administration, 221*t*
 - nursing diagnoses and interventions, 221–23
 - using NANDA, NIC, and NOC, 223, 223*t*

Nursing care—*continued*

- hypomagnesemia
 - assessment, 235
 - community-based care, 235
 - health promotion, 235
 - Medication Administration, 235*t*
 - nursing diagnoses and interventions, 235
- hyponatremia
 - assessment, 215
 - community-based care, 216
 - health promotion, 215
 - nursing diagnoses and interventions, 215–16
- hypophosphatemia, 237
- metabolic acidosis
 - assessment, 244–45
 - community-based care, 245
 - health promotion, 244
 - nursing diagnoses and interventions, 245
- metabolic alkalosis
 - assessment, 246–47
 - community-based care, 247
 - health promotion, 246
 - nursing diagnoses and interventions, 247
- respiratory acidosis
 - assessment, 249
 - community-based care, 250
 - health promotion, 249
 - nursing diagnoses and interventions, 249–50
 - using NANDA, NIC, and NOC, 250, 250*t*
- respiratory alkalosis
 - assessment, diagnoses, and interventions, 251
 - community-based care, 252
 - health promotion, 251
- gastrointestinal/nutritional disorders
 - cirrhosis
 - assessment, 720–21
 - community-based care, 723
 - health promotion, 720–21
 - Medication Administration, 717*t*
 - nursing diagnoses and interventions, 722–23
 - using NANDA, NIC, and NOC, 723, 723*t*
 - gallstones
 - assessment, 701
 - community-based care, 703
 - health promotion, 701
 - nursing diagnoses and interventions, 701–3
 - hepatitis
 - assessment, 709
 - community-based care, 710
 - health promotion, 709
 - nursing diagnoses and interventions, 709–10
 - using NANDA, NIC, and NOC, 710, 710*t*
- malnutrition
 - assessment, 648
 - community-based care, 650
 - health promotion, 648
 - Medication Administration, 645*t*
 - nursing diagnoses and interventions, 648–50
 - using NANDA, NIC, and NOC, 650, 650*t*
- obesity
 - assessment, 638–39
 - community-based care, 640–41
 - health promotion, 638
 - Medication Administration, 634*t*
 - nursing diagnoses and interventions, 639–40
 - using NANDA, NIC, and NOC, 640, 640*t*
- pancreatitis
 - assessment, 729–30
 - community-based care, 731
 - health promotion, 729
 - nursing diagnoses and interventions, 730–31
 - using NANDA, NIC, and NOC, 731, 731*t*
- genetic conditions. *See also* Genetics
 - assessment, 159–60
 - evaluation, 165
 - nurse's role in genetic testing, 158–59
 - nursing diagnoses and interventions, 160–65
- hematologic disorders
 - anemias
 - assessment, 1112–13
 - community-based care, 1114–15
 - health promotion, 1112
 - Medication Administration, 1112*t*
 - nursing diagnoses and interventions, 1113–14
 - using NANDA, NIC, and NOC, 1114, 1115*t*
 - disseminated intravascular coagulation
 - assessment, 1148
 - community-based care, 1149
 - nursing diagnoses and interventions, 1148–49
 - hemophilia
 - assessment, 1144
 - community-based care, 1146
 - health promotion, 1144
 - nursing diagnoses and interventions, 1144–46
 - using NANDA, NIC, and NOC, 1146, 1146*t*
 - leukemia
 - assessment, 1126
 - community-based care, 1129
 - health promotion, 1125–26
 - nursing diagnoses and interventions, 1126–28
 - using NANDA, NIC, and NOC, 1128, 1128*t*
 - lymphoma
 - assessment, 1133
 - community-based care, 1135–36
 - nursing diagnoses and interventions, 1133–35
 - using NANDA, NIC, and NOC, 1135, 1136*t*
 - multiple myeloma
 - assessment, 1137
 - community-based care, 1138
 - nursing diagnoses and interventions, 1137–38
 - myelodysplastic syndrome
 - community-based care, 1117
 - nursing diagnoses and interventions, 1116
 - neutropenia, 1139
 - polycythemia, 1118
 - thrombocytopenia
 - assessment, 1141
 - community-based care, 1142
 - nursing diagnosis, 1141–42
- HIV/AIDS
 - assessment, 361–62
 - community-based care, 365
 - Medication Administration, 357*t*
 - nursing diagnoses and interventions, 362–65
 - prevention, 359–61, 361*t*
 - using NANDA, NIC, and NOC, 365, 365*t*
- hypersensitivity reaction
 - assessment, 338
 - community-based care, 339
 - health promotion, 338
 - nursing diagnoses and interventions, 338–39
- immunization
 - assessment, 302
 - community-based care, 303
 - health promotion, 301
 - nursing diagnoses and interventions, 302
- infections
 - assessment, 322–23
 - community-based care, 324–25
 - health promotion, 322
 - Medication Administration, 319–21*t*, 450*t*
 - nursing diagnoses and interventions, 323–24
 - using NANDA, NIC, and NOC, 324, 325*t*
- inflammatory conditions
 - assessment, 308
 - community-based care, 309
 - health promotion, 308
 - nursing diagnoses and interventions, 308–9
- integumentary disorders
 - acne, 459, 459*t*
 - bacterial skin infections, 447–48
 - cutaneous and plastic surgery
 - community-based care, 481
 - nursing diagnoses and interventions, 479–81
 - dermatitis, 457
 - fungal skin infections, 450
 - hair disorders, 482–83
 - malignant melanoma
 - assessment, 470, 470*t*
 - community-based care, 471
 - health promotion, 468–69
 - nursing diagnoses and interventions, 470–71
 - using NANDA, NIC, and NOC, 471, 471*t*
 - nail disorders, 483
 - parasitic infestations, 451
 - pemphigus vulgaris, 460
 - pressure ulcers
 - community-based care, 476
 - nursing diagnoses and interventions, 474–76, 475*t*
 - in older adults, 474*t*
 - psoriasis
 - community-based care, 445–46
 - nursing diagnoses and interventions, 445–46
 - viral infections
 - community-based care, 455
 - nursing diagnoses and interventions, 453, 455
 - using NANDA, NIC, and NOC, 455, 455*t*
- kidney disorders
 - acute renal failure
 - assessment, 911
 - community-based care, 913
 - health promotion, 910–11
 - Medication Administration, 905–6*t*
 - nursing diagnoses and interventions, 911–13
 - using NANDA, NIC, and NOC, 913, 913*t*
 - chronic renal failure
 - assessment, 923
 - Case Study, 931*t*
 - community-based care, 926
 - health promotion, 923
 - nursing diagnoses and interventions, 923–25
 - in older adults, 914*t*
 - glomerular disorders
 - assessment, 891
 - community-based care, 894
 - health promotion, 891
 - nursing diagnoses and interventions, 891–94
- loss and grief. *See also* Death and dying
 - assessment, 95–96
 - community-based care, 98
 - health promotion, 95
 - nursing diagnoses and interventions, 96–97
 - using NANDA, NIC, and NOC, 97, 97*t*
- lymphedema
 - community-based care, 1201
 - nursing diagnoses and interventions, 1200–1201
- male reproductive system disorders
 - benign prostatic hyperplasia
 - client having prostatectomy, 1780–81*t*
 - community-based care, 1782
 - discharge instructions after prostate surgery, 1783*t*
 - nursing diagnoses and interventions, 1781–82
 - benign scrotal mass, 1773
 - cancer of the penis, 1772

- epididymitis, 1773
- erectile dysfunction
 community-based care, 1771
 nursing diagnoses and interventions, 1770–71
- priapism, 1772
- prostate cancer
 assessment, 1787
 client having prostatectomy, 1780–81*t*
 community-based care, 1789
 discharge instructions after prostate surgery, 1783*t*
 health promotion, 1786–87
 nursing diagnoses and interventions, 1787–89
 using NANDA, NIC, and NOC, 1789, 1789*t*
- prostatitis, 1777
- testicular cancer
 community-based care, 1776
 nursing diagnoses and interventions, 1776
- musculoskeletal disorders
 amputation
 assessment, 1424
 community-based care, 1426–27, 1427*t*
 health promotion, 1424
 nursing diagnoses and interventions, 1424–26
 using NANDA, NIC, and NOC, 1426, 1426*t*
- ankylosing spondylitis, 1470
- bone tumors
 community-based care, 1484
 nursing diagnoses and interventions, 1483–84
- contusion, strain, or sprain, 1400
- dislocations
 community-based care, 1401
 nursing diagnoses and interventions, 1401
- fibromyalgia, 1487
- foot deformities
 community-based care, 1493
 nursing diagnoses and interventions, 1493
- fractures
 assessment, 1417–18
 Case Study, 1499*t*
 client in traction, 1409*t*
 client with a cast, 1410*t*
 client with internal fixation, 1412*t*
 clients with fracture of the humerus, 1413*t*
 community-based care, 1420–21
 health promotion, 1416–17
 nursing diagnoses and interventions, 1418–20
 using NANDA, NIC, and NOC, 1420, 1420*t*
- gout
 community-based care, 1447
 Medication Administration, 1446*t*
 nursing diagnoses and interventions, 1447
- Lyme disease, 1477
- muscular dystrophy, 1459
- osteoarthritis
 assessment, 1455
 client having total joint replacement, 1453–1454*t*
 community-based care, 1457
 health promotion, 1455
 nursing diagnoses and interventions, 1455, 1457
 using NANDA, NIC, and NOC, 1457, 1457*t*
- osteomyelitis
 of client undergoing surgical debridement, 1479*t*
 community-based care, 1480–81
 nursing diagnoses and interventions, 1480
- osteoporosis
 assessment, 1438–39
- community-based care, 1400
 health promotion, 1437–38
 Medication Administration, 1437*t*
 nursing diagnoses and interventions, 1439–40
 using NANDA, NIC, and NOC, 1400, 1400*t*
- Paget's disease
 community-based care, 1443
 Medication Administration, 1442*t*
 nursing diagnoses and interventions, 1443
- polymyositis, 1476
- reactive arthritis, 1470
- repetitive use injury
 community-based care, 1429
 nursing diagnoses and interventions, 1428
- rheumatoid arthritis
 assessment, 1468
 community-based care, 1469
 health promotion, 1466–68
 nursing diagnoses and interventions, 1468–69
 using NANDA, NIC, and NOC, 1469, 1469*t*
- scleroderma
 community-based care, 1486
 nursing interventions, 1486
- septic arthritis, 1481
- spinal deformities
 community-based care, 1490
 nursing diagnoses and interventions, 1489–90
- systemic lupus erythematosus
 community-based care, 1475
 Medication Administration, 1474*t*
 nursing diagnoses and interventions, 1474–75
- neurologic system disorders
 altered level of consciousness
 nursing diagnoses and interventions, 1534–35
 support of the family, 1533–34
- Alzheimer's disease
 assessment, 1623
 communication techniques, 1624*t*
 community-based care, 1625–26
 health promotion, 1621, 1623
 Medication Administration, 1621*t*
 nursing diagnoses and interventions, 1623–25
 safety interventions, 1623*t*
 using NANDA, NIC, and NOC, 1625, 1625*t*
- amyotrophic lateral sclerosis
 community-based care, 1647
 nursing diagnoses and interventions, 1646
- arteriovenous malformation, 1595
- Bell's palsy, 1656
- botulism, 1662
- brain tumor
 community-based care, 1575
 nursing diagnoses and interventions, 1572–75
 using NANDA, NIC, and NOC, 1575, 1575*t*
- central nervous system infections
 assessment, 1567
 community-based care, 1569
 health promotion, 1567
 nursing diagnoses and interventions, 1567–68
 using NANDA, NIC, and NOC, 1568, 1568*t*
- Creutzfeldt-Jakob disease, 1659
- epilepsy
 assessment, 1552, 1553*t*
 client having surgery for seizures, 1551*t*
 community-based care, 1553–54
 health promotion, 1551–52
- Medication Administration, 1550*t*
 nursing diagnoses and interventions, 1552–53
 using NANDA, NIC, and NOC, 1553, 1553*t*
- Guillain-Barré syndrome
 community-based care, 1655
 nursing diagnoses and interventions, 1654–55
- headache
 assessment, 1544
 community-based care, 1547
 health promotion, 1544, 1544*t*
 Medication Administration, 1545–46*t*
 nursing diagnoses and interventions, 1544, 1546
- herniated intervertebral disk
 assessment, 1610
 of client having posterior laminectomy, 1609–10*t*
 client teaching, 1611*t*
 community-based care, 1611–12
 health promotion, 1610
 nursing diagnoses and interventions, 1610–11
- Huntington's disease
 community-based care, 1645
 nursing diagnoses and interventions, 1644
- increased intracranial pressure
 client and family education, 1541
 Medication Administration, 1539*t*
 nursing diagnoses and interventions, 1541–42
- intracranial aneurysm
 nursing diagnoses and interventions, 1594–95
- multiple sclerosis
 assessment, 1632
 community-based care, 1634–35
 health promotion, 1632
 Medication Administration, 1631*t*
 nursing diagnoses and interventions, 1632–34
 using NANDA, NIC, and NOC, 1634, 1634*t*
- myasthenia gravis
 client and family teaching, 1651*t*
 of client having a thymectomy, 1650*t*
 of client undergoing plasmapheresis, 1650*t*
 community-based care, 1651–52
 Medication Administration, 1649*t*
 nursing diagnoses and interventions, 1651
- Parkinson's disease
 assessment, 1639–40
 community-based care, 1642
 health promotion, 1639
 Medication Administration, 1637*t*
 nursing diagnoses and interventions, 1640–41
 using NANDA, NIC, and NOC, 1642, 1642*t*
- postpoliomyelitis syndrome, 1660
- rabies, 1660
- spinal cord injury
 assessment, 1602
 of client with halo external fixation, 1602*t*
 community-based care, 1606–7
 health promotion, 1602
 Medication Administration, 1600*t*
 nursing diagnoses and interventions, 1602–6
 using NANDA, NIC, and NOC, 1606, 1606*t*
- spinal cord tumor, 1613
- stroke
 assessment, 1587
 Case Study, 1667*t*
 client having endarterectomy, 1586*t*
 community-based care, 1591–92

- Nursing care—*continued*
- health promotion, 1587
 - nursing diagnoses and interventions, 1587–91
 - overview, 1586–87
 - using NANDA, NIC, and NOC, 1591, 1591*t*
- tetanus, 1661
- traumatic brain injury
- assessment, 1560
 - community-based care, 1562–63
 - health promotion, 1560
 - nursing diagnoses and interventions, 1560–62
 - using NANDA, NIC, and NOC, 1562, 1562*t*
- trigeminal neuralgia
- of client undergoing percutaneous rhizotomy, 1656*t*
 - community-based care, 1657
 - nursing diagnoses and interventions, 1656–57
 - teaching for home care, 1657*t*
- pain
- assessment, 186–88
 - community-based care, 190
 - Medication Administration, 179*t*, 182*t*
 - nursing diagnoses and interventions, 188–90
 - using NANDA, NIC, and NOC, 190, 190*t*
- peripheral vascular disorders
- acute arterial occlusion
 - assessment, 1185
 - community-based care, 1186
 - nursing diagnoses and interventions, 1185–86 - aortic aneurysm
 - assessment, 1173–74
 - community-based care, 1175–76
 - nursing diagnoses and interventions, 1174–75
 - postoperative, 1174*t*
 - preoperative, 1174*t*
- chronic venous insufficiency, 1195, 1196*t*
- hypertension
- assessment, 1164
 - Case Study, 1207*t*
 - community-based care, 1166–67
 - health promotion, 1163–64, 1164*t*
 - Medication Administration, 1161–62*t*
 - nursing diagnoses and interventions, 1164–66
 - in older adults, 1157*t*
 - using NANDA, NIC, and NOC, 1166, 1166*t*
- peripheral vascular disease
- assessment, 1178
 - community-based care, 1180
 - health promotion, 1178
 - nursing diagnoses and interventions, 1179–80
 - in older adults, 1178*t*
 - using NANDA, NIC, and NOC, 1180, 1180*t*
- Raynaud's disease/phenomenon, 1183
- thromboangiitis obliterans, 1182
- varicose veins
- assessment, 1197
 - community-based care, 1199
 - health promotion, 1197
 - nursing diagnoses and interventions, 1197–99
- venous thrombosis
- assessment, 1190, 1191
 - community-based care, 1193
 - health promotion, 1190
 - Medication Administration, 1189–90*t*
 - nursing diagnoses and interventions, 1191–93
 - using NANDA, NIC, and NOC, 1193, 1193*t*
- respiratory disorders
- acute bronchitis, 1267
 - acute respiratory distress syndrome
 - community-based care, 1372
 - nursing diagnoses and interventions, 1367, 1370–71
 - using NANDA, NIC, and NOC, 1371, 1371*t* - acute respiratory failure
 - assessment, 1361
 - community-based care, 1365
 - endotracheal suctioning, 1363*t*
 - health promotion, 1361
 - nursing diagnoses and interventions, 1361–65
 - using NANDA, NIC, and NOC, 1365, 1365*t*
- asthma
- assessment, 1326
 - client teaching, 1325*t*
 - community-based care, 1330
 - health promotion, 1326
 - Medication Administration, 1327–28*t*
 - nursing diagnoses and interventions, 1329–30
- atelectasis, 1344
- bronchiectasis, 1344
- chronic obstructive pulmonary disease
- assessment, 1336
 - Case Study, 1377*t*
 - client teaching, 1341*t*
 - community-based care, 1340
 - health promotion, 1336
 - nursing diagnoses and interventions, 1336–40
 - using NANDA, NIC, and NOC, 1340, 1340*t*
- cystic fibrosis
- community-based care, 1343
 - nursing diagnoses and interventions, 1343
- diphtheria, 1241–42
- epistaxis
- assessment, 1244
 - of client with nasal packing, 1245*t*
 - community-based care, 1245
 - nursing diagnoses and interventions, 1244–45
- fungal lung infections, 1295
- influenza
- assessment, 1234
 - community-based care, 1235
 - health promotion, 1234
 - nursing diagnoses and interventions, 1234–35
 - using NANDA, NIC, and NOC, 1235, 1235*t*
- inhalation injury
- assessment, 1307
 - community-based care, 1308
 - health promotion, 1307
 - nursing diagnoses and interventions, 1307–8
- laryngeal cancer
- assessment, 1258
 - community-based care, 1261–62
 - health promotion, 1258
 - nursing diagnoses and interventions, 1258–61
 - using NANDA, NIC, and NOC, 1261, 1262*t*
- laryngeal obstruction or trauma, 1250
- lung abscess, 1280
- lung cancer
- assessment, 1313–14
 - Case Study, 418*t*
 - of client having lung surgery, 1313*t*
 - of client having radiation therapy, 1314*t*
 - community-based care, 1316–17
 - health promotion, 1313
 - nursing diagnoses and interventions, 1314–16
 - using NANDA, NIC, and NOC, 1316, 1317*t*
- nasal polyps, 1252
- nasal trauma
- assessment, 1247
 - community-based care, 1248–49
 - health promotion, 1247
 - nursing diagnoses and interventions, 1247–48
 - using NANDA, NIC, and NOC, 1248, 1248*t*
- nursing care, 1302
- obstructive sleep apnea, 1251–52
- occupational lung diseases
- community-based care, 1346
 - health promotion, 1346
 - nursing diagnoses and interventions, 1346
- pertussis, 1243
- pharyngitis, 1239–40
- pleural effusion, 1296, 1297*t*
- pneumonia
- assessment, 1275
 - community-based care, 1276
 - health promotion, 1274
 - nursing diagnoses and interventions, 1275–76
 - of older adults, 1268*t*
 - using NANDA, NIC, and NOC, 1276, 1276*t*
- pneumothorax
- assessment, 1301
 - client having chest tube insertion, 1300*t*
 - community-based care, 1301–2
 - health promotion, 1300–1301
 - nursing diagnoses and interventions, 1301
- pulmonary embolism
- assessment, 1350
 - community-based care, 1351–52
 - health promotion, 1349–50
 - nursing diagnoses and interventions, 1350–51
 - using NANDA, NIC, and NOC, 1351, 1352*t*
- pulmonary hypertension, 1353
- sarcoidosis, 1347
- severe acute respiratory syndrome
- assessment, 1278
 - community-based care, 1279–80
 - health promotion, 1278
 - nursing diagnoses and interventions, 1278–79
- sinusitis
- assessment, 1237
 - community-based care, 1238
 - health promotion, 1237
 - nursing diagnoses and interventions, 1237–38
- thoracic trauma
- assessment, 1304
 - community-based care, 1305
 - health promotion, 1304
 - nursing diagnoses and interventions, 1304–5
- tonsillitis, 1239–40
- tuberculosis
- assessment, 1290
 - community-based care, 1293
 - health promotion, 1289–90
 - Medication Administration, 1288–89*t*
 - nursing diagnoses and interventions, 1290–93
 - of older adults, 1282*t*
 - using NANDA, NIC, and NOC, 1293, 1293*t*
- viral upper respiratory infections
- community-based care, 1231
 - health promotion, 1231
 - Medication Administration, 1230*t*
- sexually transmitted infections
- chlamydia, 1845
 - genital herpes

- community-based care, 1840
- nursing diagnoses and interventions, 1840
- genital warts
 - community-based care, 1842
 - Medication Administration, 1842*t*
 - nursing diagnoses and interventions, 1841–42
- gonorrhea
 - community-based care, 1846
 - nursing diagnoses and interventions, 1846
- pelvic inflammatory disease
 - community-based care, 1852
 - nursing diagnoses and interventions, 1851–52
- syphilis
 - community-based care, 1849–50
 - nursing diagnoses and interventions, 1849
- vaginal infections
 - community-based care, 1844
 - nursing diagnoses and interventions, 1844, 1844*t*
- shock
 - community-based care, 283*t*
 - health promotion and assessment, 279–80
 - Medication Administration, 278*t*
 - nursing diagnoses and interventions, 280–83
 - in older adults, 280*t*
 - using NANDA, NIC, and NOC, 283, 283*t*
- substance abuse
 - assessment, 114–17
 - community-based care, 120
 - health promotion, 114
 - nursing diagnoses and interventions, 117–20
 - using NANDA, NIC, and NOC, 120, 121*t*, 122*t*
- surgical client
 - Clinical Scenarios, 144*t*
 - community-based care, 80
 - intraoperative nursing care, 73
 - managing acute postoperative pain, 79–80
 - postoperative complications, 74–79
 - postoperative nursing care, 74
 - preoperative client and family teaching, 71
 - preoperative client preparation, 71–73
 - preoperative nursing care, 71
 - using NANDA, NIC, and NOC, 80, 80*t*
- transplant procedures
 - assessment, 346–47
 - community-based care, 348
 - health promotion, 349
 - kidney transplant, 922*t*
 - liver transplant, 922*t*
 - Medication Administration, 345–46*t*
 - nursing diagnoses and interventions, 347–48
- trauma
 - assessment, 265
 - Case Study, 145*t*
 - community-based care, 268
 - health promotion, 265
 - nursing diagnoses and interventions, 265–68
 - using NANDA, NIC, and NOC, 268, 268*t*
- upper gastrointestinal disorders
 - esophageal cancer
 - assessment, 670
 - community-based care, 670–71
 - health promotion, 670
 - nursing diagnoses and interventions, 670
 - gastric cancer
 - assessment, 691
 - community-based care, 694
 - health promotion, 691
 - nursing diagnoses and interventions, 691, 693
 - using NANDA, NIC, and NOC, 693, 693*t*
 - gastritis
 - assessment, 679
 - community-based care, 680
 - health promotion, 679
 - Medication Administration, 665–66*t*
 - nursing diagnoses and interventions, 679–80
 - gastroesophageal reflux disease
 - assessment, 666
 - community-based care, 667
 - Medication Administration, 665–66*t*
 - nursing diagnoses and interventions, 667
 - using NANDA, NIC, and NOC, 667, 667*t*
 - gastrointestinal bleeding
 - assessment, 675
 - community-based care, 677
 - health promotion, 675
 - nursing diagnoses and interventions, 675
 - nausea and vomiting
 - community-based care, 674
 - Medication Administration, 673*t*
 - nursing diagnoses and interventions, 672
- oral cancer
 - assessment, 661
 - community-based care, 663
 - health promotion, 661
 - nursing diagnoses and interventions, 661–63
- peptic ulcer disease
 - assessment, 685
 - Case Study, 737*t*
 - community-based care, 688
 - health promotion, 685
 - Medication Administration, 665–66*t*
 - nursing diagnoses and interventions, 686–88
 - using NANDA, NIC, and NOC, 688, 688*t*
- stomatitis
 - assessment, 658–59
 - community-based care, 659–60
 - health promotion, 658
 - Medication Administration, 658*t*
 - nursing diagnoses and interventions, 659
 - using NANDA, NIC, and NOC, 659, 659*t*
- urinary system disorders
 - bladder cancer
 - assessment, 865
 - client undergoing cystectomy and urinary diversion, 866*t*
 - community-based care, 868
 - health promotion, 865
 - nursing diagnoses and interventions, 865–68
 - neurogenic bladder, 872
 - urinary calculi
 - assessment, 860
 - community-based care, 862
 - health promotion, 859
 - nursing diagnoses and interventions, 860–61
 - urinary incontinence
 - assessment, 877
 - client undergoing bladder neck suspension, 876*t*
 - community-based care, 879
 - health promotion, 876
 - nursing diagnoses and interventions, 877–79
 - using NANDA, NIC, and NOC, 879, 879*t*
 - urinary retention, 869–70
 - urinary tract infection
 - assessment, 852
 - community-based care, 854–55
 - health promotion, 851–52
 - nursing diagnoses and interventions, 852–54
 - in older adults, 315*t*, 873*t*
- Nursing Care of the Client Having....:
 - adrenalectomy, 550*t*
 - aortic surgery, 1174*t*
 - bladder neck suspension, 876*t*
 - bowel surgery, 804*t*
 - breast reconstruction, 1827*t*
 - carotid endarterectomy, 1586*t*
 - cast, 1410*t*
 - chest tube insertion, 1300*t*
 - colostomy, 806*t*
 - coronary artery bypass graft, 980–82*t*
 - cystectomy and urinary diversion, 866*t*
 - dilation and curettage, 1803*t*
 - ear surgery, 1725*t*
 - eye surgery, 1699*t*
 - fibrinolytic therapy, 989*t*
 - gastric surgery, 690*t*
 - gastrostomy or jejunostomy tube, 692*t*
 - halo external fixation, 1602*t*
 - hemodialysis, 908*t*
 - hemodynamic monitoring, 1031*t*
 - hysterectomy, 1804*t*
 - ileostomy, 789–90*t*
 - immunotherapy, 398*t*
 - intraspinal analgesia, 184*t*
 - kidney transplant, 922*t*
 - laparoscopic cholecystectomy, 700*t*
 - laparoscopy of female reproductive system, 1801*t*
 - laryngectomy, 1256*t*
 - lithotripsy, 859*t*
 - liver transplantation, 720*t*
 - lung surgery, 1313*t*
 - mastectomy, 1826*t*
 - nasal packing, 1245*t*
 - nephrectomy, 897
 - percutaneous coronary revascularization, 978*t*
 - peritoneal dialysis, 910*t*
 - permanent pacemaker implant, 1012*t*
 - plasmapheresis, 1650*t*
 - posterior laminectomy, 1609–10*t*
 - prostatectomy, 1780–81*t*
 - radiation therapy, 396*t*
 - rhizotomy, 1656*t*
 - subtotal thyroidectomy, 539*t*
 - surgery for seizures, 1551*t*
 - surgical debridement for osteomyelitis, 1479*t*
 - thoracocentesis, 1297*t*
 - thymectomy, 1650*t*
 - total joint replacement, 1453–54*t*
 - T-tube, 701*t*
 - ureteral stent, 851*t*
 - Whipple's procedure, 732*t*
- Nursing Care of the Older Adult:
 - age-related changes and effects on pain, 175*t*
 - cancer, 371*t*
 - cardiac dysrhythmias, 996*t*
 - chronic venous insufficiency, 1196*t*
 - end-of-life checklist, 95*t*
 - fluid volume deficit, 203*t*
 - heart failure, 1023*t*
 - hypertension, 1157*t*
 - hypothyroidism, 545*t*
 - infections, 315*t*
 - minimizing risk for urinary tract infection and urinary incontinence, 873*t*
 - peripheral vascular disease, 1178*t*
 - pneumonia, 1268*t*
 - pressure ulcer prevention, 474*t*
 - renal failure, 914*t*
 - shock, 280*t*
 - tuberculosis, 1282*t*
- Nursing Care Plans:
 - acute glomerulonephritis, 892*t*
 - acute myocardial infarction, 991–92*t*
 - acute renal failure, 912*t*
 - acute respiratory distress syndrome, 1370*t*
 - Addison's disease, 556*t*
 - alcohol withdrawal, 119*t*

Nursing Care Plans—*continued*

- Alzheimer's disease, 1622–23*t*
 - amputation, 1425*t*
 - appendicitis, 768*t*
 - bacterial meningitis, 1567*t*
 - bladder cancer, 867*t*
 - brain tumor, 1573*t*
 - breast cancer, 1828*t*
 - burns, 507*t*
 - cancer, 403–4*t*
 - cardiac dysrhythmia, 1013*t*
 - cervical cancer, 1814*t*
 - cholelithiasis, 702*t*
 - chronic obstructive pulmonary disease, 1338*t*
 - chronic pain, 191*t*
 - chronic renal failure, 924*t*
 - cirrhosis, alcoholic, 721*t*
 - client experiencing grief and loss, 98*t*
 - client having surgery, 80–81*t*
 - client with hand and foot injuries and suffering from trauma of natural disaster, 139*t*
 - client with multiple injuries, 266*t*
 - colorectal cancer, 807*t*
 - coronary artery bypass surgery, 983*t*
 - Cushing's syndrome, 551*t*
 - diabetes mellitus, 593*t*
 - endometriosis, 1811*t*
 - epilepsy, 1552*t*
 - fluid volume excess, 212*t*
 - folic acid deficiency anemia, 1113*t*
 - gastric cancer, 692–93*t*
 - glaucoma and cataracts, 1711*t*
 - gonorrhea, 1847*t*
 - heart failure, 1037*t*
 - hemophilia, 1145*t*
 - herpes zoster, 454*t*
 - hip fracture, 1417*t*
 - HIV infection, 363*t*
 - Hodgkin's disease, 1134*t*
 - hyperkalemia, 226*t*
 - hypertension, 1168*t*
 - hypokalemia, 222*t*
 - hypothyroidism, 546*t*
 - immunization, 303*t*
 - leukemia, 1125*t*
 - lung cancer, 1315*t*
 - malignant melanoma, 469*t*
 - malnutrition, 649*t*
 - migraine headache, 1547*t*
 - mitral valve prolapse, 1064*t*
 - multiple sclerosis, 1633*t*
 - myasthenia gravis, 1652*t*
 - nasal trauma, 1247*t*
 - obesity, 639*t*
 - oral cancer, 661*t*
 - osteoarthritis, 1456*t*
 - osteoporosis, 1438*t*
 - pancreatitis, acute, 729*t*
 - peptic ulcer disease, 686*t*
 - peripheral vascular disease, 1181*t*
 - peritonsillar abscess, 1240*t*
 - pneumonia, 1277*t*
 - prostate cancer, 1788*t*
 - respiratory acidosis, 249*t*
 - rheumatoid arthritis, 1467*t*
 - septic shock, 281*t*
 - spinal cord injury, 1603*t*
 - stroke, 1588*t*
 - subdural hematoma, 1561*t*
 - sypilis, 1850*t*
 - total joint replacement, 1456*t*
 - tuberculosis, 1291*t*
 - ulcerative colitis, 793*t*
 - urinary calculi, 861*t*
 - urinary incontinence, 878*t*
 - urinary tract infection, 853*t*
- Nursing diagnosis. *See also* NANDA, NIC, and NOC Linkages; NANDA nursing diagnoses
- critical thinking skills in, 7*t*
 - data analysis in, 8
 - functional health patterns and, 9*t*
 - overview, 8–9
 - reasoning in, 8
 - writing, 9
- Nursing ethics:
- codes
 - American Nurses Association (ANA), 11, 11*t*
 - International Council of Nurses (ICN), 10
 - dilemmas
 - confidentiality, 12
 - in end-of-life care, 12
 - genetic information, 164*t*
 - patients' rights, 12
- Nursing Interventions Classification (NIC). *See* NANDA, NIC, and NOC Linkages
- Nursing Outcomes Classification (NOC). *See* NANDA, NIC, and NOC Linkages
- Nursing practice:
- codes of ethics
 - American Nurses Association (ANA), 11, 11*t*
 - International Council of Nurses (ICN), 10
 - standards, 11, 11*t*
- Nursing process:
- benefits, 6–7
 - in clinical practice, 10
 - critical thinking skills in, 7*t*
 - definition, 6
 - steps, 7, 7*t*, 8*f*
- Nursing research, 15
- Nursing Research: Evidence-Based Practice:
- acute myocardial infarction in women, 995*t*
 - antibiotic regimens, 310*t*
 - assisting older adults to communicate
 - postoperative pain, 65*t*
 - breast cancer diagnosis and treatment in African American women, 1829*t*
 - burn injuries, prevention of pressure ulcers, 510*t*
 - chronic obstructive pulmonary disease
 - management, 1335*t*
 - diabetes mellitus, individualized teaching about foot care, 591*t*
 - disaster preparedness training in nursing
 - education, 138*t*
 - end-of-life care, 90*t*
 - enteral feeding in the critically ill client, 772*t*
 - family presence during resuscitation, 1066*t*
 - fecal incontinence, self-care practices, 764*t*
 - feeding tube placement methods, 647*t*
 - fluid volume imbalance assessment
 - techniques, 208*t*
 - gastric residual volume assessment in enteral feeding, 662*t*
 - hemodialysis, 926*t*
 - HIV/AIDS, nurses' willingness to care for clients with, 360*t*
 - hormone replacement therapy, risks vs. benefits, 965*t*
 - hypertension, relaxation training in, 1164*t*
 - leukemia and lymphoma, care of physical problems during treatment, 1126*t*
 - male catheterization, 854*t*
 - multiple sclerosis in aging clients, 1634*t*
 - online health information use in older adults, 1458*t*
 - osteoporosis risk assessment, 1439*t*
 - pain assessment in intubated clients, 1364*t*
 - pain management, 189*t*
 - pain management after ambulatory surgery, 700*t*
 - pressure ulcer treatment and prevention, 475*t*
 - prostatectomy discharge teaching, 1785*t*
 - rheumatoid arthritis, use of Internet for client teaching, 1458*t*
 - skeletal pins, care of insertion sites, 1419*t*
 - smoking cessation for hospitalized patients, 106*t*
 - speech-generating devices after laryngectomy, 1260*t*
 - stem cell transplant, fatigue and depression following, 1133*t*
 - stroke treatment, 1589*t*
 - thyroid hormone and calcium supplements, 545*t*
 - traumatic brain injury in young adults, caregiver burden, 1563*t*
 - tuberculosis screening in homeless persons, 1290*t*
 - urinary incontinence, stress vs. urge, 876*t*
 - venous leg ulcers, rest periods for improved healing, 1196*t*
 - ventilator-associated pneumonia, prevention strategies, 280*t*
 - vision impairments in older adults, 1715*t*
- Nutraderm, 441*t*
- Nutrasweet. *See* Aspartame
- Nutrients. *See also* Nutrition
- carbohydrates
 - recommended daily intake, 606
 - sources, 606
 - use by body, 606, 607*f*
 - deficiencies, 642*t*. *See also* Malabsorption; Malnutrition; *specific nutrients*
 - definition, 605, 631
 - dietary guidelines 2005, 605
 - fats
 - sources, 579, 608
 - types, 607–8
 - use by body, 607*f*
 - proteins
 - recommended daily intake, 606
 - sources, 606
 - uses in body, 606–7
- Nutrition. *See also* Nutrients
- assessment of status
 - diagnostic tests, 642, 644, 644*t*
 - functional health pattern interview, 618*t*
 - in older adult, 642*t*
 - physical assessment
 - anthropometric assessment, 620–22*t*
 - findings in malnutrition, 619*t*
 - oral cavity, 622–23*t*
 - overview, 619
 - sample documentation, 613*t*
 - by system, 402*t*
 - considerations in specific conditions
 - acute renal failure, 906
 - burns, 505
 - chronic renal failure, 919
 - diabetes mellitus
 - alcohol, 579
 - carbohydrates, 576–77
 - diet plan for the older adult, 580
 - fiber, 579
 - goals, 576
 - meal planning, 579–80
 - protein, 577, 579
 - sick-day management, 580
 - sodium, 579
 - sweeteners, 579
 - definition, 605
 - dietary guidelines, 20, 20*t*, 606*t*
 - disorders
 - Clinical Scenarios, 737*t*
 - eating disorders
 - anorexia nervosa, 650, 651*t*
 - binge-eating disorder, 651, 651*t*

- bulimia nervosa, 650–51, 651*t*
 - interdisciplinary care, 651–52
 - nursing care, 652
 - malabsorption. *See* Malabsorption
 - malnutrition. *See* Malnutrition
 - obesity. *See* Obesity
 - Food Guide Pyramid, 21*f*
 - in healing process, 307–8
 - metabolic processes, 613, 631
 - postsurgical, 70
 - Nutritional supplements. *See also* Herbal supplements/therapy
 - for cancer, 399*t*
 - minerals, 645*t*
 - vitamins
 - in cirrhosis, 717
 - Medication Administration, 645*t*
 - in substance abuse/withdrawal treatment, 114*t*
 - Nutritional-metabolic patterns:
 - altered endocrine function. *See also* Endocrine system
 - Build Clinical Competence, 600*t*
 - Clinical Scenarios, 601*t*
 - altered integumentary structure and function. *See also* Hair; Integumentary system; Nails; Skin
 - Build Clinical Competence, 513*t*
 - Clinical Scenarios, 514*t*
 - altered nutrition and gastrointestinal function.
 - See also* Nutrition
 - Build Clinical Competence, 735*t*
 - Clinical Scenarios, 736*t*
 - NANDA nursing diagnoses, 420*t*
 - Nydrizid. *See* Isoniazid
 - Nystagmus:
 - assessment, 1678
 - definition, 1519*t*, 1678
 - in labyrinthitis, 1726
 - Nystatin:
 - Medication Administration, 450*t*, 658*t*
 - for thrush, 359*t*, 657*t*, 658, 658*t*
- O**
- OA. *See* Osteoarthritis
 - Oatmeal, in therapeutic baths, 441*t*
 - Obesity:
 - cancer risk and, 372
 - complications, 630*t*, 632
 - coronary heart disease risk and, 964
 - definition, 630, 964
 - diabetes mellitus and, 567, 632
 - ethnic considerations, 630*t*, 631*t*
 - hypertension and, 1157
 - incidence and prevalence, 630
 - interdisciplinary care
 - diagnosis, 632, 632*t*, 633*t*
 - maintaining weight loss, 638
 - medications, 633, 634*t*
 - treatments
 - behavior modification, 636, 637*t*
 - dietary, 635, 635*t*, 636*t*
 - exercise, 634, 634*f*, 635*t*
 - surgical, 636–38, 637*f*, 638*t*
 - in middle adults, 26
 - nursing care
 - assessment, 638–39
 - community-based care, 640–41
 - health promotion, 638
 - Medication Administration, 634*t*
 - nursing diagnoses and interventions
 - activity intolerance, 640
 - chronic low self-esteem, 640
 - imbalanced nutrition: more than body requirements, 639–40
 - ineffective therapeutic regimen management, 640
 - using NANDA, NIC, and NOC, 640, 640*t*
 - Nursing Care Plan
 - assessment, 639*t*
 - critical thinking in the nursing process, 639*t*
 - diagnoses, 639*t*
 - evaluation, 639*t*
 - expected outcomes, 639*t*
 - planning and implementation, 639*t*
 - osteoarthritis risk and, 1450
 - pathophysiology, 631–32
 - risk factors, 631
 - surgical risk and nursing implications, 57*t*
 - Obestin-30. *See* Phentermine
 - Objective data, 8
 - Oblique fracture, 1401, 1402*f*
 - Obstructive jaundice, 704
 - Obstructive shock, 274
 - Obstructive sleep apnea:
 - complications, 1250–51, 1580
 - incidence, 1250
 - interdisciplinary care
 - diagnosis, 1251
 - surgery, 1251
 - treatments, 1251, 1251*f*
 - manifestations, 1250, 1251*t*
 - nursing care, 1251–52
 - pathophysiology, 1250
 - risk factors, 1250
 - Obtundation, 1529*t*
 - ObyTrim. *See* Phentermine
 - Occipital lobe, 1506*f*, 1506*t*
 - Occult blood:
 - definition, 744*t*
 - stool
 - in colorectal cancer diagnosis, 803
 - definition, 674
 - possible causes, 387*t*
 - purpose and description, 744*t*
 - related nursing care, 744*t*
 - Occupation, cancer risk and, 371, 372*t*
 - Occupational lung diseases:
 - asbestosis, 1345
 - causes, 1345*t*
 - classification, 1344
 - coal worker's pneumoconiosis, 1345
 - hypersensitivity pneumonitis, 1345–46
 - interdisciplinary care, 1346
 - manifestations, 1345–46
 - nursing care
 - community-based care, 1346
 - health promotion, 1346
 - nursing diagnoses and interventions, 1346
 - pathophysiology, 1345–46
 - physiology review, 1344
 - silicosis, 1345
 - Occupational therapy:
 - in Guillain-Barré syndrome, 1654
 - in Parkinson's disease, 1639
 - Octreotide:
 - for cryptosporidiosis, 778*t*
 - for Cushing's syndrome, 550
 - for esophageal varices, 718
 - for pancreatitis, 728
 - Oculocutaneous albinism, 427*t*
 - Oculomotor nerve (cranial nerve III):
 - anatomy, 1510*f*
 - assessment, 1519*t*
 - functions, 1511*t*, 1671*t*
 - Ocupress. *See* Carteolol
 - Odynophagia, 1240
 - Off-pump coronary artery bypass (OPCAB), 978
 - Ofloxacin, 849, 1846
 - OGTT (oral glucose tolerance test), 526*t*, 569
 - Oil retention enema, 760
 - Oil slides, 428*t*
 - Ointments, for skin disorders, 441*t*
 - OKT3. *See* Muromonab-CD3
 - Older adults:
 - chronic venous insufficiency, 1196*t*
 - Older adults (over age 65):
 - abuse, 256*t*
 - acute myocardial infarction, 984*t*
 - age-related changes
 - bowel elimination, 746*t*
 - cardiac, 952*t*
 - cardiovascular system, 29*t*
 - ears, 1686*t*
 - endocrine system, 529*t*, 545*t*
 - eyes, 1676*t*
 - female reproductive system, 1760*t*
 - gastrointestinal system, 619*t*, 746*t*
 - hematologic system, 1091*t*
 - immune function, 330, 1091*t*
 - kidneys, 883, 884*t*
 - male reproductive system, 1749*t*
 - musculoskeletal system, 1389*t*
 - neurologic system, 1518*t*
 - overview, 29*t*
 - pancreas, 529*t*
 - peripheral vascular system, 1091*t*
 - respiratory system, 1214*t*, 1222*t*
 - skin, 430*t*
 - urinary system, 841*t*, 883, 884*t*
 - age-related macular degeneration, 1715*t*
 - breast cancer, 1823*t*
 - burns, 508*t*
 - cancer, 371*t*
 - cardiac dysrhythmias, 996*t*
 - constipation, 761*t*
 - demographics, 28–29, 30*f*
 - diabetes mellitus, 567–68, 568*t*, 580
 - diversity, 28*t*
 - end-of-life checklist, 95*t*. *See also* End-of-life care
 - epilepsy, 1548*t*
 - fall prevention, 1418*t*
 - family-related risk factors for alterations in health, 32*t*, 33
 - fecal incontinence self-care practices, 764*t*
 - fire deaths, 487
 - fluids and electrolytes
 - changes with aging, 202
 - fluid volume deficit, 203*t*, 207*t*
 - hypocalcemia, 227–28
 - health needs
 - assessment guidelines, 30
 - promoting health behaviors, 30, 31*t*
 - risks for alterations in health
 - injuries, 29–30
 - pharmacologic effects, 30
 - physical and psychosocial stressors, 30
 - heart failure, 1023*t*
 - hip fractures, 1415
 - HIV/AIDS in, 349–50
 - home care of dementing disorder, 43*t*
 - hypertension, 1157*t*
 - hypothyroidism, 545*t*
 - infections, 314–15, 315*t*
 - kidney function, 883, 884*t*
 - malnutrition, 641, 642*t*
 - medication toxicity, 30
 - multiple sclerosis, 1634*t*
 - nutritional needs, 642*t*
 - online health information use, 1458*t*
 - osteomyelitis, 1477
 - pain management, 65*t*, 175, 175*t*

- peripheral vascular disease, 1178t
pneumonia, 1268t
pressure ulcer, 474t, 475t
renal failure, 914t
sexuality function in women, 1794t
shock, 273–74, 280t
special considerations
in disasters, 138
in surgery
intraoperative, 68, 70
Nursing Research: assisting in
communicating postoperative pain, 65t
postoperative, 79, 80t
substance abuse, 115t
tuberculosis, 1282t
upper respiratory disorders, 315t
urinary incontinence, 873t
urinary tract infection, 315t, 847, 848, 873t
- Olfactory nerve (cranial nerve I):
anatomy, 1510f
assessment, 1223t, 1519t
function, 1511t
- Oligodendrocytes, 1628t
Oligodendroglioma, 1570t. *See also* Brain tumors
Oligomenorrhea, 1802. *See also* Dysfunctional
uterine bleeding
- Oliguria, 839, 886
Olmesartan, 1161t
Olsalazine, 786, 787t
Omega-3 polyunsaturated fatty acids, 1326
Omeprazole:
Medication Administration, 665t
preoperative use and nursing implications, 62t
in specific conditions
gastritis, 678
gastroesophageal reflux disease, 665
pancreatitis, 728
short bowel syndrome, 799
- Ommaya reservoir, 1571, 1571f
Omnipen. *See* Ampicillin
Oncogenes, 374, 1121
Oncologic emergencies:
hypercalcemia. *See* Hypercalcemia
hyperuricemia, 410
obstructive uropathy, 410
pericardial effusions and neoplastic cardiac
tamponade, 409
sepsis and septic shock, 410
spinal cord compression, 410
superior vena cava syndrome, 409, 410f
syndrome of inappropriate diuretic hormone, 410
tumor lysis syndrome, 410–11
- Oncology, 369
Oncology nurse, 369
Oncotic pressure. *See* Osmotic pressure
Oncovin. *See* Vincristine
Ondansetron, 672, 673t
Onycholysis, 483
Onychomycosis, 483
Oophorectomy, 1809, 1819
Oophoritis, 1850
OPCAB (off-pump coronary artery bypass), 978
Open (guillotine) amputation, 1421, 1422t. *See also*
Amputation
- Open commissurotomy, 1060
Open (compound) fracture, 1401, 1402f. *See also*
Fractures
- Open pneumothorax, 1299. *See also*
Pneumothorax
- Open reduction and internal fixation (ORIF):
hip fracture, 1415, 1416f
nursing interventions, 1412t
procedure, 1411, 1411f
- Open-angle glaucoma. *See* Glaucoma
- Operating room technician (ORT), 66
Ophthalmoscope, guidelines for use, 1681f, 1681t
Opiates. *See* Narcotic analgesics
Opioids. *See* Narcotic analgesics
Opium, 756t
Opium derivatives, 756t
Opportunistic infections, in AIDS, 353–54, 359t
Opsonization, 293, 294t
Optic cup, 1706
Optic disc, 1680, 1681f, 1681t
Optic nerve (cranial nerve II):
anatomy, 1510f, 1673f
assessment, 1519t
function, 1511t, 1672–73
OptiPranolol. *See* Metipranolol
Orabase, 657
Orajel, 658t
Oral cancer:
incidence, 660
interdisciplinary care, 660
manifestations, 660, 660t
nursing care
assessment, 661
community-based care, 663
health promotion, 661
nursing diagnoses and interventions
disturbed body image, 663
imbalanced nutrition: less than body
requirements, 662
impaired verbal communication, 662–63
risk for ineffective airway clearance, 662
Nursing Care Plan
assessment, 661t
critical thinking in the nursing process, 661t
diagnoses, 661t
evaluation, 661t
expected outcomes, 661t
planning and implementation, 661t
pathophysiology, 660, 660f
risk factors, 660
staging, 660t
- Oral contraceptives:
coronary heart disease risk and, 964
for dysfunctional uterine bleeding, 1803
for dysmenorrhea, 1802t
Medication Administration, 1802t
- Oral endotracheal tube, 1357t. *See also*
Endotracheal tube
- Oral glucose tolerance test (OGTT), 526t, 569
Oral health:
in diabetes mellitus, 592
physical assessment, 622–23t
- Oral hypoglycemic agents, 578t
Oral mucositis, 657t. *See also* Stomatitis
- Oral rehydration:
for diarrhea, 755
for fluid volume deficit, 205
for gastroenteritis, 776–77
- Orasone. *See* Prednisone
Orbital blowout fracture, 1702
Orchiectomy:
in advanced prostate cancer, 1787t
in testicular cancer, 1775
in testicular torsion, 1774
- Orchitis, 1774
Oretic. *See* Hydrochlorothiazide
- Organ donation:
caring for donor, 265
donor criteria, 342, 920
process, 263–65
- Organ transplantation. *See* Transplant procedures
Organic solvents, abuse by inhalation, 111
ORIF. *See* Open reduction and internal fixation
Orinase. *See* Tolbutamide
- Orlistat, 633, 634t
Ornade. *See* Phenylpropranolamine
Ornish diet, 968t
Oropharynx, 1211
Orphenadrine citrate, 1600t
ORT (operating room technician), 66
Orthoclone. *See* Muromonab-CD3
Orthopnea, 209, 1026
Orthostatic hypotension:
client teaching, 208
definition, 1093t
in fluid volume deficit, 205
- Orthovisc. *See* Hyaluronan injections
Orudis. *See* Ketoprofen
Orudis KT. *See* Ketoprofen
Oruvail. *See* Ketoprofen SR
Oseltamivir, 1234
Osler's nodes, 1046
Osmolality:
definition, 198
serum. *See* Serum osmolality
urine. *See* Urine, osmolality
- Osmolarity, 198
Osmotic diuretics:
Medication Administration, 905t, 1539t
in specific conditions
acute renal failure, 904, 905t
increased intracranial pressure, 1538, 1539t
- Osmotic laxatives, 759t
Osmotic pressure:
in body fluid movement, 198
definition, 198
in glomerular filtration, 831, 996
- Osseous metastases, 181
Ossicles, 1682, 1682f
Ossification, 1381
Osteitis deformans. *See* Paget's disease
Osteoarthritis (OA):
complementary and alternative therapies, 1455
complications, 1450–51
definition, 1449
hand, 1450, 1450f
incidence, 1449
interdisciplinary care
conservative management, 1451–52
diagnosis, 1451
medications, 1451
surgery
arthroscopy, 1452
joint arthroplasty. *See* Total joint replacement
osteotomy, 1452
viscosupplementation, 1452
- management, 1451t
manifestations, 1450
nursing care
assessment, 1455
community-based care, 1457
health promotion, 1455
nursing diagnoses and interventions, 1455,
1457
using NANDA, NIC, and NOC, 1457, 1457t
- Nursing Care Plan
assessment, 1456t
critical thinking in the nursing process, 1456t
diagnoses, 1456t
evaluation, 1456t
expected outcomes, 1456t
planning and implementation, 1456t
pathophysiology, 1450
racial/ethnic considerations, 1449t
vs. rheumatoid arthritis, 1460t
risk factors, 1450
- Osteoblasts, 1380
Osteochondroma, 1482t

- Osteoclasts, 1380
 Osteocytes, 1380
 Osteoid, 1482t
 Osteolysis, 1482
 Osteoma, 1482t
 Osteomalacia:
 causes, 1447, 1448t
 in chronic renal failure, 918
 definition, 1447
 interdisciplinary care
 diagnosis, 1436t, 1448–49
 medications, 1449
 manifestations, 1448, 1448t
 nursing care, 1449
 vs. osteoporosis and Paget's disease, 1436t
 pathophysiology, 1436t, 1488
 risk factors, 1447–88
 Osteomyelitis:
 from a contiguous infection, 1478
 definition, 1477
 hematogenous, 1478
 interdisciplinary care
 diagnosis, 1479
 medications, 1479
 surgery, 1479
 manifestations, 1479t
 nursing care
 of client undergoing surgical debridement
 health education for client and family, 1479t
 postoperative, 1479t
 preoperative, 1479t
 community-based care, 1480–81
 nursing diagnoses and interventions
 acute pain, 1480
 hyperthermia, 1480
 impaired physical mobility, 1480
 risk for infection, 1480
 in older adults, 1477
 pathophysiology, 1477–78, 1478f
 in vascular insufficiency, 1478
 Osteophytes, 1450
 Osteoporosis:
 in chronic renal failure, 918
 complications, 1435
 definition, 1433
 incidence, 1433
 interdisciplinary care
 diagnosis, 1436, 1436t
 medications, 1436, 1437t
 prevention, 1435
 manifestations, 1435, 1435f
 nursing care
 assessment, 1438–39
 community-based care, 1400
 health promotion
 exercise, 1438
 healthy behaviors, 1438
 nutrition, 1437–38
 Medication Administration, 1437t
 nursing diagnoses and interventions
 acute pain, 1440
 health-seeking behaviors, 1439
 imbalanced nutrition: less than body requirements, 1440
 risk for injury, 1439–40
 using NANDA, NIC, and NOC, 1400, 1400t
 Nursing Care Plan
 assessment, 1438t
 critical thinking in the nursing process, 1438t
 diagnoses, 1438t
 evaluation, 1438t
 expected outcomes, 1438t
 planning and implementation, 1438t
 Nursing Research: risk assessment, 1439t
 vs. osteomalacia and Paget's disease, 1436t
 pathophysiology, 1434–35, 1436t
 racial/ethnic considerations, 1434, 1434t
 risk factors, 1433–34, 1433t, 1439t
 Osteosarcoma, 1482t. *See also* Bone tumors
 Osteotomy, 1452
 Ostomy, 746. *See also* Colostomy; Ileostomy
 Otitis externa:
 definition, 1718
 interdisciplinary care, 1719–20
 manifestations, 1719
 nursing care
 community-based care, 1720–21
 nursing diagnoses and interventions, 1720
 teaching to prevent, 1720t
 pathophysiology, 1719
 risk factors, 1719
 Otitis media:
 acute, 1722
 chronic, 1724–25
 definition, 1721
 interdisciplinary care
 diagnosis, 1722
 medications, 1722
 surgery, 1723
 manifestations, 1722, 1722f
 nursing care
 assessment, 1723
 community-based care, 1723
 health promotion, 1723
 nursing diagnoses and interventions, 1723
 pathophysiology, 1721
 serous, 1721–22
 Otorrhea, 1555
 Otosclerosis, 1725–26
 Otolaryngology, guidelines for use, 1686–87t, 1686f
 Outcomes, 9
 Outpatient surgery, 54–55
 Output, pacemaker, 1010t. *See also* Pacemakers
 Ovarian cancer:
 complications, 1818, 1818t
 genetic considerations, 1755t, 1758
 incidence, 1817
 interdisciplinary care
 diagnosis, 1818
 medications, 1818–19
 radiation therapy, 1819
 surgery, 1819
 manifestations, 1818
 nursing care, 1819
 pathophysiology, 1818
 risk factors, 1817
 staging, 1818, 1818t
 Ovarian cycle, 1754, 1754f
 Ovaries:
 anatomy, physiology, and functions, 1751t, 1753, 1753f
 cancer. *See* Ovarian cancer
 cysts, 1808, 1809t
 physical assessment, 1754–65t
 Overdose:
 signs, 113t
 treatment, 112, 113t, 114t
 Overflow urinary incontinence, 874t. *See also* Urinary incontinence
 Oversensing, pacemaker, 1011t. *See also* Pacemakers
 Overweight, 630. *See also* Obesity
 Oviducts. *See* Fallopian tubes
 Ovral. *See* Norgestrel/ethinyl estradiol
 Oxacillin, 319t, 1046
 Oxalate, 858, 858t
 Oxaliplatin, 805
 Oxaprozin, 178t, 1464t
 Oxazepam, 114t, 716
 Oxazolidinones, 320t
 Oxycams, 178t, 306
 Oxiconazole, 450t
 Oximetry:
 pulse. *See* Pulse oximetry
 transcutaneous. *See* Pulse oximetry
 Oxistat. *See* Oxiconazole
 Oxybutynin, 871, 871t, 875
 Oxycodone:
 abuse, 110, 110f
 equianalgesic drug chart, 180t
 for long-term analgesia at home, 190t
 nursing considerations, 180t
 preoperative use and nursing implications, 62t
 OxyContin. *See* Oxycodone
 Oxygen concentration (FIO₂), 1360, 1360t
 Oxygen therapy:
 in acute respiratory failure, 1355
 in chronic obstructive pulmonary disease, 1335
 in pneumonia, 1272, 1272f, 1273f
 Oxygen-hemoglobin dissociation curve, 1216, 1216f
 Oxyhemoglobin, 1076, 1216
 Oxymorphone HCl, 180t, 182t
 Oxytetracycline, 320t
 Oxytocin, 520
P
 P wave, 948f, 948t
 p24 assay, 355
 PABA (*p*-aminobenzoic acid), 465t
 Pacemakers:
 artifacts on ECG, 1009, 1010f
 client safety considerations, 1010t
 modes and functions, 1010t
 nursing care for implant procedure
 home care, 1012t
 postoperative, 1012t
 preoperative, 1012t
 problems and corrective strategies, 1011t
 types, 1008–9, 1009f
 Pacific Islanders:
 substance use, 105t
 tuberculosis incidence, 1281t
 Pacing spike, 1010t. *See also* Pacemakers
 Packed red blood cells (RBCs), 263t
 Paclitaxel, 391, 1819
 PaCO₂:
 abnormal findings, 1560t
 definition, 239
 in gastroenteritis and diarrhea, 776t
 in metabolic acidosis, 242
 in metabolic alkalosis, 246
 normal values, 239, 240t, 1560t
 in respiratory acidosis, 242t, 247
 in respiratory alkalosis, 242t, 250
 significance, 240t
 PACs. *See* Premature atrial contractions
 Paget's disease:
 breast, 1823
 characteristics, 1441
 complications, 1441
 incidence, 1441
 interdisciplinary care
 diagnosis, 1436t, 1441–42
 medications, 1442, 1442t
 surgery, 1442
 manifestations, 1441, 1441t
 nursing care
 community-based care, 1443
 Medication Administration, 1442t
 nursing diagnoses and interventions

- Paget's disease—*continued*
 chronic pain, 1443
 impaired physical mobility, 1443
 vs. osteoporosis and osteomalacia, 1436t
 pathophysiology, 1436t, 1441
 Pagitane. *See* Cycrimine
- Pain:
 acute
 definition, 173
 physical responses to, 173–74
 referred, 173, 173f
 somatic, 173
 visceral, 173
 breakthrough, 174
 cancer
 causes, 381
 management, 399–400
 types, 381
 central, 174
 Chapter Highlights, 192t
 chronic
 categories, 174
 conditions, 174
 definition, 174
 definition, 170
 factors affecting responses
 age, 175–76, 175t
 emotional status, 176
 knowledge, 177
 past experiences, 176
 sociocultural influences, 176
 source and meaning of pain, 176
 inhibitory mechanisms, 171–72
 interdisciplinary care
 complementary therapies
 acupuncture, 185
 biofeedback, 185
 cutaneous stimulation, 186
 distraction, 186
 hypnotism, 185
 relaxation, 185–86
 medications
 anticonvulsants, 179. *See also* Antiepileptic drugs
 antidepressants, 179. *See also*
 Antidepressants
 bisphosphonates, 181
 for cancer pain, 399–400
 dosing schedules, 181–82
 duration of action, 181
 local anesthetics, 179
 narcotic analgesics. *See* Narcotic analgesics
 nonnarcotic analgesics, 178
 nonsteroidal anti-inflammatory drugs, 178,
 178t. *See also* Nonsteroidal anti-inflammatory drugs
 opiates/opioids. *See* Narcotic analgesics
 radiopharmaceuticals, 181
 routes of administration, 182–83, 183f
 WHO analgesic ladder, 177, 177f
 surgical procedures
 cordotomy, 184, 185f
 neurectomy, 184, 185f
 rhizotomy, 184, 185f
 sympathectomy, 184, 185f
 transcutaneous electrical nerve stimulation,
 184–85, 185f
 myths and misconceptions, 177
 neurophysiology, 170, 170t, 171f
 nursing care
 acute postoperative pain, 79–80. *See also*
 Postoperative period, pain management
 assessment
 behavioral responses, 188
 client perceptions, 186–87
 McGill Pain Questionnaire, 187f
 pain scales, 187f
 physiologic responses, 188
 self-management, 188
 in client with a fracture, 1408t
 community-based care, 190, 190t
 in dying client, 92
 Medication Administration
 narcotic analgesics, 182t
 nonsteroidal anti-inflammatory drugs, 179t
 nursing diagnoses and interventions, 188–90
 using NANDA, NIC, and NOC, 190, 190t
 Nursing Care Plan
 assessment, 191t
 critical thinking in the nursing process, 191t
 diagnosis, 191t
 evaluation, 191t
 expected outcomes, 191t
 planning and implementation, 191t
 Nursing Research: observational studies of pain
 management, 189t
 pathway, 171, 171f
 phantom, 174
 postoperative. *See* Postoperative period, pain
 management
 psychogenic, 175
 theories, 172–73, 172f
 Pain behaviors, 188
 Pain scales, 186, 187f
 Pain threshold, 175
 Pain tolerance, 175
 Palifermin, 658
 Palliative care, 92
 Palliative procedure, 54t
 Pallidotomy, 1639
 Pallor:
 assessment in light and dark skin, 426t
 causes, 426t, 1093t
 definition, 425t, 1093t
 Pamidronate:
 Medication Administration, 1442t
 in specific conditions
 bony metastases, 181
 hypercalcemia, 232, 547
 Paget's disease, 1442, 1442t
p-aminobenzoic acid (PABA), 465t
 Pancreas:
 age-related changes, 529t
 anatomy, 611f, 613
 cell types, 521
 disorders
 cancer. *See* Pancreatic cancer
 diagnostic tests, 526t, 616–17t, 728t
 endocrine function. *See* Diabetes mellitus
 pancreatitis. *See* Pancreatitis
 functions
 endocrine, 521, 564
 exocrine, 613, 725–26, 742
 Pancreas transplant, 342t, 581. *See also* Transplant
 procedures
 Pancreatic cancer:
 incidence, 731
 interdisciplinary care, 732–33
 manifestations, 731
 nursing care of client undergoing Whipple's
 procedure, 732t
 pathophysiology, 731
 risk factors, 731
 Pancreatic polypeptide, 521
 Pancreatitis:
 acute
 complications, 726–27
 manifestations, 726, 727t
 pathophysiology, 726
 chronic
 complications, 727
 manifestations, 727, 727t
 pathophysiology, 727
 definition, 726
 interdisciplinary care
 diagnosis, 616–17t, 727, 728t
 medications, 727–28, 728t
 treatments
 complementary therapies, 728
 nutrition, 728
 surgery, 728
 manifestations, 726, 727t
 nursing care
 assessment, 729–30
 community-based care, 731
 health promotion, 729
 Medication Administration, 728t
 nursing diagnoses and interventions
 imbalanced nutrition: less than body
 requirements, 730
 pain, 730
 risk for deficient fluid volume, 730–31
 using NANDA, NIC, and NOC, 731, 731t
 pathophysiology, 726–27
 Pancreatoduodenectomy. *See* Whipple's procedure
 Pancrelipase, 728t
 Pancuronium bromide, 1356t
 Pancytopenia, 1109
 Pantoprazole, 502, 665, 665t
 Pantothenic acid, 609t
 PaO₂:
 abnormal findings, 1560t
 in acid–base imbalances, 242t
 definition, 239
 normal values, 239, 240t, 1560t
 significance, 240t
 PAP (prostatic acid phosphatase), 384t
 Papanicolaou smear (Pap test):
 classification systems, 1813t
 purpose and description, 1755, 1756t
 related nursing care, 1756t
 Papaverine, 1769
 Papillary thyroid carcinoma, 546
 Papilledema, 1158
 Papilloma:
 laryngeal, 1253
 urinary tract, 862, 862f
 Papillomavirus. *See* Human papillomavirus
 Papular warts, 1841. *See also* Genital warts
 Papule, 432t
 Paracentesis, 717, 719t
 Paradoxical movement, 1303, 1303f
 Paraesophageal hiatal hernia, 667, 668f
 Paraflex. *See* Chlorzoxazone
 Paraldehyde, 108
 Paralytic ileus. *See also* Intestinal obstruction
 after abdominal surgery, 811
 in peritonitis, 770
 in spinal cord injury, 1599
 Paraneoplastic syndromes:
 laboratory indicators, 380t
 in lung cancer, 1311
 pathophysiology, 380
 in renal cancer, 896
 Paraphasia, 1620
 Paraphimosis, 1771
 Paraplatin. *See* Carboplatin
 Paraplegia, 1584f, 1599
 Parasites, 311t, 450–51
 Parasympathetic nervous system:
 in blood pressure regulation, 1085
 effects of stimulation, 1512
 physiology, 1512

- Parathyroid glands. *See also* Parathyroid hormone
 anatomy, physiology, and functions, 520
 disorders
 diagnostic tests, 524*t*
 hyperparathyroidism
 definition, 547
 interdisciplinary care, 547
 manifestations, 547, 547*t*
 nursing care. *See* Hypercalcemia
 pathophysiology, 547
 hypoparathyroidism
 definition, 548
 interdisciplinary care, 548
 manifestations, 548, 548*t*
 nursing care. *See* Hypocalcemia
 pathophysiology, 548
- Parathyroid hormone (PTH):
 abnormal, possible causes, 387*t*
 in calcium balance, 227, 227*f*; 1381
 diagnostic test, 524*t*
 feedback mechanism, 519*t*
 functions, 520, 520*t*
 normal values, 387*t*, 524*t*
 in specific conditions
 cancer, 380
 hypercalcemia, 232
 osteomalacia, 1436*t*
 osteoporosis, 1436*t*
 Paget's disease, 1436*t*
 paraneoplastic syndromes, 380*t*
- Paraurethral. *See* Skene's glands
- Paregoric, 756*t*
- Parenchyma, 294, 847
- Parenteral nutrition. *See* Total parenteral nutrition
- Paresthesias, 589, 1105
- Parietal lobe, 1506*f*, 1506*t*
- Parish nursing, 37
- Parkinsonism, secondary, 1635
- Parkinson's disease:
 characteristics, 1635
 complications, 1636*t*, 1637
 genetic considerations, 1513*t*
 incidence and prevalence, 1635
 interdisciplinary care
 deep brain stimulation, 1639
 diagnosis, 1637
 medications, 1637–38*t*
 rehabilitation, 1639
 surgery, 1639
 manifestations
 abnormal posture, 1636
 autonomic and neuroendocrine effects, 1636
 interrelated effects, 1636–37
 mood and cognition, 1636
 overview, 1636*t*
 rigidity and bradykinesia, 1635–36, 1636*f*
 sleep disturbances, 1636
 tremor, 1635
 nursing care
 assessment, 1639–40
 community-based care, 1642
 health promotion, 1639
 Medication Administration, 1637*t*
 nursing diagnoses and interventions
 disturbed sleep pattern, 1641
 imbalanced nutrition: less than body requirements, 1641
 impaired physical mobility, 1640–41
 impaired verbal communication, 1641
 using NANDA, NIC, and NOC, 1642, 1642*t*
 pathophysiology, 1635
 stages, 1635*t*
- Parkland formula, 499
- Parlodol. *See* Bromocriptine
- Paromomycin, 778*t*, 780*t*
- Paronychia, 483
- Paroxetine, 1798
- Paroxysmal, 1000
- Paroxysmal nocturnal dyspnea (PND), 1027
- Paroxysmal supraventricular tachycardia (PSVT), 997*t*, 1001
- Partial gastrectomy, 689, 689*f*
- Partial laryngectomy, 1255
- Partial parenteral nutrition, 648
- Partial seizures, 1548–49
- Partial thromboplastin time (PTT), 60*t*
- Partial-thickness burn, 489*t*, 490, 490*f*. *See also* Burns
- Partner abuse. *See* Intimate partner violence
- Passive immunity, 299, 300*t*
- Patch, skin, 432*t*
- Patch test, 337, 428*t*
- Patellar reflex, 1523*f*
- Pathogens, 309, 310–12, 311*t*. *See also* Infections
- Pathologic fracture, 1136, 1401
- Pathophysiology Illustrated:
 acute glomerulonephritis, 887*t*
 acute renal failure, 901*t*
 acute respiratory distress syndrome, 1368–69*t*
 bone healing, 1404–5*t*
 cirrhosis and esophageal varices, 712–13*t*
 coronary heart disease, 960–61*t*
 multiple sclerosis, 1628–29*t*
 peptic ulcer disease, 682–83*t*
 sickle cell anemia, 1108*t*
 tuberculosis, 1284–85*t*
- Patient-controlled analgesia, 183, 183*f*
- Pavementing, 293, 293*f*
- Pavulon. *See* Pancuronium bromide
- PAWP (pulmonary artery wedge pressure), 1031, 1032*f*
- Paxil. *See* Paroxetine
- PBSCT (peripheral blood stem cell transplantation), 398, 1132, 1333*t*. *See also* Stem cell transplant
- PCOS (polycystic ovarian syndrome), 632, 1808, 1809*t*
- PCP. *See* *Pneumocystis carinii* pneumonia
- PCP (phencyclidine), 110–11, 113*t*
- PCR (percutaneous coronary revascularization), 977, 977*f*, 978*t*
- PCR (polymerase chain reaction), 1287
- Peak expiratory flow rate (PEFR), 1324
- Peau d'orange, 1761*t*, 1823
- Pediculosis, 450–51
- Pedigrees:
 challenges, 160
 characteristics, 159–60
 ethical implications, 164*t*
 facts and information included, 163*t*
 sample three-generation, 161*f*
 steps in drawing, 162*t*
 symbols used, 160*f*
- Pedunculated polyps, 800, 800*f*. *See also* Polyps
- PEEP (positive end-expiratory pressure), 1358, 1359*t*
- PEFR (peak expiratory flow rate), 1324
- Pelvic exenteration, 1813
- Pelvic floor muscle exercises, 876, 877*t*
- Pelvic inflammatory disease (PID):
 in AIDS, 354
 Case Study, 51
 chlamydia and, 1845
 complications, 1851
 definition, 1850
 gonorrhea and, 1846
 incidence, 1851
 interdisciplinary care
- diagnosis, 1851
 medications, 1851
 surgery, 1851
 manifestations, 1851
 nursing care
 community-based care, 1852
 nursing diagnoses and interventions
 deficient knowledge, 1851–52
 risk for injury, 1851
 pathophysiology, 1851
- Pelvis:
 bimanual examination, 1765*t*
 fracture, 1414
- Pemphigus vulgaris:
 interdisciplinary care, 460
 manifestations, 460
 nursing care, 460
 pathophysiology, 460
- Penbutolol, 1161*t*
- Pendred syndrome, 527*t*
- Penectomy, 1772
- Penetrance, 155
- Penetrating trauma, 256, 1702
- Penetrex. *See* Enoxacin
- Penicillamine, 1465*t*, 1466, 1485
- Penicillin G:
 Medication Administration, 319*t*
 in specific conditions
 pneumonia, 1271*t*
 rheumatic fever, 1043
 syphilis, 1849
- Penicillin V, 319*t*
- Penicillin-resistant *Streptococcus pneumoniae* (PRSP), 314
- Penicillins:
 Medication Administration, 319*t*
 in specific conditions
 endocarditis, 1046
 lung abscess, 1280
 tonsillitis, 1239
 topical
 in conjunctivitis, 1694
 in corneal infections, 1697
- Penile implants, 1770, 1770*f*
- Penis:
 age-related changes, 1749*t*, 1769
 anatomy, physiology, and functions, 1744, 1744*f*; 1745*t*
 disorders
 cancer
 incidence, 1772
 interdisciplinary care, 1772
 nursing care, 1772
 pathophysiology, 1772
 phimosis, 1749*t*, 1771
 priapism, 1771–72, 1772*t*
 physical assessment, 1749–50*t*, 1749*f*; 1750*f*
- Penred syndrome, 1684*t*
- Pentamidine, 359*t*, 1271*t*
- Pentazocine, 180*t*, 182*t*, 816
- Pentoxifylline, 1177, 1182
- Penumbra, 1580
- Pepcid. *See* Famotidine
- Peppermint tea, 792
- Peptic ulcer disease (PUD):
 Case Study, 737*t*
 complications
 gastric outlet obstruction, 681*t*, 684
 hemorrhage, 681, 681*t*
 perforation, 681*t*, 684
 definition, 680
 incidence, 680
 interdisciplinary care
 diagnosis, 684

- Peptic ulcer disease (PUD)—*continued*
 medications, 684–85
 treatments
 nutrition, 685
 surgery, 685
 treatment of complications, 685
 manifestations, 681, 681*t*
 nursing care
 assessment, 685
 community-based care, 688
 health promotion, 685
 nursing diagnoses and interventions
 deficient fluid volume, 687–88
 disturbed sleep pattern, 687
 imbalanced nutrition: less than body requirements, 687
 pain, 686–87
 using NANDA, NIC, and NOC, 688, 688*t*
 Nursing Care Plan
 assessment, 686*t*
 critical thinking in the nursing process, 686*t*
 diagnoses, 686*t*
 evaluation, 686*t*
 expected outcomes, 686*t*
 planning and implementation, 686*t*
 pathophysiology, 680–81, 681*f*; 682–83*t*
 risk factors, 680, 680*t*
 Zollinger-Ellison syndrome, 684
 Peptic ulcers, 680
 Pepto-Bismol, 685, 756*t*
 Percocet. *See* Oxycodone
 Percussion, in chest physiotherapy, 1272–73, 1273*f*
 Percutaneous balloon valvuloplasty, 1060, 1060*f*
 Percutaneous cholecystostomy, 701
 Percutaneous coronary revascularization (PCR):
 nursing care, 978*t*
 procedure, 977, 977*f*
 Percutaneous transluminal angioplasty (PTA), 1177–78
 Percutaneous transluminal coronary angioplasty (PTCA), 977, 977*f*
 Percutaneous ultrasonic lithotripsy, 858, 859*f*
 Perforation, peptic ulcer, 681*t*, 684
 Perfusion lung scan, 1349. *See also* Pulmonary ventilation/perfusion scan
 Pergolide, 1638*t*, 1639
 Pericardial effusion, 409, 1050
 Pericardial friction rub, 986
 Pericardiectomy, 1052
 Pericardiocentesis:
 purpose and description, 943, 946*t*, 1052
 related nursing care, 946*t*
 Pericarditis:
 after acute myocardial infarction, 985–86
 causes, 1050*t*
 complications
 cardiac tamponade. *See* Cardiac tamponade
 chronic constrictive pericarditis, 1051, 1051*f*
 pericardial effusion, 1050
 definition, 985–86, 1050
 interdisciplinary care
 diagnosis, 1051–52
 medications, 1052
 pericardiocentesis. *See* Pericardiocentesis
 surgery, 1052
 manifestations, 1050
 nursing care
 assessment, 1052
 community-based care, 1053
 health promotion, 1052
 nursing diagnoses and interventions
 activity intolerance, 1053
 acute pain, 1052
 ineffective breathing pattern, 1052
 risk for decreased cardiac output, 1053
 pathophysiology, 1050
 Pericardium, 936–37, 937*f*; 1049
 Perimenopause. *See* Menopause
 Perimetrium, 1752
 Perindopril, 1161*t*
 Perineal prostatectomy, 1781*t*, 1785
 Perineum:
 anatomy, 1751*t*, 1752*f*
 physical assessment, 1763*t*
 Periodontal disease, in diabetes mellitus, 589–90
 Perioperative nursing, 54. *See also* Surgery
 Periorbital edema, 886
 Peripheral blood stem cell transplant (PBSCT), 398, 1132, 1333*t*. *See also* Stem cell transplant
 Peripheral nervous system:
 anatomy, physiology and functions
 autonomic nervous system
 parasympathetic division. *See* Parasympathetic nervous system
 physiology, 1511
 sympathetic division. *See* Sympathetic nervous system
 cranial nerves, 1509, 1510*f*; 1511*t*
 reflexes, 1510–11, 1511*f*
 spinal nerves, 1508*f*, 1509, 1510*f*
 disorders
 peripheral nerves
 Guillain-Barré syndrome. *See* Guillain-Barré syndrome
 myasthenia gravis. *See* Myasthenia gravis
 Peripheral neuropathies, in diabetes mellitus, 589
 Peripheral obesity, 632
 Peripheral T-cell lymphoma, 1130*t*. *See also* Lymphomas
 Peripheral vascular disease (PVD):
 complications, 1177, 1478
 definition, 1176
 in diabetes mellitus, 588
 incidence, 1176
 interdisciplinary care
 complementary therapies, 1178
 diagnosis, 1177
 foot care, 1178*t*
 medications, 1177
 revascularization, 1177–78
 treatments, 1177
 manifestations, 590, 590*t*, 1176–77, 1177*t*
 nursing care
 assessment, 1178
 community-based care, 1180
 health promotion, 1178
 nursing diagnoses and interventions
 activity intolerance, 1179–80
 impaired skin integrity, 1179
 ineffective tissue perfusion: peripheral, 1179
 pain, 1179
 of older adults, 1178*t*
 using NANDA, NIC, and NOC, 1180, 1180*t*
 Nursing Care Plan
 assessment, 1181*t*
 critical thinking in the nursing process, 1181*t*
 diagnoses, 1181*t*
 evaluation, 1181*t*
 expected outcomes, 1181*t*
 planning and implementation, 1181*t*
 pathophysiology, 1176
 risk factors, 1176
 Peripheral vascular resistance (PVR), 1082, 1085
 Peripheral vascular system:
 age-related changes, 1091*t*
 anatomy, physiology, and functions
 arterial circulation, 1082, 1085, 1176
 blood vessel structure, 1082, 1176
 major arteries, 1083*f*
 major veins, 1084*f*
 venous circulation, 1186
 assessment
 diagnostic tests, 1088, 1088*t*
 functional health pattern interview, 1090*t*
 genetic considerations, 1088, 1089*t*
 health assessment interview, 1089
 physical assessment
 abdomen, 1098*f*, 1098*t*
 arteries and veins, 1094–95*t*
 blood pressure, 1092–93*t*
 lower extremity, 1096–97*t*, 1097*f*
 peripheral pulses, 1091*f*
 pulse pressure, 1093*t*
 skin characteristics, 1093*t*
 techniques, 1091
 upper extremity, 1095–96*t*
 sample documentation, 1087
 disorders
 acute arterial occlusion. *See* Acute arterial occlusion
 aortic aneurysm. *See* Aortic aneurysm
 Chapter Highlights, 1202*t*
 Clinical Scenarios, 1206*t*
 hypertension. *See* Hypertension
 peripheral atherosclerosis. *See* Peripheral vascular disease
 thromboangiitis obliterans. *See* Thromboangiitis obliterans
 venous thrombosis. *See* Venous thrombosis
 Peristalsis, 610, 743
 Peritoneal dialysis:
 definition, 906
 long-term, 920
 nursing care, 910*t*
 procedure, 909–10, 909*f*
 Peritoneal lavage, 770
 Peritonitis:
 complications, 770
 definition, 769
 interdisciplinary care
 diagnosis, 770
 intestinal decompression, 770, 771*f*
 medications, 770
 nutrition, 770
 surgery, 770
 manifestations, 769–70, 769*t*
 mortality rate, 770*t*
 nursing care
 assessment, 771
 community-based care, 773
 nursing diagnoses and interventions
 acute pain, 771
 anxiety, 772–73
 deficient fluid volume, 771–72
 ineffective protection, 772
 using NANDA, NIC, and NOC, 769*t*, 773
 pathophysiology, 769
 spontaneous bacterial, in cirrhosis, 716
 Peritonsillar abscess:
 interdisciplinary care, 1239
 Nursing Care Plan
 assessment, 1240*t*
 critical thinking in the nursing process, 1240*t*
 diagnoses, 1240*t*
 evaluation, 1240*t*
 expected outcomes, 1240*t*
 planning and implementation, 1240*t*
 pathophysiology, 1239
 Permanent cells, 295

- Permanent pacemakers, 1009, 1009*f*. *See also* Pacemakers
- Permax. *See* Pergolide
- Permethrin, 451
- Pernicious anemia, 1105. *See also* Anemia; Vitamin B₁₂, deficiency
- PERRL, 1519*t*
- Persantine. *See* Dipyridamole
- Persistent vegetative state, 1532. *See also* Altered level of consciousness
- Personal protective equipment (PPE), 134–35, 134*t*
- Pertussis:
 - characteristics, 1242
 - interdisciplinary care, 1242
 - manifestations, 1242, 1242*t*
 - nursing care, 1243
 - pathophysiology, 1242
- Pertussis vaccine, 1242
- PES method, nursing diagnosis, 9
- Pessary, 1806–7
- PET. *See* Positron emission tomography
- Petechiae:
 - causes, 434*t*
 - characteristics, 434*f*
 - definition, 434*t*, 1045
 - in endocarditis, 1045
 - localization/distribution, 434*t*
- Pfannenstiel incision, 1804
- pH:
 - arterial blood
 - in gastroenteritis and diarrhea, 776*t*
 - in metabolic acidosis, 240, 242, 242*t*
 - in metabolic alkalosis, 240, 242*t*, 245
 - normal range, 240*t*
 - in respiratory acidosis, 240, 242*t*, 248
 - in respiratory alkalosis, 240, 242*t*, 251
 - significance, 240*t*
 - esophageal, monitoring
 - in gastroesophageal reflux disease, 664
 - purpose and description, 615*t*
 - related nursing care, 615*t*
 - urine
 - abnormal, possible causes, 832*t*
 - normal values, 832*t*
- Phagocytes, 293
- Phagocytic, 288
- Phagocytosis, 293–94, 294*t*
- Phagosome, 293
- Phalen's test, 1395*f*, 1395*t*
- Phantom limb pain, 1423
- Phantom pain, 174. *See also* Pain
- Pharyngitis:
 - characteristics, 1238
 - complications, 1239
 - gonococcal, 1238, 1845
 - interdisciplinary care, 1239
 - manifestations, 1238, 1238*f*, 1239*t*
 - nursing care, 1239–40
 - pathophysiology, 1238
- Pharynx:
 - anatomy, physiology, and functions, 611*f*, 1211
 - physical assessment, 623*t*
- Phenacetin, 862
- Phenazopyridine, 832*t*, 850, 850*t*
- Phencyclidine (PCP), 110–11, 113*t*
- Phenergan. *See* Promethazine
- Phenobarbital, 114*t*, 1550*t*, 1551*t*
- Phenol, 479
- Phenolax. *See* Phenolphthalein
- Phenolphthalein, 759–60*t*, 832*t*
- Phenothiazines, 672
- Phenotype, 151
- Phenoxene. *See* Chlorphenoxamine
- Phentermine, 633, 634*t*
- Phentolamine, 1169*t*
- D-Phenylalanine derivative, 578*t*
- Phenylbutazone, 178*t*
- Phenylephrine, 1230, 1230*t*, 1243
- Phenylpropanolamine:
 - for appetite suppression, 633
 - Medication Administration, 1230*t*
 - in specific conditions
 - upper respiratory infections, 1230*t*
 - urinary incontinence, 874
- Phenytoin:
 - Medication Administration, 1006*t*, 1550*t*
 - in specific conditions
 - cardiac dysrhythmias, 1006*t*
 - central nervous system infections, 1566
 - intracranial aneurysm, 1593
 - seizures, 1550*t*
 - trigeminal neuralgia, 1656
 - urine color changes caused by, 832*t*
- Pheochromocytoma, 557
- Philadelphia chromosome, 151, 1121, 1122*f*
- Phimosis, 1749*t*, 1771
- Phlebotomy, 1117
- Phosphate enema, 760
- Phosphate (PO₄⁻²):
 - balance, 236
 - in body fluid compartments, 197*f*
 - functions, 236
 - imbalances. *See* Hyperphosphatemia; Hypophosphatemia
 - normal values, 198*t*
 - serum levels. *See* Serum phosphate supplements, 237
- Phosphodiesterase inhibitors, 1034*t*
- Phosphorus, 610*t*, 1388*t*
- Photoaging, 430*t*
- Photochemotherapy. *See* Photodynamic therapy
- Photodynamic therapy, 398, 445
- Photofrin, 398
- Photoradiation. *See* Photodynamic therapy
- Photoreactive keratectomy (PRK), 1697
- Phototherapeutic keratectomy, 1697
- Phototherapy. *See* Photodynamic therapy
- Physical activity. *See* Exercise
- Physical dependence, 103*t*, 179*t*. *See also* Substance abuse
- Physical inactivity, 964
- Physical stressors:
 - in middle adults, 27
 - in older adults, 30
 - in young adults, 25–26
- Physical therapy:
 - in Parkinson's disease, 1639
 - in scleroderma, 1485–86
 - in total joint replacement, 1455
- Phytotherapy, 1781. *See also* Herbal supplements/therapy
- Pica, 1105
- PID. *See* Pelvic inflammatory disease
- Pigmented lesions, 431*t*
- “Piles.” *See* Hemorrhoids
- “Pill-rolling” motion, 1635
- Pilonidal disease, 821
- Pima. *See* Potassium iodide
- Pindolol, 1161*t*
- “Pink eye,” 1692. *See also* Conjunctivitis
- Pinworm infections, 781*t*
- Pioglitazone, 578*t*
- Piperacillin, 319*t*
- Piperacillin-tazobactam, 816
- Pipracil. *See* Piperacillin
- Pirbuterol, 1327*t*
- Piroxicam, 178*t*, 1445, 1464*t*
- Pitting edema, 1097*t*. *See also* Edema
- Pituitary adenoma, 1570*t*. *See also* Brain tumors
- Pituitary gland:
 - age-related changes, 529*t*
 - anatomy, 518, 518*f*
 - anterior
 - disorders
 - acromegaly, 529*t*, 558, 558*f*
 - gigantism, 558
 - hyperfunction, 557
 - hypofunction, 557
 - interdisciplinary care, 558
 - nursing care, 558
 - pathophysiology, 557
 - hormones secreted by, 518, 519*f*; 519*t*, 520
 - diagnostic tests, 523*t*
 - hormones secreted by, 518, 519*f*; 519*t*. *See also* specific hormones
 - posterior
 - disorders
 - diabetes insipidus. *See* Diabetes insipidus
 - pathophysiology, 520
 - syndrome of inappropriate antidiuretic hormone. *See* Syndrome of inappropriate diuretic hormone
 - hormones secreted by, 520
 - in shock, 270
- PLAC test, 1585
- Planning:
 - critical thinking skills in, 7*t*
 - outcome criteria in, 9–10
 - overview, 9–10
- Plant alkaloids, 391, 393*t*. *See also* Chemotherapy
- Plantar flexion, 1386*t*
- Plantar warts, 452
- Plaque, 432*t*
- Plaquenil. *See* Hydroxychloroquine
- Plaques, in multiple sclerosis, 1626
- Plasma, 196, 197*f*, 236*t*
- Plasma cell mastitis. *See* Duct ectasia
- Plasma cells:
 - disorders. *See* Multiple myeloma
 - formation, 1077*f*
 - functions, 295, 1136
- Plasma exchange therapy. *See* Plasmapheresis
- Plasma protein fraction, 279*t*
- Plasma prothrombin antecedent, 1082*t*
- Plasma prothrombin component, 1082*t*
- Plasmanate. *See* Plasma protein fraction
- Plasmapheresis:
 - definition, 891
 - nursing care, 1650*t*
 - in specific conditions
 - glomerular disorders, 891
 - Guillain-Barré syndrome, 1654
 - hemorrhagic colitis, 777
 - immune complex responses, 338
 - multiple myeloma, 1137
 - myasthenia gravis, 1650, 1651*f*
 - pemphigus vulgaris, 460
 - thrombocytopenia, 1141
- Plasma-Plex. *See* Plasma protein fraction
- Plasmatein. *See* Plasma protein fraction
- Plastic surgery:
 - blepharoplasty, 479
 - chemical peeling, 479
 - dermabrasion, 479
 - liposuction, 479
 - rhinoplasty, 479
 - rhytidectomy, 479
 - skin grafts and flaps, 478–79, 478*f*
- Platelet count:
 - abnormal, possible causes, 387*t*
 - normal values, 387*t*, 1078*t*

- Platelet count—*continued*
 perioperative, significance and nursing implications, 60*t*
 in specific conditions
 disseminated intravascular coagulation, 1148
 leukemia, 1123*t*
- Platelet transfusions, 1141
- Platelets:
 disorders. *See* Thrombocytopenia
 formation, 1077*f*, 1140
 functions, 1079, 1080, 1080*f*, 1140
 medications affecting function, 1142*t*
 as volume resuscitation therapy, 263*t*
- Platinol. *See* Cisplatin
- Plavix. *See* Clopidogrel
- Pleindil. *See* Felodipine
- Pletal. *See* Cilostazol
- Plethora, 1117
- Plethysmography, 1188
- Pleura, 1213, 1295
- Pleural cavity, 1295
- Pleural effusion:
 causes, 1295
 definition, 1295
 interdisciplinary care
 thoracentesis. *See* Thoracentesis
 treatments, 1296
 manifestations, 1295–96
 nursing care, 1296, 1297*t*
 pathophysiology, 1295
- Pleurisy. *See* Pleuritis
- Pleuritic pain, 1269
- Pleuritis:
 definition, 1295
 interdisciplinary care, 1295
 manifestations, 1295
 nursing care, 1295
 in pneumonia, 1269
- Pleurodesis, 1296, 1299–1300
- Plicamycin, 232
- PMDD (premenstrual dysphoric disorder), 1798
- PMNs (polymorphonuclear leukocytes). *See* Neutrophils
- PMS. *See* Premenstrual syndrome
- PND (paroxysmal nocturnal dyspnea), 1027
- Pneumococcal vaccine:
 contraindications, 21*t*, 1274
 indications, 21*t*, 300, 301*t*, 1271
 nursing implications, 301*t*
- Pneumocystis carinii* pneumonia (PCP):
 in AIDS, 353, 359*t*, 1270
 manifestations, 353, 1270, 1270*t*
 pharmacologic treatment, 359*t*, 1271*t*
- Pneumomediastinum, 1360
- Pneumonectomy, 1312*t*
- Pneumonia:
 acute bacterial
 complications, 1269
 manifestations, 1269, 1270*t*
 pathophysiology, 1268, 1269*f*
 aspiration, 1270
 classification, 1267
 community acquired, 1267*t*
 definition, 1267
 incidence, 1267
 interdisciplinary care
 complementary therapies, 1273–74
 diagnosis, 1270–71
 treatments
 chest physiotherapy, 1272–73, 1273*f*, 1274*f*
 incentive spirometry, 1272
 oxygen therapy, 1272, 1272*f*, 1273*f*
 mortality from, 1267
 nosocomial, 313, 1267*t*. *See also* Ventilator-associated pneumonia
 nursing care
 assessment, 1275
 community-based care, 1276
 health promotion, 1274
 nursing diagnoses and interventions
 activity intolerance, 1275–76
 ineffective airway clearance, 1275
 ineffective breathing pattern, 1275
 of older adults, 1268*t*
 using NANDA, NIC, and NOC, 1276, 1276*t*
- Nursing Care Plan
 assessment, 1277*t*
 critical thinking in the nursing process, 1277*t*
 diagnoses, 1277*t*
 evaluation, 1277*t*
 expected outcomes, 1277*t*
 planning and implementation, 1277*t*
 in older adults, 1268*t*
- opportunistic, 1267*t*. *See also* *Pneumocystis carinii* pneumonia
 pathophysiology
 inflammatory response, 1267, 1267*f*
 organisms causing, 1267*t*
 pathogen entry routes, 1267
 patterns of lung involvement, 1268*t*
 physiology review, 1267
 postoperative
 assessment findings, 75
 nursing care, 76
 prevention. *See* Pneumococcal vaccine
 primary atypical, 1269, 1270*t*
 ventilator-associated. *See* Ventilator-associated pneumonia
 viral, 1269, 1270*t*
- Pneumothorax:
 definition, 258, 1297
 interdisciplinary care
 diagnosis, 1299
 treatments
 surgery, 1300
 manifestations, 1298*t*
 in mechanical ventilation, 1360
 nursing care
 assessment, 1301
 of client having chest tube insertion, 1300*t*
 community-based care, 1301–2
 health promotion, 1300–1301
 nursing diagnoses and interventions
 impaired gas exchange, 1301
 risk for injury, 1301
 pathophysiology, 1297, 1298*t*, 1299
 spontaneous
 manifestations, 1297, 1298*t*
 pathophysiology, 1297, 1298*t*
 tension
 emergency treatment, 258, 258*f*
 manifestations, 258, 1298*t*, 1299
 pathophysiology, 258, 1298*t*, 1299
 traumatic
 causes, 1299
 manifestations, 1298*t*, 1299
 pathophysiology, 1298*t*
 types, 1299
- “Pocket talker,” 1731
- Podofilox, 1841
- Podofin. *See* Podophyllin
- Podophyllin, 1841, 1842*t*
- Podophyllum, 755
- Poliomyelitis virus, 1659
- Polycillin. *See* Ampicillin
- Polycyclic hydrocarbons, 372*t*
- Polycystic kidney disease:
 genetic considerations, 839*t*, 884, 884*t*
 interdisciplinary care, 885
 manifestations, 885
 nursing care, 885
 pathophysiology, 884, 885*f*
- Polycystic ovarian syndrome (PCOS), 632, 1808, 1809*t*
- Polycythemia:
 definition, 1076, 1117
 interdisciplinary care
 diagnosis, 1117
 nursing care, 1118
 treatments, 1117–18
 manifestations, 1117
 pathophysiology, 1117
 primary, 1117
 in pulmonary hypertension, 1353
 relative, 1117
 secondary, 1117
- Polycythemia vera, 1117
- Polydipsia, 566
- Polyethylene glycol, 759*t*
- Polymerase chain reaction (PCR), 1287
- Polymorphisms, 152
- Polymorphonuclear leukocytes (PMNs). *See* Neutrophils
- Polymyositis:
 definition, 1476
 interdisciplinary care, 1476
 manifestations, 1476
 nursing care, 1476
- Polymyxin B-neomycin-hydrocortisone, 1719
- Polyneuropathies, 589
- Polypectomy, 1252
- Polyphagia, 566
- Polyplody, 150*t*
- Polyps:
 colon
 characteristics, 800, 800*f*
 definition, 800
 interdisciplinary care, 801
 laryngeal, 1253, 1253*f*
 manifestations, 801
 nursing care
 assessment, 801
 community-based care, 801
 health promotion, 801
 nursing diagnoses and interventions, 801
 pathophysiology, 800
 female reproductive tissue, 1808–9, 1809*t*
 laryngeal, 1252, 1253
 nasal. *See* Nasal polyps
- Polysomnography, 1251
- Polysporin, 441*t*
- Polysubstance abuse, 103*t*, 115
- Polytar. *See* Coal tar derivatives
- Polythiazide, 210*t*
- Polyuria:
 definition, 209, 566, 839
 in fluid volume excess, 209
 in type 1 diabetes mellitus, 566
- Pons, 1505*f*, 1506
- Ponstel. *See* Mefenamic acid
- Popliteal artery, aneurysm, 1172, 1172*f*
- Porphyria, 1089*t*
- Port-access coronary artery bypass, 979
- Portal hypertension, 704, 711
- Portal systemic encephalopathy, 704, 715, 715*t*
- Port-wine stain, 443
- Positioning, surgical, 67, 69*f*
- Positive end-expiratory pressure (PEEP), 1358, 1359*t*
- Positive pressure ventilators, 1357, 1357*f*. *See also* Mechanical ventilation

- Positron emission tomography (PET):
 brain, 1512, 1514*t*, 1627
 heart, 945*t*
 in lymphoma, 1131
 thorax, 1218*t*
- Postconcussion syndrome, 1558*t*. *See also*
 Traumatic brain injury
- Posterior descending artery, 939*f*, 959
- Posterior infarct, 984
- Posterior laminectomy:
 nursing care, 1609–10*t*
 procedure, 1608
- Posterior syndrome, 1597*t*. *See also* Spinal cord
 injury
- Postherpetic neuralgia, 453
- Posticteric/convalescent phase, hepatitis, 706, 706*t*
- Postmenopausal women. *See also* Menopause;
 Older adults
 breast cancer in, 1823*t*
 coronary heart disease risk factors, 964
 hormone replacement therapy. *See* Hormone
 replacement therapy
- Postoperative period. *See also* Surgery
 definition, 54
 interdisciplinary care, 70
 nursing care
 care after client is stable, 74
 immediate care, 74
 NANDA, NIC, and NOC Linkages, 80*t*
 postoperative complications
 cardiovascular, 74–75
 elimination-related, 78–79
 respiratory, 75–76
 special considerations for older adults, 79, 79*t*
 wound. *See* Wounds
 pain management. *See also* Pain
 interdisciplinary care, 64
 nursing care, 79–80
 Nursing Research
 assisting older adults to communicate
 postoperative pain, 65*t*
 pain management after ambulatory
 surgery, 700*t*
- Postpoliomyelitis syndrome:
 characteristics, 1659
 interdisciplinary care, 1659
 manifestations, 1659
 nursing care, 1660
- Postrenal acute renal failure, 900, 900*t*. *See also*
 Acute renal failure
- Post-trauma syndrome, 268
- Postural drainage, in chest physiotherapy,
 1273, 1274*f*
- Postural hypotension. *See* Orthostatic hypotension
- Postvoid residual urine, 836*t*, 870, 874
- Potassium (K⁺):
 in action potential, 1505
 balance, 217–18
 in body fluid compartments, 197*t*
 foods high in, 218*t*
 imbalances. *See* Hyperkalemia; Hypokalemia
 nurse, 217
 oral and parenteral administration, 221, 221*t*, 223
 recommended dietary guidelines, 606*t*
 serum levels
 abnormal, possible causes, 387*t*
 in gastroenteritis and diarrhea, 776*t*
 normal values, 198*t*, 387*t*
 perioperative, significance and nursing
 implications, 60*t*
- Potassium acetate, 221*t*
- Potassium bicarbonate, 221*t*
- Potassium channel blockers, 1006, 1006*t*
- Potassium chloride, 221*t*
- Potassium citrate, 221*t*, 858
- Potassium gluconate, 221*t*
- Potassium hydroxide (KOH), 428*t*
- Potassium iodide, 538*t*, 1272
- Potassium permanganate, 441*t*, 449
- Potassium phosphate, 232
- Potassium-sparing diuretics, 210, 210*t*
- Potassium-wasting diuretics, 225*t*
- PPD (purified protein derivative), 1286, 1286*f*,
 1286*t*
- PPE (personal protective equipment), 134–35, 134*t*
- PQRST technique, pain assessment, 186
- PR interval, 948*f*, 948*t*
- Pramipexole, 1638*t*
- Prandin. *See* Repaglinide
- Pravachol. *See* Pravastatin
- Pravastatin, 967*t*, 968
- Prazosin, 1161*t*, 1485
- Prealbumin, 642, 644*t*
- Precose. *See* Acarbose
- Precursor T-cell lymphoblastic
 leukemia/lymphoma, 1130*t*. *See also*
 Leukemia; Lymphomas
- Prediabetes, 569
- Predictive genetic testing, 157
- Prednisolone, 555*t*, 787–88*t*
- Prednisone:
 adverse/side effects, 393*t*
 as chemotherapy, 393*t*
 Medication Administration, 555*t*, 787–88*t*, 1631*t*
 nursing implications, 393*t*
 in specific conditions
 Addison's disease, 555*t*
 glomerular disorders, 890
 inflammatory bowel disease, 787–88*t*
 leukemia, 1123*t*
 multiple myeloma, 1137
 multiple sclerosis, 1631*t*
 organ transplantation, 344
- Pregnancy:
 diabetes in, 566*t*
 hypertension in, 1167
 substance abuse in
 cocaine, 109
 marijuana, 107
 smoking, 107
- Preicteric phase, hepatitis, 705, 706*t*
- Preimplantation genetic diagnosis, 157
- Preload, 940, 1023, 1024*t*
- Premature atrial contractions (PACs):
 causes, 1000–1001
 ECG characteristics, 997*t*, 1001
 management, 997*t*
 manifestations, 1001
 pathophysiology, 1001
- Premature ejaculation, 1771
- Premature junctional contractions, 1002
- Premature ventricular contractions (PVCs):
 after acute myocardial infarction, 985
 causes, 1002
 ECG characteristics, 998*t*
 in heart failure, 1034
 management, 998*t*
 patterns, 1002
 as warning signs, 1002
- Premenstrual dysphoric disorder (PMDD), 1798
- Premenstrual syndrome (PMS):
 definition, 1798
 incidence, 1798
 interdisciplinary care
 complementary and alternative therapies, 1800
 diagnosis, 1798
 medications, 1798, 1800
 manifestations, 1798
- Multisystem Effects, 1799*t*
 nursing care
 community-based care, 1800
 nursing diagnoses and interventions
 acute pain, 1800
 ineffective coping, 1800
 pathophysiology, 1798
- Preoperative period. *See also* Surgery
 definition, 54
 interdisciplinary care
 client preparation
 positioning, 67, 69*f*
 shaving, 68*f*
 skin preparation, 67
 diagnosis, 60–61, 60*t*
 medications, 61, 62*t*
 nursing care
 client and family teaching
 coughing exercise, 72*t*
 diaphragmatic breathing exercise, 72*t*
 information needs, 71
 leg, ankle, and foot exercises, 73*t*
 turning in bed, 73*t*
 client preparation, 71–73
 nursing care, 71
 nursing diagnoses, 70*t*
- Preparedness, disaster, 133. *See also* Disasters
- Prerenal acute renal failure, 900, 900*t*. *See also*
 Acute renal failure
- Presbycusis, 1730. *See also* Hearing loss
- Presbyopia, 1677*t*
- Pressure support ventilation, 1358, 1359*t*
- Pressure trauma, in disasters, 129*t*
- Pressure ulcer:
 definition, 472, 1093*t*
 incidence, 472
 interdisciplinary care
 diagnosis, 473
 medications, 473, 474*t*
 surgical treatment, 473
 nursing care
 community-based care, 476
 nursing diagnoses and interventions, 474–76,
 475*t*
 of older adults, 474*t*
- Nursing Research
 prevention in clients with major burn, 510*t*
 treatment and prevention in older adults, 475*t*
 pathophysiology, 472
 prevention, 474*t*, 475*t*
 risk factors, 472
 staging, 473*f*, 473*t*
- Pressure-control ventilation, 1358
- Pressure-cycled ventilators, 1358
- Pretibial myxedema, 536
- Prevacid. *See* Lansoprazole
- Priapism, 1107, 1771–72, 1772*t*
- Prick test, 337
- Prilosec. *See* Omeprazole
- Primacor. *See* Milrinone
- Primary dysmenorrhea, 1800
- Primary hypertension, 1155. *See also*
 Hypertension
- Primary intention, wound healing by, 76, 76*f*
- Primary lymphedema, 1199, 1199*t*. *See also*
 Lymphedema
- Primary motor area, 1506*t*
- Primary prevention, 24
- Primary pulmonary hypertension, 1352
- Primary syphilis, 1847–48, 1848*f*, 1848*t*. *See also*
 Syphilis
- Primary tuberculosis, 1281. *See also* Tuberculosis
- Primidone, 1550*t*
- Prinivil. *See* Lisinopril

- Prinzmetal's angina, 969-70. *See also* Angina pectoris
- Prioderm lotion. *See* Malathion
- Prion protein, 1658
- Pritikin diet, 968*t*
- PRL (prolactin), 518
- prn dosing, 181
- Pro re nata (prn), 181
- Proacelerin, 1082*t*
- Pro-Banthine. *See* Propantheline
- Probenecid, 1445, 1446*t*
- Procainamide, 1006*t*, 1471
- Procalcitonin, 316
- Procan SR. *See* Procainamide
- Procardia. *See* Nifedipine
- Procedures:
- nursing care
 - changing a one- or two-piece drainable ostomy pouch, 791*t*
 - client self-catheterization, 1605*t*
 - elective synchronized cardioversion, 1007*t*
 - emergency external defibrillation, 1008*t*
 - endotracheal suctioning, 1363*t*
 - gastric lavage, 676*t*
 - ileostomy lavage, 792*t*
 - initiating cardiac monitoring, 1005*t*
 - obtaining a sputum specimen, 1220*t*
 - prosthetic eye removal and insertion, 1719*t*
 - tracheostomy care, 1257*t*
 - surgical. *See* Surgery, procedures
- Prochlorperazine, 672, 673*t*, 1727
- Procidencia, 1805
- Procyclidine, 1638*t*
- Prodromal phase, hepatitis, 705
- Progesterone, 1753, 1816
- Prograf. *See* Tacrolimus
- Progressive muscle relaxation, 186
- Prolactin (PRL), 518
- Proliferation, in burn wound healing, 493. *See also* Wounds
- Proloprim. *See* Trimethoprim
- Promethazine, 672, 673*t*
- Promotility agent. *See* Metoclopramide
- Pronation, 1386*t*
- Prone position, 69*f*
- Pronestyl. *See* Procainamide
- Propafenone, 1006*t*
- Propantheline bromide, 871, 871*t*
- Propionibacterium acnes*, 458
- Propionic acids, 178*t*, 306
- Propoxyphene napsylate, 110, 180*t*, 182*t*
- Propranolol:
- Medication Administration, 973*t*, 1006*t*, 1161*t*
 - in specific conditions
 - acute myocardial infarction, 988
 - angina, 973*t*
 - aortic aneurysm, 1173
 - cardiac dysrhythmias, 1006*t*
 - headache, 1545*t*
 - hypertension, 1161*t*
 - hyperthyroidism, 537
 - migraine headache, 1544
 - Parkinson's disease, 1639
- Proprioception, 1105
- Proptosis, 536
- Propylthiouracil, 538*t*
- Propyl-Thyracil. *See* Propylthiouracil
- Proscar. *See* Finasteride
- Prostaglandin(s):
- in inflammatory response, 292*t*, 304*t*
 - parenteral, in peripheral vascular disease, 1177
- Prostaglandin analogs, 685, 1709, 1710*t*
- Prostaglandin E, in erectile dysfunction, 1769
- Prostaphlin. *See* Oxacillin
- Prostate cancer:
- complications, 1784
 - incidence, 1782-83
 - interdisciplinary care
 - diagnosis, 1784
 - hormonal manipulation, 1786, 1787*t*
 - overview by stage, 1784*t*
 - radiation therapy, 1785*t*, 1786
 - research for prevention, 1785
 - staging, 1784*t*
 - surgery, 1785-86, 1786*f*, 1787*t*. *See also* Prostatectomy
 - manifestations, 1783, 1784*t*
 - nursing care
 - assessment, 1787
 - community-based care, 1789
 - health promotion, 1786-87
 - nursing diagnoses and interventions
 - acute/chronic pain, 1789
 - sexual dysfunction, 1788-89
 - urinary incontinence, 1787
 - using NANDA, NIC, and NOC, 1789, 1789*t*
 - Nursing Care Plan
 - assessment, 1788*t*
 - critical thinking in the nursing process, 1788*t*
 - diagnoses, 1788*t*
 - evaluation, 1788*t*
 - expected outcomes, 1788*t*
 - planning and implementation, 1788*t*
 - Nursing Research: discharge teaching, 1785*t*
 - pathophysiology, 1783
 - prognosis, 1783
 - racial/ethnic considerations, 1783*t*
 - risk factors, 1783
 - screening guidelines, 401*t*
- Prostate gland:
- age-related changes, 1749*t*
 - anatomy, physiology, and functions, 1745, 1745*t*
 - diagnostic tests, 1746*t*
 - disorders
 - benign prostatic hyperplasia. *See* Benign prostatic hyperplasia
 - cancer. *See* Prostate cancer
 - prostatitis. *See* Prostatitis
 - physical assessment, 1750*t*
- Prostatectomy:
- complications, 1785*t*
 - nursing care
 - community-based care, 1782
 - discharge instructions, 1783*t*
 - nursing diagnoses and interventions
 - deficient knowledge, 1781-82
 - risk for imbalanced fluid volume, 1782, 1782*t*
 - risk for infection, 1782
 - urinary retention, 1782
 - perineal, 1781*t*
 - postoperative, 1780*t*
 - preoperative, 1780*t*
 - retropubic, 1781*t*
 - suprapubic, 1781*t*
 - transurethral resection, 1780*t*
 - Nursing Research: discharge teaching, 1785*t*
 - procedure, 1785
- Prostate-specific antigen (PSA):
- abnormal, possible causes, 384*t*, 387*t*
 - in benign prostatic hyperplasia, 1778
 - normal values, 387*t*
 - in prostate cancer, 1784
 - purpose and description, 1746*t*
- Prostatic acid phosphatase (PAP), 384*t*
- Prostatitis:
- acute bacterial, 1776
 - chronic bacterial, 1776
 - in chronic pelvic pain syndrome, 1776-77
 - definition, 1776
 - inflammatory, 1777
 - interdisciplinary care
 - diagnosis, 1777
 - medications, 1777
 - manifestations, 1776-77, 1777*t*
 - noninflammatory, 1777
 - nursing care, 1777
 - pathophysiology, 1776-77
- Prostatodynia, 1777, 1777*t*
- Prosthetic eyes, 1718, 1719*t*
- Prosthetic valves:
- advantages and disadvantages, 1061, 1061*t*
 - endocarditis in, 1045. *See also* Endocarditis types, 1061*f*, 1061*t*
- Prostigmin. *See* Neostigmine
- Protease inhibitors, 358
- Protectants, intestinal, 756*t*
- Protein(s):
- dietary
 - deficiency, 642*t*
 - in diabetes mellitus, 577-79
 - recommended daily intake, 606
 - restriction
 - in cirrhosis, 717, 718*t*
 - in glomerular disorders, 891*t*, 891
 - sources, 606, 691*t*
 - uses in body, 606-7
 - digestion, 742
 - serum levels. *See* Serum protein
 - as tumor marker, 384, 384*t*
 - urine levels. *See* Urine, protein
- Protein electrophoresis, 300, 1137
- Protein-calorie malnutrition, 641
- Proteinuria, 885
- Protenate. *See* Plasma protein fraction
- Proteolytic enzymes, 474*t*
- Prothrombin, 1082*t*
- Prothrombin time (protime; PT), 60*t*
- Protonix. *See* Pantoprazole
- Proton-pump inhibitors:
- Medication Administration, 665*t*
 - preoperative use and nursing implications, 62*t*
 - in specific conditions
 - burns, 502
 - gastritis, 665*t*, 678
 - gastroesophageal reflux disease, 665, 665*t*
 - pancreatitis, 728
 - peptic ulcer disease, 665*t*, 684
 - short bowel syndrome, 799
- Protozoal bowel infections:
- amebiasis, 778, 778*t*
 - cryptosporidiosis, 778*t*, 779
 - giardiasis, 778, 779*t*
 - interdisciplinary care
 - diagnosis, 779
 - medications, 778*t*, 779, 780*t*
 - nursing care, 779, 780*t*
- Protraction, 1386*t*
- Proventil. *See* Albuterol
- Provigil. *See* Modafinil
- Prozac. *See* Fluoxetine
- Pruritus/pruritic lesions:
- in cirrhosis, 723
 - definition, 440
 - examples, 431*t*
 - management, 440, 441*t*, 723
 - pathophysiology, 440
 - secondary effects, 440
 - teaching, 441*t*
- PSA. *See* Prostate-specific antigen
- Pseudoaddiction, 179*t*
- Pseudoephedrine, 1230*t*

- Pseudohyperkalemia, 223
Pseudomonas aeruginosa, 1719
 Pseudopodia, 293
 Psoriasis:
 definition, 443
 incidence, 443f
 interdisciplinary care
 diagnosis, 444
 medications, 444, 444t
 treatments
 photochemotherapy, 445
 ultraviolet light therapy, 444-45
 manifestations, 443-44, 443f
 nursing care
 community-based care, 446
 nursing diagnoses and interventions
 disturbed body image, 445-46
 impaired skin integrity, 445
 pathophysiology, 443
 Psorigel. *See* Coal tar derivatives
 PSVT (paroxysmal supraventricular tachycardia), 997t, 1001
 Psychogenic pain, 175
 Psychologic dependence, 103t, 179t. *See also*
 Substance abuse
 Psychosocial development theory (Erikson), 25t
 Psychosocial stressors:
 in diasters, 135, 135t, 137
 in middle adults, 27
 in older adults, 30
 in young adults, 26
 Psychosomatic disease, 22t
 Psychostimulants, 108-10
 Psyllium hydrophilic mucilloid, 759t, 819
 PT (prothrombin time), 60t
 PTA (percutaneous transluminal angioplasty), 1177-78
 PTCA (percutaneous transluminal coronary angioplasty), 977, 977f
 Pterygium, 1679
 PTH. *See* Parathyroid hormone
 Ptosis:
 assessment, 1679
 causes, 1520t
 definition, 1520t, 1679, 1679f, 1718
 in Kaposi's lesions of the eye, 1718
 in myasthenia gravis, 1648, 1648f
 PTU. *See* Propylthiouracil
 PUD. *See* Peptic ulcer disease
 Pulmonary angiography, 1218t, 1349
 Pulmonary artery pressure monitoring:
 in acute respiratory distress syndrome, 1367
 normal values, 1032
 procedure, 1030-31, 1031
 waveforms, 1032f
 Pulmonary artery wedge pressure (PAWP), 1031, 1032f
 Pulmonary circulation, 938, 938f
 Pulmonary contusion, 1303. *See also* Thoracic trauma
 Pulmonary edema:
 in burns, 495
 cardiogenic
 definition, 1039
 interdisciplinary care, 1040-41
 manifestations, 1040, 1040t
 pathophysiology, 1040
 definition, 1039
 nursing care
 community-based care, 1042
 nursing diagnoses and interventions
 decreased cardiac output, 1041
 fear, 1041-42
 impaired gas exchange, 1041
 Pulmonary embolism:
 causes, 1347
 definition, 1347
 incidence, 1347
 interdisciplinary care
 diagnosis, 1349
 medications, 1349
 prevention, 1348
 surgery, 1349
 manifestations, 1348, 1348t
 nursing care
 assessment, 1350
 community-based care, 1351-52
 health promotion, 1349-50
 nursing diagnoses and interventions
 anxiety, 1351
 decreased cardiac output, 1350-51
 impaired gas exchange, 1350
 ineffective protection, 1351
 using NANDA, NIC, and NOC, 1351, 1352t
 pathophysiology, 1187, 1347-48, 1348f
 physiology review, 1347
 postoperative
 assessment, 75
 nursing care, 75
 risk factors, 1347
 Pulmonary function tests:
 in acute respiratory distress syndrome, 1367
 in asthma, 1324
 in chronic obstructive pulmonary disease, 1333
 procedure, 1214t
 values, 1214t
 Pulmonary hypertension:
 complications, 1352-53
 definition, 1352
 interdisciplinary care, 1353
 manifestations, 1352
 nursing care, 1353
 pathophysiology, 1352
 primary, 1352
 secondary, 1352
 Pulmonary vascular resistance (PVR), 940
 Pulmonary ventilation/perfusion scan (V/Q scan):
 in chronic obstructive pulmonary disease, 1333, 1333f
 in pulmonary embolism, 1349
 purpose and description, 1218t
 Pulmonic valve:
 anatomy, 937f, 938
 disorders, 1059
 function, 1054
 Pulsations, 952
 Pulse:
 abnormal findings, 1094t, 1096t
 assessment
 carotid, 1094t
 jugular, 1094t
 lower extremity, 1097t
 temporal, 1094t
 upper extremity, 1096t
 physiology, 1082
 Pulse oximetry:
 purpose and description, 1217t
 related nursing care, 1217t
 in specific conditions
 chronic obstructive pulmonary disease, 1334
 peripheral vascular disease, 1177
 pneumonia, 1271
 severe acute respiratory syndrome, 1278
 Pulse patterns, 1094t
 Pulse pressure, 1093t, 1154
 Pulsus alternans, 1094t
 Pulsus bisferiens, 1094t
 Pulsus paradoxus, 1050
 Punch skin biopsy, 428t
 Puncture wounds, 259, 259f
 Pupillary light reflex, 1671
 Pupils:
 age-related changes, 1676t
 anatomy, physiology, and functions, 1671
 assessment, 1678-79t
 Purified protein derivative (PPD), 1286, 1286f, 1286t
 Purines, 858, 858t
 Purinethol. *See* Mercaptopurine
 Purpura, 434f, 434t
 Purulent exudate, 293
 Pus, 304
 Pustule/pustular lesions, 431t, 432t
 PVCs. *See* Premature ventricular contractions
 PVD. *See* Peripheral vascular disease
 PVR (peripheral vascular resistance), 1082, 1085
 PVR (pulmonary vascular resistance), 940
 Pyelolithotomy, 859
 Pyelonephritis. *See also* Urinary tract infection
 acute, 848, 848t
 chronic, 848-49
 definition, 847
Pygeum africanum, 1781
 Pyoderma, 446
 Pyrantel pamoate, 779-80
 Pyrazinamide, 1288t, 1289t
 Pyrazoles, 178t, 306
 Pyridium. *See* Phenazopyridine
 Pyridostigmine:
 Medication Administration, 1649t
 in specific conditions
 myasthenia gravis, 1649, 1649t, 1650
 neurogenic bladder, 870
 Pyridoxine. *See* Vitamin B₆
 Pyrimethamine, 359t
 Pyuria, 839
- ## Q
- Qigong, 728
 QRS complex, 948f, 948t
 QT interval, 948f, 948t
 Quadramet. *See* Samarium-153
 Quadriplegia, 1599
 Quality assurance, 15
 Quercetin, 1326
 Quesstran. *See* Cholestyramine
 Quibron. *See* Theophylline
 Quinacrine, 778t
 Quinaglute. *See* Quinidine
 Quinapril, 1033t, 1161t
 Quinidex. *See* Quinidine
 Quinidine, 1006t
 Quinine, 321
 Quinsy. *See* Peritonsillar abscess
 Q-wave myocardial infarction, 983
- ## R
- RA. *See* Rheumatoid arthritis
 Rabeprazole, 665, 665t
 Rabies:
 characteristics, 1660
 incidence, 1660
 interdisciplinary care, 1660
 manifestations, 1660
 nursing care, 1660
 pathophysiology, 1660
 postexposure prophylaxis, 302t, 1660
 "Raccoon eyes," 1555

- Race/ethnicity. *See also specific racial/ethnic groups*
 considerations in specific disorders
 breast cancer, 1822t
 cancer, 370t
 cirrhosis, 711t
 diabetes mellitus, 564t
 G6PD anemia, 1160t
 gallstones, 697t
 heart disease, 958t
 heart failure, 1023t, 1035t
 hemolytic anemias, 1106t
 HIV/AIDS, 349t
 hypertension, 1156, 1157t
 inflammatory bowel disease, 782t
 lactase deficiency, 798t
 obesity, 630t, 631t
 osteoarthritis, 1449t
 osteoporosis, 1434, 1434t
 prostate cancer, 1783t
 sickle cell anemia, 1106-7, 1106t, 1107t
 stroke, 1580t
 substance abuse, 105, 105f, 105t
 thalassemia, 1106t, 1199
 tuberculosis, 1281t, 1291
 death/dying experience and, 88, 89t
 demographics of older adults, 28t
 health and, 20
 pain response and, 176
- Radial pulse, 1096t
- Radiation exposure:
 burn injuries from, 488, 488t, 498. *See also*
 Burns
 cancer risk and, 375-76
 in nuclear detonation, 130t, 131
- Radiation sickness, 131
- Radiation therapy:
 cancer sensitivity to, 396t
 definition, 395
 delivery methods, 395
 nursing care
 external radiation, 397t
 internal radiation, 397t
 lung cancer, 1314t
 safety principles, 396t
 in specific conditions
 bladder cancer, 863
 brain tumor, 1572
 breast cancer, 1826-27
 cervical cancer, 1813
 colorectal cancer, 805
 endometrial cancer, 1817
 laryngeal cancer, 1254
 leukemia, 1123-24
 lung cancer, 1312-13
 malignant melanoma, 468
 nonmelanoma skin cancer, 464
 ovarian cancer, 1819
 spinal cord tumor, 1613
 testicular cancer, 1775
- Radical mastectomy, 1825. *See also* Mastectomy
- Radical neck dissection, 660, 1255
- Radical nephrectomy, 896. *See also* Nephrectomy
- Radical orchiectomy. *See* Orchiectomy
- Radical prostatectomy, 1785. *See also*
 Prostatectomy
- Radioactive iodine therapy, 537
- Radioactive iodine uptake (RIA), 524t, 537
- Radioallergosorbent test (RAST), 336
- Radiologic dispersion bomb, 128, 130t, 131
- Radionuclide imaging:
 in acute myocardial infarction, 987
 in heart failure, 1027
 liver and/or spleen, 1088t
- Radionuclide stress tests, 944t, 970-71
- Radiopharmaceuticals, 181
- Radius, fracture, 1413
- Radon, 1308
- Raloxifene, 391, 1436, 1796
- Ramipril, 1033t, 1161t
- Range of motion (ROM), 1391, 1391f, 1392-94t, 1392f, 1393f
- Ranitidine:
 Medication Administration, 665t
 preoperative use and nursing implications, 62t
 in specific conditions
 gastroesophageal reflux disease, 665
 pancreatitis, 728
- RAP (right atrial pressure), 1030
- Rapamune. *See* Sirolimus
- Rapid plasma reagin (RPR), 1746t, 1756t, 1849
- Rapidly progressive glomerulonephritis, 887-88.
See also Glomerular disorders
- RAS (reticular activating system), 1529-30
- RAST (radioallergosorbent test), 336
- Raynaud's disease/phenomenon:
 characteristics, 1182
 interdisciplinary care, 1182-83
 manifestations, 1182, 1183f
 nursing care, 1183
 pathophysiology, 1182
 in scleroderma, 1485
 vs. thromboangiitis obliterans, 1183t
- Reactivation tuberculosis, 1281. *See also*
 Tuberculosis
- Reactive airway disorders:
 asthma. *See* Asthma
 atelectasis. *See* Atelectasis
 bronchiectasis. *See* Bronchiectasis
 chronic obstructive pulmonary disease. *See*
 Chronic obstructive pulmonary disease
 cystic fibrosis. *See* Cystic fibrosis
- Reactive arthritis (ReA):
 causes, 1470
 interdisciplinary care, 1470
 manifestations, 1470
 nursing care, 1470
- Reasoning, 6
- Rebetol. *See* Ribavirin
- Rebif. *See* Interferon(s)
- Receptive aphasia, 1583
- Reconstruction:
 in disaster response, 133
 in healing process, 294
- Reconstructive procedure, 54t
- Recovery, in disaster response, 133
- Rectocele, 1805, 1807t
- Rectovaginal fistula, 1808
- Rectum:
 anatomy and functions, 743, 743f
 physical assessment, 750f, 750t
- Recurrent infections, 1839
- Red blood cells (RBCs):
 abnormal
 possible causes, 387t
 types, 1103
 anatomy, 1076, 1078f
 destruction, 1078-79
 disorders
 anemia. *See* Anemia
 myelodysplastic syndrome. *See*
 Myelodysplastic syndrome
 polycythemia. *See* Polycythemia
 formation, 1077f
 functions, 1102
 indices, 1078t
 normal values, 387t, 890t, 1078t
 packed, 263t. *See also* Blood transfusion
- production and regulation, 1076, 1078, 1079f
 in specific conditions
 glomerular disorders, 890t
 leukemia, 1123t
 rheumatic heart disease, 1043t
 tonicity and, 199f
 in urine. *See* Urine, RBCs
- Red (corneal light) reflex, 1678, 1680
- Reducible hernia, 810. *See also* Hernia
- Reed-Sternberg cells, 1130
- Reentry phenomenon, 996
- Refeeding syndrome, 236
- Referral source, 39
- Referred pain, 173, 173f
- Reflection, 6
- Reflex arc, 1511f
- Reflex sympathetic dystrophy, 1407
- Reflexes:
 assessment, 1523-24f, 1523-24t
 physiology, 1511, 1511f
- Refludan. *See* Lepirudin
- Reflux:
 gastroesophageal. *See* Gastroesophageal reflux
 disease
 urinary, 847, 847f
- Refraction:
 definition, 1673
 errors of, 1696
 testing, 1674t
- Refractometry, 1674t
- Refractoriness, 995
- Regional anesthesia, 63
- Regitine. *See* Phentolamine
- Reglan. *See* Metoclopramide
- Regonol. *See* Pyridostigmine
- Regulator cells, 297. *See also* T lymphocytes
- Regurgitation, 985, 1043, 1054. *See also* Valvular
 heart disease
- Rehabilitation:
 cancer, 412
 cardiac, 990
 in Parkinson's disease, 1639
- Rehabilitation nursing, 47
- Reiter's syndrome. *See* Reactive arthritis
- Rejection, transplant, 342-43, 343t, 921-22. *See*
also Transplant procedures
- Relafen. *See* Nabumetone
- Relaxation, 185-86
- Relenza. *See* Zanamivir
- Remicade. *See* Infliximab
- Reminyl. *See* Galantamine hydrobromide
- Remission, 23
- Remodeling, in burn wound healing, 493
- Remodulin. *See* Treprostinil
- Renal arteriogram, 837t
- Renal artery occlusion, 894-95
- Renal artery stenosis, 895
- Renal biopsy:
 health education for the client and family, 838t
 purpose and description, 838t
 related nursing care, 838t
 in specific conditions
 chronic renal failure, 918
 glomerular disorders, 889
 renal failure, 904
- Renal cell carcinoma:
 incidence, 896
 interdisciplinary care, 896-97
 manifestations, 896, 896t
 nursing care
 community-based care, 899
 nursing diagnoses and interventions
 anticipatory grieving, 899
 ineffective breathing pattern, 898

- pain, 897-98
 risk for impaired urinary elimination, 898-99
 pathophysiology, 896
 staging, 896t
- Renal colic, 856
- Renal cortex, 830, 830f
- Renal failure. *See also* Acute renal failure; Chronic renal failure
 definition, 899
 in diabetes mellitus, 588
 surgical risk and nursing implications, 57t
- Renal medulla, 830, 830f
- Renal osteodystrophy, 918
- Renal pelvis, 830, 830f
- Renal plasma clearance, 834
- Renal replacement therapy:
 dialysis. *See* Dialysis
 kidney transplant. *See* Kidney transplant
- Renal ultrasonography:
 purpose and description, 837t
 in specific conditions
 acute renal failure, 904
 chronic renal failure, 918
 polycystic kidney disease, 885
 renal mass, 896
- Renal vein occlusion, 895
- Renin, 201
- Renin-angiotensin-aldosterone system:
 in blood pressure regulation, 1155
 in body fluid regulation, 201, 202f
 in heart failure, 1025
 in hypertension, 1157-58
 in shock, 270
 in sodium balance regulation, 214
- ReoPro. *See* Abciximab
- Repaglinide, 578t
- Repetitive use injury:
 carpal tunnel syndrome, 1427-28
 interdisciplinary care
 conservative management, 1428
 diagnosis, 1428
 medications, 1428
 surgery, 1428
 nursing care
 community-based care, 1429
 nursing diagnoses and interventions
 acute pain, 1428
 impaired physical mobility, 1428
- Repolarization, 942-43, 942f
- Requip. *See* Ropinirole
- Receptor. *See* Delavirdine
- Researcher, nurse as, 15. *See also* Nursing research
- Reserpine, 1162t
- Residual urine test, 836t
- Residual volume, 1214t
- Residual volume (RV), 1214
- Resistance, vascular, 1176
- Resolution, in healing process, 294
- Respiration. *See also* Respiratory system
 breathing techniques in respiratory disorders, 1341t
 factors affecting
 air pressures, 1214-15, 1215f
 airway resistance, lung compliance, and elasticity, 1216
 alveolar surface tension, 1216
 oxygen, carbon dioxide, and hydrogen ion concentrations, 1215-16
 respiratory volume and capacity, 1214, 1214t
 patterns in altered level of consciousness, 1530, 1530t
 phases, 1210
- Respiratory acidosis:
 arterial blood gases in, 240t
 causes, 242t
 compensation, 243t
 definition, 240, 241f
 interdisciplinary care
 diagnosis, 248
 medications, 248
 respiratory support, 248-49
 laboratory values, 242t, 247
 manifestations, 248, 248t
 nursing care
 assessment, 249
 community-based care, 250
 health promotion, 249
 nursing diagnoses and interventions
 impaired gas exchange, 250
 ineffective airway clearance, 250
 using NANDA, NIC, and NOC, 250, 250t
- Nursing Care Plan
 assessment, 249t
 critical thinking in the nursing process, 249t
 diagnoses, 249t
 evaluation, 249t
 expected outcomes, 249t
 planning and implementation, 249t
- pathophysiology
 acute, 247-48
 chronic, 248
 risk factors, 247
- Respiratory alkalosis:
 arterial blood gases in, 240t
 causes, 242t
 compensation, 243t
 definition, 240, 241f
 interdisciplinary care
 diagnosis, 251
 medications, 251
 respiratory therapy, 251
 laboratory values, 242t, 250
 manifestations, 251, 251t
 nursing care
 assessment, diagnoses, and interventions, 251
 community-based care, 252
 health promotion, 251
 pathophysiology, 250-51
 risk factors, 250
- Respiratory failure. *See* Acute respiratory distress syndrome; Acute respiratory failure
- Respiratory rate:
 assessment, 1223t
- Respiratory syncytial virus (RSV), 1231
- Respiratory system:
 age-related changes
 in middle adults, 29t
 in older adults, 29t, 1214t, 1222t
 in young adults, 26t
 anatomy, physiology, and functions
 lower respiratory system
 airway response, 1322
 bronchi and alveoli, 1212f, 1213
 defense systems, 1267
 lungs, 1211-12, 1212f
 overview, 1212f
 pleura, 1213
 rib cage and intercostal muscles, 1213, 1213f
 upper respiratory system
 larynx, 1211
 nose, 1210-11
 overview, 1210f
 pharynx, 1211
 sinuses, 1211, 1211f
 trachea, 1211
 assessment
 diagnostic tests, 1217-19t, 1219, 1220t
 functional health pattern interview, 1221-22t
 genetic considerations, 1219
- health assessment interview, 1220-21
 physical assessment
 breath sounds, 1225-26t, 1225f
 nose, 1222-23t
 overview, 1222
 sinuses, 1223t
 thorax, 1223-25t, 1224-25f
 sample documentation, 1217
- blood gases
 carbon dioxide transport, 1216-17
 oxygen transport and unloading, 1216, 1216f
- disorders
 Clinical Scenarios, 1376t
 genetic considerations, 1220t
 lower respiratory tract. *See* Lower respiratory disorders
 surgical risk and nursing implications, 57t
 upper respiratory tract. *See* Upper respiratory disorders
- factors affecting ventilation and respiration
 air pressures, 1214-15, 1215f
 airway resistance, lung compliance, and elasticity, 1216
 alveolar surface tension, 1216
 oxygen, carbon dioxide, and hydrogen ion concentrations, 1215-16
 respiratory volume and capacity, 1214, 1214t
- Respiratory tract infections. *See* Lower respiratory disorders; Upper respiratory disorders
- Respite care, 38
- Response, disaster, 133. *See also* Disasters
- Rest pain, 1177
- Restless leg syndrome, 916
- Restrictive cardiomyopathy, 1066
- Rete testis, 1745
- Reteplase (rPA), 988
- Reticular activating system (RAS), 1529-30
- Reticular formation, 1507
- Retina:
 age-related changes, 1676t
 anatomy, physiology, and functions, 1672, 1672f
 assessment, 1680, 1681t
 disorders
 diabetic retinopathy. *See* Diabetic retinopathy
 retinal detachment. *See* Retinal detachment
 retinitis pigmentosa, 1717-18
- Retin-A. *See* Tretinoin
- Retinal detachment:
 interdisciplinary care, 1716-17
 manifestations, 1716, 1716t
 nursing care
 community-based care, 1717
 nursing diagnoses and interventions
 anxiety, 1717
 ineffective tissue perfusion: retinal, 1717
 pathophysiology, 1716
- Retinitis pigmentosa, 1717-18
- Retinol. *See* Vitamin A
- Retinoscopy:
 purpose and description, 1674t
 related nursing care, 1674t
- Retraction, 952, 1386t
- Retroflexion, uterus, 1805, 1806f
- Retrograde amnesia, 1559
- Retrograde conduction, 1001
- Retrograde ejaculation, 1771
- Retrograde pyelogram:
 purpose and description, 837t
 related nursing care, 837t
 in specific conditions
 acute renal failure, 904
- Retropubic prostatectomy, 1781t, 1785
- Retroversion, uterus, 1805, 1806f
- Retrovir. *See* Zidovudine

- Reverse transcriptase, 350*f*, 351
Reverse transcriptase polymerase chain reaction (RT-PCR), 1278
Reverse triage, 133
ReVia. *See* Naltrexone
Reye's syndrome, 1233
RF (rheumatoid factor), 341, 1388*t*, 1460
Rhabdomyolysis, 219, 902
Rhabdovirus, 1660
Rheumatic disorders, 1443. *See also specific diseases*
Rheumatic fever/heart disease:
 incidence, 1042
 interdisciplinary care
 diagnosis, 1043, 1043*t*
 medications, 1043–44
 manifestations, 1043, 1043*t*
 nursing care
 assessment, 1044
 community-based care, 1044
 health promotion, 1044
 nursing diagnoses and interventions
 activity intolerance, 1044
 acute pain, 1044
 pathophysiology, 1042–43
 risk factors, 1042
Rheumatoid arthritis (RA):
 causes, 1460
 coronary heart disease risk in, 1461–62
 course, 1460
 definition, 1459
 incidence, 1459, 1460
 interdisciplinary care
 diagnosis, 341, 1463, 1463*t*
 goals, 1463
 medications
 aspirin, 1463–64, 1464*t*
 corticosteroids, 1464
 disease-modifying drugs, 1464–66, 1465*t*
 immunosuppressants, 1466
 nonsteroidal anti-inflammatory drugs, 1464, 1464*t*
 treatments
 assistive devices and splints, 1466
 heat and cold, 1466
 nutrition, 1466
 other therapies, 1466
 rest and exercise, 1466
 surgery, 1466
 manifestations
 extra-articular, 1461
 joints, 1461, 1461*f*
Multisystem Effects, 1462*t*
nursing care
 assessment, 1468
 community-based care, 1469
 health promotion, 1466–68
 nursing diagnoses and interventions
 chronic pain, 1468
 disturbed role performance, 1469
 fatigue, 1468
 ineffective role performance, 1468
 using NANDA, NIC, and NOC, 1469, 1469*t*
Nursing Care Plan
 assessment, 1467*t*
 critical thinking in the nursing process, 1467*t*
 diagnoses, 1467*t*
 evaluation, 1467*t*
 expected outcomes, 1467*t*
 planning and implementation, 1467*t*
Nursing Research: client use of Internet for
 disease information, 1458*t*
 vs. osteoarthritis, 1460*t*
 pathophysiology, 1460, 1460*f*
Rheumatoid factor (RF), 341, 1388*t*, 1460
Rheumatrex. *See* Methotrexate
Rhinitis, 1229. *See also* Upper respiratory disorders, viral infections
Rhinoplasty, 479, 1246–47
Rhinorrhea, 1555
Rhizotomy:
 for neurogenic bladder, 872
 nursing care, 1656*t*
 for pain management, 184, 185*f*
 for trigeminal neuralgia, 1656
Rhodialose. *See* Lactulose
Rhytidectomy, 479
RIA (radioactive iodine uptake), 524*t*, 537
Rib cage, 1213, 1213*f*
Rib fracture, 1302–3, 1414. *See also* Thoracic trauma
Ribavirin, 708, 1231, 1234
Riboflavin. *See* Vitamin B₂
RICE (rest, ice, compression, elevation) therapy, 1399, 1400*t*
Ricketts, adult. *See* Osteomalacia
Rickettsia, 311*t*
Ridaura. *See* Auranofin
Rifadin. *See* Rifampin
Rifampin, 1288*t*, 1289*t*, 1566
Right atrial pressure (RAP), 1030
Right coronary artery, 939*f*; 959
Right ventricular infarct, 984
Right-sided heart failure, 1026–27, 1026*f*
Rilutek. *See* Riluzole
Riluzole, 1646
Rimactane. *See* Rifampin
Rimantadine, 1234
Ringer's lactate, 263*t*, 499
Ringworm. *See* Dermatophytoses
Rinne test:
 in hearing evaluation, 1730
 in inner ear disorders, 1727
 procedure, 1688*f*, 1688*t*
Riopan, 666*t*
Risedronate, 1442*t*
Ritalin. *See* Methylphenidate
Ritonavir, 358
Rivastigmine tartrate, 1620, 1621*t*
Rizatriptan benzoate, 1545*t*
Robaxin. *See* Methocarbamol
Robinul. *See* Glycopyrrolate
Rocephin. *See* Ceftriaxone
Rocuronium, 1356*t*
Rods, 1672
Rofecoxib, 179*t*
Roferon-A. *See* Interferon(s)
Rogaine. *See* Minoxidil
ROM (range of motion), 1391, 1391*f*, 1392–94*t*, 1392*f*, 1393*f*
Romberg's test, 1523*t*
Ropinirole, 1638*t*
Rosenbaum chart, 1677, 1677*f*
Rosiglitazone, 578*t*
Roth's spots, 1046
Routes of administration, pain medication:
 epidural, 183
 intramuscular, 183
 intravenous, 183
 nerve blocks, 183
 oral, 182
 rectal, 182
 subcutaneous, 183
 transdermal, 182–83, 183*f*
Roux-en-Y gastric bypass, 637, 637*f*
Rowasa. *See* Mesalamine
Roxicodone. *See* Oxycodone
Royonate. *See* Potassium gluconate
rPA (reteplase), 988
RPR (rapid plasma reagin), 1746*t*, 1756*t*, 1849
RSV (respiratory syncytial virus), 1231
RT-PCR (reverse transcriptase polymerase chain reaction), 1278
Rubber band ligation, for hemorrhoids, 819
Rubella:
 postexposure prophylaxis, 302*t*
 vaccine. *See* Measles-mumps-rubella vaccine
Rubor, 1097*t*, 1177
Rugae, 1752
“Rule of nines,” 490–91, 491*f*
Ruptured intervertebral disk. *See* Herniated intervertebral disk
Rythmol. *See* Propafenone
S
S₁ heart sound, 954*t*, 1054
S₂ heart sound, 954*t*, 1054
S₃ heart sound, 955*t*
Saccharin, 579
Saccular aneurysm, 1170, 1171*f*, 1592
Saddle nose deformity, 1246
Salflex. *See* Salsalate
Salicylates. *See also* Aspirin
 characteristics, 178*t*
 examples, 178*t*, 306
 nonacetylated, 1463–64
 as sunscreen, 465*t*
 topical, 1451
Saline enema, 760
Saline laxatives, 759*t*
Saline solutions, 207*t*
Salmeterol, 1327*t*
Salmeterol/fluticasone, 1327, 1328*t*
Salmon calcitonin, 1442. *See also* Calcitonin
Salmonella, 774*t*, 775
Salmonellosis, 774*t*, 775
Salpingitis, 1850
Salsalate, 178*t*, 1463
Samarium-153, 181
Sandimmune. *See* Cyclosporine
Sanguineous exudate, 293
Sansert. *See* Methysergide maleate
Santyl. *See* Collagenase
Saquinavir, 358
Sarcoidosis:
 manifestations, 1346
 nursing care, 1347
 treatment, 1346–47
Sarcoma:
 bony, 1483*t*
 soft tissue, 1483*t*
Sarcoptes scabiei, 451
SARS. *See* Severe acute respiratory syndrome
Satic. *See* Metronidazole
Saw palmetto, 851, 1781
Scabies, 451
Scald burn, 493
Scales/scaly lesions, 431*t*, 433*t*
Scalp reduction, 482
Scanning speech, 1620
Scar, 433*t*
SCD. *See* Sudden cardiac death
Schilling test, 1111
Schirmer's test, 1486
Schistocytes, 1148
Schistosoma haematobium, 862
Sciatica, 1608
Sclera:
 anatomy and physiology, 1671, 1672*f*
 assessment, 1679
Scleral buckling, 1716

- Scleroderma:
 characteristics, 1484
 incidence, 1484
 interdisciplinary care
 diagnosis, 1485
 medications, 1485
 physical therapy, 1485–86
 manifestations, 1485, 1485*f*
 nursing care
 community-based care, 1486
 nursing interventions, 1486
 pathophysiology, 1485
- Sclerodex. *See* Aethoxysclerol
- Sclerosing cholangitis, 784–85
- Sclerotherapy:
 for benign skin lesions, 478
 for hemorrhoids, 819
 for varicose veins, 1197
- Scoliosis:
 definition, 1391*t*, 1487
 incidence, 1487
 interdisciplinary care
 diagnosis, 1489
 treatments, 1489
 manifestations, 1488*f*, 1488*t*
 nursing care
 community-based care, 1490
 nursing diagnoses and interventions
 risk for injury, 1489
 risk for peripheral neurovascular
 dysfunction, 1489–90
 pathophysiology, 1488
- Scopolamine, 62*t*, 869, 1727
- Scratch test, 428*t*
- Scrotum:
 anatomy, physiology, and functions, 1744, 1744*f*, 1745*t*
 benign mass
 nursing care, 1773
 pathophysiology, 1772–73
 physical assessment, 1750*t*
- Scrub person, 66, 66*f*
- SCT. *See* Stem cell transplant
- Sebaceous glands, 424
- Seborrheic blepharitis, 1700
- Seborrheic dermatitis, 457
- Seborrheic keratoses, 443
- Sebum, 424
- Secondary dysmenorrhea, 1800
- Secondary hypertension, 894, 1167. *See also* Hypertension
- Secondary intention, wound healing by, 76, 76*f*
- Secondary lymphedema, 1199. *See also* Lymphedema
- Secondary parkinsonism, 1635
- Secondary prevention, 24
- Secondary pulmonary hypertension, 1352
- Secondary syphilis, 1848
- Second-degree AV blocks:
 causes, 1003
 ECG characteristics, 999*t*, 1003
 management, 999*t*
 pathophysiology, 1003
- Sectral. *See* Acebutolol
- Sed rate. *See* Erythrocyte sedimentation rate
- Segmental mastectomy, 1825
- Segmental pressure measurements, 1177
- Segmental resection, lung, 1312*t*
- Seizure disorder. *See* Epilepsy
- Seizures. *See also* Epilepsy
 absence, 1549
 complex partial, 1549
 definition, 1547
 pathophysiology, 1548
 simple partial, 1548–49
 status epilepticus, 1549
 tonic-clonic, 1549, 1549*f*
- Selective estrogen receptor modulators (SERMs).
See Raloxifene; Tamoxifen
- Selective serotonin reuptake inhibitors (SSRIs), 652, 763, 1798
- Selegiline, 1638*t*, 1639
- Selenium, 610*t*
- Self-recognition, 295
- Semen, 1745
- Semen analysis, 1746*t*
- Semicircular canals, 1683
- Semicomatose, 1529*t*. *See also* Altered level of consciousness
- Seminal fluid, 1745
- Seminal vesicles, 1745, 1745*t*
- Seminomas, 1774
- Semisitting position, 69*f*
- Sengstaken-Blakemore tube, 719, 719*f*
- Senile disease complex. *See* Alzheimer's disease
- Senna, 759–60*t*
- Sensing, pacemaker, 1010*t*. *See also* Pacemakers
- Sensitivity, test, 157
- Sensitization theory, pain, 173
- Sensorineural hearing loss, 1730. *See also* Hearing loss
- Sensory ataxia, 1523*t*
- Sensory system. *See also* Hearing; Vision
 age-related changes
 in middle adults, 27*t*
 in older adults, 29*t*
 assessment, 530*t*, 1521–22*t*, 1522*f*
 deficits, special considerations in
 disasters, 140
- Sentinel node biopsy, 1825
- Septic arthritis:
 definition, 1481
 interdisciplinary care, 1481
 manifestations, 1481
 nursing care, 1481
 pathophysiology, 1481
- Septic shock:
 assessment, 280
 in cancer, 410
 definition, 275
 manifestations, 275, 275*t*
- Nursing Care Plan
 assessment, 281*t*
 critical thinking in the nursing process, 281*t*
 diagnoses, 281*t*
 evaluation, 281*t*
 expected outcomes, 281*t*
 planning and implementation, 281*t*
 pathophysiology, 275
- Septicemia, 275, 769
- Septra. *See* Trimethoprim-sulfamethoxazole
- Sequestration crises, in sickle cell anemia, 1109
- Serax. *See* Oxazepam
- Serevent. *See* Salmeterol
- SERMs (selective estrogen receptor modulators).
See Raloxifene; Tamoxifen
- Seroconversion, 351
- Serologic testing, 316, 684
- Serophene. *See* Clomiphene
- Serotonin, 292*t*, 1505
- Serotonin receptor antagonists, 672, 673*t*
- Serotonin selective agonists, 1545*t*
- Serous exudate, 293
- Serous otitis media. *See* Otitis media
- Sertoli's cells, 1745
- Sertraline:
 in eating disorders, 652
 in irritable bowel syndrome, 763
- in premenstrual syndrome, 1798
 in substance abuse/withdrawal treatment, 114*t*
- Serum albumin:
 abnormal, possible causes, 386*t*
 normal values, 300, 386*t*, 890*t*
 in specific conditions
 diabetic nephropathy, 588
 glomerular disorders, 890*t*
 hypocalcemia, 229
 malnutrition, 642
- Serum amylase, 617*t*, 728*t*
- Serum bicarbonate, 239. *See also* Bicarbonate
- Serum bilirubin:
 abnormal, possible causes, 386*t*, 699*t*
 in gallbladder disorders, 699
 in jaundice, 704
 normal values, 386*t*, 699*t*
 in pancreatitis, 728*t*
- Serum calcium:
 abnormal, possible causes, 386*t*
 in musculoskeletal system assessment, 1388*t*
 normal values, 198*t*, 524*t*, 1388*t*
 in specific conditions
 osteomalacia, 1436*t*
 osteoporosis, 1436*t*
 Paget's disease, 1436*t*
 pancreatitis, 728*t*
 parathyroid evaluation, 524*t*
- Serum cholesterol:
 drugs for lowering, 967*t*
 goals in diabetes mellitus, 569
 high-risk levels, 963*t*
 normal values, 944*t*, 963*t*
- Serum creatinine:
 abnormal, possible causes, 386*t*
 normal values, 386*t*, 890*t*
 purpose and description, 835*t*
 related nursing care, 835*t*
 in specific conditions
 acute renal failure, 904
 chronic renal failure, 918
 glomerular disorders, 890, 890*t*
 neurogenic bladder, 870
- Serum ferritin, 1110
- Serum lipase, 616*t*, 728*t*
- Serum osmolality:
 abnormal, possible causes, 387*t*
 normal values, 198, 198*t*, 387*t*
 in specific conditions
 altered level of consciousness, 1533
 fluid volume deficit, 205
 fluid volume excess, 210
 gastroenteritis and diarrhea, 776*t*
 hypernatremia, 214*t*, 216
 hyponatremia, 214*t*, 215
 increased intracranial pressure, 1538
 intestinal obstruction, 813
- Serum phosphate, 198*t*, 1388*t*, 1436*t*
- Serum protein, 300, 387*t*
- Serum prothrombin conversion
 accelerator, 1082*t*
- Serum sickness, 334
- Serum triglycerides:
 goal in diabetes mellitus, 569
 high-risk levels, 963, 963*t*
 normal values, 944*t*, 963*t*
- Serum trypsinogen, 728*t*
- Sessile polyps, 800, 800*f*. *See also* Polyps
- Severe acute respiratory syndrome (SARS):
 complications, 1278
 definition, 1276
 interdisciplinary care
 diagnosis, 1278
 infection control, 1278

- Severe acute respiratory syndrome—*continued*
 medications, 1278
 treatments, 1278
 manifestations, 1278
 nursing care
 assessment, 1278
 community-based care, 1279–80
 health promotion, 1278
 nursing diagnoses and interventions
 impaired gas exchange, 1279
 risk for infection, 1279
 pathophysiology, 1276–77
- Sex chromosomes, 149
- Sex hormones:
 female, 1753. *See also* Estrogen
 male, 1745–46. *See also* Testosterone
- Sex-determining region Y gene (*SRY*), 1747*t*
- Sexual activity:
 response cycle, 1794–95
 safer sex practices, 359, 361*t*
- Sexual dysfunction:
 in cirrhosis, 715*t*
 in diabetes mellitus, 595
 in men
 ejaculatory dysfunction, 1771
 erectile dysfunction. *See* Erectile dysfunction
 in women
 anorgasmia, 1795
 dyspareunia, 1795
 inhibited sexual desire, 1795
 nursing care, 1795
- Sexuality-reproductive patterns:
 altered reproductive function. *See also* Female reproductive system; Male reproductive system
 Build Clinical Competence, 1854*t*
 Clinical Scenarios, 1855*t*
 NANDA nursing diagnoses, 1501*t*
- Sexually transmitted infections (STIs):
 Chapter Highlights, 1852*t*
 characteristics, 1837–38
 chlamydia. *See* Chlamydia
 definition, 1837
 genital herpes. *See* Genital herpes
 genital warts. *See* Genital warts
 gonorrhea. *See* Gonorrhea
 health promotion teaching, 1838*t*
 HIV/AIDS and, 1837
 incidence and prevalence, 1837
 pelvic inflammatory disease. *See* Pelvic inflammatory disease
 prevention and control, 1838
 resources, 1838*t*
 syphilis. *See* Syphilis
 vaginal infections. *See* Vaginal infections
 in young adults, 24
- Shave skin biopsy, 428*t*
- Shaving, preoperative, 67, 68*f*
- Shearing, 256
- Shigella*, 774*t*, 775
- Shigellosis, 774*t*, 775
- Shingles. *See* Herpes zoster
- Shock:
 assessment in light and dark skin, 426*t*
 cellular homeostasis and hemodynamics, 268–69
 Chapter Highlights, 283–84*t*
 definition, 268
 effect on body systems
 cardiovascular, 270, 272
 gastrointestinal and hepatic, 272
 Multisystem Effects, 273*t*
 neurologic, 272
 renal, 272
 respiratory, 272
 skin, temperature, and thirst, 272
- interdisciplinary care
 diagnosis, 276–77
 fluid replacement
 blood and blood products, 279
 colloid solutions, 277–78
 crystalloid solutions, 277
 medications, 277, 278*t*
 oxygen therapy, 277
 nursing care
 community-based care, 283
 health promotion and assessment, 279–80
 Medication Administration, 278*t*
 nursing diagnoses and interventions
 anxiety, 282–83
 decreased cardiac output, 280–82, 282*f*
 ineffective tissue perfusion, 282
 of older adults, 280*t*
 using NANDA, NIC, and NOC, 283, 283*t*
- Nursing Care Plan. *See* Septic shock, Nursing Care Plan
- pathophysiology, 269–70
 postoperative, 74
 stages, 269–70, 269*t*
- types
 anaphylactic, 276, 276*t*
 cardiogenic, 274, 274*t*
 distributive, 274
 hypovolemic, 273–74, 273*f*
 neurogenic, 275–76, 276*t*
 obstructive, 274
 septic, 275, 275*t*
- Short bones, 1380
- Short bowel syndrome:
 causes, 799
 interdisciplinary care
 diagnosis, 799
 medications, 799
 nursing care, 799–800
 pathophysiology, 799
- Shoulder:
 physical assessment, 1394*t*
 replacement. *See* Total joint replacement
- SIADH. *See* Syndrome of inappropriate antidiuretic hormone
- Sibutramine, 633, 634*t*
- Sick sinus syndrome, 1000
- Sickle cell anemia:
 complications, 1107, 1109
 genetic considerations, 1089*t*, 1106, 1107*f*
 interdisciplinary care
 diagnostic tests, 1110
 focus, 1110*t*
 medications, 1111
 manifestations, 1107
 pathophysiology, 1107, 1108*t*
 physical assessment, 1107*f*
 racial/ethnic considerations, 1106–7, 1106*t*, 1107*t*
 stroke risk and, 1580
- Sickle cell crisis, 1107
- Sickle cell disease, 1107
- Sickle cell test, 1110
- Sickle cell trait, 1107
- Sigmoid colon, 742*f*, 743
- Sigmoid colostomy, 804
- Sigmoidoscopy:
 in bowel disorders, 745*t*
 in cancer, 385
 in diarrhea, 755
 in gastroenteritis, 776
 in protozoal bowel infections, 779
- Sildenafil citrate, 987, 1769
- Silent myocardial ischemia, 970
- Silicosis, 1345
- Silvadene. *See* Silver sulfadiazine
- Silver nitrate, 500, 501*t*, 1243
- Silver sulfadiazine, 441*t*, 500, 501*t*
- Silymarin, 709
- Simple diffusion, 199–200
- Simple (closed) fracture, 1401, 1402*f*. *See also* Fractures
- Simple mastectomy, 1825
- Simple obstruction, 811, 812*f*. *See also* Intestinal obstruction
- Simple partial seizure, 1548–49
- Simple Triage and Rapid Transport (START) System, 134*t*
- Simlect. *See* Basiliximab
- SIMV (synchronized intermittent mandatory ventilation), 1358, 1359*t*
- Simvastatin, 98, 967*t*
- Sinemet. *See* Carbidopa-levodopa
- Single nucleotide polymorphisms (SNPs), 152
- Single-chamber pacing, 1009, 1010*t*. *See also* Pacemakers
- Single-gene disorders, 152
- Single-photon emission computed tomography (SPECT), 1512, 1514*t*
- Singulair. *See* Montelukast
- Sinoatrial (SA) node, 941, 941*f*
- Sinus arrhythmia:
 causes, 1000
 ECG characteristics, 997*t*
 management, 997*t*
- Sinus bradycardia:
 causes, 1000
 ECG characteristics, 997*t*
 management, 997*t*
 manifestations, 1000
- Sinus tachycardia:
 causes, 1000
 ECG characteristics, 997*t*
 management, 997*t*
 manifestations, 1000
 pathophysiology, 1000
- Sinuses:
 anatomy, physiology, and functions, 1211, 1211*f*, 1235
 infection. *See* Sinusitis
 physical assessment, 1223*t*
- Sinusitis:
 complications, 1236, 1236*t*
 definition, 1235
 interdisciplinary care
 complementary therapies, 1237
 diagnosis, 1236
 medications, 1236
 surgery, 1236–37, 1237*f*
 manifestations, 1236
 nursing care
 assessment, 1237
 community-based care, 1238
 health promotion, 1237
 nursing diagnoses and interventions
 imbalanced nutrition: less than body requirements, 1237–38
 pain, 1237
 pathophysiology, 1235–36
 physiology review, 1235
- Sirolimus, 345*t*
- SIRS (systemic inflammatory response syndrome), 275
- Sitz baths, 819, 821
- Sjögren's syndrome:
 associated disorders, 1486

- incidence, 1486
- interdisciplinary care, 1486
- nursing care, 1486
- pathophysiology, 1486
- Skeletal traction, 1408, 1409*f*
- Skeletal tuberculosis, 1283
- Skelid. *See* Tiludronate
- Skene's glands:
 - location and function, 1751*t*, 1752, 1752*f*
 - physical assessment, 1763*f*, 1763*t*
- Skin:
 - age-related changes
 - in middle adults, 27*t*
 - in older adults, 29*t*, 430*t*
 - in young adults, 26*t*
 - anatomy, physiology, and functions
 - anatomy, 424*f*
 - dermis, 423-24
 - epidermis, 423, 423*t*
 - glands, 424-25
 - skin color, 425
 - superficial fascia, 424
 - assessment
 - abnormal findings, 431*t*, 435*f*, 435*t*, 529*t*, 1093*t*
 - diagnosis, 427, 428*t*
 - Genetic Considerations, 427, 427*t*
 - health assessment interview, 427, 429
 - sample documentation, 427*t*
 - technique/normal findings, 431*t*, 435*t*, 529*t*
 - variations in people with light and dark skin, 426*t*
 - disorders
 - benign lesions
 - angiomas, 430*t*, 434*t*, 443
 - cysts, 432*t*, 442
 - keloid. *See* Keloid
 - keratosis, 430*t*, 443
 - nevi, 442-43, 442*f*
 - in older adults, 430*t*
 - primary, 432*t*
 - secondary, 433*t*
 - skin tags, 430*t*, 443
 - terminology, 431*t*
 - vascular, 434*t*
 - Chapter Highlights, 483-84*t*
 - Clinical Scenarios, 514*t*
 - infections/infestations. *See* Skin infections/infestations
 - inflammatory disorders
 - acne. *See* Acne
 - dermatitis. *See* Dermatitis
 - lichen planus, 460
 - malignant lesions
 - actinic keratosis, 461, 461*f*
 - malignant melanoma. *See* Malignant melanoma
 - skin cancer. *See* Skin cancer
 - medications for, 441*t*
 - pemphigus vulgaris, 460
 - pressure ulcer. *See* Pressure ulcer
 - pruritus, 440, 441*t*
 - psoriasis. *See* Psoriasis
 - terminology, 431*t*
 - toxic epidermal necrolysis, 460-61
 - xerosis (dry skin), 441, 441*t*
 - self-examination, 465*t*
 - surgical procedures
 - cutaneous
 - chemical destruction, 478
 - cryosurgery, 477
 - curettage, 477
 - electrosurgery, 477
 - fusiform excision, 477
 - laser surgery, 477-78
 - sclerotherapy, 478
 - nursing care
 - community-based care, 481
 - nursing diagnoses and interventions, 479-81
 - plastic
 - blepharoplasty, 479
 - chemical peeling, 479
 - dermabrasion, 479
 - liposuction, 479
 - rhinoplasty, 479
 - rhytidectomy, 479
 - skin grafts and flaps, 478-79, 478*f*
 - tenting, 435*f*, 435*t*
 - transplantation
 - indications, 342*t*
 - success rate, 342*t*
 - trauma
 - burns. *See* Burns
 - frostbite, 476-77
 - injuries, 258-59, 259*f*
 - pressure ulcer. *See* Pressure ulcer
 - turgor, 205, 435
- Skin biopsy, 428*t*
- Skin cancer:
 - malignant melanoma. *See* Malignant melanoma
 - nonmelanoma
 - basal cell cancer, 462-63, 462*t*, 463*f*
 - incidence, 461
 - interdisciplinary care
 - diagnosis, 463
 - treatments, 463-64
 - nursing care
 - assessment, 470*t*
 - community-based care, 465
 - health promotion, 464, 464*t*, 465*t*
 - risk factors, 461-62
 - squamous cell cancer, 463, 463*f*
 - prevention, 464*t*
- Skin flap, 479
- Skin grafts:
 - in burns, 503, 503*f*
 - types, 478, 478*f*
- Skin infections/infestations:
 - bacterial
 - interdisciplinary care
 - diagnosis, 447
 - medications, 447
 - nursing care
 - community-based care, 448
 - nursing diagnoses and interventions, 447-48
 - pathophysiology, 446
 - types
 - carbuncles, 447
 - cellulitis, 447, 447*f*
 - erysipelas, 447
 - folliculitis, 446, 446*f*
 - furuncles, 446-47, 447*f*
 - fungus
 - interdisciplinary care, 449-50, 450*t*
 - nursing care, 450
 - types
 - candidiasis. *See* Candidiasis
 - dermatophytoses, 448-49
 - parasitic
 - interdisciplinary care
 - diagnosis, 451
 - medications, 451
 - nursing care, 451
 - types
 - pediculosis, 450-51
 - scabies, 451
- viral
 - interdisciplinary care
 - diagnosis, 453
 - medications, 453
 - nursing care
 - community-based care, 455
 - nursing diagnoses and interventions, 453, 455
 - using NANDA, NIC, and NOC, 455, 455*t*
 - types
 - herpes simplex, 452, 452*f*
 - herpes zoster. *See* Herpes zoster
 - warts, 451-52
- Skin tags, 430*t*, 443*t*
- Skin tests:
 - in hypersensitivity reactions, 337-38, 338*f*
 - in immunity assessment, 300
 - types and related nursing care, 428*t*
- Skin traction, 1408, 1409*f*
- Skull fracture. *See also* Traumatic brain injury
 - definition, 1554
 - interdisciplinary care, 1412, 1555
 - nursing care, 1555-56
 - pathophysiology, 1555
 - types, 1555, 1555*t*
- SLE. *See* Systemic lupus erythematosus
- Sleep apnea:
 - central, 1250
 - definition, 1250
 - obstructive. *See* Obstructive sleep apnea
 - stroke risk and, 1580
- Sleeve resection, lung, 1312*t*
- Sliding hiatal hernia, 667, 668*f*
- Slo-Phyllin. *See* Theophylline
- "Slow codes," 91
- Small intestine:
 - anatomy, physiology, and functions, 605*f*, 612, 742
 - disorders. *See* Bowel disorders
 - obstruction. *See* Intestinal obstruction
- Small-bowel obstruction. *See* Intestinal obstruction
- Small-bowel series, 744*t*
- Small-cell carcinoma, 1308, 1309*t*. *See also* Lung cancer
- Smallpox, 128*t*
- Smell, assessment, 1223*t*
- Smoke inhalation/poisoning, 496, 1305. *See also* Inhalation injury
- Smoking:
 - cancer risk and, 371-72, 862, 1308, 1337*t*
 - cessation
 - in chronic obstructive pulmonary disease, 1334
 - coronary heart disease risk reduction from, 966
 - in hospital patients (Nursing Research), 106*t*
 - chronic obstructive pulmonary disease and, 1331
 - client teaching, 1337*t*
 - coronary heart disease risk and, 964
 - hypertension and, 1160
 - nicotine characteristics, 106
 - nursing diagnoses, 1337*t*
 - nursing interventions, 1337*t*, 1340
 - osteoporosis risk and, 1434
 - rates in women, 106-7
 - stroke risk and, 1580*t*
 - surgical risk and nursing implications, 58*t*
 - thromboangiitis obliterans and, 1180, 1182
- Snellen chart, 1676-77, 1677*f*
- Sniffing, 111
- Snowstorm, 129*t*, 131
- Soap-suds enema, 760
- Social support systems, 37, 87
- Socioeconomic factors:
 - health and, 20, 37
 - in heart disease, 958*t*

- Sodium (Na⁺):
 in action potential, 1505
 balance, 213–14
 in body fluid compartments, 197t
 foods high in, 211t
 in hypertension, 1157
 imbalances. *See* Hyponatremia; Hyponatremia
 intake in diabetes mellitus, 579
 intake in hypertension, 1157
 recommended dietary guidelines, 606t
 restriction
 in chronic renal failure, 919
 in cirrhosis, 717
 client teaching, 213t
 for fluid volume excess, 210–11
 in heart failure, 1034
 in hypertension, 1159
 serum levels
 abnormal, possible causes, 387t
 in gastroenteritis and diarrhea, 776t
 normal values, 198t, 387t
 perioperative, significance and nursing implications, 60t
- Sodium bicarbonate:
 Medication Administration, 906t
 in specific conditions
 acute renal failure, 906t
 chronic renal failure, 919
 hyperkalemia, 225t
 metabolic acidosis, 244
 mouthwash, 658
 in therapeutic baths, 441t
- Sodium channel blockers, 1005–6, 1006t
- Sodium citrate, 62t
- Sodium ferric gluconate, 1111, 1112t
- Sodium fluoride. *See* Fluoride therapy
- Sodium nitroprusside. *See* Nitroprusside
- Sodium phosphate, 232
- Sodium polystyrene sulfonate:
 Medication Administration, 225t, 906t
 in specific conditions
 acute renal failure, 904, 906t
 chronic renal failure, 919
 hyperkalemia, 224, 225t, 904
 tumor lysis syndrome, 411
- Sodium salicylate, 178t
- Sodium-potassium pump, 200, 201f
- Soft tissue sarcomas, 1483t
- Solganal. *See* Aurothioglucose
- Solu-Medrol. *See* Methylprednisolone
- Solutes, 198
- Soma. *See* Carisoprodol
- Somatic cells, 149
- Somatic mutation, 152
- Somatic neuropathies. *See* Peripheral neuropathies
- Somatic pain, 173
- Somatomedin C, 523t
- Somatosensory evoked potential (SSEP), 1388t
- Somatostatin, 521, 564, 718
- Somatostatin analog. *See* Octreotide
- Somogyi phenomenon, 582
- Somophyllin. *See* Aminophylline
- Sorbitol, 225t, 579, 759t
- Sotalol, 1006t
- Sound conduction, 1683
- Spastic bowel. *See* Irritable bowel syndrome
- Spastic hemiparesis, 1523t
- Spastic neurogenic bladder, 870. *See also*
 Neurogenic bladder
- Spasticity:
 causes, 1522t
 definition, 1522t, 1584
 in stroke, 1584
- Specific gravity, urine. *See* Urine tests, specific gravity
- Specific reactivity, 290
- Specificity, test, 157–58
- Spectazole. *See* Econazole
- Speculum, vaginal, 1764t
- Speech area, 1506t
- Speech audiometry, 1730
- Speech rehabilitation, 1255–56, 1255f
- Speech-generating devices, 1258, 1258f, 1260t
- Spermatocele, 1773, 1773f
- Spermatogenesis, 1475
- Spider angioma, 434f, 434t, 443, 624t
- Spinal accessory nerve. *See* Accessory nerve
- Spinal analgesia. *See* Epidural analgesia
- Spinal anesthesia, 63
- Spinal cord:
 anatomy, 1508–9, 1509f
 ascending tracts, 1508, 1509f
 compression, as oncologic emergency, 410
 descending tracts, 1508–9, 1509f
 disorders
 acute injury. *See* Spinal cord injury
 herniated intervertebral disk. *See* Herniated intervertebral disk
 tumor. *See* Spinal cord tumors
 upper and lower motor neurons, 1509
- Spinal cord injury:
 complete, 1597
 complications
 autonomic dysreflexia, 1599
 by body system, 1598t
 paraplegia and quadriplegia, 1599
 upper and lower motor neuron deficits, 1598–99
 incidence and prevalence, 1595
 incomplete, 1597, 1597t
 interdisciplinary care
 diagnosis, 1600
 emergency care, 1599, 1600t
 medications, 1600, 1600t
 treatments
 stabilization and immobilization, 1600–1601, 1601f
 surgery, 1600
 manifestations, 1597–98, 1598t
 nursing care
 assessment, 1602
 of client with halo external fixation, 1602t
 community-based care, 1606–7
 health promotion, 1602
 Medication Administration, 1600t
 nursing diagnoses and interventions
 dysreflexia, 1604
 impaired gas exchange, 1602–3
 impaired physical mobility, 1602
 impaired urinary elimination and constipation, 1604–5, 1605t
 ineffective breathing patterns, 1604
 low self-esteem, 1606
 sexual dysfunction, 1605–6
 using NANDA, NIC, and NOC, 1606, 1606t
- Nursing Care Plan
 assessment, 1603t
 critical thinking in the nursing process, 1603t
 diagnoses, 1603t
 evaluation, 1603t
 expected outcomes, 1603t
 planning and implementation, 1603t
 pathophysiology
 anatomic considerations, 1596
 mechanisms, 1596–97, 1596f
 pathologic changes, 1596
- sites, 1597
 tissue repair, 1596
 risk factors, 1595
 self-catheterization procedure, 1605t
- Spinal cord tumors:
 classification, 1612
 interdisciplinary care
 diagnosis, 1613
 medications, 1613
 radiation therapy, 1613
 surgery, 1613
 manifestations, 1612–13, 1612t
 nursing care, 1613
 pathophysiology, 1612
- Spinal fusion, 1608
- Spinal nerves, 1508f, 1509, 1510f
- Spinal reflexes, 1511. *See also* Reflexes
- Spinal shock, 1598, 1600t
- Spine:
 fracture, 1412
 physical assessment, 1391t, 1392t, 1393f
- Spinocerebellar ataxia, 1513t
- Spiral fracture, 1401, 1402f
- Spiramycin, 778t
- Spiritual development, theories, 25t
- Spiritual therapy, 399t
- Spirituality:
 assessment in dying clients and their families, 88, 96
 considerations in disasters, 140
- Spiriva. *See* Tiotropium bromide
- Spironolactone:
 Medication Administration, 210t, 717t, 1033t
 in specific conditions
 cirrhosis, 716, 717t
 heart failure, 1033t
- Spleen:
 anatomy, 291, 291f
 enlargement. *See* Splenomegaly
 functions, 291, 1086
 physical assessment, 626f, 626t, 1098–99t, 1099f
- Splenda. *See* Sucralose
- Splenectomy, 1141
- Splenomegaly, 711
- Splinter hemorrhages, 1046
- Split-thickness graft, 478, 478f
- Spondylitis, tuberculous, 1283
- Spongiform encephalopathy. *See* Creutzfeldt-Jakob disease
- Spontaneous pneumothorax. *See also*
 Pneumothorax
 manifestations, 1297, 1298t
 pathophysiology, 1297, 1298t
- Spoon-shaped nails, 436f, 436t, 1105
- Sporadic Alzheimer's disease, 1618
- Sportscreme. *See* Salicylates
- Spousal abuse. *See* Intimate partner violence
- Sprain:
 interdisciplinary care, 1399–1400, 1400t
 manifestations, 1399
 nursing care, 1400
 vs. strain, 1399
- Sprue:
 celiac, 746t, 796, 1106
 definition, 796
 interdisciplinary care
 diagnosis, 797
 medications, 797
 nutrition, 797, 797t
 manifestations, 796
 nursing care
 assessment, 797
 community-based care, 798

- nursing diagnoses and interventions
 diarrhea, 797-98
 imbalanced nutrition: less than body requirements, 798
 pathophysiology, 796
 tropical, 796
- SPS Suspension. *See* Sodium polystyrene sulfonate
- Sputum studies:
 procedure, 1220t
 purpose and description, 1217t, 1219
 related nursing care, 1217t
 in specific conditions
 lung cancer, 1311
 pneumonia, 1270
 severe acute respiratory syndrome, 1278
 tuberculosis, 1287
 types, 1217t
- Squamous cell carcinoma:
 cervix. *See* Cervical cancer
 esophageal, 669. *See also* Esophageal cancer
 larynx. *See* Laryngeal cancer
 lung, 1309t. *See also* Lung cancer
 oral, 660. *See also* Oral cancer
 penis, 1772
 skin, 463, 463f. *See also* Skin cancer
- SSEP (somatosensory evoked potential), 1388t
- SSKI. *See* Potassium iodide
- SSRIs (selective serotonin reuptake inhibitors), 652, 763, 1798
- St. John's wort, 709
- ST segment, 948f, 948t
- Stable angina, 969. *See also* Angina pectoris
- Stable cells, 295
- Stable fracture, 1402
- Stadol. *See* Butorphanol
- Staghorn stones, 856
- Standard precautions, 321-22
- Standards, 11, 11t
- Stanford mouthwash, 409t
- Stapedectomy, 1725
- Stapedotomy, 1725
- Stapes, 1682, 1682f
- Staphcillin. *See* Methicillin
- Staphylococcal food poisoning, 774t, 775
- Staphylococcus aureus*:
 antibiotic therapy, 1271t
 in endocarditis, 1045
 methicillin-resistant, 313-14
 in osteomyelitis, 1477, 1479
 in skin infections, 446-47
 vancomycin-resistant, 314
- Staphylococcus saprophyticus*, 846
- Starling's law of the heart, 940
- Starlix. *See* Nateglinide
- START (Simple Triage and Rapid Transport) System, 134t
- Starvation, 641. *See also* Malnutrition
- Stasis ulcer, 1194, 1194f. *See also* Chronic venous insufficiency
- Statins, 967t, 968
- Status asthmaticus, 1323
- Status epilepticus, 1549
- Stavudine, 356
- Steatorrhea:
 in cystic fibrosis, 1342
 definition, 727, 750t, 1342
 in pancreatitis, 727, 728
 in sprue, 797
 in Zollinger-Ellison syndrome, 684
- Stein-Leventhal syndrome. *See* Polycystic ovarian syndrome
- Stem cell transplant (SCT):
 allogeneic, 1124
 autologous peripheral blood
 advantages, 398
 Nursing Research: fatigue and depression following treatment, 1133t
 procedure, 1132
 complications, 1124
 in specific conditions
 leukemia, 1124
 lymphoma, 1132
 multiple myeloma, 1137
 myelodysplastic syndrome, 1116
- Stenosis, 1043, 1054, 1054f. *See also* Valvular heart disease
- Stents, intracoronary, 977
- Steppage gait, 1523t
- Stereotaxic thalamotomy, 1639
- Stimate. *See* Desmopressin acetate
- Stimulant laxatives, 759-60t
- Stimulants. *See* Psychostimulants
- STIs. *See* Sexually transmitted infections
- Stokes-Adams attack, 1003
- Stoma. *See also* Colostomy; Ileostomy
 characteristics, 789f
 definition, 789
 urinary. *See* Urinary diversion
- Stomach:
 anatomy, physiology, and functions, 611-12, 611f, 671
 disorders
 bleeding. *See* Gastrointestinal bleeding
 cancer. *See* Gastric cancer
 diagnostic tests, 615-16t
 nausea and vomiting. *See* Nausea and vomiting
 peptic ulcer disease. *See* Peptic ulcer disease
- Stomafate suspension, 409t
- Stomatitis:
 definition, 656
 interdisciplinary care
 medications, 657-58, 657t, 658t
 management, 657t
 manifestations, 656-87
 nursing care
 assessment, 658-59
 health promotion, 658
 Medication Administration, 658t
 nursing diagnoses and interventions
 community-based care, 659-60
 imbalanced nutrition: less than body requirements, 659
 impaired oral mucous membrane, 659
 using NANDA, NIC, and NOC, 659, 659t
 pathophysiology, 656
 risk factors, 656-57, 656t
- Stool:
 assessment, 743, 750-51t
 characteristics, 750t
 tests
 culture, 744t
 occult blood, 744t
- Strabismus, 1678t
- Strain:
 interdisciplinary care, 1399-1400, 1400t
 manifestations, 1399
 nursing care, 1400
 vs. sprain, 1399
- Strangulated hernia, 810. *See also* Hernia
- Strangulated obstruction, 811. *See also* Intestinal obstruction
- Stratum basale, 423, 424f
 Stratum corneum, 423
 Stratum granulosum, 423, 424f
 Stratum lucidum, 424f
 Stratum spinosum, 423, 424f
- Streptococcus, group A. *See* Group A beta-hemolytic streptococcus
- Streptococcus pneumoniae*:
 antibiotic therapy, 1271t
 penicillin-resistant, 314
 in pneumonia, 1267, 1268, 1269t. *See also* Pneumonia
- Streptokinase, 988, 1184, 1188
- Streptomycin:
 adverse/side effects, 1287, 1288t
 dosage, 1288t
 Medication Administration, 320t, 1289t
 nursing implications, 1288t
 in tuberculosis, 1289t
- Stress:
 cancer risk and, 370-71
 hypertension and, 1157
 reduction, 1160
 responses to, 135t, 370
- Stress echocardiography, 945t
- Stress fracture. *See* Pathologic fracture
- Stress ulcers:
 in burn clients, 496
 in mechanical ventilation, 1360
 pathophysiology, 502
 prevention, 502
 in trauma clients, 272
- Stress urinary incontinence, 874t. *See also* Urinary incontinence
- Stress/exercise tests:
 nuclear dobutamine, 944t
 nuclear persantine (dipyridamole), 944t
 purpose and description, 943, 944t
 related nursing care, 944t
 in specific conditions
 angina, 970
 coronary heart disease, 965
 peripheral vascular disease, 1177
 thallium/technetium, 944t, 970-71
- Stress-induced gastritis, 677. *See also* Gastritis; Stress ulcers
- Striae, 624t, 748t
- Stridor, 231
- Stroke:
 Case Study, 1667t
 complications
 by body system, 1583t
 cognitive and behavioral changes, 1583
 communication disorders, 1583
 elimination disorders, 1584
 motor deficits, 1584, 1584f
 sensoriperceptual deficits, 1582-83, 1582f
 definition, 1579
 in diabetes mellitus, 588
 hemorrhagic, 1581-82
 incidence and prevalence, 1579
 interdisciplinary care
 diagnosis, 1584-85, 1585t
 goals, 1584
 medications
 acute stroke, 1585-86
 prevention, 1585
 rehabilitation, 1586
 surgery, 1586, 1586f, 1586t
 ischemic, 1581
 manifestations, 1582, 1582t, 1583t
 nursing care
 assessment, 1587
 of client having endarterectomy, 1586t
 community-based care, 1591-92
 health promotion, 1587

- Stroke—*continued*
 nursing diagnoses and interventions
 impaired physical mobility, 1589–90, 1590f
 impaired swallowing, 1591
 impaired urinary elimination and risk for constipation, 1591
 impaired verbal communication, 1590–91
 ineffective tissue perfusion: cerebral, 1587–89
 self-care deficit, 1590
 overview, 1586–87
 using NANDA, NIC, and NOC, 1591, 1591t
- Nursing Care Plan
 assessment, 1588t
 critical thinking in the nursing process, 1588t
 diagnoses, 1588t
 evaluation, 1588t
 expected outcomes, 1588t
 planning and implementation, 1588t
- Nursing Research: improving use of rapid treatment, 1589t
- pathophysiology, 1580
 racial/ethnic considerations, 1580t
 risk factors, 1579–80, 1580t, 1589t
- Stroke volume (SV):
 definition, 269, 940, 1023
 in hypovolemic shock, 273f
 normal values, 940
- Stroke-in-evolution, 1581
- Strong iodine solution, 538t
- Struvite stones, 856, 856t. *See also* Urinary calculi
- Stuart factor, 1082t
- Stunned, 984
- Stupor, 1529t. *See also* Altered level of consciousness
- Sty (hordeolum), 1700
- Subacute infective endocarditis, 1045, 1046t. *See also* Endocarditis
- Subarachnoid hemorrhage, 884, 1593. *See also* Intracranial aneurysm
- Subcutaneous emphysema, 1360
- Subdural hematoma. *See also* Traumatic brain injury
 causes, 1557t, 1558
 characteristics, 1557f, 1558
 manifestations, 1557t
- Nursing Care Plan
 assessment, 1561t
 critical thinking in the nursing process, 1561t
 diagnoses, 1561t
 evaluation, 1561t
 expected outcomes, 1561t
 planning and implementation, 1561t
- Subendocardial infarction, 983. *See also* Acute myocardial infarction
- Subjective data, 8
- Sublimaze. *See* Fentanyl
- Subluxation, 1401
- Submucous fibroid tumors, 1809, 1810f
- Subserous fibroid tumors, 1809, 1810f
- Substance abuse:
 addictive substances
 alcohol. *See* Alcohol
 caffeine, 106
 central nervous system depressants, 108
 cocaine, 108–9
 hallucinogens, 110–11
 inhalants, 111
 marijuana, 107
 methamphetamine, 109–10, 109f
 nicotine, 106–7. *See also* Smoking
 opiates/opioids, 110, 110f. *See also* Narcotic analgesics
 psychostimulants, 108–10
 street names, 111
 cancer risk and, 372
 Chapter Highlights, 122–23t
 characteristics of abusers, 105
 definition, 102, 103t
 genetic considerations, 104t
 impaired nurses, 121, 122t
 interdisciplinary care
 diagnostic tests, 112
 overdose, 112, 113t, 114t
 withdrawal, 112, 113t
 in middle adults, 27
 nursing care
 assessment
 history of past substance abuse, 115
 medical and psychiatric history, 115
 open-ended questions for, 114–15, 115t
 psychosocial issues, 116
 relapse behaviors, 121t
 screening tools, 116–17, 116f
 withdrawal assessment tools, 117, 118f
 community-based care, 120–21
 health promotion, 114
 nursing diagnoses and interventions
 chronic low or situational low self-esteem, 120
 deficient knowledge, 120
 disturbed sensory perceptions, 120
 disturbed thought processes, 120
 imbalanced nutrition: less than body requirements, 119
 ineffective coping, 117
 ineffective denial, 117
 risk for injury and risk for violence, 117
 settings, 114
 using NANDA, NIC, and NOC, 120, 120t, 121t
 in older adults, 115, 115t
 pain management considerations in, 181t
 pathophysiology, 102–3, 104, 104f
 in pregnancy. *See* Pregnancy, substance abuse in
 racial/ethnic considerations, 105f, 105t
 risk factors
 biologic, 104, 104f
 genetic, 104, 104t
 psychologic, 104
 sociocultural, 105, 105t
 stroke risk and, 1580
 vs. substance dependence, 102t
 terminology, 103t
 in young adults, 25
- Substance dependence, 102, 102t, 103t
- Substernal, 984
- Sucking chest wound, 1299. *See also* Pneumothorax
- Sucralfate, 665–66t, 678, 685
- Sucralose, 579
- Sudafed. *See* Pseudoephedrine
- Sudden cardiac death (SCD):
 causes, 1015
 definition, 1015
 in hypertrophic cardiomyopathy, 1066
 interdisciplinary care
 advanced life support, 1016–17
 basic life support, 1016, 1016f, 1017t
 postresuscitation care, 1017
 manifestations, 1016
 nursing care, 1018
 Nursing Research: family presence during resuscitation, 1066t
 pathophysiology, 1016
 risk factors, 1015–16
- Sular. *See* Nisoldipine
- Sulfacetamide sodium, 1694, 1697
- Sulfadiazine. *See* Silver sulfadiazine
- Sulfamethizole, 321t
- Sulfamethoxazole, 321t. *See also* Trimethoprim-sulfamethoxazole
- Sulfamylon. *See* Mafenide acetate
- Sulfasalazine:
 Medication Administration, 787t
 in specific conditions
 ankylosing spondylitis, 1470
 autoimmune disorders, 341
 inflammatory bowel disease, 786, 787t
 rheumatoid arthritis, 1465t, 1466
- Sulfipyrazone, 1446t, 1455
- Sulfisoxazole, 321t, 832t
- Sulfonamides, 321t, 832t
- Sulfonylureas, 578t
- Sulindac, 178t, 1445, 1464t
- Sumatriptan, 1544, 1545t
- Sun exposure:
 cancer risk and, 372t, 462
 minimizing, 464t
- Sunburn, 493
- Sundowning, 1620
- Sunnette. *See* Acesulfame potassium
- Sunscreens, 465t
- Supartz. *See* Hyaluronan injections
- Superficial burn, 489–90, 489t. *See also* Burns
- Superficial partial-thickness burn, 490, 490f. *See also* Burns
- Superficial venous thrombosis, 1187t, 1188. *See also* Venous thrombosis
- Superior vena cava syndrome:
 in lung cancer, 1311
 nursing interventions, 409
 pathophysiology, 409, 410f
- Supination, 1386t
- Support garments, for burn wounds, 505, 505f
- Suppressor T cells, 297, 298. *See also* T lymphocytes
- Suprapubic prostatectomy, 1781t, 1785
- Supraventricular aortic stenosis, 950t
- Supraventricular dysrhythmias. *See also* Cardiac dysrhythmias
 causes, 1000–1001
 ECG characteristics, 997–98t
 management, 997–98t
 manifestations, 1000–1001
 pathophysiology, 1000–1001
- Supraventricular rhythms, 996, 997t, 1000
- Surface tension, alveolar, 1216
- Surfactant, 1216, 1367
- Surfak. *See* Docusate
- Surge capacity, 133
- Surgery:
 Chapter Highlights, 82t
 definition, 54
 interdisciplinary care
 client preparation
 positioning, 67, 69f
 shaving, 67, 68f
 skin preparation, 67
 diagnosis, 60–61
 intraoperative awareness, 67
 laboratory tests for perioperative assessment, 60t
 medications
 intraoperative, 61–64. *See also* Anesthesia
 postoperative, 64, 65. *See also* Postoperative period, pain management
 preoperative, 61, 62t
 sliding scale insulin, 572–73, 574t
 nutrition, 70

- Practice Alerts, 64
 special considerations in older adults, 68, 70
 surgical environment
 surgical attire, 66–67, 67f
 surgical scrub, 67
 team members, 64–66
 legal requirements, 55
 nursing care
 Case Study, 145t
 Clinical Scenarios, 144t
 community-based care, 80
 intraoperative phase, 73
 laminectomy, 1609–10t
 postoperative complications
 cardiovascular, 74–75
 elimination-related, 78–79
 respiratory, 75–76
 special considerations for older adults, 79, 79t
 wound. *See* Wounds
 postoperative phase
 acute pain management, 79–80
 care after client is stable, 74
 immediate care, 74
 preoperative phase
 client and family teaching, 71, 72–73t
 client preparation, 71–73
 nursing care, 71
 nursing diagnoses, 70t
 for specific procedures
 adrenalectomy, 550t
 aortic aneurysm repair, 1174t
 bladder neck suspension, 876t
 bowel surgery, 804t
 breast reconstruction, 1827t
 carotid endarterectomy, 1586t
 colostomy, 806t
 coronary artery bypass graft, 980–82t
 cystectomy and urinary diversion, 866t
 dilation and curettage, 1803t
 ear surgery, 1725t
 eye surgery, 1699t
 gastric surgery, 690t
 gastrostomy or jejunostomy tube, 692t
 halo external fixation, 1602t
 hysterectomy, 1804t
 ileostomy, 789–90t
 kidney transplant, 922t
 laparoscopic cholecystectomy, 700t
 laryngectomy, 1256t
 liver transplantation, 720t
 lung surgery, 1313t
 mastectomy, 1826t
 nephrectomy, 897
 percutaneous coronary revascularization, 978t
 permanent pacemaker implant, 1012t
 physiology review, 1783t
 posterior laminectomy, 1609–10t
 prostatectomy, 1780–81t
 subtotal thyroidectomy, 539t
 surgery for seizures, 1551t
 surgical debridement for osteomyelitis, 1479t
 thoracocentesis, 1297t
 thymectomy, 1650t
 total joint replacement, 1452–53
 T-tube, 701t
 ureteral stent, 851t
 Whipple's procedure, 732t
 using NANDA, NIC, and NOC, 80, 80t
 Nursing Care Plan
 assessment, 81t
 case description, 80t
 critical thinking in the nursing process, 81t
 diagnoses, 81t
 evaluation, 81t
 expected outcomes, 81t
 planning and implementation, 81t
 phases, 54
 procedures
 cancer diagnosis, 388–89, 388t
 cardiac
 coronary artery bypass graft. *See* Coronary artery bypass grafting
 heart transplant. *See* Heart transplant
 minimally invasive coronary artery surgery, 979
 percutaneous coronary revascularization. *See* Percutaneous coronary revascularization
 transmyocardial laser revascularization, 979
 valve replacement, 1060–61, 1061f, 1061t
 valvuloplasty, 1060
 cerebrovascular
 carotid endarterectomy, 1586, 1586f
 for intracranial aneurysm, 1594
 classifications, 54t
 cutaneous
 chemical destruction, 478
 cryosurgery, 477
 curettage, 477
 electrosurgery, 477
 fusiform excision, 477
 laser surgery, 477–78
 sclerotherapy, 478
 ear disorders
 cochlear implant, 1731–32, 1732f
 endolymphatic decompression, 1727
 labyrinthectomy, 1727
 mastoidectomy, 1724
 myringotomy, 1722, 1723
 tympanoplasty, 1724
 vestibular neurectomy, 1727
 endocrine
 adrenalectomy, 550, 550t
 thyroidectomy, 537–38, 539t
 eye disorders
 cataracts, 1705, 1705f
 corneal transplant. *See* Corneal transplant
 glaucoma, 1709
 laser surgery, 1697
 female reproductive system
 breast reconstruction, 1825–26
 colporrhaphy, 1806
 conization, 1813, 1813f
 dilation and curettage, 1803
 hysterectomy, 1803–4, 1810
 Marshall-Marchetti-Krantz procedure, 1806
 mastectomy. *See* Mastectomy
 myomectomy, 1810
 pelvic exenteration, 1813
 vulvectomy, 1819–20, 1820f
 lower gastrointestinal
 appendectomy, 766f, 767
 bariatric, 636–38, 637f
 cholecystectomy, 699, 700t
 colectomy, 788, 788f
 colostomy. *See* Colostomy
 hemorrhoidectomy, 819
 hemiorrhaphy, 810
 ileostomy, 789, 789f
 Whipple's procedure, 732, 732f, 732t
 male reproductive system disorders
 prostatectomy, 1779, 1779f
 musculoskeletal
 fracture fixation, 1410–11, 1411f
 total joint replacement, 1452–53
 neurologic
 brain tumor, 1571, 1571f
 foraminotomy, 1610
 intradiscal electrothermal therapy, 1610
 laminectomy, 1608
 microdissection, 1610
 pallidotomy, 1639
 rhizotomy. *See* Rhizotomy
 for seizure control, 1551
 spinal fusion, 1608
 stereotaxic thalamotomy, 1639
 thymectomy, 1649–50
 pain management
 cordotomy, 184, 185f
 neurectomy, 184, 185f
 rhizotomy. *See* Rhizotomy
 sympathectomy, 184, 185f
 peripheral vascular
 aortic aneurysm repair, 1173, 1174f, 1174t
 varicose veins, 1197
 venous thrombosis, 1190
 plastic
 blepharoplasty, 479
 chemical peeling, 479
 dermabrasion, 479
 liposuction, 479
 rhinoplasty, 479, 1246–47
 rhytidectomy, 479
 skin grafts and flaps, 478–79, 478f
 respiratory
 Caldwell-Luc procedure, 1237
 endoscopic sinus surgery, 1236–37
 external sphenoethmoidectomy, 1237, 1237f
 laryngectomy, 1256t
 in lung cancer, 1312, 1312t
 transplant. *See* Transplant procedures
 upper gastrointestinal
 esophagectomy, 669–70
 fundoplication, 666, 667f
 gastrectomy, 689, 689f
 urinary system
 bladder neck suspension, 875, 876t
 cystectomy, 864, 866t
 kidney transplant. *See* Kidney transplant
 nephrectomy, 896–97, 898f
 urinary diversion, 864, 864f, 865t, 866t
 risk factors, 55, 57–58t, 58–59
 setting, 54–55
 Surgical assistant, 65
 Surgical debridement, 502
 Surgical menopause, 1795
 Surveillance, 127
 Sustentacular cells, 1745
 Sustiva. *See* Efavirenz
 SV. *See* Stroke volume
 SVR. *See* Systemic vascular resistance
 Swan-Ganz catheter, 1030. *See also* Pulmonary artery pressure monitoring
 Swan-neck deformity, 1393, 1461, 1461f
 Sweat analysis, in cystic fibrosis, 1342
 Sweat glands, 424
 Sweet & Low. *See* Saccharin
 Sweeteners, 579
 Swimmer's ear. *See* Otitis externa
 Sycosis barbae, 446
 Syme amputation, 1422t
 Symmetrel. *See* Amantadine
 Sympathectomy:
 for pain management, 184
 procedure, 185f
 in thromboangiitis obliterans, 1182
 Sympathetic nervous system:
 in blood pressure regulation, 1085, 1155
 effects of stimulation, 1512
 in heart failure, 1024–25
 physiology, 1511–12
 Sympathetic tone, 269
 Sympatholytics, 1162t

- Sympathomimetics. *See* Adrenergics
- Synarthrosis, 1383*t*
- Synchronized cardioversion, 1007, 1007*t*
- Synchronized intermittent mandatory ventilation (SIMV), 1358, 1359*t*
- Syndrome of inappropriate antidiuretic hormone (SIADH):
- antidiuretic hormone production in, 202
 - diagnostic test, 523*t*
 - manifestations, 559
 - as oncologic emergency, 410
 - pathophysiology, 558
 - treatment, 559
- Synovial joint, 1383, 1386, 1386*f*, 1386*t*
- Synovitis, 1394*t*
- Synthroid. *See* Levothyroxine sodium
- Synvisc. *See* Hyaluronan injections
- Syphilis:
- aortic aneurysm in, 1171
 - characteristics, 1846–47
 - diagnostic tests, 1746*t*, 1756*t*
 - incidence, 1847
 - interdisciplinary care
 - diagnosis, 1849
 - medications, 1849
 - latent, 1848
 - manifestations, 1847–48, 1848*f*, 1848*t*
 - nursing care
 - community-based care, 1849–50
 - nursing diagnoses and interventions
 - anxiety, 1849
 - low self-esteem, 1849
 - risk for injury, 1849
- Nursing Care Plan
- assessment, 1850*t*
 - critical thinking in the nursing process, 1850*t*
 - diagnoses, 1850*t*
 - evaluation, 1850*t*
 - expected outcomes, 1850*t*
 - planning and implementation, 1850*t*
 - pathophysiology, 1847
 - primary, 1847–48
 - secondary, 1848
 - tertiary, 1848
- Syringomyelia, 1613
- Systemic circulation, 938, 938*f*
- Systemic inflammatory response syndrome (SIRS), 275
- Systemic lupus erythematosus (SLE):
- causes, 1471
 - definition, 1471
 - incidence, 1471
 - interdisciplinary care
 - diagnosis, 1473
 - medications, 1473, 1474*t*
 - treatments, 1474
 - manifestations, 1471, 1471*f*, 1473, 1473*t*
 - Multisystem Effects, 1472*t*
 - nursing care
 - community-based care, 1475
 - Medication Administration, 1474*t*
 - nursing diagnoses and interventions
 - impaired health maintenance, 1475
 - impaired skin integrity, 1474
 - ineffective protection, 1474–75
 - pathophysiology, 1471
- Systemic sclerosis. *See* Scleroderma
- Systemic vascular resistance (SVR). *See also* Blood pressure
- definition, 940, 1030, 1154
 - factors affecting, 1154–55, 1155*f*
 - intra-arterial monitoring, 1030
- Systole, 939, 939*f*
- Systolic blood pressure, 1154. *See also* Blood pressure
- Systolic failure, 1025. *See also* Heart failure
- T**
- T cells. *See* T lymphocytes
- T lymphocytes (T cells):
- aging and, 314
 - classification, 297
 - development, 290, 290*f*
 - functions, 288*t*
 - in immune response, 297–98, 298*f*
 - location, 288*t*
- T wave, 948*f*, 948*t*
- T₃. *See* Triiodothyronine
- T₄. *See* Thyroxine
- TA. *See* Thyroid antibodies
- Tachycardia, 953*t*
- Tachypnea, 1223*t*
- Tacrine hydrochloride, 1620, 1621*t*
- Tacrolimus, 345*t*
- Tactile fremitus, 1124*t*
- Tadalafil, 1769
- Tagamet. *See* Cimetidine
- Talwin. *See* Pentazocine
- Tambacor. *See* Flecainide
- Tamiflu. *See* Oseltamivir
- Tamoxifen:
- adverse/side effects, 394*t*, 1816
 - mechanism of action, 391, 1796
 - Medication Administration, 1825*t*
 - nursing implications, 394*t*
 - in specific conditions
 - female breast cancer, 1825, 1825*t*
 - gynecomastia, 1790
 - male breast cancer, 1790
 - menopause, 1796
 - target malignancies, 394*t*
- Tamsulosin, 1779
- Tangier disease, 614*t*
- Tapazole. *See* Methimazole
- Tapeworm, 781*t*
- Tap-water enema, 760
- Tar preparations. *See* Coal tar derivatives
- Tasmar. *See* Tolcapone
- Taste, age-related changes, 27*t*, 29*t*
- Tau protein, 1618
- Tavist. *See* Clemastine
- Taxoids, 391
- Taxol. *See* Paclitaxel
- Taxotere, 391
- Tay-Sachs disease, 1513*t*
- Tazarotene gel, 444
- Tazorac. *See* Tazarotene gel
- TB. *See* Tuberculosis
- TBI. *See* Traumatic brain injury
- 3-TC. *See* Lamivudine
- TCA (trichloroacetic acid), 479, 1841, 1842*t*
- T-cell lymphomas, 1130*t*. *See also* Non-Hodgkin's lymphoma
- T-cell suppressors, 345*t*
- Tebrazid. *See* Pyrazinamide
- TEE. *See* Transesophageal echocardiography
- Teeth, 623*t*
- Tegaderm. *See* Transparent dressing
- Tegaserod mesylate, 762
- Tegretol. *See* Carbamazepine
- Telangiectases, 430*t*, 443
- Telemetry, 1004
- Teletherapy, 395. *See also* Radiation therapy
- Telmisartan, 1033*t*, 1161*t*
- Temporal arteries, 1094*t*
- Temporal lobe, 1506*f*, 1506*t*
- Temporary pacemakers, 1008, 1009*f*. *See also* Pacemakers
- Temporomandibular joint, 1392*f*, 1392*t*
- TEN. *See* Toxic epidermal necrolysis
- Tendonitis, 1394*t*
- Tendons, 1386
- Tenecteplase (TNK), 988
- Tenesmus, 775
- Tenex. *See* Guanfacine
- Tennis elbow, 1428
- Tenormin. *See* Atenolol
- TENS (transcutaneous electrical nerve stimulation), 184–85, 185*f*
- Tensilon test. *See* Edrophonium chloride
- Tension headache, 1542*t*, 1543. *See also* Headache
- Tension pneumothorax. *See also* Pneumothorax
- definition, 258
 - emergency treatment, 258, 258*f*
 - manifestations, 1298*t*, 1299
 - pathophysiology, 258, 1298*t*, 1299
- Tenting, skin, 435*f*, 435*t*
- Tequin. *See* Gatifloxacin
- Terazosin, 1161*t*, 1779
- Terbutaline, 1327*t*
- Teriparatide, 1436
- Terminal blast crisis phase, 1121
- Terramycin. *See* Oxytetracycline
- Terrorism, 127, 128. *See also* Disasters
- Tertiary intention, wound healing by, 76, 76*f*
- Tertiary prevention, 24
- Tertiary syphilis, 1848
- Test sensitivity, 157
- Test specificity, 157–58
- Testes:
- anatomy, physiology, and functions, 1744, 1744*f*, 1745*t*
 - disorders
 - cancer. *See* Testicular cancer
 - orchitis, 1774
 - torsion, 1774
 - physical assessment, 1750*t*
 - self-examination, 1775*t*
- Testicular cancer:
- incidence, 1774
 - interdisciplinary care
 - diagnosis, 1775
 - medications, 1775
 - radiation therapy, 1775
 - surgery, 1775
 - manifestations, 1774, 1775*t*
 - nursing care
 - community-based care, 1776
 - health promotion, 1775, 1775*t*
 - nursing diagnoses and interventions
 - deficient knowledge, 1776
 - ineffective sexuality patterns, 1776
 - pathophysiology, 1774
 - racial/ethnic considerations, 1774, 1774*t*
 - risk factors, 1774
- Testicular torsion, 1774
- Testosterone:
- in erectile dysfunction, 1769
 - functions, 1746
 - hirsutism and, 482
- Tetanus:
- characteristics, 1661
 - incidence, 1661
 - interdisciplinary care, 1661
 - manifestations, 1661
 - nursing care, 1661
 - pathophysiology, 1661
 - postexposure prophylaxis, 302*t*

- Tetanus immune globulin (TIG), 302t
- Tetanus vaccine:
 in adults, 1661
 in burn clients, 493, 502
 in children, 1661
 contraindications, 21t
 indications, 21t, 300, 301t
 nursing implications, 301t
 in trauma clients, 262, 267
- Tetany, 229, 531, 531t
- Tetracycline HCl, 320t
- Tetracyclines:
 Medication Administration, 320t
 in specific conditions
 Lyme disease, 1477
 scleroderma, 1485
 syphilis, 1849
- Tetraplegia, 1599
- Teveten. *See* Eprosartan
- Thalamus, 1506
- Thalassemias:
 complications, 1109
 genetic considerations, 1089t
 interdisciplinary care, 1110t
 manifestations, 1109
 pathophysiology, 1109
 racial/ethnic considerations, 1106t, 1109
- Thalidomide, 1124
- Thallium/technetium stress test, 944t, 970–71
- THC (delta-9-tetrahydrocannabinol), 107
- Theo-Dur. *See* Theophylline
- Theolair. *See* Theophylline
- Theophylline, 1326, 1327t, 1334
- TheraCys. *See* Bacillus Calmette-Guérin
- Therapeutic baths, 441t
- Thermal burns. *See also* Burns
 causative agents, 487, 488t
 in nuclear detonation, 130t, 131
 prehospital management, 498
 priority treatment, 488t
- Thermololol, 1031
- Thiamine. *See* Vitamin B₁
- Thiazide diuretics:
 mechanism of action, 210
 Medication Administration, 210t
 in specific conditions
 heart failure, 1032
 hypertension, 1163
 urinary calculi, 858
- Thiazolidinediones, 578t
- Thiethylperazine, 672, 673t
- Thioridazine, 1621
- Thiosulfil Forte. *See* Sulfamethizole
- Third spacing, 203, 258. *See also* Fluid volume deficit
- Third-degree AV block, 999t, 1003
- Thirst:
 in hypernatremia, 216
 mechanism, 200–201, 201f
- Thomas test, 1396f, 1396t
- Thoracic aortic aneurysm. *See also* Aortic aneurysm
 complications, 1171t
 genetic considerations, 1172t
 incidence, 1171
 management, 1171–72
 manifestations, 1171t
 pathophysiology, 1171
- Thoracic trauma:
 flail chest, 1303, 1303f
 interdisciplinary care, 1303–4
 nursing care
 assessment, 1304
 community-based care, 1305
 health promotion, 1304
 nursing diagnoses and interventions
 acute pain, 1304
 impaired gas exchange, 1304
 ineffective airway clearance, 1304
 pathophysiology, 1302–3
 pulmonary contusion, 1303
 rib fracture, 1302–3
- Thoracocentesis:
 complications, 1296
 nursing care, 1297t
 procedure, 1296, 1296f
 purpose and description, 1219t
- Thoracostomy. *See* Chest tubes
- Thoracotomy, 1312t
- Thorazine. *See* Chlorpromazine
- Threshold, pain, 175
- Thrill, 953t
- Throat culture, 889, 1043
- Throat swab, 1239
- Thromboangiitis obliterans:
 course of disease, 1180
 definition, 1180
 incidence, 1180
 interdisciplinary care, 1182
 manifestations, 1180–81
 nursing care, 1182
 pathophysiology, 1180
 vs. Raynaud's disease, 1183t
 risk factors, 1180
- Thrombocytes. *See* Platelets
- Thrombocytopenia:
 causes, 1140, 1140t
 definition, 1079, 1139
 heparin-induced, 1140–41
 incidence, 1140
 interdisciplinary care
 diagnosis, 1141
 medications, 1141
 surgery, 1141
 treatments, 1141
 manifestations, 1139–40, 1139f
 nursing care
 assessment, 1141
 community-based care, 1142
 nursing diagnoses and interventions
 impaired oral mucous membranes, 1142
 ineffective protection, 1141–42
 pathophysiology, 1140
 types, 1140
- Thrombocytosis, 1079
- Thromboembolus, 1184. *See also* Pulmonary embolism
- Thromboendarterectomy, 1184
- Thrombophlebitis. *See* Venous thrombosis
- Thromboplastin, 1082t
- Thrombosed external hemorrhoid, 818–19
- Thrombotic stroke, 1581. *See also* Stroke
- Thrombotic thrombocytopenic purpura (TTP), 1140. *See also* Thrombocytopenia
- Thrombus, 1184. *See also* Acute arterial occlusion; Venous thrombosis
- Thrush:
 in AIDS, 353, 359t
 characteristics, 449t
 manifestations, 657t
 treatment, 657t
- Thrust, 952
- Thunderstorm, 129t, 130
- Thymectomy:
 nursing care, 1650t
 procedure, 1649–50
- Thymus gland, 291, 291f
- Thyro-Block. *See* Potassium iodide
- Thyroglobulin, 520
- Thyroid antibodies (TA):
 diagnostic test, 524t
 in hyperthyroidism, 536t, 537
 in hypothyroidism, 543t
 normal values, 524t
- Thyroid cartilage, 1211
- Thyroid crisis, 537
- Thyroid gland:
 age-related changes, 529t, 545t
 anatomy, physiology, and functions, 520, 520f
 diagnostic tests, 523–24t, 536t, 537
 disorders
 cancer, 546
 hyperthyroidism. *See* Hyperthyroidism
 hypothyroidism. *See* Hypothyroidism
 hormones produced by, 519f, 520. *See also* specific hormones
 physical assessment, 530t
- Thyroid hormone, 519t, 520. *See also* Thyroxine
- Thyroid storm, 537
- Thyroid suppression test:
 in hyperthyroidism, 536t, 537
 in hypothyroidism, 543t
- Thyroidectomy:
 nursing care, 539t
 procedure, 537–38
- Thyroiditis, 536–37, 543
- Thyroid-stimulating hormone (TSH):
 diagnostic tests, 523t
 functions, 518
 in hyperthyroidism, 536t, 537
 in hypothyroidism, 543t
 normal values, 536t
- Thyrolar. *See* Liotrix
- Thyrotoxicosis, 534. *See also* Hyperthyroidism
- Thyroxine (T₄):
 diagnostic tests, 380t, 523t
 functions, 519t, 520
 in hyperthyroidism, 536t, 537
 in hypothyroidism, 543t
 normal values, 523t, 536t
- TIA (transient ischemic attack), 1581. *See also* Stroke
- Tiagabine, 1550t
- Tibia, fracture, 1416
- Tic douloureux. *See* Trigeminal neuralgia
- Ticar. *See* Ticarcillin
- Ticarcillin, 319t
- Ticarcillin-clavulanate, 816
- Ticlid. *See* Ticlopidine
- Ticlopidine, 1585
- Tidal volume (V_T), 1214, 1358, 1360t
- TIG (tetanus immune globulin), 302t
- Tikosyn. *See* Dofetilide
- Tilade. *See* Nedocromil
- Tiludronate, 1442, 1442t
- Time-cycled ventilators, 1358
- Timentin. *See* Ticarcillin-clavulanate
- Timolol:
 Medication Administration, 1161t, 1545t
 in specific conditions
 headache, 1545t
 hypertension, 1161t
 topical ophthalmic, 1710t
- Timoptic. *See* Timolol
- Tinactin. *See* Tolnaftate
- Tincture of opium, 756t
- Tine test, 1286
- Tinea capitis, 448, 449, 450t
- Tinea corporis, 448
- Tinea cruris, 449, 450t
- Tinea pedis, 448, 448f, 449, 450t
- Tinea versicolor, 448

- Timidazole, 1843
 Tinnitus, 1718, 1730. *See also* Hearing loss
 Tinzaparin, 1189t
 Tiotropium bromide, 1327–28t
 TIPS (transjugular intrahepatic portosystemic shunt), 719, 719f
 Tirofiban, 976, 976t
 Tissue plasminogen activator (t-PA):
 for acute arterial occlusion, 1184
 for acute myocardial infarction, 988
 for thrombotic stroke, 1585
 for venous thrombosis, 1188
 Tissue transplantation. *See* Transplant procedures
 Titanium dioxide, 465t
 Titrate, 183
 TIVA (total intravenous anesthesia), 61
 TLC (total lung capacity), 1214t
 TMP-SMX. *See* Trimethoprim-sulfamethoxazole
 TNF (tumor necrosis factor), 299t, 443
 TNK (tenecteplase), 988
 TNM staging:
 bladder cancer, 863t
 colorectal cancer, 803t
 laryngeal cancer, 1254t
 lung cancer, 1311t
 oral cancer, 660t
 overview, 383t
 Tobacco use. *See* Smoking
 Tobramycin, 320t
 Tocainide, 1006t
 Toes, 1394t
 Tofranil. *See* Imipramine
 Tolazamide, 578t
 Tolbutamide, 578t
 Tolcapone, 1638t, 1639
 Tolectin. *See* Tolmetin
 Tolerance:
 to drug or substance, 102, 103t, 179t
 to nitroglycerin, 971
 to pain, 175
 Tolinase. *See* Tolazamide
 Tolmetin, 178t, 1445, 1464t
 Tolnaftate, 1720
 Tolterodine, 871, 871t, 875
 Tongue, assessment, 622t
 Tongue turgor, 205
 Tonic-clonic seizures, 1549, 1549f
 Tonicity, 198, 199f
 Tonocard. *See* Tocainide
 Tonometry, 1674t, 1708, 1708f
 Tonsillectomy, 1239
 Tonsillitis:
 characteristics, 1238
 complications, 1239. *See also* Peritonsillar abscess
 interdisciplinary care, 1239
 manifestations, 1238, 1238f, 1239t
 nursing care, 1239–40
 pathophysiology, 1238
 Topamax. *See* Topiramate
 Tophi, 1443
 Topical anesthetics, 657, 658t
 Topical medications:
 antimicrobial
 for burns, 501t
 for conjunctivitis, 1694
 for corneal infections, 1697
 for eyelid infections, 1701
 beta-blockers, for glaucoma, 1709, 1710t
 guidelines for application, 444t
 for osteoarthritis, 1451
 for pruritus, 440, 441t
 for psoriasis, 444
 for stasis dermatitis, 1194
 Topiramate, 1544
 Toprol. *See* Metoprolol
 Toradol. *See* Ketorolac tromethamine
 Torecan. *See* Thiethylperazine
 Toremifene, 1785, 1796
 Tornado, 129t, 130
 Tornalate. *See* Bitolterol
 Torsades de pointes, 1002, 1003f
 Torsemide, 210t, 905t
 Torsion, testicular, 174
 Total gastrectomy, 689, 689f
 Total incontinence, 873. *See also* Urinary incontinence
 Total intravenous anesthesia (TIVA), 61
 Total joint replacement:
 cemented vs. uncemented, 1452
 definition, 1452
 elbow, 1453
 hip, 1452, 1452f
 knee, 1452–53, 1453f
 nursing care
 postoperative, 1454t
 preoperative, 1453–54t
 Nursing Care Plan
 assessment, 1456t
 critical thinking in the nursing process, 1456t
 diagnoses, 1456t
 evaluation, 1456t
 expected outcomes, 1456t
 planning and implementation, 1456t
 physical therapy and rehabilitation, 1455
 shoulder, 1453
 Total laryngectomy, 1255. *See also* Laryngectomy
 Total lung capacity (TLC), 1214t
 Total parenteral nutrition (TPN):
 administration, 648
 catheter for, 647f
 complications, 648
 definition, 646
 indications, 648
 risks, 70
 Total proctocolectomy with permanent ileostomy, 789
 Toxic epidermal necrolysis (TEN):
 complications, 461
 interdisciplinary care, 461
 manifestations, 460
 pathophysiology, 460–61
 Toxic hepatitis, 707. *See also* Hepatitis
 Toxic megacolon, 785
 Toxic multinodular goiter, 536, 536f
 Toxic shock syndrome, 275
 Toxoplasmosis, 354, 359t
 TPN. *See* Total parenteral nutrition
 Trabeculectomy, 1709
 Trabeculectomy, laser, 1709
 Trachea:
 anatomy, physiology, and functions, 1211
 physical assessment, 1224t
 Tracheoesophageal puncture, 1255–56
 Tracheostomy:
 in acute respiratory failure, 1356
 vs. endotracheal intubation, 1356, 1357t
 nursing care, 1257t
 Trachoma, 1693–94
 Tracleer. *See* Bosentan
 Tracrium. *See* Atracurium besylate
 Traction:
 cervical, 1601, 1601f
 nursing interventions, 1409t
 types, 1408, 1409f
 Tramadol, 62t, 178
 Trandate. *See* Labetalol
 Trandolapril, 1033t, 1161t
 Transcellular fluid, 196f, 197
 Transcranial Doppler study, 1515t
 Transcutaneous electrical nerve stimulation (TENS), 184–85, 185f
 Transcutaneous oximetry. *See* Pulse oximetry
 TransCyte, 504
 Transdermal administration, 182–83, 183f
 Transderm-Nitro. *See* Nitroglycerin
 Transesophageal echocardiography (TEE):
 in angina, 971
 in aortic aneurysm, 1173
 purpose and description, 943, 945t
 Transfusion, 262. *See also* Blood transfusion
 Transfusion reactions, 262
 Transient ischemic attack (TIA), 1581. *See also* Stroke
 Transjugular intrahepatic portosystemic shunt (TIPS), 719, 719f
 Translocation, 151
 Transmural infarction, 983
 Transmyocardial laser revascularization, 979
 Transparent dressing, 474t
 Transplant procedures:
 indications, 342t
 interdisciplinary care
 diagnosis, 343
 medications, 343–44, 345–46t
 nursing care
 assessment, 346–47
 community-based care, 348
 health promotion, 346
 Medication Administration, 345–46t
 nursing diagnoses and interventions
 anxiety, 348
 ineffective protection, 347
 risk for impaired tissue integrity: allograft, 347–48
 pathophysiology, 341–43
 rejection episodes, 342–43, 343t
 success rate, 342t
 types, 342t
 hair, 482
 heart. *See* Heart transplant
 kidney. *See* Kidney transplant
 liver. *See* Liver transplant
 lung. *See* Lung transplant
 pancreas. *See* Pancreas transplant
 Transrectal ultrasonography, 1784
 Transtentorial herniation, 1538, 1538f
 Transthyretin. *See* Prealbumin
 Transudate, 1295
 Transurethral incision of the prostate (TUIP), 1779
 Transurethral microwave thermotherapy, 1779
 Transurethral needle ablation (TUNA), 1779
 Transurethral resection:
 bladder tumor, 864t
 prostate (TURP)
 nursing care, 1780–81t
 procedure, 1779, 1779f
 Transverse colon, 742f, 743
 Transverse loop colostomy, 804
 Trastuzumab, 1825
 Trauma:
 Case Study, 145t
 Chapter Highlights, 283–84t
 components, 255–56
 definition, 255
 effects
 abdominal, 259
 airway obstruction
 assessment, 257
 in burn injuries, 258
 in cervical spine injury, 257
 in closed head injury, 257

- in direct airway trauma, 257
 - interventions, 257, 257f
 - in maxillofacial trauma, 257
- on family, 260
- hemorrhage, 258, 258f
- integumentary, 258–59, 259f
- multiple organ dysfunction syndrome, 259
- musculoskeletal, 259. *See also* Musculoskeletal system, trauma
- neurological, 259. *See also* Traumatic brain injury
- tension pneumothorax, 258, 258f
- interdisciplinary care
 - emergency department care
 - blood transfusions, 262, 263t
 - brain death criteria, 265t
 - diagnosis, 261
 - emergency surgery, 263
 - forensic considerations, 265
 - medications, 261–62
 - organ donation, 263–65
 - volume resuscitation, 263t
 - prehospital care
 - critical interventions, 260–61, 260f
 - injury identification, 260
 - rapid transport, 261, 261f
 - scoring systems, 260, 260t. *See also* Glasgow Coma Scale
- mechanisms, 255t
- nursing care
 - assessment, 265
 - community-based care, 268
 - health promotion, 265
 - nursing diagnoses and interventions
 - impaired physical mobility, 267, 267f
 - ineffective airway clearance, 266
 - post-trauma syndrome, 268
 - risk for infection, 266–67
 - spiritual distress, 267–68
 - using NANDA, NIC, and NOC, 268, 268t
- Nursing Care Plan
 - assessment, 266t
 - critical thinking in the nursing process, 266t
 - diagnoses, 266t
 - evaluation, 266t
 - expected outcomes, 266t
 - planning and implementation, 266t
- Nursing Research: prevention of ventilator-associated pneumonia in clients with multiple trauma, 280t
- types
 - brain. *See* Traumatic brain injury
 - chest. *See* Thoracic trauma
 - classification, 256
 - eye. *See* Eyes, trauma
 - head. *See* Traumatic brain injury
 - kidney, 895–96
 - liver, 725
 - nose. *See* Nasal trauma
 - skin
 - burns. *See* Burns
 - frostbite, 476–77
 - injuries, 258–59, 259f
 - pressure ulcer. *See* Pressure ulcer
 - spinal cord. *See* Spinal cord injury
- Traumatic brain injury (TBI). *See also* Skull fracture
 - airway obstruction in, 257
 - caregiver considerations, 1563t
 - causes, 1554
 - classification, 1554
 - definition, 1554
 - diffuse
 - classic cerebral concussion, 1559
 - diffuse axonal injury, 1559
 - manifestations, 1558t
 - mechanism, 1558
 - mild concussion, 1559
 - pathophysiology, 1558
- focal
 - contusion, 1557
 - epidural hematoma, 1557–58, 1557f, 1557t
 - intracerebral hematoma, 1557f, 1557t, 1558
 - mechanisms, 1556
 - pathophysiology, 1556
 - subdural hematoma, 1557f, 1557t, 1558
- interdisciplinary care
 - acute injury, 1559, 1560t
 - concussion, 1559
 - diagnosis, 1559
 - managing increased intracranial pressure, 1559
 - surgery, 1560, 1560f
- manifestations, 1557t, 1558t
- mechanisms, 1554
- nursing care
 - assessment, 1560
 - community-based care
 - acute brain injury, 1563
 - concussion, 1562
 - health promotion, 1560
 - nursing diagnoses and interventions
 - decreased intracranial adaptive capacity, 1560
 - ineffective airway clearance, 1562
 - ineffective breathing pattern, 1562
 - using NANDA, NIC, and NOC, 1562, 1562t
- Nursing Care Plan
 - assessment, 1561t
 - critical thinking in the nursing process, 1561t
 - diagnoses, 1561t
 - evaluation, 1561t
 - expected outcomes, 1561t
 - planning and implementation, 1561t
- Nursing Research: considerations for caregivers of young adults, 1563t
- pathophysiology, 1556
- systemic effects, 1556, 1556t
- Traumatic pneumothorax. *See also* Pneumothorax
 - causes, 1299
 - manifestations, 1298t, 1299
 - pathophysiology, 1298t
 - types, 1299
- Travatan. *See* Travoprost
- Travoprost, 1710t
- Treadmill test, 944t. *See also* Stress/exercise tests
- Tremors, 1522t, 1635
- Trench mouth, 657t. *See also* Stomatitis
- Trendelenburg test, 1197
- Trental. *See* Pentoxifylline
- Treponema pallidum*, 1846, 1849. *See also* Syphilis
- Treprostinil, 1353
- Tretinoin, 458, 459t
- Trexall. *See* Methotrexate
- Triage, in disasters, 133–34, 134t
- Triamcinolone acetate, 657–58, 658t
- Triamcinolone acetonide, 1328t
- Triaminic. *See* Phenylpropanolamine
- Triamterene, 210t, 1033t
- Triceps reflex, 1523f
- Triceps skinfold thickness (TSF), 621t
- Trichinosis, 779, 780, 781t
- Trichlormethiazide, 210t
- Trichloroacetic acid (TCA), 479, 1841, 1842t
- Trichomonas vaginalis*, 1843
- Tricor. *See* Fenofibrate
- Tricosal. *See* Choline magnesium trisalicylate
- Tricuspid valve:
 - anatomy, 937f, 938
 - disorders, 1055t, 1059
 - function, 1054
- Tricyclic antidepressants:
 - Medication Administration, 1545t
 - in specific conditions
 - fibromyalgia, 1487
 - headache, 1545t
 - irritable bowel syndrome, 763
 - pain management, 179
- Tridil. *See* Nitroglycerin
- Trigeminal nerve (cranial nerve V):
 - anatomy, 1510f
 - assessment, 1520t
 - functions, 1511t
 - sensory and motor distribution, 1655, 1655f
- Trigeminal neuralgia:
 - characteristics, 1655
 - interdisciplinary care
 - medications, 1656
 - surgery, 1656
 - manifestations, 1656
 - nursing care
 - of client undergoing percutaneous rhizotomy, 1656t
 - community-based care, 1657
 - nursing diagnoses and interventions
 - acute pain, 1656–57
 - risk for altered nutrition: less than body requirements, 1657
 - teaching for home care, 1657t
 - pathophysiology, 1655
- Trigger, 1358
- Trigger zones, 1655
- Triglycerides:
 - formation, 631
 - functions, 959
 - serum levels. *See* Serum triglycerides
 - uses in body, 608
- Trihexyphenidyl, 1638t
- Triiodothyronine (T₃):
 - diagnostic tests, 523t, 536t, 537
 - in hypothyroidism, 543t
 - normal values, 523t, 536t
- Tri-K. *See* Potassium acetate
- Trilisate. *See* Choline magnesium trisalicylate
- Trimethoprim, 850, 850t
- Trimethoprim-sulfamethoxazole (TMP-SMZ):
 - Medication Administration, 321t
 - in organ transplantation, 343
 - in specific conditions
 - diverticulitis, 816
 - epiglottitis, 1241
 - gastroenteritis, 776
 - otitis media, 1722
 - P. carinii* pneumonia, 359t
 - pertussis, 1242
 - pneumonia, 1271t
 - urinary tract infection, 849, 850
- Trimpez. *See* Trimethoprim
- Triphenylethylene. *See* Tamoxifen
- Tripolidine, 1230t
- Trismus, 1611
- Trisomy, 150t
- Trisomy 21 (Down syndrome), 150
- Trochlear nerve (cranial nerve IV):
 - anatomy, 1510f
 - assessment, 1519t
 - function, 1511t, 1671t
- Tropical sprue, 796. *See also* Sprue
- Trousseau's sign, 229, 229f, 531t
- True aneurysm, 1170
- Trusopt. *See* Dorzolamide

- Trypsinogen. *See* Serum trypsinogen
- TSF (triceps skinfold thickness), 621*t*
- TSH. *See* Thyroid-stimulating hormone
- Tsunami, 129*t*, 130
- TTP (thrombotic thrombocytopenic purpura), 1140. *See also* Thrombocytopenia
- T-tube:
nursing care, 701*t*
procedure, 699–700, 699*f*
- Tube feeding. *See also* Enteral nutrition
nursing care, 692*t*
procedure, 691, 691*f*
- Tube thoracostomy. *See* Chest tubes
- Tubercle, 305, 1281
- Tuberculin tests, 1286–87, 1286*f*, 1286*t*
- Tuberculosis (TB):
in AIDS
incidence, 353
manifestations, 353
pharmacologic treatment, 359*t*
definition, 1280
extrapulmonary
characteristics, 1283
genitourinary, 1283
miliary, 1283
skeletal, 1283
tuberculous meningitis, 1283
granuloma, 305
homelessness and, 1290*t*
incidence and prevalence, 1280–81
interdisciplinary care
diagnosis, 1287
goals, 1283
medications, 1287–89, 1288–89*t*
noncompliance issues, 1286
screening, 1286–87, 1286*f*, 1286*t*
multidrug-resistant, 313
nursing care
assessment, 1290
community-based care, 1293
health promotion, 1289–90
Medication Administration, 1288–89*t*
nursing diagnoses and interventions
deficient knowledge, 1290–92
ineffective therapeutic regimen
management, 1292
risk for infection, 1292–93
of older adults, 1282*t*
using NANDA, NIC, and NOC, 1293, 1293*t*
- Nursing Care Plan
assessment, 1291*t*
critical thinking in the nursing process, 1291*t*
diagnoses, 1291*t*
evaluation, 1291*t*
expected outcomes, 1291*t*
planning and implementation, 1291*t*
- Nursing Research: screening in homeless persons, 1290*t*
- pathophysiology, 1284–85*t*
- pulmonary
complications, 1283
management, 1283*t*
manifestations, 1283
pathophysiology, 1281–82
racial/ethnic considerations, 1281, 1281*t*
risk factors, 1281
transmission, 1280
- Tuberculous spondylitis, 1283
- Tubular adenomas, 800, 800*f*. *See also* Polyps
- Tubulovillous adenomas, 800. *See also* Polyps
- TUIP (transurethral incision of the prostate), 1779
- Tumor(s):
brain. *See* Brain tumors
definition, 376
laryngeal, 1252, 1253
malignant. *See* Cancer
nasal polyps, 1252
skin, 432*t*
spinal cord. *See* Spinal cord tumors
Tumor lysis syndrome, 410–11
Tumor markers, 383–84, 384*t*
Tumor necrosis factor (TNF), 299*t*, 443
Tumor suppressor genes, 374
Tums, 666*t*
TUNA (transurethral needle ablation), 1779
Tunica adventitia, 1082, 1091*t*
Tunica intima, 1082, 1091*t*
Tunica media, 1082, 1091*t*
Turner syndrome, 1755*t*
Turning in bed, preoperative teaching, 73*t*
TURP (transurethral resection of the prostate):
nursing care, 1780–81*t*
procedure, 1779, 1779*f*
- Two-point discrimination, 1522*f*, 1522*t*
- Tylenol. *See* Acetaminophen
- Tympanic membrane:
anatomy, physiology, and functions, 1682, 1682*f*
physical assessment, 1687*f*, 1687*t*, 1688*f*, 1688*t*
- Tympanocentesis. *See* Myringotomy
- Tympanometry, 1730
- Tympanoplasty, 1724
- Tympanostomy tubes, 1723
- Type 1 diabetes mellitus. *See also* Diabetes mellitus
characteristics, 566*t*
definition, 563
manifestations, 565–66*t*
pathophysiology, 565, 567*f*
risk factors, 565
- Type 2 diabetes mellitus. *See also* Diabetes mellitus
characteristics, 566*t*
definition, 563
incidence, 567
manifestations, 567
pathophysiology, 566, 567
risk factors, 567
- Type A dissection, 1172. *See also* Aortic dissection
- Type A gastritis, 678
- Type and crossmatch, 262
- Type B dissection, 1172. *See also* Aortic dissection
- Type B gastritis, 678
- Tzanck test, 428*t*
- U**
- U wave, 948*t*
- UI. *See* Urinary incontinence
- Ulcer:
corneal, 1696–97. *See also* Corneal disorders
definition, 680
peptic. *See* Peptic ulcer disease
skin, 431*t*, 433*t*. *See also* Pressure ulcer
stasis. *See also* Chronic venous insufficiency
characteristics, 1194, 1194*f*
leg, arterial vs. venous, 1195*t*
- Ulcerative colitis. *See also* Inflammatory bowel disease
Case Study, 826*t*
characteristics, 782*t*, 784
complications, 785
incidence, 784
manifestations, 784
Nursing Care Plan
assessment, 793*t*
critical thinking in the nursing process, 793*t*
diagnoses, 793*t*
evaluation, 793*t*
expected outcomes, 793*t*
planning and implementation, 793*t*
pathophysiology, 784, 784*t*
Ulcerative keratitis, 1696
- Ulna, fracture, 1413
- Ulnar pulse, 1096*t*
- Ultrafiltration, 906
- Ultram. *See* Tramadol
- Ultrasonography:
abdominal
in aortic aneurysm, 1173
in female reproductive system disorders, 1757*t*
liver disorders, 716
purpose and description, 744*t*, 1757*t*
related nursing care, 744*t*, 1757*t*
tumors, cysts, and ascites, 616*t*
bladder, 836*t*
bone density measurement, 1436
breast, 1757*t*
in cancer, 385
color-flow Doppler, 1177
Doppler, 1177, 1197
duplex Doppler
in peripheral vascular disease, 1177
in varicose veins, 1197
in venous thrombosis, 1188
kidneys. *See* Renal ultrasonography
principles, 385
prostate, 1746*t*, 1784
vaginal, 1757*t*
Ultraviolet light therapy, 444–45
Ultraviolet radiation, 462
Umbilical hernia, 810
Unasyn. *See* Ampicillin/sulbactam
Uncal herniation, 1538, 1538*f*. *See also* Increased intracranial pressure
Unconjugated bilirubin, 699*t*
Undecylenic acid, 450*t*
Undersensing, pacemaker, 1011*t*
Underwater weighing, 632
Unfractionated heparin. *See* Heparin
Unguis incarnatus, 483
Uniform Anatomical Gift Act, 263
Unilateral neglect, 1518*t*
Unipen. *See* Nafcillin
Univalent, 196
Univasc. *See* Moexipril
“Universal donor,” 262
“Universal recipient,” 262
Unlicensed assistive personnel (UAP), 14
Unstable angina, 970. *See also* Angina pectoris
Unstable fracture, 1402
Upper body obesity, 632
Upper endoscopy. *See*
Esophagogastroduodenoscopy
Upper extremity:
amputation sites, 1422*f*
fractures, 1413–14, 1413*t*
physical assessment, 1095–96*t*
Upper gastrointestinal (GI) series:
normal stomach appearance, 614*f*
purpose and description, 615*t*
related nursing care, 615*t*
in specific conditions
esophageal cancer, 669
gastroesophageal reflux disease, 664
peptic ulcer disease, 684
Upper motor neurons, 1509
Upper respiratory disorders:
diphtheria. *See* Diphtheria
epiglottitis, 1240–41
epistaxis. *See* Epistaxis
influenza. *See* Influenza
laryngeal cancer. *See* Laryngeal cancer

- laryngeal obstruction or trauma
interdisciplinary care, 1249–50, 1249f
manifestations, 1249
nursing care, 1250
pathophysiology, 1249
- laryngeal tumors, 1252, 1253
- laryngitis, 1241
- nasal polyps, 1252
- nasal trauma. *See* Nasal trauma
- obstructive sleep apnea. *See* Obstructive sleep apnea
- in older adults, 315t
- pertussis. *See* Pertussis
- pharyngitis. *See* Pharyngitis
- respiratory syncytial virus, 1231
- sinusitis. *See* Sinusitis
- tonsillitis. *See* Tonsillitis
- viral infections. *See also* Influenza
complications, 1229
incidence, 1229
interdisciplinary care
complementary therapies, 1231
diagnosis, 1230
medications, 1230, 1230t
treatment, 1230
manifestations, 1229
nursing care
community-based care, 1231
health promotion, 1231
Medication Administration, 1230t
pathophysiology, 1229
- Upper respiratory system:
anatomy, physiology, and functions
larynx, 1211
nose, 1210–11
overview, 1210f
pharynx, 1211
sinuses, 1211, 1211f
trachea, 1211
disorders. *See* Upper respiratory disorders
physical assessment
nose, 1222–23t
overview, 1222
sinuses, 1223t
- UPPP (uvulopalatopharyngoplasty), 1251
- Urea. *See also* Blood urea nitrogen
Medication Administration, 905t, 1539t
production by kidney, 834
in specific conditions
acute renal failure, 905t
increased intracranial pressure, 1539t
- Urea breath test, 684
- Urecholine. *See* Bethanechol chloride
- Uremia, 906. *See also* Chronic renal failure
- Uremic fetor, 916
- Uremic frost, 918
- Ureteral stent:
characteristics, 851, 851f
definition, 851
nursing care, 851t
- Ureterolithotomy, 859
- Ureteroplasty, 851
- Ureteroscopy, 863
- Ureters, 834
- Urethra, 835, 1745t
- Urethritis, epididymitis and, 1773
- Urge urinary incontinence, 874t. *See also* Urinary incontinence
- Urgency, urinary, 847
- Urgent procedure, 54t
- Uric acid:
abnormal, possible causes, 387t
in gout, 1444, 1445
in musculoskeletal system assessment, 1388t
normal values, 387t
nurse, 1388t
production, 834
- Uric acid stones, 856, 856t. *See also* Urinary calculi
- Uricosuric drugs, 1445, 1446t
- Urinalysis. *See also* Urine tests
normal and abnormal findings, 832t
perioperative, significance and nursing implications, 60t
purpose and description, 835t
related nursing care, 835t
in specific conditions
acute renal failure, 904
bladder cancer, 863
burns, 500
chronic renal failure, 918
glomerular disorders, 890
neurogenic bladder, 870
urinary calculi, 857
urinary tract infection, 849
- Urinary analgesic, 850t
- Urinary anti-infectives, 850t
- Urinary calculi:
complications
hydronephrosis, 857
infection, 857
obstruction, 857
composition, 856
definition, 855
incidence, 855
interdisciplinary care
diagnosis, 857
management by stone type, 856t
medications, 857–58
nutrition and fluid management, 858, 858t
surgery, 858–59, 859f, 860f
locations, 855, 855f
manifestations, 856, 856t
nursing care
assessment, 860
community-based care, 862
health promotion, 859
nursing diagnoses and interventions
acute pain, 860
deficient knowledge, 860–61
impaired urinary elimination, 860
Nursing Care Plan
assessment, 861t
critical thinking in the nursing process, 861t
diagnoses, 861t
evaluation, 861t
expected outcomes, 861t
planning and implementation, 861t
pathophysiology, 855–56
risk factors, 855, 856t
urinary tract infection and, 850–51
- Urinary diversion:
nursing care, 866t
nursing considerations, 865t
procedures, 864, 864f, 865t
stoma care, 868t
- Urinary drainage system, 846. *See also* Urinary system
- Urinary incontinence (UI):
after prostatectomy, 1786, 1786f, 1787
definition, 872
incidence and prevalence, 872
interdisciplinary care
complementary therapies, 875–76
diagnosis, 874
evaluation, 874, 875f
medications, 874–75
surgery, 875
- nursing care
assessment, 877
community-based care, 879
health promotion, 876, 877t
nursing diagnoses and interventions
self-care deficit: toileting, 877–79
social isolation, 879
urinary incontinence: stress and/or urge, 876t, 877
using NANDA, NIC, and NOC, 879, 879t
- Nursing Care Plan
assessment, 878t
critical thinking in the nursing process, 878t
diagnoses, 878t
evaluation, 878t
expected outcomes, 878t
planning and implementation, 878t
- Nursing Research: stress vs. urge incontinence, 876t
- in older adults, 873t
pathophysiology, 872–73, 874t
types, 873, 874t
in uterine displacement disorders, 1807t
- Urinary retention:
interdisciplinary care, 869
manifestations, 869
medications causing, 869
nursing care, 869–70
pathophysiology, 869
postoperative, 78, 869
- Urinary sphincter, artificial, 1786, 1786f
- Urinary system:
age-related changes, 27t, 29t, 841t
anatomy, physiology, and functions
kidneys. *See* Kidney(s)
maintenance of sterility, 847, 847f
overview, 829f
ureters, 834
urethra, 835
urinary bladder, 834–35, 834f. *See also* Bladder
- assessment
diagnostic tests, 835–38t, 838. *See also* Urine tests; *specific tests*
functional health pattern interview, 840t
genetic considerations, 838, 839t
health assessment interview, 838–39
physical assessment
abdominal, 842t
bladder, 843t
kidneys, 841t, 842–43t
overview, 839
skin, 842t
urinary meatus, 842t
sample documentation, 835t
- disorders
bladder cancer. *See* Bladder cancer
calculi. *See* Urinary calculi
Chapter Highlights, 880t
Clinical Scenarios, 930t
infection. *See* Urinary tract infection
neurogenic bladder. *See* Neurogenic bladder
urinary incontinence. *See* Urinary incontinence
urinary retention. *See* Urinary retention
- Urinary tract infection (UTI):
bacterial causing, 846
categorization, 847
catheter-associated, 846, 848
cystitis, 847–48
interdisciplinary care
complementary therapies, 851
diagnosis, 849
medications, 849–50
surgery, 850–51

- Urinary tract infection (UTI)—*continued*
 manifestations, 847
 nosocomial, 313, 847, 848
 nursing care
 assessment, 852
 community-based care, 854–55
 health promotion, 851–52
 nursing diagnoses and interventions
 impaired urinary elimination, 852–54
 ineffective health maintenance, 854
 pain, 852
 of older adults, 315*t*, 873*t*
 Nursing Care Plan
 assessment, 853*t*
 critical thinking in the nursing process, 853*t*
 diagnoses, 853*t*
 evaluation, 853*t*
 expected outcomes, 853*t*
 planning and implementation, 853*t*
 obstruction as cause of, 850–51, 850*t*
 in older adults
 nursing care, 315*t*, 873*t*
 risk factors, 847
 pathophysiology, 847
 pyelonephritis, 848–49
 risk factors, 846, 846*t*
 Urine:
 formation
 glomerular filtration, 831–33, 831*f*
 tubular reabsorption, 831*f*, 833
 tubular secretion, 831*f*, 833
 maintenance of normal composition and volume,
 833–34, 833*f*
 Urine tests:
 24-hour
 in Cushing's syndrome, 549–50
 in hyponatremia, 215
 amylase, 728*t*
 for bacteria, 849
 in bladder cancer, 863
 creatinine
 in glomerular disorders, 890, 890*t*
 culture
 in chronic renal failure, 918
 in neurogenic bladder, 870
 purpose and description, 835*t*
 related nursing care, 835*t*
 in urinary tract infection, 849
 drug screen
 in substance abuse assessment, 112
 in trauma clients, 261
 glucose
 abnormal, possible causes, 832*t*
 in diabetes mellitus, 569
 normal values, 832*t*
 ketones
 abnormal, possible causes, 832*t*
 in diabetes mellitus, 569
 normal values, 832*t*
 osmolality
 abnormal, possible causes, 387*t*
 in fluid volume deficit, 205
 normal values, 387*t*
 protein
 abnormal, possible causes, 832*t*
 in diabetes mellitus, 569
 in glomerular disorders, 890*t*
 normal values, 832*t*, 890*t*
 RBCs
 abnormal, possible causes, 832*t*
 in glomerular disorders, 890*t*
 normal values, 832*t*, 890*t*
 specific gravity
 abnormal, possible causes, 832*t*
 in fluid volume deficit, 205
 in gastroenteritis and diarrhea, 776*t*
 normal values, 832*t*
 in urinary calculi, 857
 in urinary tract infection, 849
 WBCs, 832*t*
 Urispas. *See* Flavoxate
 Uroflowmetry, 836*t*, 874
 Urokinase, 1184
 Urolithiasis. *See* Urinary calculi
 Uroxatral. *See* Alfuzosin
 Ursodiol, 699
 Urticaria, 333, 431*t*
 Uterine cancer. *See* Endometrial cancer
 Uterine displacement:
 classification, 1805, 1806*f*, 1807*f*
 interdisciplinary care
 diagnosis, 1806
 Kegel exercises, 1806
 pessary, 1806–7
 surgery, 1806
 manifestations, 1805, 1807*f*, 1807*t*
 nursing care
 community-based care, 1807
 nursing diagnoses and interventions
 anxiety, 1807
 stress incontinence, 1807
 pathophysiology, 1805
 Uterine fibroid embolization, 1810
 Uterine tubes. *See* Fallopian tubes
 Uterus:
 anatomy, physiology, and functions, 1751*t*,
 1752–53, 1753*f*
 disorders
 displacement. *See* Uterine displacement
 dysfunctional uterine bleeding. *See*
 Dysfunctional uterine bleeding
 endometrial cancer. *See* Endometrial cancer
 endometriosis. *See* Endometriosis
 leiomyoma. *See* Leiomyoma
 physical assessment, 1764–65*t*
 UTI. *See* Urinary tract infection
 Uvea, 1672, 1672*f*
 Uveitis:
 in ankylosing spondylitis, 1470
 manifestations, 1684*t*, 1704
 pathophysiology, 1703–4
 treatment, 1704
 in ulcerative colitis, 784
 Uvulopalatopharyngoplasty (UPPP), 1251
- V**
- V tach. *See* Ventricular tachycardia
 Vaccines, 300. *See also* Immunizations; *specific vaccines*
 Vacuum constriction device (VCD), 1769
 Vacuum-assisted closure (VAC):
 for burns, 504, 504*f*
 for pressure ulcers, 474*t*
 Vacuum-assisted mammatome, 1757*t*
 VADs (ventricular assist devices), 990
 Vagal nerve stimulation therapy, 1551
 Vagina:
 anatomy and function, 1751*t*, 1752, 1753*f*
 cultures, 1756*t*
 infections. *See* Vaginal infections
 physical assessment, 1763–64*t*
 Vaginal fistula:
 characteristics, 1807–8
 interdisciplinary care, 1808
 nursing care, 1808
 Vaginal hysterectomy, 1804
 Vaginal infections:
 bacterial vaginosis, 1842, 1843*t*
 candidiasis, 449*t*, 1842–43, 1842*t*, 1843*f*
 interdisciplinary care
 diagnosis, 1843
 medications, 1843
 manifestations, 1842–43, 1843*t*
 nursing care
 community-based care, 1844
 nursing diagnoses and interventions
 acute pain, 1844, 1844*t*
 deficient knowledge, 1844
 pathophysiology, 1842–43
 risk factors, 1842
 trichomoniasis, 1843, 1843*t*
 Vaginismus, 1795
 Vaginitis. *See* Vaginal infections
 Vagus nerve (cranial nerve X):
 anatomy, 1510*f*
 assessment, 1520*t*
 functions, 1511*t*
 Valacyclovir:
 Medication Administration, 658*t*
 in specific conditions
 genital herpes, 1839
 herpes zoster, 453
 oral herpes simplex, 658, 658*t*
 Valium. *See* Diazepam
 Valproic acid:
 interaction with phenobarbital, 1551*t*
 Medication Administration, 1550*t*
 for migraine prophylaxis, 1544
 for seizures, 1550*t*
 Valsalva's maneuver, 743, 1013
 Valsartan, 1033*t*, 1161*t*
 Valtrex. *See* Valacyclovir
 Valve replacement, 1060–61, 1061*f*, 1061*t*
 Valves of Houston, 743
 Valvular heart disease:
 aortic regurgitation, 1058–59, 1058*f*
 aortic stenosis, 1057–58, 1058*f*
 causes, 1053–54
 interdisciplinary care
 diagnosis, 1059–60
 medications, 1060
 percutaneous balloon valvuloplasty, 1060, 1060*f*
 surgery
 reconstructive, 1060
 valve replacement, 1060–61, 1061*f*, 1061*t*
 mitral regurgitation, 1056, 1056*f*
 mitral stenosis, 1055–56, 1056*f*
 mitral valve prolapse, 1056–57
 murmur characteristics, 1055*t*
 nursing care
 assessment, 1062
 community-based care, 1063
 health promotion, 1062
 nursing diagnoses and interventions
 activity intolerance, 1062
 decreased cardiac output, 1062
 ineffective protection, 1063
 risk for infection, 1062–63
 Nursing Care Plan
 assessment, 1064*t*
 critical thinking in the nursing process, 1064*t*
 diagnoses, 1064*t*
 evaluation, 1064*t*
 expected outcomes, 1064*t*
 planning and implementation, 1064*t*
 pathophysiology, 1054, 1054*f*
 pulmonic regurgitation, 1059
 pulmonic stenosis, 1059
 tricuspid regurgitation, 1059
 tricuspid stenosis, 1059
 Valvuloplasty, 1060, 1060*f*

- Vanceril. *See* Beclomethasone dipropionate
- Vancocin. *See* Vancomycin
- Vancomycin:
 adverse/side effects, 1730
 Medication Administration, 319*t*
 in specific conditions
 bacterial meningitis, 1566
 endocarditis prophylaxis, 1047*t*
 endocarditis treatment, 1046
 pneumonia, 1271*t*
- Vancomycin-intermediate *S. aureus* (VISA), 314
- Vancomycin-resistant *Enterococci* (VRE), 314
- Vancomycin-resistant *S. aureus* (VRSA), 314
- Vanillylmandelic acid, 557
- VAP. *See* Ventilator-associated pneumonia
- Vardenafil hydrochloride, 1769
- Variable expression, 155
- Variceal ligation, 718
- Varicella, 302*t*. *See also* Herpes zoster
- Varicella vaccine, 21*t*
- Varicella-zoster immune globulin (VZIG), 302*t*
- Varicocele, 1773, 1773*f*
- Varicose veins:
 complications, 1196
 definition, 1093*t*, 1195
 incidence, 1195
 interdisciplinary care
 compression sclerotherapy, 1197
 diagnosis, 1197
 surgery, 1197
 treatments, 1197
 manifestations, 1196, 1196*t*
 nursing care
 assessment, 1197
 community-based care, 1199
 health promotion, 1197
 nursing diagnoses and interventions
 chronic pain, 1197–98
 ineffective tissue perfusion: peripheral, 1198
 risk for impaired skin integrity, 1198
 risk for peripheral neurovascular
 dysfunction, 1198–99
 pathophysiology, 1196
 physical assessment, 1096*t*
 risk factors, 1195
- Vas deferens, 1745*t*
- Vasor. *See* Bepridil
- Vascular access devices:
 for chemotherapy, 394, 395*f*
 for dialysis, 908–9, 909*f*
- Vascular dementia, 1618*t*
- Vascular tunic. *See* Uvea
- Vaseline, 441*t*
- Vasoconstriction, 1176
- Vasoconstrictors, 278*t*, 1243
- Vasodilation, 1176
- Vasodilators:
 avoidance in aortic aneurysm, 1173
 Medication Administration, 278*t*, 1162*t*
 in specific conditions
 heart failure, 1032
 hypertension, 1162*t*, 1163
 pulmonary edema, 1041
 pulmonary hypertension, 1353
 Raynaud's disease/phenomenon, 1182–83
 shock, 278*t*
- Vasogenic edema, 1537. *See also* Increased intracranial pressure
- Vasogenic shock, 274
- Vasomotor rhinitis, 1229
- Vasooclusive crises, 1107
- Vasopressin. *See* Antidiuretic hormone
- Vasotec. *See* Enalapril
- Vasotec IV. *See* Enalaprilat
- VBG (vertical banded gastroplasty), 637, 637*f*
- VCD (vacuum constriction device), 1769
- Veins:
 anatomy, 1082, 1083*f*, 1085*f*
 assessment, 1094–95*t*
- Vena caval filters, 1190, 1190*f*, 1349
- Venereal Disease Research Laboratory (VDRL), 1746*t*, 1756*t*, 1849
- Venereal diseases. *See* Sexually transmitted infections
- Venofor. *See* Iron sucrose
- Venous lakes, 430*t*, 443
- Venous pressure monitoring, 1030. *See also* Central venous pressure
- Venous return, 1023
- Venous star, 434*f*, 434*t*
- Venous stasis, 426*t*, 1194. *See also* Chronic venous insufficiency
- Venous thrombectomy, 1190
- Venous thrombosis:
 complications, 1187
 definition, 1186
 interdisciplinary care
 diagnosis, 1188
 medications, 1188, 1189–90*t*
 prophylaxis, 1188
 surgery, 1190, 1190*f*
 treatments, 1190
 locations, 1187*f*
 manifestations, 1187, 1187*t*
 nursing care
 assessment, 1190, 1191
 community-based care, 1193
 health promotion, 1190
 Medication Administration, 1189–90*t*
 nursing diagnoses and interventions
 impaired physical mobility, 1192–93
 ineffective protection, 1192
 ineffective tissue perfusion:
 cardiopulmonary, 1193
 ineffective tissue perfusion:
 peripheral, 1192
 pain, 1191–92
 using NANDA, NIC, and NOC, 1193, 1193*t*
- Nursing Care Plan
 assessment, 1191*t*
 critical thinking in the nursing process, 1191*t*
 diagnoses, 1191*t*
 evaluation, 1191*t*
 expected outcomes, 1191*t*
 planning and implementation, 1191*t*
 pathophysiology, 1186–87
 risk factors, 1186, 1186*t*
- Ventilation. *See* Respiration
- Ventilation scan, 1349. *See also* Pulmonary ventilation/perfusion scan
- Ventilation/perfusion scan (V/Q scan). *See* Pulmonary ventilation/perfusion scan
- Ventilator-assisted breaths, 1358
- Ventilator-associated pneumonia (VAP):
 Nursing Research: prevention strategies, 280*t*
 pathophysiology, 1360
- Ventilator-controlled breaths, 1358
- Ventolin. *See* Albuterol
- Ventral hernia, 810. *See also* Hernia
- Ventricles, 938
- Ventricular aneurysm, 985
- Ventricular assist devices (VADs), 990
- Ventricular bigeminy, 1002
- Ventricular dysrhythmias. *See also* Cardiac dysrhythmias
 causes, 1002–3
 ECG characteristics, 998–99*t*, 1002–3
 management, 998–99*t*
 manifestations, 1002–3
 pathophysiology, 996
- Ventricular fibrillation:
 causes, 1002–3
 ECG characteristics, 999*t*
 management, 999*t*
 pathophysiology, 1002
- Ventricular hypertrophy, 1024*t*, 1025
- Ventricular remodeling, 1025
- Ventricular tachycardia (VT, V tach):
 ECG characteristics, 998*t*
 management, 998*t*
 manifestations, 1002
 pathophysiology, 1002
- Ventricular trigeminy, 1002
- Venturi mask, 1272, 1273*f*
- VePesid. *See* Etoposide
- Verapamil:
 Medication Administration, 973*t*, 1006*t*, 1162*t*, 1545–46*t*
 in specific conditions
 acute myocardial infarction, 988
 angina, 973–74*t*
 aortic aneurysm, 1173
 cardiac dysrhythmias, 1006*t*
 headache, 1545–46*t*
 hypertension, 1162*t*
 thromboangiitis obliterans, 1182
- Verelan. *See* Verapamil
- Vermox. *See* Mebendazole
- Verruca plana, 452
- Verruca vulgaris, 452, 452*f*
- Verrucous, 1819
- Versed. *See* Midazolam
- Vertical banded gastroplasty (VBG), 637, 637*f*
- Vertigo, 1722, 1726. *See also* Inner ear disorders
- Very low calorie diets (VLCDs), 635
- Very-low-density lipoproteins, 959
- Vesicle/vesicular lesions, 431*t*, 432*t*
- Vesicoureteral junction, 847, 847*f*
- Vesicovaginal fistula, 1807
- Vestibular neurectomy, 1727
- Vestibule, 1683, 1751*t*, 1752, 1752*f*
- Viagra. *See* Sildenafil citrate
- Vibramycin. *See* Doxycycline
- Vibration, in chest physiotherapy, 1273, 1273*f*
- Vibrio cholerae*, 774*t*, 775
- Vicodin. *See* Hydrocodone
- Vidarabine, 322*t*, 1566
- Vidaza. *See* Azacitidine
- Videx. *See* Didanosine
- Vietnamese, end-of-life practices, 89
- Villi, 612, 742
- Villous adenomas, 800, 800*f*. *See also* Polyps
- Vinblastine, 359*t*, 393*t*
- Vinca alkaloids, 391, 393*t*
- Vincristine:
 adverse/side effects, 393*t*
 nursing implications, 393*t*
 in specific conditions
 bone tumors, 1483*t*
 leukemia, 1123*t*
 target malignancies, 393*t*
- Vinyl chloride polymers, 372*t*
- Vioxx. *See* Rofecoxib
- Vira-A. *See* Vidarabine
- Viracept. *See* Nelfinavir
- Viral encephalitis, 1565, 1565*t*
- Viral meningitis, 1564–65. *See also* Central nervous system infections
- Viral pneumonia, 1269, 1270*t*. *See also* Pneumonia
- Viramune. *See* Nevirapine
- Virazole. *See* Ribavirin

- Virchow's triad, 1186
 Virilization, 481
 Virulence, 1267
 Viruses:
 cancer associated with, 374–75, 375t
 characteristics, 311t
 in hepatitis. *See* Hepatitis
 herpes simplex. *See* Herpes simplex
 herpes zoster. *See* Herpes zoster
 HIV. *See* Human immunodeficiency virus (HIV) infection
 human papillomavirus. *See* Human papillomavirus
 influenza. *See* Influenza
 in pneumonia, 1269, 1270t. *See also* Pneumonia
 upper respiratory, 1229. *See also* Upper respiratory disorders, viral infections
 VISA (vancomycin-intermediate *S. aureus*), 314
 Visceral neuropathies, 589
 Visceral pain, 173
 Viscosupplementation, 1452
 Vision. *See also* Eyes
 age-related changes
 in middle adults, 27t
 in older adults, 29t, 1676t
 in young adults, 26t
 impairments
 incidence, 1692
 nursing care, 1693t
 Nursing Research: effect on older adults, 1715t
 special considerations in disasters, 140
 Visken. *See* Pindolol
 Vistaril. *See* Hydroxyzine
 Visual field testing:
 in glaucoma diagnosis, 1708
 procedure, 1675–76, 1676f, 1709f
 Visual pathways:
 age-related changes, 1676t
 anatomy and physiology, 1672–73, 1673f
 Vital capacity (VC), 1214, 1214t
 Vitamin(s):
 categories, 608
 in healing process, 306t, 307
 recommended daily intakes, 608t, 609t
 supplements
 in cirrhosis, 717
 Medication Administration, 645t
 in substance abuse/withdrawal treatment, 114t
 Vitamin A (retinol):
 deficiency, 642t
 functions, 608t
 in healing, 306t, 307
 recommended daily intake, 608t
 sources, 608t
 Vitamin B complex, in healing, 306t, 307
 Vitamin B₁ (thiamine):
 deficiency, 642t
 functions, 609t
 recommended daily intake, 609t
 sources, 609t
 for substance abuse/withdrawal treatment, 114t
 Vitamin B₂ (riboflavin):
 deficiency, 642t
 functions, 609t
 recommended daily intake, 609t
 sources, 609t
 Vitamin B₃ (nicotinamide):
 functions, 609t
 recommended daily intake, 609t
 sources, 609t
 Vitamin B₆ (pyridoxine):
 coronary heart disease risk and, 966
 functions, 609t
 recommended daily intake, 609t
 sources, 609t, 966
 Vitamin B₁₂ (cyanocobalamin):
 deficiency
 causes, 1105
 interdisciplinary care
 diagnostic tests, 1111
 focus, 1110t
 medications, 1111, 1112t
 nutrition, 1111, 1111t
 manifestations, 1105
 pathophysiology, 1105
 functions, 609t
 recommended daily intake, 609t
 replacement therapy, 1112t
 sources, 609t, 1111t
 Vitamin C (ascorbic acid):
 coronary heart disease risk and, 966
 deficiency, 642t
 functions, 609t
 in healing, 306t, 307
 recommended daily intake, 609t
 sources, 609t, 966
 Vitamin D:
 activation in kidney, 834
 deficiency, 1447–48, 1448t
 functions, 608t
 limiting intake, in urinary calculi, 858
 metabolism, 1448
 recommended daily intake, 608t
 sources, 608t, 1449
 toxicity, 1449
 Vitamin E:
 functions, 608t
 in gout treatment, 1445
 recommended daily intake, 608t
 sources, 608t
 Vitamin K:
 in cirrhosis, 415
 functions, 608t
 in healing, 307
 recommended daily intake, 608t
 sources, 608t
 Vitiligo, 426t, 431t
 Vitreous humor, 1672, 1672f
 Vivox. *See* Doxycycline
 VLCDs (very low calorie diets), 635
 Voice sounds, assessment, 1226t
 Voiding cystogram. *See* Cystometrogram
 Voiding cystourethrography. *See* Cystometrogram
 Voiding diary, 875f
 Volatile acids, 238
 Volatile nitrites, 111, 113t
 Volkmann's contracture, 1406, 1413
 Voltaren. *See* Diclofenac sodium
 Volume resuscitation therapies, 263t
 Volume-cycled ventilators, 1358
 Volutrauma, 1360
 Vomiting, 671. *See also* Nausea and vomiting
 Von Willebrand's disease, 1143, 1143t. *See also* Hemophilia
 VP-16. *See* Etoposide
 V/Q scan. *See* Pulmonary ventilation/perfusion scan
 VRE (vancomycin-resistant *Enterococci*), 314
 VRSA (vancomycin-resistant *S. aureus*), 314
 VT. *See* Ventricular tachycardia
 V_t (tidal volume), 1214, 1358, 1360t
 Vulvar cancer:
 incidence, 1819
 interdisciplinary care, 1819–20
 manifestations, 1819
 nursing care
 community-based care, 1820
 nursing diagnoses and interventions, 1820
 pathophysiology, 1819
 Vulvar cysts, 1808, 1809t
 Vulvectomy, 1819–20, 1820f
 VZIG (varicella-zoster immune globulin), 302t
- ## W
- Waist circumference, 632
 Waist-to-hip ratio, 622t, 631
 Warfarin:
 interaction with phenobarbital, 1551t
 Medication Administration, 1189–90t
 in specific conditions
 ischemic stroke, 1585
 pulmonary embolism, 1349
 venous thrombosis, 1188
 Warm phase, septic shock, 275, 275t
 Warm zone, in disaster, 133t
 Warts:
 genital. *See* Genital warts
 nongenital
 interdisciplinary care, 453
 manifestations, 452
 pathophysiology, 451–52, 452f
 Wasting syndrome, in AIDS, 353, 353f
 Water. *See also* Body fluids
 in body fluids, 195–96
 function in body, 195
 Water deprivation test, 216, 523t
 Water-hammer pulse, 1059, 1094t
 Water-soluble vitamins, 608, 609t
 WBC count. *See* White blood cell (WBC) count
 WBC differential. *See* White blood cell (WBC) differential
 WBCs. *See* White blood cells
 Weaning, mechanical ventilation, 1360–61, 1361f
 Weber test:
 in hearing evaluation, 1730
 in inner ear disorders, 1727
 procedure, 1687f, 1687t
 Wedge resection, lung, 1312t
 Weepy lesions, 431t
 Weight. *See* Body weight
 Welchol. *See* Colesevelam
 Wellferon. *See* Interferon(s)
 Wellness, 19
 Wernicke-Korsakoff syndrome, 108
 Wernicke's aphasia, 1583
 Wernicke's encephalopathy, 103t, 108
 Westerhoff, spiritual development theory, 25t
 Western blot testing, 355
 Wetting agents, 759t
 Wet-to-dry dressing, 474t
 Wheal, 432t
 Wheezes, 1226t
 Whipple's procedure:
 characteristics, 732, 732f
 nursing care, 732t
 Whisper test, 1688
 Whispered pectoriloquy, 1226t
 White blood cell (WBC) count:
 abnormal, possible causes, 307t, 387t
 normal values, 287, 387t, 1078t, 1118t
 perioperative, significance and nursing implications, 60t
 in specific conditions
 hypersensitivity reaction, 336
 inflammation, 306
 leukemia, 1123t

rheumatic heart disease, 1043t
 shock, 277

White blood cell (WBC) differential:
 abnormal, possible causes, 307t
 normal values, 1118t

White blood cells (WBCs):
 abnormal, possible causes, 387t
 development and differentiation, 287, 298f,
 1077f, 1079, 1118

disorders
 leukemia. *See* Leukemia
 neutropenia. *See* Neutropenia

functions, 290–91, 1118

in inflammatory response, 293, 293f

laboratory assessment. *See* White blood cell
 (WBC) count

normal values, 387t

types
 basophils. *See* Basophils
 granulocytes, 288, 288t, 289f
 lymphocytes. *See* Lymphocytes
 monocytes, macrophages, and dendritic cells,
 288–89, 288t, 289f. *See also* Monocytes
 neutrophils. *See* Neutrophils
 in urine. *See* Urine tests, WBCs

WHO. *See* World Health Organization

Whole blood, as volume resuscitation therapy, 263t

Whooping cough. *See* Pertussis

Wild-type gene, 152

Williams syndrome, 950t

Withdrawal:
 assessment tools, 117, 118f
 definition, 102
 Nursing Care Plan
 assessment, 119t
 critical thinking in the nursing process, 119t
 diagnoses, 119t
 evaluation, 119t
 expected outcomes, 119t
 planning and implementation, 119t
 signs, 102, 113t
 treatment, 112, 113t

Withdrawal symptoms, 102. *See also* Withdrawal

Withdrawal syndrome, 103t. *See also* Withdrawal

Wood's lamp, 428t

World Health Organization (WHO):
 analgesic ladder, 177, 177f
 definition of health, 19

Wounds:
 burn. *See* Burns

complications
 dehiscence, 78, 78f
 evisceration, 78, 78f
 infections, 77–78
 nursing care, 77–78

drainage
 devices, 77f
 types, 77

healing, 76–77, 76f, 77t. *See also* Healing

Wrist:
 fracture, 1413–14
 physical assessment, 1393t, 1395f, 1395t

X

Xalatan. *See* Latanoprost

Xenical. *See* Orlistat

Xenograft, 342, 503

Xeroderma, 441

Xerophthalmia, 1486

Xerosis, 441, 441t

Xerostomia:
 definition, 408, 1486
 nursing interventions, 409
 in Sjögren's syndrome, 1486

X-linked dominant inheritance, 155

X-linked recessive inheritance, 153–54, 153f, 154t

XomaZyme. *See* Immunotoxin

X-ray imaging:
 in cancer, 384
 in multiple myeloma, 1137
 in musculoskeletal system assessment, 1387t
 sinuses, 1236
 skull and spine, 1514t

Xylitol, 579

Xylocaine, 441t. *See also* Lidocaine

Xyloxylin suspension, 409t

Y

Yodoxin. *See* Iodoquinol

Young adults (ages 18 to 40):
 family-related risk factors for alterations in
 health, 32t, 33

health needs
 assessment guidelines, 26, 26t
 promoting healthy behaviors, 26, 27t
 risks for alterations in health
 injuries, 24
 physical and psychosocial stressors, 25–26

sexually transmitted infections, 24. *See also*
 Sexually transmitted infections

substance abuse, 25. *See also* Substance
 abuse

physical status and changes, 26t

Z

Zafirlukast, 1328t

Zanamivir, 1234

Zantac. *See* Ranitidine

Zarontin. *See* Ethosuximide

Zaroxolyn. *See* Metolazone

Zebeta. *See* Bisoprolol

Zelnorm. *See* Tegaserod mesylate

Zemuron. *See* Rocuronium

Zenapax. *See* Daclizumab

Zerit. *See* Stavudine

Zestril. *See* Lisinopril

Zetar. *See* Coal tar derivatives

Ziagen. *See* Abacavir

Zidovudine:
 for cryptosporidiosis, 778t
 in HIV infection, 356
 Medication Administration, 322t, 357t

Zileuton, 1328t

Zinacef. *See* Cefuroxime

Zinc:
 deficiency, 1223t
 recommended daily intake, 610t

Zinc gluconate, 1231

Zinc oxide, 465t

Zithromax. *See* Azithromycin

Zocor. *See* Simvastatin

Zofran. *See* Ondansetron

Zoledronate (zoledronic acid), 181, 547

Zollinger-Ellison syndrome, 684

Zolmitriptan, 1544, 1545t

Zoloft. *See* Sertraline

Zometa. *See* Zoledronate

Zomig. *See* Zolmitriptan

Zostavax, 453

Zostrix. *See* Capsaicin

Zosyn. *See* Piperacillin-tazobactam

Zovirax. *See* Acyclovir

Zyflo. *See* Zileuton

Zyloprim. *See* Allopurinol

Zynol. *See* Sulfapyrazone

Zyrtec. *See* Cetirizine

